<SEC-DOCUMENT>0001387131-13-001759.txt : 20130513
<SEC-HEADER>0001387131-13-001759.hdr.sgml : 20130513
<ACCEPTANCE-DATETIME>20130513165221
ACCESSION NUMBER:		0001387131-13-001759
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20130331
FILED AS OF DATE:		20130513
DATE AS OF CHANGE:		20130513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALATIN TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000911216
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954078884
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15543
		FILM NUMBER:		13838037

	BUSINESS ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		609-495-2200

	MAIL ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERFILM INC
		DATE OF NAME CHANGE:	19930825
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptn-10q_033113.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
    <title>ptn-10q_033113.htm</title>
    <!--Licensed to: QualityEdgar-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-VARIANT: small-caps; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-VARIANT: small-caps; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Washington, DC 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Mark One)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For <font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the quarterly period ended March 31, 2013</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></font></div>
</td>
<td align="left" valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 12pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the transition period from ___________ to __________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission file number: 001-15543</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<hr style="COLOR: black" align="center" noshade size="2" width="25%">
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">95-4078884</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">incorporation or organization)</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer Identification No.)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4B Cedar Brook Drive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cranbury, New Jersey</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">08512</font></div>
</td>
</tr><tr>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(609) 495-2200</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant's telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes <font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;Yes&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font>&#160;&#160;&#160;&#160;</font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="34%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="41%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></td>
<td width="13%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="34%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></td>
<td width="6%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt">&#160;(Do not check if a smaller reporting company)<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;No <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of May 10, 2013, 38,947,912 shares of the registrant's common stock, par value $.01 per share, were outstanding.</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">PALATIN </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">TECHNOLOGIES, INC</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Table of Contents</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Page</font></font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="91%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a001">PART I &#8211; FINANCIAL INFORMATION</a></font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="91%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a002">Item 1. Financial Statements (Unaudited)</a></font></div>
</td>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a003">Consolidated Balance Sheets as of March 31, 2013 and June 30, 2012</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a href="#a004"><!--efplaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Operations for the Three and Nine Months Ended </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2013 and 2012</font></a></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a href="#a005"><!--efplaceholder--><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Cash Flows for the Nine Months Ended </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2013 and 2012</font></a></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="#a006">Notes to Consolidated Financial Statements</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a007">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a008">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a009">Item 4. Controls and Procedures</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="2" valign="top" width="91%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a010">PART II &#8211; OTHER INFORMATION</a></font></div>
</td>
</tr><tr>
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a011">Item 1. Legal Proceedings</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a012">Item 1A. Risk Factors</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a013">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a014">Item 3. Defaults Upon Senior Securities</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a015">Item 4. Mine Safety Disclosures</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a016">Item 5. Other Information</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="94%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#a017">Item 6. Exhibits</a></font></div>
</td>
<td align="right" valign="bottom" width="6%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A001">PART I - FINANCIAL INFORMATION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A002">Item 1.&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A003">Consolidated Balance Sheets</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">June 30, 2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,537,053</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,827,198</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Short-term investments</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,998,740</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,631</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Restricted cash</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">350,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">488,185</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">532,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,023,978</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,736,839</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">307,020</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">318,653</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,337</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">324,992</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,389,335</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,380,484</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital lease obligations</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,591</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,277</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">733,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">294,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,986,240</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,706,496</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued compensation</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">433,333</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,743,274</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,457,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital lease obligations</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,048</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,909</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred rent</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44,764</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">72,677</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,790,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,549,586</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock of $0.01 par value &#8211; authorized 10,000,000 shares; </font>Series A Convertible; issued and outstanding 4,697 shares as of March 31, 2013 and 4,997 as of June 30, 2012</font></div>
</div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">47</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock of $0.01 par value &#8211; authorized 200,000,000 shares; </font>issued and outstanding 38,947,912 shares as of March 31, 2013 and 34,900,591 as of June 30, 2012, respectively</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">389,479</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">349,006</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">282,597,134</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,725,127</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated deficit</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(255,387,411</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(239,243,285</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stockholders&#8217; equity</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,599,249</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,830,898</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,389,335</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,380,484</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A004">&#160;Consolidated Statements of Operations</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">REVENUES:</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,996</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,361</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,705</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OPERATING EXPENSES:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,944,587</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,705,662</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,733,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,683,112</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,079,197</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,344,861</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,141,751</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,473,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,023,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,050,523</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,875,421</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,157,102</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from operations</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,023,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,026,527</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,865,060</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,094,397</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">OTHER INCOME (EXPENSE):</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investment income</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,629</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,955</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,017</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,229</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,103</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,830</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,746</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,650</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase in fair value of warrants</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,069,165</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on disposition of supplies and equipment</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,620</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other income (expense), net</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,526</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,825</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(7,032,274</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,279</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss before income taxes</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,015,258</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,020,702</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17,897,334</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(13,068,118</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income tax benefit</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,753,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,068,233</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NET LOSS</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,015,258</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,020,702</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,144,126</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,999,885</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted net loss per common share</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.17</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.17</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.34</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">106,424,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,900,591</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">94,754,789</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,900,591</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A005">Consolidated&#160; Statements of Cash Flows</a></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" colspan="4" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,144,126</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,999,885</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">82,360</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">737,120</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued interest and amortization on premium/discount</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(451</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on sale of supplies and equipment</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,620</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">475,329</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">716,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Increase in fair value of warrants</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,069,165</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,631</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">114,549</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses, restricted cash and other assets</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,480</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(215,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">438,549</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60,994</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses, compensation and deferred rent</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,181,502</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">578,144</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unearned revenue</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(46,105</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,577,185</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,059,475</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of supplies and equipment</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,620</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,700</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchases of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(70,727</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(15,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchases of investments</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,998,289</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,064,396</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments on capital lease obligations</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,547</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,615</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment of withholding taxes related to restricted </font>stock units</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(34,785</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of common stock units</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,402,768</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by (used in) financing activities</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34,351,436</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(29,615</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NET INCREASE (DECREASE) IN CASH </font>AND CASH EQUIVALENTS</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,709,855</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,099,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS, beginning of period</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,827,198</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,869,639</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS, end of period</font></div>
</td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,537,053</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,770,249</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="60%">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SUPPLEMENTAL CASH FLOW INFORMATION:</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="60%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for interest</font></div>
</td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,746</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,650</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="notes"><!--EFPlaceholder--></a><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A006">Notes to Consolidated Financial Statements</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;ORGANIZATION:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Nature of Business</font> &#8211; Palatin Technologies, Inc. (Palatin or the Company) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin&#8217;s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, pigmentation disorders and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The Company&#8217;s primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). The Company also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. The Company has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome, with drug candidates in preclinical evaluation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Key elements of the Company&#8217;s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that the Company is developing; and partially funding its product candidate development programs with the cash flow generated from the Company&#8217;s license agreements with AstraZeneca and any other companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Business Risk and Liquidity </font>&#8211; The Company has incurred negative cash flows from operations since its inception, and has expended, and expects to continue to expend in the future, substantial funds to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company has an accumulated deficit as of March 31, 2013 and incurred a net loss for the three and nine months ended March 31, 2013. The Company anticipates incurring additional losses in the future as a result of spending on its development programs. To achieve profitability, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and there can be no assurance that the Company will be able to achieve profitability on a sustained basis, if at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>As of March 31, 2013, the Company&#8217;s cash, cash equivalents and short-term investments were $29.5million. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including its clinical trial program with bremelanotide for FSD, preclinical and clinical development of its peptide melanocortin receptor-1 program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management believes that the Company&#8217;s existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) and initiating those studies, through at least calendar year 2013. Phase 3 clinical trials of bremelanotide for FSD will require significant additional resources and capital.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Concentrations &#8211;</font> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company&#8217;s cash and cash equivalents are primarily invested in one money market fund sponsored by a large financial institution and, secondarily, in U.S government securities. For the nine months ended March 31, 2013 and the three and nine months ended March 31, 2012, 100% of revenues were from AstraZeneca.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(2)&#160;&#160;&#160;&#160;&#160;&#160; BASIS OF PRESENTATION:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q.&#160;Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2013, and its results of operations and its cash flows for the three and nine months ended March 31, 2013 and 2012. The results of operations for the three and nine months ended March 31, 2013 may not necessarily be indicative of the results of operations expected for the full year, except that the Company expects to incur a significant loss for the fiscal year ending June 30, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended June 30, 2012, filed with the Securities and Exchange Commission (SEC), which includes consolidated financial statements as of June 30, 2012 and 2011 and for each of the fiscal years in the three-year period ended June 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(3)&#160;&#160;&#160;&#160;&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Principles of Consolidation</font> &#8211; The consolidated financial statements include the accounts of Palatin and its wholly-owned inactive subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Use of Estimates</font> &#8211; The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Cash and Cash Equivalents</font> &#8211; Cash and cash equivalents include cash on hand, cash in banks and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consist of $19,056,321in a money market fund and $1,499,925 in U.S. government securities at March 31, 2013 and $3,344,146in a money market fund at June 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Investments</font> &#8211; The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet, based on the contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&#8217; equity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Fair Value of Financial Instruments</font> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts receivable, accounts payable, and capital lease obligations. Management believes that the carrying value of these assets and liabilities are representative of their respective fair values based on the short-term nature of these instruments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Property and Equipment</font> &#8211; Property and equipment consists of office and laboratory equipment, office furniture and leasehold improvements and includes assets acquired under capital leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under capital leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Impairment of Long-Lived Assets</font> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Deferred Rent </font>&#8211;<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>The Company&#8217;s operating leases provide for rent increases over the terms of the leases. Deferred rent consists of the difference between periodic rent payments and the amount recognized as rent expense on a straight-line basis, as well as tenant allowances for leasehold improvements. Rent expenses are being recognized ratably over the terms of the leases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Revenue Recognition </font>&#8211; Revenue from corporate collaborations and licensing agreements consists of up-front fees, research and development funding, and milestone payments. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. The Company estimates the performance period as the period in which it performs certain development activities under the applicable agreement. Reimbursements for research and development activities are recorded in the period that the Company performs the related activities under the terms of the applicable agreements. Revenue resulting from the achievement of milestone events stipulated in the applicable agreements is recognized when the milestone is achieved, provided that such milestone is substantive in nature. Revenue from grants is recognized as the Company provides the services stipulated in the underlying grants based on the time and materials incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Research and Development Costs</font> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Stock-Based Compensation &#8211;</font> The Company charges to expense the fair value of stock options and other equity awards granted. The Company determines the value of stock options utilizing the Black-Scholes option pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Income Taxes</font> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>During the nine months ended March 31, 2013 and 2012, the Company sold New Jersey state net operating loss (NJ NOL)carryforwards, which resulted in the recognition of $1,753,208 and $1,068,233, respectively, in tax benefits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="FONT-STYLE: italic; DISPLAY: inline">Net Loss per Common Share </font>&#8211; Basic and diluted earnings per common share (EPS) are calculated in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 260, &#8220;Earnings per Share,&#8221; which includes guidance pertaining to the warrants, issued in connection with the July 3, 2012 private placement offering, that are exercisable for nominal consideration and, therefore, are to be considered in the computation of basic and diluted net loss per common share. The Series A 2012 warrants to purchase up to 31,988,151 shares of common stock are exercisable starting at July 3, 2012 and, therefore, are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 3, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Series B 2012 warrants to purchase up to 35,488,380 shares of common stock were considered contingently issuable shares and were not included in computing basic net loss per common share until the Company received stockholder approval for the increase in authorized underlying common stock on September 27, 2012 (see note 6). For diluted EPS, contingently issuable shares are to be included in the calculation as of the beginning of the period in which the conditions were satisfied, unless the effect would be anti-dilutive. The Series B 2012 warrants have been excluded from the calculation of diluted net loss per common share during the period from July 3, 2012 until September 27, 2012 as the impact would be anti-dilutive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>As of March 31, 2013 and 2012, common shares issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the warrants issued in connection with the July 3, 2013 private placement offering), and the vesting of restricted stock units amounted to an aggregate of 27,672,437 and 27,462,700shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be anti-dilutive.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">(4)&#160;&#160;&#160;&#160;&#160;&#160; AGREEMENT WITH ASTRAZENECA:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>In January 2007, the Company entered into an exclusive global research collaboration and license agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. In June 2008, the license agreement was amended to include additional compounds and associated intellectual property developed by the Company. In December 2008, the license agreement was further amended to include additional compounds and associated intellectual property developed by the Company and extended the research collaboration for an additional year through January 2010. In September 2009, the license agreement was further amended to modify royalty rates and milestone payments. The collaboration is based on the Company&#8217;s melanocortin receptor obesity program and includes access to compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development. As part of the September 2009 amendment to the research collaboration and license agreement, the Company agreed to conduct additional studies on the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>In December 2009 and 2008, the Company also entered into clinical trial sponsored research agreements with AstraZeneca, under which the Company agreed to conduct studies of the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters. Under the terms of these clinical trial agreements, AstraZeneca paid $5,000,000 as of March 31, 2009 upon achieving certain objectives and paid all costs associated with these studies. The Company recognized $10,361 as revenue in the nine months ended March 31, 2013 and $23,996 and $62,705, respectively, as revenue in the three and nine months ended March 31, 2012 under these clinical trial sponsored research agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company received an up-front payment of $10,000,000 from AstraZeneca on execution of the research collaboration and license agreement. Under the September 2009 amendment the Company was paid an additional $5,000,000 in consideration of reduction of future milestones and royalties and providing specific materials to AstraZeneca. The Company is now eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets. In addition, the Company is eligible to receive mid to high single digit royalties on sales of any approved products. AstraZeneca assumed responsibility for product commercialization, product discovery and development costs, with both companies contributing scientific expertise in the research collaboration. The Company provided research services to AstraZeneca through January 2010, the expiration of the research collaboration portion of the research collaboration and license agreement, at a contractual rate per full-time-equivalent employee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(5)&#160;&#160;&#160;&#160;&#160;&#160; FAIR VALUE MEASUREMENTS:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The fair value of cash equivalents and short-term investments are classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The following table provides the assets carried at fair value:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total carrying </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">value as of </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2013</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Quoted prices in </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">active markets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Level 1)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">quoted/observable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">inputs</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Level 2)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Significant</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;unobservable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">inputs</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Level 3)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31, 2013:</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Money Market Fund</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,056,321</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,056,321</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. government securities</font></div>
</td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,498,665</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,496,925</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,554,986</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,553,246</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30, 2012:</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="36%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Money Market Fund</font></div>
</td>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,344,146</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="3%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,344,146</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="3%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(6)&#160;&#160;&#160;&#160;&#160; STOCKHOLDERS&#8217; EQUITY:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Common Stock Transactions</font> &#8211;<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>On July 3, 2012, the Company closed on a private placement offering in which the Company sold, for aggregate proceeds of $35.0 million, 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of common stock. These warrants are exercisable at an exercise price of $0.01 per share, and expire ten years from the date of issuance. The holders may exercise the warrants on a cashless basis. The warrants are subject to a blocker provision prohibiting exercise of the warrants if the holder and its affiliates would beneficially own in excess of 9.99% of the total number of shares of common stock of the Company following such exercise (as may be adjusted to the extent set forth in the warrant). The warrants also provide that in the event of a Company Controlled Fundamental Transaction (as defined in the warrants), the Company may, at the election of the warrant holder, be required to redeem all or a portion of the warrants at an amount tied to the greater of the then market price of the Company&#8217;s common stock or the amount per share paid to any other person.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because there were not sufficient authorized shares to cover all the outstanding Series B 2012 warrants in the private placement offering as of closing, under ASC 815, &#8220;Derivatives and Hedging,&#8221; the portion of the warrants above the then authorized level of common stock was required to be classified as a liability and carried at fair value on the Company&#8217;s balance sheet. The fair value was calculated by multiplying the number of shares underlying the Series B 2012 warrants above the then authorized level of the Company&#8217;s common stock by the closing price of its common stock less the exercise price of $0.01 per share.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"> The warrants were liability classified through September 27, 2012,</font>at which time the then fair value of the warrant liability was reclassified into stockholders&#8217; equity upon stockholder approval of the increase in authorized common stock. The increase in fair value, as a result of the Company&#8217;s common stock increasing from $0.50 per share at date of issuance to $0.71 per share upon shareholder approval, of $7,069,165 has been recorded as a non-operating expense for the nine months ended March 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;The purchase agreement for the private placement provides that the purchasers, funds under the management of QVT Financial LP, have certain rights until July 3, 2018, including rights of first refusal and participation in any subsequent equity or debt financing, provided that the funds own at least 20% of the outstanding common stock of the Company calculated as if warrants held by the funds were exercised. The purchase agreement also contains certain restrictive covenants so long as the funds continue to hold specified amounts of warrants or beneficially own specified amounts of the outstanding shares of common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The net proceeds to the Company were $34.4 million, after deducting offering expenses payable by the Company and excluding the proceeds to the Company, if any, from the exercise of the warrants issued in the offering.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Stock Options</font> &#8211; In July 2012, the Company granted 285,000 options to its executive officers, 182,500 options to its employees and 112,500 options to its non-employee directors under the Company&#8217;s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these options of $182,000, $108,000 and $72,000, respectively, over the 48 months ending July 2016. The Company recognized $35,550 and $106,649, respectively, of stock-based compensation expense related to these options during the three and nine months ended March 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PALATIN TECHNOLOGIES, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Subsidiary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(unaudited)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Restricted Stock Units</font> &#8211; In July 2012, the Company granted 222,500 restricted stock units to its executive officers under the Company&#8217;s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these restricted stock units of $160,000 over the 24 months ending July 2014. The Company recognized $30,037 and $84,622, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>In June 2011, the Company granted 500,000 restricted stock units to its executive management under the Company&#8217;s 2011 Stock Incentive Plan. Half of these restricted stock units vested on June 22, 2012 and the remainder vests 24 months from the date of grant. The grant date fair value of these restricted stock units of $430,000 is being amortized over the 24 month vesting period of the award. The Company recognized $26,875 and $80,625, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2013 and $80,625 and $241,875, respectively, for the three and nine months ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Stock-based compensation cost for the three and nine months ended March 31, 2013 for stock options and equity-based instruments issued other than the stock options and restricted stock units described above was $57,008and $203,433, respectively, and $183,355 and $474,425, respectively, for the three and nine months ended March 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.&#160; <a name="A007"><!--EFPlaceholder--></a>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements filed as part of this report and the audited consolidated financial statements and notes thereto included in our annual report on Form 10-K for the year ended June 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Statements in this quarterly report on Form 10-Q, as well as oral statements that may be made by us or by our officers, directors, or employees acting on our behalf, that are not historical facts constitute &#8220;forward-looking statements&#8221;, which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). The forward-looking statements in this quarterly report on Form 10-Q do not constitute guarantees of future performance. Investors are cautioned that statements that are not strictly historical statements contained in this quarterly report on Form 10-Q, including, without limitation, current or future financial performance, management&#8217;s plans and objectives for future operations, ability to raise capital or repay debt, if required, clinical trials and results, uncertainties associated with product research and development, product plans and performance, management&#8217;s assessment of market factors, as well as statements regarding our strategy and plans and those of our strategic partners, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Our future operating results are subject to risks and uncertainties and are dependent upon many factors, including, without limitation, the risks identified in this report, in our annual report on Form 10-K for the year ended June 30, 2012, as amended by our quarterly report on Form 10-Q for the quarter ended September 30, 2012, and in our other Securities and Exchange Commission (SEC) filings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We expect to incur losses in the future as a result of spending on our planned development programs and losses may fluctuate significantly from quarter to quarter.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>In this quarterly report on Form 10-Q, references to &#8220;we&#8221;, &#8220;our&#8221;, &#8220;us&#8221; or &#8220;Palatin&#8221; means Palatin Technologies, Inc. and its subsidiary.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies and Estimates</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Our significant accounting policies, which are described in the notes to our consolidated financial statements included in this report and in our annual report on Form 10-K for the year ended June 30, 2012, have not changed as of March 31, 2013. We believe that our accounting policies and estimates relating to revenue recognition, accrued expenses and stock-based compensation are the most critical.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We are a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our primary product in clinical development is bremelanotide for the treatment of female sexual dysfunction (FSD). In addition, we have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The following drug development programs are actively under development:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Bremelanotide, a peptide melanocortin receptor agonist, for treatment of FSD. This drug candidate has completed a Phase 2B clinical trial and end-of-Phase 2 meeting with the U.S. Food and Drug Administration, and we have presented Phase 2B results at a medical meeting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Melanocortin receptor-based compounds for treatment of obesity, under development by AstraZeneca AB (AstraZeneca) pursuant to our research collaboration and license agreement.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PL-3994, a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of cardiovascular and pulmonary indications.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Melanocortin receptor-1 agonist peptides, for treatment of dermatologic and inflammatory disease indications.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following chart shows the status of our drug development programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Program</font></div>
</td>
<td valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indication</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Preclinical</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Phase 1</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Phase 2</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Phase 3</font></div>
</td>
</tr><tr>
<td align="left" rowspan="4" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Melanocortin Receptor Programs</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bremelanotide</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Female Sexual Dysfunction</font></div>
</td>
<td colspan="3" valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 2px solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><img src="arrow_001.jpg"></font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AstraZeneca Collaboration</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Obesity and Diabetes</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 2px solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><img src="arrow_002.jpg"></font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Next Generation Peptide</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Female Sexual Dysfunction and Erectile Dysfunction</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 2px solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><img src="arrow_002.jpg"></font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Melanocortin Receptor-1 Peptides</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dermatology and Inflammatory Disease</font></div>
</td>
<td valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-LEFT: #000000 2px solid; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><img src="arrow_002.jpg"></font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" rowspan="2" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Natriuretic Peptide Receptor Programs</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PL-3994</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cardiovascular Indications</font></div>
</td>
<td colspan="2" valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><img src="arrow_003.jpg"></font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PL-3994</font></div>
</td>
<td align="left" valign="middle" width="25%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pulmonary Indications</font></div>
</td>
<td colspan="2" valign="middle" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><img src="arrow_003.jpg"></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: #000000 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November 8, 2012, we reported positive top-line results, including achieving statistical significance for the primary endpoint and key secondary endpoints in our Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of FSD. The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder, hypoactive sexual desire disorder, or a combination of both disorders, the most common types of FSD, showed statistically significant increases in the number of satisfying sexual events, and statistically significant improvement in measures of overall sexual functioning and distress related to sexual dysfunction, for women taking bremelanotide compared to placebo. Bremelanotide was well-tolerated during the trial. The most common types of treatment-emergent adverse events reported more frequently in the bremelanotide arms were facial flushing, nausea and emesis, which were mainly mild-to-moderate in severity. Adverse events that most commonly led to discontinuation were nausea and emesis. No serious adverse events were attributable to bremelanotide during the trial.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We had an end-of-Phase 2 meeting with the FDA on bremelanotide for FSD, and reached preliminary agreement on key aspects of&#160;&#160;Phase 3 pivotal registration studies, including FSD patient population, primary and key secondary efficacy endpoints, study design, doses election and safety monitoring. In addition, the FDA agreed that the Phase 2 data adequately characterized blood pressure and heart rate signals of bremelanotide, and that standardized methods for in-clinic assessment of blood pressure would be sufficient for Phase 3.Based upon the discussions with FDA, we intend to complete protocols for the pivotal Phase 3 studies, with patient screening scheduled to start later this year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We have initiated preclinical studies with new peptide drug candidates for a number of indications, primarily dermatologic and inflammatory disease related, and are continuing preclinical development with a next generation peptide for FSD and erectile dysfunction.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Key elements of our business strategy include: using our technology and expertise to develop and commercialize innovative therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that we are developing; and, partially funding our product development programs with the cash flow generated from our license agreement with AstraZeneca and any other companies</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We incorporated in Delaware in 1986 and commenced operations in the biopharmaceutical area in 1996. Our corporate offices are located at 4B Cedar Brook Drive, Cranbury, New Jersey 08512 and our telephone number is (609) 495-2200. We maintain an Internet site at http://www.palatin.com, where among other things, we make available free of charge on and through this website our Forms 3, 4 and 5, proxy statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d), Section 14A and Section 16 of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website and the information contained in it or connected to it are not incorporated into this quarterly report on Form 10-Q.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="FONT-STYLE: italic; DISPLAY: inline">Three and Nine Months Ended March 31, 2013 Compared to the Three and Nine Months Ended March 31, 2012</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Revenue &#8211;</font>We recognized no revenue for the three months ended March 31, 2013 and $10,361 of revenue for the nine months ended March 31, 2013, compared to $23,996 and $62,705, respectively, for the three and nine months ended March 31, 2012 pursuant to our license agreement with AstraZeneca.&#160;Revenue for the three and nine months ended March 31, 2013 and 2012 consisted entirely of reimbursement of development costs and per-employee compensation, earned at the contractual rate.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Research and Development</font> &#8211; Research and development expenses were $2.9 million and $7.7 million, respectively, for the three and nine months ended March 31, 2013compared to $4.7 million and $9.7 million, respectively, for the three and nine months ended March 31, 2012. These expenses were primarily costs relating to our Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. We are currently completing protocols and preparing for initiation of pivotal Phase 3 studies of bremelanotide.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses related to our bremelanotide, PL-3994, peptide melanocortin agonist, obesity and other preclinical programs were $2.2 million and $5.8 million, respectively, for the three and nine months ended March 31, 2013 compared to $3.7 million and $6.8 million, respectively, for the three and nine months ended March 31, 2012. Spending to date has been primarily related to our Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD. The amount of such spending and the nature of future development activities are dependent on a number of factors, including primarily the availability of funds to support future development activities, success of our clinical trials and preclinical and discovery programs, and our ability to progress compounds in addition to bremelanotide and PL-3994 into human clinical trials.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amounts of project spending above exclude general research and development spending, which decreased to $0.7 million and $1.9 million, respectively, for the three and nine months ended March 31, 2013 compared to $1.0 million and $2.9 million, respectively, for the three and nine months ended March 31, 2012. The decrease is the result of reducing staffing levels and closing our research laboratory operations in connection with the lease expiration of our laboratory facilities in July 2012.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cumulative spending from inception to March 31, 2013 on our bremelanotide, NeutroSpec (a previously marketed imaging product which has been terminated) and other programs (which include PL-3994, other peptide melanocortin agonists, obesity and other discovery programs) amounts to approximately $161.3 million, $55.6 million and $60.4 million, respectively. Due to various risk factors described in our periodic filings with the SEC, including the difficulty in currently estimating the costs and timing of future Phase 1 clinical trials and larger-scale Phase 2 and Phase 3 clinical trials for any product under development, we cannot predict with reasonable certainty when, if ever, a program will advance to the next stage of development or be successfully completed, or when, if ever, net cash inflows will be generated.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">General and Administrative</font> &#8211; General and administrative expenses were $1.1 million and $3.1 million, respectively, for the three and nine months ended March 31, 2013 compared to $1.3 million and $3.5 million for the three and nine months ended March 31, 2012. These expenses mainly consist of compensation and related costs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Since inception, we have incurred net operating losses, primarily related to spending on our research and development programs. We have financed our net operating losses primarily through equity financings and amounts received under collaborative agreements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Our product candidates are at various stages of development and will require significant further research, development and testing and some may never be successfully developed or commercialized. We may experience uncertainties, delays, difficulties and expenses commonly experienced by early stage biopharmaceutical companies, which may include unanticipated problems and additional costs relating to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the development and testing of products in animals and humans;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">product approval or clearance;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">regulatory compliance;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">good manufacturing practices (GMPs);</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">intellectual property rights;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">product introduction;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">marketing, sales and competition; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 28.799pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">obtaining sufficient capital.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Failure to enter into collaboration agreements and obtain timely regulatory approval for our product candidates and indications would impact our ability to increase revenues and could make it more difficult to attract investment capital for funding our operations. Any of these possibilities could materially and adversely affect our operations and require us to curtail or cease certain programs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the nine months ended March 31, 2013, we used $8.6million of cash for our operating activities, compared to $10.1 million used in the nine months ended March 31, 2012. Lower net cash outflows from operations in the nine months ended March 31, 2013 were primarily the result of lower costs relating to our Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of FSD, in which the last patient completed treatment in September 2012 and, secondarily, from an increase in proceeds received from the sale of our New Jersey NOLs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the nine months ended March 31, 2013, net cash used in investing activities was $6.1 million, consisting of $6.0 million used for the purchase of short-term investments, $70,727 used for capital expenditures offset by $4,620 in proceeds from the sale of equipment. Net cash used in investing activities for the nine months ended March 31, 2012 of $10,300 consisted of $4,700 in proceeds from the sale of equipment offset by $15,000 used for capital expenditures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the nine months ended March 31, 2013, cash provided by financing activities of $34.4 million consisted primarily of the net proceeds from the completion on July 3, 2012 of our private placement of 3,873,000 shares of our common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of our common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of our common stock. Aggregate gross proceeds to us were $35.0 million, with net proceeds, after deducting offering expenses, of $34.4 million. During the nine months ended March 31, 2012, cash used in financing activities consisted of payments of $29,615 on capital lease obligations during the quarter.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 31, 2013, our cash, cash equivalents and short-term investments were $29.5million and our current liabilities were $2.7 million. We believe that our cash, cash equivalents and short-term investments will be adequate to fund our planned operations, including submitting complete protocols for pivotal Phase 3 studies to the FDA and initiating those studies, through at least calendar year 2013. If we delay initiation of Phase 3 clinical trial efforts with bremelanotide for FSD, we have sufficient funds for at least the next twelve months. Over the next twelve months we intend to focus efforts on preparing for and initiating our Phase 3 clinical trial with bremelanotide, conducting preclinical research on one or more peptide melanocortin agonists for sexual dysfunction and other indications, conducting preclinical research on peptide melanocortin agonists for inflammatory and dermatologic disease-related indications, and development and testing of an inhaled formulation of PL-3994.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current cash, cash equivalents and short-term investments are not sufficient to complete all of the clinical trials required for product approval for any of our products. We expect that the Phase 3 bremelanotide clinical trial program for FSD will require significant additional resources and capital. We intend to seek additional capital through public or private equity or debt financings, collaborative arrangements on our product candidates, including bremelanotide for FSD, or other sources. However, sufficient additional funding to support operations past calendar year 2013, including Phase 3 clinical trials with bremelanotide, may not be available on acceptable terms or at all. If additional funding is not available, we will curtail expenditures for Phase 3 clinical trials with bremelanotide, and may be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available, and relinquish, license or otherwise dispose of rights on unfavorable terms to technologies and product candidates that we would otherwise seek to develop or commercialize ourselves. The nature and timing of our development activities are highly dependent on our financing activities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We anticipate incurring additional losses over at least the next few years. To achieve profitability, if ever, we, alone or with others, must successfully develop and commercialize our technologies and proposed products, conduct preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and we do not know whether we will be able to achieve profitability on a sustained basis, if at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3.&#160; <a name="A008"><!--EFPlaceholder--></a>Quantitative and Qualitative Disclosures About Market Risk.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not required to be provided by smaller reporting companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 4.&#160; <a name="A009"><!--EFPlaceholder--></a>Controls and Procedures.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2013. There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A010">PART II - OTHER INFORMATION</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.&#160; <a name="A011"><!--EFPlaceholder--></a>Legal Proceedings.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>We may be involved, from time to time, in various claims and legal proceedings arising in the ordinary course of our business. We are not currently a party to any claim or legal proceeding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1A.&#160; <a name="A012"><!--EFPlaceholder--></a>Risk Factors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>There have been no material changes to our risk factors disclosed in Part I, Item 1A of our annual report on Form 10-K for the fiscal year ended June 30, 2012, other than as set forth in our quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.&#160; <a name="A013"><!--EFPlaceholder--></a>Unregistered Sales of Equity Securities and Use of Proceeds.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3.&#160; <a name="A014"><!--EFPlaceholder--></a>Defaults Upon Senior Securities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A015">Item 4.&#160;&#160;Mine Safety Disclosures.</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Not applicable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 5.&#160; <a name="A016"><!--EFPlaceholder--></a>Other Information.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>None.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 6.&#160; <a name="A017"><!--EFPlaceholder--></a>Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Exhibits filed or furnished with this report:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="81%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.1</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Executive Officer.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.2</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Financial Officer.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.2</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><a name="A018">SIGNATURES</a></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Palatin Technologies, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Carl Spana</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 13,2013</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Carl Spana, Ph.D.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer (Principal</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Executive Officer)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Stephen T. Wills</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: May 13, 2013</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stephen T. Wills, CPA, MST</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Executive Vice President, Chief Financial <br>
Officer and Chief Operating Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="A019">EXHIBIT INDEX</a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="81%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31-1.htm">31.1</a></font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31-1.htm">Certification of Chief Executive Officer.</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31-2.htm">31.2</a></font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex31-2.htm">Certification of Chief Financial Officer.</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32-1.htm">32.1</a></font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32-1.htm">Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350.</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32-2.htm">32.2</a></font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="ex32-2.htm">Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350.</a></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Instance Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">17</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<html>
<head>
    <title>ex31-1.htm</title>
    <!--Licensed to: 631@quality-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a href="ptn-10q_033113.htm">Palatin Technologies, Inc. 10-Q</a></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT 31.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certification of Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Carl Spana, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of Palatin Technologies, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;May 13, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Carl Spana</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Carl Spana, President and Chief Executive Officer</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<html>
<head>
    <title>ex31-2.htm</title>
    <!--Licensed to: 631@quality-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a href="ptn-10q_033113.htm">Palatin Technologies, Inc. 10-Q</a></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT 31.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certification of Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Stephen T. Wills, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this quarterly report on Form 10-Q of Palatin Technologies, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(c)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;May 13, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Stephen T. Wills</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stephen T. Wills, Executive Vice President, <br>
Chief Financial Officer and Chief Operating Officer</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<html>
<head>
    <title>ex32-1.htm</title>
    <!--Licensed to: 631@quality-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a href="ptn-10q_033113.htm">Palatin Technologies, Inc. 10-Q</a></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT 32.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certification of Principal Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 18 U.S.C. Section 1350</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Carl Spana, President and Chief Executive Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the quarterly report on Form 10-Q for the period ended March 31, 2013 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated: May 13, 2013</font></div>

<div align="left">&#160;</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Carl Spana</font></div>
</td>
<td align="left" valign="bottom" width="5%">&#160;</td>
<td align="left" valign="bottom" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Carl Spana, President and Chief Executive Officer<br>
(Principal Executive Officer)</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<html>
<head>
    <title>ex32-2.htm</title>
    <!--Licensed to: 631@quality-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a href="ptn-10q_033113.htm">Palatin Technologies, Inc. 10-Q</a></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT 32.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certification of Principal Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to 18 U.S.C. Section 1350</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the quarterly report on Form 10-Q for the period ended March 31, 2013 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated: May 13, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Stephen T. Wills</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stephen T. Wills, Executive Vice President,<br>
Chief Financial Officer and Chief Operating Officer<br>
</font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Financial Officer)</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>ptn-20130331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\Palatin\XBRL\20130331\ptn03312013.xfr; Date: 2013/05/13T15:11:38 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:PTN="http://palatin.com/20130331">
    <link:schemaRef xlink:href="ptn-20130331.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2009-07-01to2010-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2009-07-01</xbrli:startDate>
        <xbrli:endDate>2010-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-02to2012-07-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-02</xbrli:startDate>
        <xbrli:endDate>2012-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-02to2012-07-03_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-02</xbrli:startDate>
        <xbrli:endDate>2012-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-02to2012-07-03_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PTN:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-02</xbrli:startDate>
        <xbrli:endDate>2012-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-02to2012-07-03_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PTN:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-02</xbrli:startDate>
        <xbrli:endDate>2012-07-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2006-07-01to2007-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2006-07-01</xbrli:startDate>
        <xbrli:endDate>2007-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-07-03_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PTN:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-07-03_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PTN:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-07-31_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-07-31_EmployeesMember_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-07-31_NonEmployeeDirectorsMember_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:NonEmployeeDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-06-01to2011-06-30_ExecutiveOfficersMember_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:ExecutiveOfficersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-06-01</xbrli:startDate>
        <xbrli:endDate>2011-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-07-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31_PreferredClassBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31_PreferredClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2012-03-31_PreferredClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_MoneyMarketFundsMember_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_MoneyMarketFundsMember_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_MoneyMarketFundsMember_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_MoneyMarketFundsMember_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_USTreasurySecuritiesMember_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_MoneyMarketFundsMember_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_USTreasurySecuritiesMember_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_MoneyMarketFundsMember_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-31_USTreasurySecuritiesMember_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2012-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis">PTN:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31_OtherEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PTN:OtherEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31_OtherEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PTN:OtherEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2013-03-31_OtherEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PTN:OtherEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-01to2012-03-31_OtherEquityAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PTN:OtherEquityAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Squarefeet">
      <xbrli:measure>PTN:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPUnit">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>PTN:Unit</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">4997</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">4697</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">4997</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">4697</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">34900591</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">38947912</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">34900591</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-03-31" unitRef="Shares" decimals="INF">38947912</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityRegistrantName contextRef="From2012-07-01to2013-03-31">PALATIN TECHNOLOGIES INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2012-07-01to2013-03-31">0000911216</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2012-07-01to2013-03-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2012-07-01to2013-03-31">2013-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2012-07-01to2013-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2012-07-01to2013-03-31">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2012-07-01to2013-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2012-07-01to2013-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2012-07-01to2013-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2012-07-01to2013-03-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2012-07-01to2013-03-31">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2012-07-01to2013-03-31">2013</dei:DocumentFiscalYearFocus>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3827198</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">23537053</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">18869639</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-03-31" unitRef="USD" decimals="0">8770249</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Assets contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">5380484</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">30389335</us-gaap:Assets>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">324992</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">58337</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">4736839</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">30023978</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">532010</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">488185</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">27631</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3549586</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">2790086</us-gaap:Liabilities>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">72677</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">44764</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3457000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">2743274</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">2706496</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">1986240</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">433333</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">294894</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">733443</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">5380484</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">30389335</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1830898</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">27599249</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">-239243285</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">-255387411</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">240725127</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">282597134</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">349006</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">389479</us-gaap:CommonStockValue>
    <us-gaap:ShareBasedCompensation contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">475329</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">716300</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-03-31_StockOptionsMember" unitRef="USD" decimals="0">35550</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-07-01to2013-03-31_StockOptionsMember" unitRef="USD" decimals="0">106649</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-03-31_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">30037</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-07-01to2013-03-31_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">84622</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember" unitRef="USD" decimals="0">26875</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember" unitRef="USD" decimals="0">80625</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-07-01to2013-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember" unitRef="USD" decimals="0">80625</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-07-01to2012-03-31_RestrictedStockUnitsRSUMember_ExecutiveOfficersMember" unitRef="USD" decimals="0">241875</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-03-31_OtherEquityAwardsMember" unitRef="USD" decimals="0">57008</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-03-31_OtherEquityAwardsMember" unitRef="USD" decimals="0">1883355</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-07-01to2013-03-31_OtherEquityAwardsMember" unitRef="USD" decimals="0">203433</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-07-01to2012-03-31_OtherEquityAwardsMember" unitRef="USD" decimals="0">474425</us-gaap:ShareBasedCompensation>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">350000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2012-07-02to2012-07-03" unitRef="USD" decimals="0">34407446</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2012-07-02to2012-07-03" unitRef="Shares" decimals="INF">34500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2012-07-02to2012-07-03_CommonStockMember" unitRef="Shares" decimals="INF">3873000</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2012-07-02to2012-07-03_ClassAWarrantMember" unitRef="Shares" decimals="INF">31988151</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="From2012-07-02to2012-07-03_ClassBWarrantMember" unitRef="Shares" decimals="INF">35488380</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-07-03_ClassAWarrantMember" unitRef="USDPUnit" decimals="INF">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-07-03_ClassBWarrantMember" unitRef="USDPUnit" decimals="INF">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-07-01to2012-07-31_ExecutiveOfficersMember" unitRef="Shares" decimals="INF">285000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-07-01to2012-07-31_EmployeesMember_StockOptionMember" unitRef="Shares" decimals="INF">182500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-07-01to2012-07-31_NonEmployeeDirectorsMember_StockOptionsMember" unitRef="Shares" decimals="INF">112500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2012-07-01to2012-07-31_ExecutiveOfficersMember" unitRef="Shares" decimals="INF">222500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2011-06-01to2011-06-30_ExecutiveOfficersMember_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PTN:LicensingAgreementAstraZeneca contextRef="From2009-07-01to2010-06-30" unitRef="USD" decimals="0">5000000</PTN:LicensingAgreementAstraZeneca>
    <PTN:LicensingAgreementAstraZeneca contextRef="From2006-07-01to2007-06-30" unitRef="USD" decimals="0">10000000</PTN:LicensingAgreementAstraZeneca>
    <PTN:RevenueLicensingAgreementClinicalTrials contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">23996</PTN:RevenueLicensingAgreementClinicalTrials>
    <PTN:RevenueLicensingAgreementClinicalTrials contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">10361</PTN:RevenueLicensingAgreementClinicalTrials>
    <PTN:RevenueLicensingAgreementClinicalTrials contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">62705</PTN:RevenueLicensingAgreementClinicalTrials>
    <PTN:MilestonePaymentEligibility contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">145250000</PTN:MilestonePaymentEligibility>
    <PTN:ContingentPaymentEligibility contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">85250000</PTN:ContingentPaymentEligibility>
    <PTN:BlockerProvisionDescription contextRef="From2012-07-02to2012-07-03">The warrants are subject to a blocker provision prohibiting exercise of the warrants if the holder and its affiliates would beneficially own in excess of 9.99% of the total number of shares of common stock of the company following such exercise.</PTN:BlockerProvisionDescription>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-07-02to2012-07-03" unitRef="USD" decimals="0">35000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2012-07-02to2012-07-03" unitRef="Shares" decimals="INF">3873000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <PTN:FVOptionsGranted contextRef="From2012-07-01to2012-07-31_ExecutiveOfficersMember" unitRef="USD" decimals="0">182000</PTN:FVOptionsGranted>
    <PTN:FVOptionsGranted contextRef="From2012-07-01to2012-07-31_EmployeesMember_StockOptionMember" unitRef="USD" decimals="0">108000</PTN:FVOptionsGranted>
    <PTN:FVOptionsGranted contextRef="From2012-07-01to2012-07-31_NonEmployeeDirectorsMember_StockOptionsMember" unitRef="USD" decimals="0">72000</PTN:FVOptionsGranted>
    <PTN:FVRestrictedStockUnits contextRef="From2012-07-01to2012-07-31_ExecutiveOfficersMember" unitRef="USD" decimals="0">160000</PTN:FVRestrictedStockUnits>
    <PTN:FVRestrictedStockUnits contextRef="From2011-06-01to2011-06-30_ExecutiveOfficersMember_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">430000</PTN:FVRestrictedStockUnits>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-07-01to2013-03-31_PreferredClassAMember" unitRef="Shares" decimals="INF">27672437</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2011-07-01to2012-03-31_PreferredClassAMember" unitRef="Shares" decimals="INF">27462700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InterestPaid contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">4746</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">6650</us-gaap:InterestPaid>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">19709855</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-10099390</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">34351436</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-29615</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">34402768</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2011-07-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">34785</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2011-07-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-6064396</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-10300</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">70727</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">15000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">4620</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">4700</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-8577185</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-10059475</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <PTN:IncreaseDecreaseInUnearnedRevenues contextRef="From2012-07-01to2013-03-31" unitRef="USD" xsi:nil="true" />
    <PTN:IncreaseDecreaseInUnearnedRevenues contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-46105</PTN:IncreaseDecreaseInUnearnedRevenues>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-1181502</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">578144</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">438549</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">60994</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-660480</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">215892</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-27631</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-114549</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">82360</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">737120</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PaymentsToAcquireInvestments contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">5998289</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="From2011-07-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">50</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">47</us-gaap:PreferredStockValue>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">19909</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">2048</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">22277</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">23591</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">318653</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">307020</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ShortTermInvestments contextRef="AsOf2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShortTermInvestments contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">5998740</us-gaap:ShortTermInvestments>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-03-31" unitRef="Shares" decimals="INF">106424443</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-07-01to2013-03-31" unitRef="Shares" decimals="INF">94754789</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-03-31" unitRef="Shares" decimals="INF">34900591</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2011-07-01to2012-03-31" unitRef="Shares" decimals="INF">34900591</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2012-07-01to2013-03-31" unitRef="USDPShares" decimals="INF">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2011-07-01to2012-03-31" unitRef="USDPShares" decimals="INF">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-4015258</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-16144126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-6020702</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-11999885</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-1753208</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-1068233</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-4015258</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-17897334</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-6020702</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-13068118</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">8526</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-7032274</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">5825</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">26279</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1103</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">4746</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1830</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">6650</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">9629</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">37017</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">5955</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">28229</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-4023784</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-10865060</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-6026527</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">-13094397</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">4023784</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">10875421</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">6050523</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">13157102</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1079197</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">3141751</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1344861</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">3473990</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">2944587</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">7733670</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">4705662</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">9683112</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Revenues contextRef="From2013-01-01to2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">10361</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">23996</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">62705</us-gaap:Revenues>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2013-05-10" unitRef="Shares" decimals="INF">38947912</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;(1)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;ORGANIZATION:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Nature of Business&lt;/font&gt; &amp;#8211; Palatin Technologies, Inc. (Palatin or the Company) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin&amp;#8217;s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, pigmentation disorders and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;The Company&amp;#8217;s primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). The Company also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. The Company has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome, with drug candidates in preclinical evaluation.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;Key elements of the Company&amp;#8217;s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that the Company is developing; and partially funding its product candidate development programs with the cash flow generated from the Company&amp;#8217;s license agreements with AstraZeneca and any other companies.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Business Risk and Liquidity &lt;/font&gt;&amp;#8211; The Company has incurred negative cash flows from operations since its inception, and has expended, and expects to continue to expend in the future, substantial funds to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company has an accumulated deficit as of March 31, 2013 and incurred a net loss for the three and nine months ended March 31, 2013. The Company anticipates incurring additional losses in the future as a result of spending on its development programs. To achieve profitability, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and there can be no assurance that the Company will be able to achieve profitability on a sustained basis, if at all.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;As of March 31, 2013, the Company&amp;#8217;s cash, cash equivalents and short-term investments were $29.5million. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including its clinical trial program with bremelanotide for FSD, preclinical and clinical development of its peptide melanocortin receptor-1 program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Management believes that the Company&amp;#8217;s existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) and initiating those studies, through at least calendar year 2013. Phase 3 clinical trials of bremelanotide for FSD will require significant additional resources and capital.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Concentrations &amp;#8211;&lt;/font&gt; Concentrations in the Company&amp;#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company&amp;#8217;s cash and cash equivalents are primarily invested in one money market fund sponsored by a large financial institution and, secondarily, in U.S government securities. For the nine months ended March 31, 2013 and the three and nine months ended March 31, 2012, 100% of revenues were from AstraZeneca.&lt;/font&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;(2)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; BASIS OF PRESENTATION:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q.&amp;#160;Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary to present fairly the Company&amp;#8217;s financial position as of March 31, 2013, and its results of operations and its cash flows for the three and nine months ended March 31, 2013 and 2012. The results of operations for the three and nine months ended March 31, 2013 may not necessarily be indicative of the results of operations expected for the full year, except that the Company expects to incur a significant loss for the fiscal year ending June 30, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&amp;#8217;s annual report on Form 10-K for the year ended June 30, 2012, filed with the Securities and Exchange Commission (SEC), which includes consolidated financial statements as of June 30, 2012 and 2011 and for each of the fiscal years in the three-year period ended June 30, 2012.&lt;/font&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;(3)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Principles of Consolidation&lt;/font&gt; &amp;#8211; The consolidated financial statements include the accounts of Palatin and its wholly-owned inactive subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Use of Estimates&lt;/font&gt; &amp;#8211; The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Cash and Cash Equivalents&lt;/font&gt; &amp;#8211; Cash and cash equivalents include cash on hand, cash in banks and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consist of $19,056,321in a money market fund and $1,499,925 in U.S. government securities at March 31, 2013 and $3,344,146in a money market fund at June 30, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Investments&lt;/font&gt; &amp;#8211; The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet, based on the contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Fair Value of Financial Instruments&lt;/font&gt; &amp;#8211; The Company&amp;#8217;s financial instruments consist primarily of cash equivalents, accounts receivable, accounts payable, and capital lease obligations. Management believes that the carrying value of these assets and liabilities are representative of their respective fair values based on the short-term nature of these instruments.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Property and Equipment&lt;/font&gt; &amp;#8211; Property and equipment consists of office and laboratory equipment, office furniture and leasehold improvements and includes assets acquired under capital leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under capital leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Impairment of Long-Lived Assets&lt;/font&gt; &amp;#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 20pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&amp;#160; &lt;font style="font: 10pt Times New Roman"&gt;&lt;i&gt;Deferred&#13;Rent &lt;/i&gt;&amp;#8211;&lt;i&gt;&amp;#160;&lt;/i&gt;The Company&amp;#8217;s operating leases provide for rent increases over the terms of the leases.&#13;Deferred rent consists of the difference between periodic rent payments and the amount recognized as rent expense on a&#13;straight-line basis, as well as tenant allowances for leasehold improvements. Rent expenses are being recognized ratably over&#13;the terms of the leases.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Revenue Recognition &lt;/font&gt;&amp;#8211; Revenue from corporate collaborations and licensing agreements consists of up-front fees, research and development funding, and milestone payments. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. The Company estimates the performance period as the period in which it performs certain development activities under the applicable agreement. Reimbursements for research and development activities are recorded in the period that the Company performs the related activities under the terms of the applicable agreements. Revenue resulting from the achievement of milestone events stipulated in the applicable agreements is recognized when the milestone is achieved, provided that such milestone is substantive in nature. Revenue from grants is recognized as the Company provides the services stipulated in the underlying grants based on the time and materials incurred.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Research and Development Costs&lt;/font&gt; &amp;#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Stock-Based Compensation &amp;#8211;&lt;/font&gt; The Company charges to expense the fair value of stock options and other equity awards granted. The Company determines the value of stock options utilizing the Black-Scholes option pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Income Taxes&lt;/font&gt; &amp;#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;During the nine months ended March 31, 2013 and 2012, the Company sold New Jersey state net operating loss (NJ NOL)carryforwards, which resulted in the recognition of $1,753,208 and $1,068,233, respectively, in tax benefits.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Net Loss per Common Share &lt;/font&gt;&amp;#8211; Basic and diluted earnings per common share (EPS) are calculated in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 260, &amp;#8220;Earnings per Share,&amp;#8221; which includes guidance pertaining to the warrants, issued in connection with the July 3, 2012 private placement offering, that are exercisable for nominal consideration and, therefore, are to be considered in the computation of basic and diluted net loss per common share. The Series A 2012 warrants to purchase up to 31,988,151 shares of common stock are exercisable starting at July 3, 2012 and, therefore, are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 3, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Series B 2012 warrants to purchase up to 35,488,380 shares of common stock were considered contingently issuable shares and were not included in computing basic net loss per common share until the Company received stockholder approval for the increase in authorized underlying common stock on September 27, 2012 (see note 6). For diluted EPS, contingently issuable shares are to be included in the calculation as of the beginning of the period in which the conditions were satisfied, unless the effect would be anti-dilutive. The Series B 2012 warrants have been excluded from the calculation of diluted net loss per common share during the period from July 3, 2012 until September 27, 2012 as the impact would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;As of March 31, 2013 and 2012, common shares issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the warrants issued in connection with the July 3, 2013 private placement offering), and the vesting of restricted stock units amounted to an aggregate of 27,672,437 and 27,462,700shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:LongTermContractsOrProgramsDisclosureTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="display: inline; font-weight: bold"&gt;(4)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; AGREEMENT WITH ASTRAZENECA:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;In January 2007, the Company entered into an exclusive global research collaboration and license agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. In June 2008, the license agreement was amended to include additional compounds and associated intellectual property developed by the Company. In December 2008, the license agreement was further amended to include additional compounds and associated intellectual property developed by the Company and extended the research collaboration for an additional year through January 2010. In September 2009, the license agreement was further amended to modify royalty rates and milestone payments. The collaboration is based on the Company&amp;#8217;s melanocortin receptor obesity program and includes access to compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development. As part of the September 2009 amendment to the research collaboration and license agreement, the Company agreed to conduct additional studies on the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;In December 2009 and 2008, the Company also entered into clinical trial sponsored research agreements with AstraZeneca, under which the Company agreed to conduct studies of the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters. Under the terms of these clinical trial agreements, AstraZeneca paid $5,000,000 as of March 31, 2009 upon achieving certain objectives and paid all costs associated with these studies. The Company recognized $10,361 as revenue in the nine months ended March 31, 2013 and $23,996 and $62,705, respectively, as revenue in the three and nine months ended March 31, 2012 under these clinical trial sponsored research agreements.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Company received an up-front payment of $10,000,000 from AstraZeneca on execution of the research collaboration and license agreement. Under the September 2009 amendment the Company was paid an additional $5,000,000 in consideration of reduction of future milestones and royalties and providing specific materials to AstraZeneca. The Company is now eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets. In addition, the Company is eligible to receive mid to high single digit royalties on sales of any approved products. AstraZeneca assumed responsibility for product commercialization, product discovery and development costs, with both companies contributing scientific expertise in the research collaboration. The Company provided research services to AstraZeneca through January 2010, the expiration of the research collaboration portion of the research collaboration and license agreement, at a contractual rate per full-time-equivalent employee.&lt;/font&gt;&lt;/div&gt;</us-gaap:LongTermContractsOrProgramsDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;(5)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; FAIR VALUE MEASUREMENTS:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman"&gt;The&#13;fair value of cash equivalents and short-term investments are classified using a hierarchy prioritized based on inputs. Level&#13;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices&#13;for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly&#13;or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable&#13;inputs based on management&amp;#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset or&#13;liability&amp;#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the&#13;fair value measurement.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;The following table provides the assets carried at fair value:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total carrying value as of March 31, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Quoted prices in &lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;active markets &lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other quoted/observable inputs&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Significant unobservable inputs&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;March 31, 2013:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Money Market Fund&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;19,056,321&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;19,056,321&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;U.S. government securities&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7,498,665&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7,496,925&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,554,986&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,553,246&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30, 2012:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Money Market Fund&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,344,146&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,344,146&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;(6)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; STOCKHOLDERS&amp;#8217; EQUITY:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Common Stock Transactions&lt;/font&gt; &amp;#8211;&lt;font style="font-style: italic; display: inline"&gt;&amp;#160;&lt;/font&gt;On July 3, 2012, the Company closed on a private placement offering in which the Company sold, for aggregate proceeds of $35.0 million, 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of common stock. These warrants are exercisable at an exercise price of $0.01 per share, and expire ten years from the date of issuance. The holders may exercise the warrants on a cashless basis. The warrants are subject to a blocker provision prohibiting exercise of the warrants if the holder and its affiliates would beneficially own in excess of 9.99% of the total number of shares of common stock of the Company following such exercise (as may be adjusted to the extent set forth in the warrant). The warrants also provide that in the event of a Company Controlled Fundamental Transaction (as defined in the warrants), the Company may, at the election of the warrant holder, be required to redeem all or a portion of the warrants at an amount tied to the greater of the then market price of the Company&amp;#8217;s common stock or the amount per share paid to any other person.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Because there were not sufficient authorized shares to cover all the outstanding Series B 2012 warrants in the private placement offering as of closing, under ASC 815, &amp;#8220;Derivatives and Hedging,&amp;#8221; the portion of the warrants above the then authorized level of common stock was required to be classified as a liability and carried at fair value on the Company&amp;#8217;s balance sheet. The fair value was calculated by multiplying the number of shares underlying the Series B 2012 warrants above the then authorized level of the Company&amp;#8217;s common stock by the closing price of its common stock less the exercise price of $0.01 per share.&lt;font style="display: inline; font-family: Times New Roman"&gt; The warrants were liability classified through September 27, 2012,&lt;/font&gt;at which time the then fair value of the warrant liability was reclassified into stockholders&amp;#8217; equity upon stockholder approval of the increase in authorized common stock. The increase in fair value, as a result of the Company&amp;#8217;s common stock increasing from $0.50 per share at date of issuance to $0.71 per share upon shareholder approval, of $7,069,165 has been recorded as a non-operating expense for the nine months ended March 31, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;The purchase agreement for the private placement provides that the purchasers, funds under the management of QVT Financial LP, have certain rights until July 3, 2018, including rights of first refusal and participation in any subsequent equity or debt financing, provided that the funds own at least 20% of the outstanding common stock of the Company calculated as if warrants held by the funds were exercised. The purchase agreement also contains certain restrictive covenants so long as the funds continue to hold specified amounts of warrants or beneficially own specified amounts of the outstanding shares of common stock.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;The net proceeds to the Company were $34.4 million, after deducting offering expenses payable by the Company and excluding the proceeds to the Company, if any, from the exercise of the warrants issued in the offering.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman"&gt;&lt;i&gt;Stock&#13;Options&lt;/i&gt; &amp;#8211; In July 2012, the Company granted 285,000 options to its executive officers, 182,500 options to its employees&#13;and 112,500 options to its non-employee directors under the Company&amp;#8217;s 2011 Stock Incentive Plan. The Company is amortizing&#13;the fair value of these options of $182,000, $108,000 and $72,000, respectively, over the 48 months ending July 2016. The Company&#13;recognized $35,550 and $106,649, respectively, of stock-based compensation expense related to these options during the three and&#13;nine months ended March 31, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;br /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: bold 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Restricted Stock Units&lt;/font&gt; &amp;#8211; In July 2012, the Company granted 222,500 restricted stock units to its executive officers under the Company&amp;#8217;s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these restricted stock units of $160,000 over the 24 months ending July 2014. The Company recognized $30,037 and $84,622, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2013.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;In June 2011, the Company granted 500,000 restricted stock units to its executive management under the Company&amp;#8217;s 2011 Stock Incentive Plan. Half of these restricted stock units vested on June 22, 2012 and the remainder vests 24 months from the date of grant. The grant date fair value of these restricted stock units of $430,000 is being amortized over the 24 month vesting period of the award. The Company recognized $26,875 and $80,625, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2013 and $80,625 and $241,875, respectively, for the three and nine months ended March 31, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;Stock-based compensation cost for the three and nine months ended March 31, 2013 for stock options and equity-based instruments issued other than the stock options and restricted stock units described above was $57,008and $203,433, respectively, and $183,355 and $474,425, respectively, for the three and nine months ended March 31, 2012.&lt;/font&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Nature of Business&lt;/font&gt; &amp;#8211; Palatin Technologies, Inc. (Palatin or the Company) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin&amp;#8217;s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, pigmentation disorders and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;The Company&amp;#8217;s primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). The Company also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. The Company has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome, with drug candidates in preclinical evaluation.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;Key elements of the Company&amp;#8217;s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that the Company is developing; and partially funding its product candidate development programs with the cash flow generated from the Company&amp;#8217;s license agreements with AstraZeneca and any other companies.&lt;/font&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:LiquidityDisclosureTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Business Risk and Liquidity &lt;/font&gt;&amp;#8211; The Company has incurred negative cash flows from operations since its inception, and has expended, and expects to continue to expend in the future, substantial funds to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company has an accumulated deficit as of March 31, 2013 and incurred a net loss for the three and nine months ended March 31, 2013. The Company anticipates incurring additional losses in the future as a result of spending on its development programs. To achieve profitability, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and there can be no assurance that the Company will be able to achieve profitability on a sustained basis, if at all.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="margin-left: 36pt"&gt;&lt;/font&gt;As of March 31, 2013, the Company&amp;#8217;s cash, cash equivalents and short-term investments were $29.5million. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including its clinical trial program with bremelanotide for FSD, preclinical and clinical development of its peptide melanocortin receptor-1 program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;Management believes that the Company&amp;#8217;s existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) and initiating those studies, through at least calendar year 2013. Phase 3 clinical trials of bremelanotide for FSD will require significant additional resources and capital.&lt;/font&gt;&lt;/div&gt;</us-gaap:LiquidityDisclosureTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Concentrations &amp;#8211;&lt;/font&gt; Concentrations in the Company&amp;#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company&amp;#8217;s cash and cash equivalents are primarily invested in one money market fund sponsored by a large financial institution and, secondarily, in U.S government securities. For the nine months ended March 31, 2013 and the three and nine months ended March 31, 2012, 100% of revenues were from AstraZeneca.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Principles of Consolidation&lt;/font&gt; &amp;#8211; The consolidated financial statements include the accounts of Palatin and its wholly-owned inactive subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2012-07-01to2013-03-31">&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Use of Estimates&lt;/font&gt; &amp;#8211; The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Cash and Cash Equivalents&lt;/font&gt; &amp;#8211; Cash and cash equivalents include cash on hand, cash in banks and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consist of $19,056,321in a money market fund and $1,499,925 in U.S. government securities at March 31, 2013 and $3,344,146in a money market fund at June 30, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Investments&lt;/font&gt; &amp;#8211; The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet, based on the contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&amp;#8217; equity.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2012-07-01to2013-03-31">&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Fair Value of Financial Instruments&lt;/font&gt; &amp;#8211; The Company&amp;#8217;s financial instruments consist primarily of cash equivalents, accounts receivable, accounts payable, and capital lease obligations. Management believes that the carrying value of these assets and liabilities are representative of their respective fair values based on the short-term nature of these instruments.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Property and Equipment&lt;/font&gt; &amp;#8211; Property and equipment consists of office and laboratory equipment, office furniture and leasehold improvements and includes assets acquired under capital leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under capital leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Impairment of Long-Lived Assets&lt;/font&gt; &amp;#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DeferredRevenueDisclosureTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Deferred Rent &lt;/font&gt;&amp;#8211;&lt;font style="font-style: italic; display: inline"&gt;&amp;#160;&lt;/font&gt;The Company&amp;#8217;s operating leases provide for rent increases over the terms of the leases. Deferred rent consists of the difference between periodic rent payments and the amount recognized as rent expense on a straight-line basis, as well as tenant allowances for leasehold improvements. Rent expenses are being recognized ratably over the terms of the leases.&lt;/font&gt;&lt;/div&gt;</us-gaap:DeferredRevenueDisclosureTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Revenue Recognition &lt;/font&gt;&amp;#8211; Revenue from corporate collaborations and licensing agreements consists of up-front fees, research and development funding, and milestone payments. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. The Company estimates the performance period as the period in which it performs certain development activities under the applicable agreement. Reimbursements for research and development activities are recorded in the period that the Company performs the related activities under the terms of the applicable agreements. Revenue resulting from the achievement of milestone events stipulated in the applicable agreements is recognized when the milestone is achieved, provided that such milestone is substantive in nature. Revenue from grants is recognized as the Company provides the services stipulated in the underlying grants based on the time and materials incurred.&lt;/font&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Research and Development Costs&lt;/font&gt; &amp;#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;&lt;font style="font-style: italic; display: inline"&gt;Stock-Based Compensation &amp;#8211;&lt;/font&gt; The Company charges to expense the fair value of stock options and other equity awards granted. The Company determines the value of stock options utilizing the Black-Scholes option pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.&lt;/font&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Income Taxes&lt;/font&gt; &amp;#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;During the nine months ended March 31, 2013 and 2012, the Company sold New Jersey state net operating loss (NJ NOL)carryforwards, which resulted in the recognition of $1,753,208 and $1,068,233, respectively, in tax benefits.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font style="font-style: italic; display: inline"&gt;Net Loss per Common Share &lt;/font&gt;&amp;#8211; Basic and diluted earnings per common share (EPS) are calculated in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 260, &amp;#8220;Earnings per Share,&amp;#8221; which includes guidance pertaining to the warrants, issued in connection with the July 3, 2012 private placement offering, that are exercisable for nominal consideration and, therefore, are to be considered in the computation of basic and diluted net loss per common share. The Series A 2012 warrants to purchase up to 31,988,151 shares of common stock are exercisable starting at July 3, 2012 and, therefore, are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 3, 2012.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The Series B 2012 warrants to purchase up to 35,488,380 shares of common stock were considered contingently issuable shares and were not included in computing basic net loss per common share until the Company received stockholder approval for the increase in authorized underlying common stock on September 27, 2012 (see note 6). For diluted EPS, contingently issuable shares are to be included in the calculation as of the beginning of the period in which the conditions were satisfied, unless the effect would be anti-dilutive. The Series B 2012 warrants have been excluded from the calculation of diluted net loss per common share during the period from July 3, 2012 until September 27, 2012 as the impact would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;&lt;font id="TAB1" style="margin-left: 36pt"&gt;&lt;/font&gt;As of March 31, 2013 and 2012, common shares issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the warrants issued in connection with the July 3, 2013 private placement offering), and the vesting of restricted stock units amounted to an aggregate of 27,672,437 and 27,462,700shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2012-07-01to2013-03-31">&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt Times New Roman"&gt;The following table provides the assets carried at fair value:&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block"&gt;&lt;br /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&#13;&lt;div style="text-align: left"&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total carrying value as of March 31, 2013&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Quoted prices in &lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;active markets &lt;br /&gt;&#13;&lt;/font&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Other quoted/observable inputs&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Significant unobservable inputs&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;March 31, 2013:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: left; vertical-align: bottom"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Money Market Fund&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;19,056,321&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;19,056,321&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 2px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;U.S. government securities&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7,498,665&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;7,496,925&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Total&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,554,986&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;26,553,246&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="vertical-align: bottom; width: 36%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: white"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;June 30, 2012:&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;tr style="background-color: #cceeff"&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px"&gt;&#13;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;Money Market Fund&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,344,146&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;3,344,146&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"&gt;&lt;font style="display: inline; font: 10pt times new roman"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">29535793</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2013-01-01to2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">4620</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1700</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">4700</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2013-01-01to2013-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">-7069165</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2012-01-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="From2011-07-01to2012-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">16547</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2011-07-01to2012-03-31" unitRef="USD" decimals="0">29615</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-03-31" unitRef="percent" decimals="INF">1.00</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-07-01to2013-03-31" unitRef="percent" decimals="INF">1.00</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2013-03-31_MoneyMarketFundsMember" unitRef="USD" decimals="0">19056321</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2012-06-30_MoneyMarketFundsMember" unitRef="USD" decimals="0">3344146</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2013-03-31_USTreasurySecuritiesMember" unitRef="USD" decimals="0">1499925</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1753208</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">1068233</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares contextRef="From2012-07-01to2013-03-31_PreferredClassBMember" unitRef="Shares" decimals="INF">35488380</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares contextRef="From2012-07-01to2013-03-31_PreferredClassAMember" unitRef="Shares" decimals="INF">31988151</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31" unitRef="USD" decimals="0">26554986</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_FairValueInputsLevel1Member" unitRef="USD" decimals="0">26553246</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_MoneyMarketFundsMember" unitRef="USD" decimals="0">19056321</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2012-06-30_MoneyMarketFundsMember" unitRef="USD" decimals="0">3344146</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_USTreasurySecuritiesMember" unitRef="USD" decimals="0">7498665</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_MoneyMarketFundsMember_FairValueInputsLevel1Member" unitRef="USD" decimals="0">19056321</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2012-06-30_MoneyMarketFundsMember_FairValueInputsLevel1Member" unitRef="USD" decimals="0">3344146</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2012-06-30_MoneyMarketFundsMember_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2012-06-30_MoneyMarketFundsMember_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_USTreasurySecuritiesMember_FairValueInputsLevel1Member" unitRef="USD" decimals="0">7496925</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_MoneyMarketFundsMember_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_USTreasurySecuritiesMember_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_MoneyMarketFundsMember_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="AsOf2013-03-31_USTreasurySecuritiesMember_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharePrice contextRef="AsOf2013-03-31" unitRef="USDPShares" decimals="INF">0.71</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2012-07-03" unitRef="USDPShares" decimals="INF">0.50</us-gaap:SharePrice>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="From2012-07-01to2013-03-31" unitRef="USD" decimals="0">451</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="From2011-07-01to2012-03-31" unitRef="USD" xsi:nil="true" />
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ptn-20130331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\Palatin\XBRL\20130331\ptn03312013.xfr; Date: 2013/05/13T15:11:38 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aIps7xRiXgen8uHY31MOa+C+bOdwZ56eZlBvGV8bRm6ryMo94b6Oy00Qfo2EYAM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:PTN="http://palatin.com/20130331" elementFormDefault="qualified" targetNamespace="http://palatin.com/20130331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://palatin.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>0001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/BalanceSheetsUnuadited" id="BalanceSheetsUnuadited">
	  <link:definition>0002 - Statement - Consolidated Balance Sheets (Unuadited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" id="BalanceSheetsUnuaditedParenthetical">
	  <link:definition>0003 - Statement - Consolidated Balance Sheets (Unuadited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>0004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>0005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/Organization" id="Organization">
	  <link:definition>0006 - Disclosure - ORGANIZATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>0007 - Disclosure - BASIS OF PRESENTATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>0008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/AgreementWithAstrazeneca" id="AgreementWithAstrazeneca">
	  <link:definition>0009 - Disclosure - AGREEMENT WITH ASTRAZENECA</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>0010 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>0011 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/OrganizationPolicies" id="OrganizationPolicies">
	  <link:definition>0012 - Disclosure - ORGANIZATION (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>0013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>0014 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/OrganizationDetailsNarrative" id="OrganizationDetailsNarrative">
	  <link:definition>0015 - Disclosure - ORGANIZATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>0016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" id="AgreementWithAstrazenecaDetailsNarrative">
	  <link:definition>0017 - Disclosure - AGREEMENT WITH ASTRAZENECA (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
	  <link:definition>0018 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://palatin.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>0019 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ptn-20130331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptn-20130331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptn-20130331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ptn-20130331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="PTN_ClassAWarrantMember" name="ClassAWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_ClassBWarrantMember" name="ClassBWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_OtherEquityAwardsMember" name="OtherEquityAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_IncreaseDecreaseInUnearnedRevenues" name="IncreaseDecreaseInUnearnedRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_AgreementWithAstrazenecaAbstract" name="AgreementWithAstrazenecaAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_OrganizationPoliciesAbstract" name="OrganizationPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_FairValueMeasurementsTablesAbstract" name="FairValueMeasurementsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_OrganizationDetailsNarrativeAbstract" name="OrganizationDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" name="SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract" name="AgreementWithAstrazenecaDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_LicensingAgreementAstraZeneca" name="LicensingAgreementAstraZeneca" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_RevenueLicensingAgreementClinicalTrials" name="RevenueLicensingAgreementClinicalTrials" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_MilestonePaymentEligibility" name="MilestonePaymentEligibility" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_ContingentPaymentEligibility" name="ContingentPaymentEligibility" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_FairValueMeasurementsDetailsAbstract" name="FairValueMeasurementsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_StockholdersEquityDetailsNarrativeAbstract" name="StockholdersEquityDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_BlockerProvisionDescription" name="BlockerProvisionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_FVOptionsGranted" name="FVOptionsGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PTN_FVRestrictedStockUnits" name="FVRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ptn-20130331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\Palatin\XBRL\20130331\ptn03312013.xfr; Date: 2013/05/13T15:11:38 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://palatin.com/role/DocumentAndEntityInformation" xlink:href="ptn-20130331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BalanceSheetsUnuadited" xlink:href="ptn-20130331.xsd#BalanceSheetsUnuadited" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" xlink:href="ptn-20130331.xsd#BalanceSheetsUnuaditedParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StatementsOfOperations" xlink:href="ptn-20130331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StatementsOfCashFlows" xlink:href="ptn-20130331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/Organization" xlink:href="ptn-20130331.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BasisOfPresentation" xlink:href="ptn-20130331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/AgreementWithAstrazeneca" xlink:href="ptn-20130331.xsd#AgreementWithAstrazeneca" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurements" xlink:href="ptn-20130331.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StockholdersEquity" xlink:href="ptn-20130331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/OrganizationPolicies" xlink:href="ptn-20130331.xsd#OrganizationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurementsTables" xlink:href="ptn-20130331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20130331.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" xlink:href="ptn-20130331.xsd#AgreementWithAstrazenecaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20130331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StockholdersEquityDetailsNarrative" xlink:href="ptn-20130331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/BalanceSheetsUnuadited" xlink:title="0002 - Statement - Consolidated Balance Sheets (Unuadited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_PTNAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_PTNCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssetsCurrent" xlink:to="loc_PTNCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_PTNShortTermInvestments" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssetsCurrent" xlink:to="loc_PTNShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_PTNAccountsReceivableGrossCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssetsCurrent" xlink:to="loc_PTNAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_PTNRestrictedCashAndCashEquivalents" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssetsCurrent" xlink:to="loc_PTNRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PTNPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssetsCurrent" xlink:to="loc_PTNPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_PTNAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssets" xlink:to="loc_PTNAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PTNPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssets" xlink:to="loc_PTNPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_PTNOtherAssetsNoncurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNAssets" xlink:to="loc_PTNOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_PTNLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_PTNCapitalLeaseObligationsCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilitiesCurrent" xlink:to="loc_PTNCapitalLeaseObligationsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_PTNAccountsPayableCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilitiesCurrent" xlink:to="loc_PTNAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_PTNEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilitiesCurrent" xlink:to="loc_PTNEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_PTNAccruedLiabilitiesCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilitiesCurrent" xlink:to="loc_PTNAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_PTNLiabilities" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilities" xlink:to="loc_PTNLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_PTNCapitalLeaseObligationsNoncurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilities" xlink:to="loc_PTNCapitalLeaseObligationsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_PTNDeferredRentCreditNoncurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilities" xlink:to="loc_PTNDeferredRentCreditNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_PTNStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PTNPreferredStockValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNStockholdersEquity" xlink:to="loc_PTNPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_PTNCommonStockValue" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNStockholdersEquity" xlink:to="loc_PTNCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_PTNAdditionalPaidInCapital" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNStockholdersEquity" xlink:to="loc_PTNAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_PTNRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNStockholdersEquity" xlink:to="loc_PTNRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_PTNLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilitiesAndStockholdersEquity" xlink:to="loc_PTNLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNLiabilitiesAndStockholdersEquity" xlink:to="loc_PTNStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" xlink:title="0003 - Statement - Consolidated Balance Sheets (Unuadited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/StatementsOfOperations" xlink:title="0004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_PTNOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_PTNResearchAndDevelopmentExpense" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNOperatingExpenses" xlink:to="loc_PTNResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_PTNGeneralAndAdministrativeExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNOperatingExpenses" xlink:to="loc_PTNGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_PTNOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="loc_PTNRevenues" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNOperatingIncomeLoss" xlink:to="loc_PTNRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNOperatingIncomeLoss" xlink:to="loc_PTNOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_PTNNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_PTNInvestmentIncomeInterest" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNonoperatingIncomeExpense" xlink:to="loc_PTNInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_PTNInterestExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNonoperatingIncomeExpense" xlink:to="loc_PTNInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_PTNLiabilitiesFairValueAdjustment" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNonoperatingIncomeExpense" xlink:to="loc_PTNLiabilitiesFairValueAdjustment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNonoperatingIncomeExpense" xlink:to="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_PTNIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="loc_PTNOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="loc_PTNNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_PTNNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetIncomeLoss" xlink:to="loc_PTNIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_PTNIncomeTaxExpenseBenefit" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetIncomeLoss" xlink:to="loc_PTNIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/StatementsOfCashFlows" xlink:title="0005 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_PTNNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_PTNNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_PTNDepreciationDepletionAndAmortization" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_PTNAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_PTNShareBasedCompensation" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_PTNLiabilitiesFairValueAdjustment" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNLiabilitiesFairValueAdjustment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_PTNIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_PTNIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_PTNIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_PTNIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_IncreaseDecreaseInUnearnedRevenues" xlink:label="loc_PTNIncreaseDecreaseInUnearnedRevenues" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PTNIncreaseDecreaseInUnearnedRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_PTNNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_PTNProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PTNProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PTNPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PTNPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_PTNPaymentsToAcquireInvestments" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PTNPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_PTNNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_PTNRepaymentsOfLongTermCapitalLeaseObligations" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PTNRepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_PTNPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PTNPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_PTNProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PTNProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_PTNCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_PTNNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PTNCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_PTNNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/Organization" xlink:title="0006 - Disclosure - ORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/BasisOfPresentation" xlink:title="0007 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/AgreementWithAstrazeneca" xlink:title="0009 - Disclosure - AGREEMENT WITH ASTRAZENECA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurements" xlink:title="0010 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/StockholdersEquity" xlink:title="0011 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/OrganizationPolicies" xlink:title="0012 - Disclosure - ORGANIZATION (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurementsTables" xlink:title="0014 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/OrganizationDetailsNarrative" xlink:title="0015 - Disclosure - ORGANIZATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="0016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" xlink:title="0017 - Disclosure - AGREEMENT WITH ASTRAZENECA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurementsDetails" xlink:title="0018 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://palatin.com/role/StockholdersEquityDetailsNarrative" xlink:title="0019 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ptn-20130331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\Palatin\XBRL\20130331\ptn03312013.xfr; Date: 2013/05/13T15:11:38 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://palatin.com/role/DocumentAndEntityInformation" xlink:href="ptn-20130331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BalanceSheetsUnuadited" xlink:href="ptn-20130331.xsd#BalanceSheetsUnuadited" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" xlink:href="ptn-20130331.xsd#BalanceSheetsUnuaditedParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StatementsOfOperations" xlink:href="ptn-20130331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StatementsOfCashFlows" xlink:href="ptn-20130331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/Organization" xlink:href="ptn-20130331.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BasisOfPresentation" xlink:href="ptn-20130331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/AgreementWithAstrazeneca" xlink:href="ptn-20130331.xsd#AgreementWithAstrazeneca" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurements" xlink:href="ptn-20130331.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StockholdersEquity" xlink:href="ptn-20130331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/OrganizationPolicies" xlink:href="ptn-20130331.xsd#OrganizationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurementsTables" xlink:href="ptn-20130331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20130331.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" xlink:href="ptn-20130331.xsd#AgreementWithAstrazenecaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20130331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StockholdersEquityDetailsNarrative" xlink:href="ptn-20130331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/BalanceSheetsUnuadited" xlink:title="0002 - Statement - Consolidated Balance Sheets (Unuadited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" xlink:title="0003 - Statement - Consolidated Balance Sheets (Unuadited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/StatementsOfOperations" xlink:title="0004 - Statement - Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/StatementsOfCashFlows" xlink:title="0005 - Statement - Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/Organization" xlink:title="0006 - Disclosure - ORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/BasisOfPresentation" xlink:title="0007 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/AgreementWithAstrazeneca" xlink:title="0009 - Disclosure - AGREEMENT WITH ASTRAZENECA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurements" xlink:title="0010 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/StockholdersEquity" xlink:title="0011 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/OrganizationPolicies" xlink:title="0012 - Disclosure - ORGANIZATION (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurementsTables" xlink:title="0014 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/OrganizationDetailsNarrative" xlink:title="0015 - Disclosure - ORGANIZATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="0016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_PTNStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_PTNStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_PTNCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNCashAndCashEquivalentsAxis" xlink:to="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNCashAndCashEquivalentsAxis" xlink:to="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_PTNMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_PTNUSTreasurySecuritiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNUSTreasurySecuritiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_PTNStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_PTNEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNStatementEquityComponentsAxis" xlink:to="loc_PTNEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_PTNEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNStatementEquityComponentsAxis" xlink:to="loc_PTNEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_PTNPreferredClassAMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNPreferredClassAMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="loc_PTNPreferredClassBMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNPreferredClassBMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_PTNCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_PTNIncomeTaxReconciliationOtherAdjustments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNIncomeTaxReconciliationOtherAdjustments_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="loc_PTNIncrementalCommonSharesAttributableToContingentlyIssuableShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNIncrementalCommonSharesAttributableToContingentlyIssuableShares_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_PTNAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" xlink:title="0017 - Disclosure - AGREEMENT WITH ASTRAZENECA (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurementsDetails" xlink:title="0018 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_PTNStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_PTNStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_PTNCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNCashAndCashEquivalentsAxis" xlink:to="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNCashAndCashEquivalentsAxis" xlink:to="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_PTNMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_PTNUSTreasurySecuritiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNUSTreasurySecuritiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_PTNFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_PTNFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_PTNFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_PTNFairValueInputsLevel1Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_PTNFairValueInputsLevel1Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_PTNFairValueInputsLevel2Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_PTNFairValueInputsLevel2Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_PTNFairValueInputsLevel3Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_PTNFairValueInputsLevel3Member_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_PTNCashAndCashEquivalentsFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNCashAndCashEquivalentsFairValueDisclosure_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://palatin.com/role/StockholdersEquityDetailsNarrative" xlink:title="0019 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_PTNStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_PTNStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_PTNAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNAwardTypeAxis" xlink:to="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNAwardTypeAxis" xlink:to="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_PTNStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNStockOptionMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="loc_PTNStockOptionsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNStockOptionsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_PTNRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OtherEquityAwardsMember" xlink:label="loc_PTNOtherEquityAwardsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNOtherEquityAwardsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_PTNStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_PTNEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNStatementEquityComponentsAxis" xlink:to="loc_PTNEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_PTNEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNStatementEquityComponentsAxis" xlink:to="loc_PTNEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_PTNCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ClassAWarrantMember" xlink:label="loc_PTNClassAWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNClassAWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ClassBWarrantMember" xlink:label="loc_PTNClassBWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNClassBWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ExecutiveOfficersMember" xlink:label="loc_PTNExecutiveOfficersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PTNExecutiveOfficersMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_EmployeesMember" xlink:label="loc_PTNEmployeesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PTNEmployeesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_NonEmployeeDirectorsMember" xlink:label="loc_PTNNonEmployeeDirectorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PTNNonEmployeeDirectorsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_PTNStockIssuedDuringPeriodValueNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodValueNewIssues_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_PTNStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_PTNStockIssuedDuringPeriodSharesIssuedForCash_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodSharesIssuedForCash_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_PTNStockIssuedDuringPeriodValueIssuedForCash_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodValueIssuedForCash_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_PTNClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_BlockerProvisionDescription" xlink:label="loc_PTNBlockerProvisionDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNBlockerProvisionDescription_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_PTNLiabilitiesFairValueAdjustment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNLiabilitiesFairValueAdjustment_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_PTNSharePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNSharePrice_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FVOptionsGranted" xlink:label="loc_PTNFVOptionsGranted_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNFVOptionsGranted_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FVRestrictedStockUnits" xlink:label="loc_PTNFVRestrictedStockUnits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNFVRestrictedStockUnits_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_PTNShareBasedCompensation_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNShareBasedCompensation_220" xlink:type="arc" order="13" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ptn-20130331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\Palatin\XBRL\20130331\ptn03312013.xfr; Date: 2013/05/13T15:11:38 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Quoted prices in active markets (Level 1)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Other quoted/observable inputs (Level 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ClassAWarrantMember" xlink:label="PTN_ClassAWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ClassAWarrantMember" xlink:to="PTN_ClassAWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_ClassAWarrantMember_lbl" xml:lang="en-US">Series A 2012 Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ClassBWarrantMember" xlink:label="PTN_ClassBWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ClassBWarrantMember" xlink:to="PTN_ClassBWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_ClassBWarrantMember_lbl" xml:lang="en-US">Series B 2012 Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ExecutiveOfficersMember" xlink:label="PTN_ExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ExecutiveOfficersMember" xlink:to="PTN_ExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_ExecutiveOfficersMember_lbl" xml:lang="en-US">Executive Officers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_EmployeesMember" xlink:label="PTN_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_EmployeesMember" xlink:to="PTN_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_EmployeesMember_lbl" xml:lang="en-US">Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_NonEmployeeDirectorsMember" xlink:label="PTN_NonEmployeeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_NonEmployeeDirectorsMember" xlink:to="PTN_NonEmployeeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-Employee Directors</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="us-gaap_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionsMember" xlink:to="us-gaap_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionsMember_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassBMember_lbl" xml:lang="en-US">Preferred Convertible Class B</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassAMember_lbl" xml:lang="en-US">Preferred Convertible Class A</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Government Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OtherEquityAwardsMember" xlink:label="PTN_OtherEquityAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_OtherEquityAwardsMember" xlink:to="PTN_OtherEquityAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_OtherEquityAwardsMember_lbl" xml:lang="en-US">Other Equity Awards Not Separately Disclosed</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_DocumentAndEntityInformationAbstract" xlink:label="PTN_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_DocumentAndEntityInformationAbstract" xlink:to="PTN_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock of $.01 par value - authorized 10,000,000 shares; Series A Convertible; issued and outstanding 4,697 shares as of March 31, 2013 and 4,997 as of June 30, 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock of $.01 par value - authorized 200,000,000 shares; issued and outstanding 38,947,912 shares as of March 31, 2013 and 34,900,591 as of June 30, 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, Series A Convertible, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, Series A Convertible, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Increase in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposition of supplies and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accrued interest and amortization on premium/discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain on sale of supplies and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_2_lbl" xml:lang="en-US">Increase in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses, restricted cash and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses, compensation and deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_IncreaseDecreaseInUnearnedRevenues" xlink:label="PTN_IncreaseDecreaseInUnearnedRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_IncreaseDecreaseInUnearnedRevenues" xlink:to="PTN_IncreaseDecreaseInUnearnedRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_IncreaseDecreaseInUnearnedRevenues_lbl" xml:lang="en-US">Unearned revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of supplies and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchases of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Payment of withholding taxes related to restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from the sale of common stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_AgreementWithAstrazenecaAbstract" xlink:label="PTN_AgreementWithAstrazenecaAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_AgreementWithAstrazenecaAbstract" xlink:to="PTN_AgreementWithAstrazenecaAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_AgreementWithAstrazenecaAbstract_lbl" xml:lang="en-US">Agreement With Astrazeneca</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:label="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:to="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermContractsOrProgramsDisclosureTextBlock_lbl" xml:lang="en-US">AGREEMENT WITH ASTRAZENECA</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OrganizationPoliciesAbstract" xlink:label="PTN_OrganizationPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_OrganizationPoliciesAbstract" xlink:to="PTN_OrganizationPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_OrganizationPoliciesAbstract_lbl" xml:lang="en-US">Organization Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="us-gaap_LiquidityDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidityDisclosureTextBlock" xlink:to="us-gaap_LiquidityDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiquidityDisclosureTextBlock_lbl" xml:lang="en-US">Business Risk and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FairValueMeasurementsTablesAbstract" xlink:label="PTN_FairValueMeasurementsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_FairValueMeasurementsTablesAbstract" xlink:to="PTN_FairValueMeasurementsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_FairValueMeasurementsTablesAbstract_lbl" xml:lang="en-US">Fair Value Measurements Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of assets at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OrganizationDetailsNarrativeAbstract" xlink:label="PTN_OrganizationDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_OrganizationDetailsNarrativeAbstract" xlink:to="PTN_OrganizationDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_OrganizationDetailsNarrativeAbstract_lbl" xml:lang="en-US">Organization Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash and cash equivalents and short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Revenue percentage derived from AstraZeneca</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">NOL carryforwards sold, resulting in tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xml:lang="en-US">Shares issuable upon conversion of warrants, considered to be contingently issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:label="PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:to="PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract_lbl" xml:lang="en-US">Agreement With Astrazeneca Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_LicensingAgreementAstraZeneca" xlink:label="PTN_LicensingAgreementAstraZeneca" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_LicensingAgreementAstraZeneca" xlink:to="PTN_LicensingAgreementAstraZeneca_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_LicensingAgreementAstraZeneca_lbl" xml:lang="en-US">Research collaboration and license agreement with AstraZeneca</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_RevenueLicensingAgreementClinicalTrials" xlink:label="PTN_RevenueLicensingAgreementClinicalTrials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_RevenueLicensingAgreementClinicalTrials" xlink:to="PTN_RevenueLicensingAgreementClinicalTrials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_RevenueLicensingAgreementClinicalTrials_lbl" xml:lang="en-US">Revenue recognized under clinical trail sponsored research agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_MilestonePaymentEligibility" xlink:label="PTN_MilestonePaymentEligibility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_MilestonePaymentEligibility" xlink:to="PTN_MilestonePaymentEligibility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PTN_MilestonePaymentEligibility_lbl" xml:lang="en-US">Milestone Payment Eligibility</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ContingentPaymentEligibility" xlink:label="PTN_ContingentPaymentEligibility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ContingentPaymentEligibility" xlink:to="PTN_ContingentPaymentEligibility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PTN_ContingentPaymentEligibility_lbl" xml:lang="en-US">Contingent Payment Eligibility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents, fair value disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_lbl" xml:lang="en-US">Sale of common stock units, net of costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForCash_lbl" xml:lang="en-US">Sale of common stock units, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_BlockerProvisionDescription" xlink:label="PTN_BlockerProvisionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_BlockerProvisionDescription" xlink:to="PTN_BlockerProvisionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_BlockerProvisionDescription_lbl" xml:lang="en-US">Blocker provision, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FVOptionsGranted" xlink:label="PTN_FVOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_FVOptionsGranted" xlink:to="PTN_FVOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_FVOptionsGranted_lbl" xml:lang="en-US">Fair value of options granted, to be amortized over 48 months ending July 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted Stock Units granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FVRestrictedStockUnits" xlink:label="PTN_FVRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_FVRestrictedStockUnits" xlink:to="PTN_FVRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_FVRestrictedStockUnits_lbl" xml:lang="en-US">Fair value of restricted stock units granted, amortized over 24 month vesting period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_IncreaseDecreaseInUnearnedRevenues" xlink:to="PTN_IncreaseDecreaseInUnearnedRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_IncreaseDecreaseInUnearnedRevenues_doc" xml:lang="en-US">The net change during the reporting period in the amount of unearned revenues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ClassAWarrantMember" xlink:to="PTN_ClassAWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_ClassAWarrantMember_doc" xml:lang="en-US">Information pertaining to Series A 2012 Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ClassBWarrantMember" xlink:to="PTN_ClassBWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_ClassBWarrantMember_doc" xml:lang="en-US">Information pertaining to Series B 2012 Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_LicensingAgreementAstraZeneca" xlink:to="PTN_LicensingAgreementAstraZeneca_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_LicensingAgreementAstraZeneca_doc" xml:lang="en-US">The amount paid to the company from AstraZeneca as a result of a research collaboration and licensing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_RevenueLicensingAgreementClinicalTrials" xlink:to="PTN_RevenueLicensingAgreementClinicalTrials_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_RevenueLicensingAgreementClinicalTrials_doc" xml:lang="en-US">Revenue recognized under clinical trial sponsored research agreements in conjunction with a research collaboration and licensing agreement with AstraZeneca.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_MilestonePaymentEligibility" xlink:to="PTN_MilestonePaymentEligibility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_MilestonePaymentEligibility_doc" xml:lang="en-US">As a result of the amended research collaboration and licensing agreement with AstraZeneca, the Company is eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ContingentPaymentEligibility" xlink:to="PTN_ContingentPaymentEligibility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_ContingentPaymentEligibility_doc" xml:lang="en-US">As a result of the amended research collaboration and licensing agreement with AstraZeneca, the Company is eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ExecutiveOfficersMember" xlink:to="PTN_ExecutiveOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_ExecutiveOfficersMember_doc" xml:lang="en-US">Executive Officers Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_EmployeesMember" xlink:to="PTN_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_EmployeesMember_doc" xml:lang="en-US">Employees Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_NonEmployeeDirectorsMember" xlink:to="PTN_NonEmployeeDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_NonEmployeeDirectorsMember_doc" xml:lang="en-US">Non-Employee Directors Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_BlockerProvisionDescription" xlink:to="PTN_BlockerProvisionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_BlockerProvisionDescription_doc" xml:lang="en-US">The description for a blocker provision associated with the issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_FVOptionsGranted" xlink:to="PTN_FVOptionsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_FVOptionsGranted_doc" xml:lang="en-US">The total fair value of options granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_FVRestrictedStockUnits" xlink:to="PTN_FVRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_FVRestrictedStockUnits_doc" xml:lang="en-US">The total fair value of restricted stock units granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_OtherEquityAwardsMember" xlink:to="PTN_OtherEquityAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PTN_OtherEquityAwardsMember_doc" xml:lang="en-US">Information pertaining to other stock options and equity awards not separately disclosed in the financial statements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_2_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_2_lbl" xml:lang="en-US">Capital Lease Obligations, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_MilestonePaymentEligibility" xlink:to="PTN_MilestonePaymentEligibility_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_MilestonePaymentEligibility_3_lbl" xml:lang="en-US">MilestonePaymentEligibility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PTN_ContingentPaymentEligibility" xlink:to="PTN_ContingentPaymentEligibility_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PTN_ContingentPaymentEligibility_3_lbl" xml:lang="en-US">ContingentPaymentEligibility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ptn-20130331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 3.4e -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\Palatin\XBRL\20130331\ptn03312013.xfr; Date: 2013/05/13T15:11:38 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://palatin.com/role/DocumentAndEntityInformation" xlink:href="ptn-20130331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BalanceSheetsUnuadited" xlink:href="ptn-20130331.xsd#BalanceSheetsUnuadited" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" xlink:href="ptn-20130331.xsd#BalanceSheetsUnuaditedParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StatementsOfOperations" xlink:href="ptn-20130331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StatementsOfCashFlows" xlink:href="ptn-20130331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/Organization" xlink:href="ptn-20130331.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/BasisOfPresentation" xlink:href="ptn-20130331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/AgreementWithAstrazeneca" xlink:href="ptn-20130331.xsd#AgreementWithAstrazeneca" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurements" xlink:href="ptn-20130331.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StockholdersEquity" xlink:href="ptn-20130331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/OrganizationPolicies" xlink:href="ptn-20130331.xsd#OrganizationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurementsTables" xlink:href="ptn-20130331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20130331.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20130331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" xlink:href="ptn-20130331.xsd#AgreementWithAstrazenecaDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20130331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://palatin.com/role/StockholdersEquityDetailsNarrative" xlink:href="ptn-20130331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/DocumentAndEntityInformation" xlink:title="0001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_DocumentAndEntityInformationAbstract" xlink:label="loc_PTNDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_PTNEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_PTNEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="loc_PTNDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_PTNDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_PTNAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_PTNCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_PTNEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_PTNEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_PTNEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_PTNEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_PTNEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityPublicFloat" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_PTNEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_PTNDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_PTNDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDocumentAndEntityInformationAbstract" xlink:to="loc_PTNDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/BalanceSheetsUnuadited" xlink:title="0002 - Statement - Consolidated Balance Sheets (Unuadited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_PTNStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_PTNAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_PTNAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsAbstract" xlink:to="loc_PTNAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_PTNCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_PTNShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_PTNAccountsReceivableGrossCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNAccountsReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_PTNRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PTNPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_PTNAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PTNPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_PTNOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_PTNAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAssetsCurrentAbstract" xlink:to="loc_PTNAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_PTNLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_PTNLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_PTNLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_PTNCapitalLeaseObligationsCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesCurrentAbstract" xlink:to="loc_PTNCapitalLeaseObligationsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_PTNAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesCurrentAbstract" xlink:to="loc_PTNAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_PTNAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesCurrentAbstract" xlink:to="loc_PTNAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_PTNEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesCurrentAbstract" xlink:to="loc_PTNEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_PTNLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesCurrentAbstract" xlink:to="loc_PTNLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_PTNCapitalLeaseObligationsNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_PTNCapitalLeaseObligationsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_PTNDeferredRentCreditNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_PTNDeferredRentCreditNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_PTNLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_PTNLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_PTNStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PTNPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityAbstract" xlink:to="loc_PTNPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_PTNCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityAbstract" xlink:to="loc_PTNCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_PTNAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityAbstract" xlink:to="loc_PTNAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_PTNRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityAbstract" xlink:to="loc_PTNRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_PTNStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityAbstract" xlink:to="loc_PTNStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_PTNLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityAbstract" xlink:to="loc_PTNLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/BalanceSheetsUnuaditedParenthetical" xlink:title="0003 - Statement - Consolidated Balance Sheets (Unuadited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_PTNStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PTNPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PTNPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PTNPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PTNPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_PTNCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_PTNCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_PTNCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_PTNCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfFinancialPositionAbstract" xlink:to="loc_PTNCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/StatementsOfOperations" xlink:title="0004 - Statement - Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_PTNIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="loc_PTNRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_PTNOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_PTNResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOperatingExpensesAbstract" xlink:to="loc_PTNResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_PTNGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOperatingExpensesAbstract" xlink:to="loc_PTNGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_PTNOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOperatingExpensesAbstract" xlink:to="loc_PTNOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_PTNOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_PTNNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_PTNInvestmentIncomeInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNonoperatingIncomeExpenseAbstract" xlink:to="loc_PTNInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_PTNInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNonoperatingIncomeExpenseAbstract" xlink:to="loc_PTNInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_PTNLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNonoperatingIncomeExpenseAbstract" xlink:to="loc_PTNLiabilitiesFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNonoperatingIncomeExpenseAbstract" xlink:to="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_PTNNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNonoperatingIncomeExpenseAbstract" xlink:to="loc_PTNNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_PTNIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_PTNIncomeTaxExpenseBenefit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_PTNNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_PTNEarningsPerShareBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_PTNWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncomeStatementAbstract" xlink:to="loc_PTNWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/StatementsOfCashFlows" xlink:title="0005 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_PTNStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_PTNNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_PTNNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PTNNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_PTNDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PTNDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_PTNAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PTNAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PTNGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_PTNShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PTNShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_PTNLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_PTNLiabilitiesFairValueAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_PTNIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PTNIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_PTNIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PTNIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_PTNIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PTNIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_PTNIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PTNIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_IncreaseDecreaseInUnearnedRevenues" xlink:label="loc_PTNIncreaseDecreaseInUnearnedRevenues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PTNIncreaseDecreaseInUnearnedRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_PTNNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_PTNNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_PTNNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_PTNProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PTNProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PTNPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PTNPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_PTNPaymentsToAcquireInvestments" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PTNPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_PTNNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PTNNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_PTNNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_PTNRepaymentsOfLongTermCapitalLeaseObligations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PTNRepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_PTNPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PTNPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_PTNProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PTNProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_PTNNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PTNNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_PTNCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_PTNCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_PTNCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_PTNSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementOfCashFlowsAbstract" xlink:to="loc_PTNSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_PTNInterestPaid" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSupplementalCashFlowInformationAbstract" xlink:to="loc_PTNInterestPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/Organization" xlink:title="0006 - Disclosure - ORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_PTNOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_PTNOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_PTNOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/BasisOfPresentation" xlink:title="0007 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_PTNOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_PTNBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_PTNBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_PTNAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_PTNSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAccountingPoliciesAbstract" xlink:to="loc_PTNSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/AgreementWithAstrazeneca" xlink:title="0009 - Disclosure - AGREEMENT WITH ASTRAZENECA">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_AgreementWithAstrazenecaAbstract" xlink:label="loc_PTNAgreementWithAstrazenecaAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermContractsOrProgramsDisclosureTextBlock" xlink:label="loc_PTNLongTermContractsOrProgramsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAgreementWithAstrazenecaAbstract" xlink:to="loc_PTNLongTermContractsOrProgramsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurements" xlink:title="0010 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_PTNFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_PTNFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueDisclosuresAbstract" xlink:to="loc_PTNFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/StockholdersEquity" xlink:title="0011 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_PTNEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_PTNStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNEquityAbstract" xlink:to="loc_PTNStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/OrganizationPolicies" xlink:title="0012 - Disclosure - ORGANIZATION (Policies)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OrganizationPoliciesAbstract" xlink:label="loc_PTNOrganizationPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_PTNNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationPoliciesAbstract" xlink:to="loc_PTNNatureOfOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_PTNLiquidityDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationPoliciesAbstract" xlink:to="loc_PTNLiquidityDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_PTNConcentrationRiskCreditRisk" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationPoliciesAbstract" xlink:to="loc_PTNConcentrationRiskCreditRisk" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="0013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_PTNConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_PTNUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_PTNCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_PTNInvestmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_PTNFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_PTNPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_PTNImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueDisclosureTextBlock" xlink:label="loc_PTNDeferredRevenueDisclosureTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNDeferredRevenueDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_PTNRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_PTNResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_PTNShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_PTNIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_PTNEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_PTNEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurementsTables" xlink:title="0014 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FairValueMeasurementsTablesAbstract" xlink:label="loc_PTNFairValueMeasurementsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_PTNFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueMeasurementsTablesAbstract" xlink:to="loc_PTNFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/OrganizationDetailsNarrative" xlink:title="0015 - Disclosure - ORGANIZATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OrganizationDetailsNarrativeAbstract" xlink:label="loc_PTNOrganizationDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_PTNCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationDetailsNarrativeAbstract" xlink:to="loc_PTNCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_PTNConcentrationRiskPercentage1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNOrganizationDetailsNarrativeAbstract" xlink:to="loc_PTNConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="0016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_SummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:label="loc_PTNSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_PTNStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNSummaryOfSignificantAccountingPoliciesDetailsNarrativeAbstract" xlink:to="loc_PTNStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_PTNStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_PTNCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNCashAndCashEquivalentsAxis" xlink:to="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_PTNMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_PTNUSTreasurySecuritiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_PTNStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_PTNEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementEquityComponentsAxis" xlink:to="loc_PTNEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_PTNPreferredClassAMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNPreferredClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="loc_PTNPreferredClassBMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNPreferredClassBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_PTNCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_PTNIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="loc_PTNIncrementalCommonSharesAttributableToContingentlyIssuableShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNIncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_PTNAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative" xlink:title="0017 - Disclosure - AGREEMENT WITH ASTRAZENECA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:label="loc_PTNAgreementWithAstrazenecaDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_LicensingAgreementAstraZeneca" xlink:label="loc_PTNLicensingAgreementAstraZeneca" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:to="loc_PTNLicensingAgreementAstraZeneca" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_RevenueLicensingAgreementClinicalTrials" xlink:label="loc_PTNRevenueLicensingAgreementClinicalTrials" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:to="loc_PTNRevenueLicensingAgreementClinicalTrials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_MilestonePaymentEligibility" xlink:label="loc_PTNMilestonePaymentEligibility" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:to="loc_PTNMilestonePaymentEligibility" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ContingentPaymentEligibility" xlink:label="loc_PTNContingentPaymentEligibility" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAgreementWithAstrazenecaDetailsNarrativeAbstract" xlink:to="loc_PTNContingentPaymentEligibility" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/FairValueMeasurementsDetails" xlink:title="0018 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FairValueMeasurementsDetailsAbstract" xlink:label="loc_PTNFairValueMeasurementsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_PTNStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueMeasurementsDetailsAbstract" xlink:to="loc_PTNStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_PTNStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_PTNCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNCashAndCashEquivalentsAxis" xlink:to="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_PTNMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_PTNUSTreasurySecuritiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_PTNUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_PTNFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_PTNFairValueInputsLevel1Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_PTNFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_PTNFairValueInputsLevel2Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_PTNFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_PTNFairValueInputsLevel3Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_PTNFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_PTNCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://palatin.com/role/StockholdersEquityDetailsNarrative" xlink:title="0019 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_StockholdersEquityDetailsNarrativeAbstract" xlink:label="loc_PTNStockholdersEquityDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_PTNStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStockholdersEquityDetailsNarrativeAbstract" xlink:to="loc_PTNStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_PTNStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_PTNAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNAwardTypeAxis" xlink:to="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_PTNStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="loc_PTNStockOptionsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_PTNRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_OtherEquityAwardsMember" xlink:label="loc_PTNOtherEquityAwardsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PTNOtherEquityAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_PTNStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_PTNEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementEquityComponentsAxis" xlink:to="loc_PTNEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_PTNCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ClassAWarrantMember" xlink:label="loc_PTNClassAWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNClassAWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ClassBWarrantMember" xlink:label="loc_PTNClassBWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNEquityComponentDomain" xlink:to="loc_PTNClassBWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementTable" xlink:to="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_ExecutiveOfficersMember" xlink:label="loc_PTNExecutiveOfficersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PTNExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_EmployeesMember" xlink:label="loc_PTNEmployeesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PTNEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_NonEmployeeDirectorsMember" xlink:label="loc_PTNNonEmployeeDirectorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PTNNonEmployeeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_PTNStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_PTNStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_PTNStockIssuedDuringPeriodSharesIssuedForCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodSharesIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_PTNStockIssuedDuringPeriodValueIssuedForCash" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNStockIssuedDuringPeriodValueIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_PTNClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_BlockerProvisionDescription" xlink:label="loc_PTNBlockerProvisionDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNBlockerProvisionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_PTNLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNLiabilitiesFairValueAdjustment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_PTNSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FVOptionsGranted" xlink:label="loc_PTNFVOptionsGranted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNFVOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptn-20130331.xsd#PTN_FVRestrictedStockUnits" xlink:label="loc_PTNFVRestrictedStockUnits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNFVRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_PTNShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PTNStatementLineItems" xlink:to="loc_PTNShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>arrow_001.jpg
<TEXT>
begin 644 arrow_001.jpg
M_]C_X``02D9)1@`!`0$`2`!(``#_X09B17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````H@```,X`"OR````G
M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,3,Z,#4Z
M,3`@,3,Z,#<Z,#@```.@`0`#`````?__``"@`@`$`````0```-J@`P`$````
M`0```!X`````````!@$#``,````!``8```$:``4````!```!'`$;``4````!
M```!)`$H``,````!``(```(!``0````!```!+`("``0````!```%+0``````
M``!(`````0```$@````!_]C_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#
M`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``.`*`#`2$``A$!`Q$!_\0`'P``
M`04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0`
M``%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!
M`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P"M_P`-+WG_`$+$
M'_@8?_B*/^&E[S_H6(/_``,/_P`10`?\-+WG_0L0?^!A_P#B*/\`AI>\_P"A
M8@_\##_\10`?\-+WG_0L0?\`@8?_`(BC_AI>\_Z%B#_P,/\`\10`?\-+WG_0
ML0?^!A_^(H_X:7O/^A8@_P#`P_\`Q%`!_P`-+WG_`$+$'_@8?_B*/^&E[S_H
M6(/_``,/_P`10`?\-+WG_0L0?^!A_P#B*/\`AI>\_P"A8@_\##_\10`?\-+W
MG_0L0?\`@8?_`(BC_AI>\_Z%B#_P,/\`\10`?\-+WG_0L0?^!A_^(H_X:7O/
M^A8@_P#`P_\`Q%`!_P`-+WG_`$+$'_@8?_B*/^&E[P_\RQ!_X&'_`.(H`X_2
M_C/XETGQ)J&I0,)K2]G:7[!<R-(D0+%L(<@C&<<<'TKV[PA\:_#/B=H[6X9]
M,OV(`AN""K$D`!7'!Y/<"@#-_P"&=?!O_/YK/_@1'_\`&Z/^&=?!O_/WK/\`
MX$1__&Z`#_AG7P;_`,_>L_\`@1'_`/&Z/^&=?!O_`#^:S_X$1_\`QN@`_P"&
M=?!O_/WK/_@1'_\`&Z/^&=?!O_/YK/\`X$1__&Z`#_AG7P;_`,_>L_\`@1'_
M`/&Z/^&=?!O_`#]ZS_X$1_\`QN@`_P"&=?!O_/YK/_@1'_\`&Z/^&=?!O_/W
MK/\`X$1__&Z`#_AG7P;_`,_FL_\`@1'_`/&Z/^&=?!O_`#]ZS_X$1_\`QN@`
M_P"&=?!O_/WK/_@1'_\`&Z/^&=?!O_/WK/\`X$1__&Z`#_AG7P;_`,_>L_\`
M@1'_`/&Z/^&=?!O_`#^:S_X$1_\`QN@`_P"&=?!O_/WK/_@1'_\`&Z7_`(9U
M\&@_\?>L_P#?^/\`^-T`>;:'\&3XD\6ZW96VJBTTS3[J2$-(IEE8*Y4<<#^$
M\Y_"O=?"WPU\+>$U633]-1KK:%:YG)D<X.<C/"\^@%`'_]D`_^T*HE!H;W1O
M<VAO<"`S+C``.$))300$```````''`(```(``@`X0DE-!"4``````!!&#/*)
M)KA6VK"<`:&PIY!W.$))30/M```````0`$@````!``$`2`````$``3A"24T$
M)@``````#@`````````````_@```.$))300-```````$````>#A"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/T```````2`#4````!`"T````&
M```````!.$))30/W```````<``#_____________________________`^@`
M`#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````
M.$))300:``````-'````!@``````````````'@```-H````)`&$`<@!R`&\`
M=P!?`#``,``Q`````0`````````````````````````!``````````````#:
M````'@`````````````````````!`````````````````````````!`````!
M````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````
M!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG
M````'@````!29VAT;&]N9P```-H````&<VQI8V5S5FQ,<P````%/8FIC````
M`0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)
M1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U
M=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@
M````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`
M`````````$QE9G1L;VYG``````````!"=&]M;&]N9P```!X`````4F=H=&QO
M;F<```#:`````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````
M37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X
M=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI
M9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!
M;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#
M;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)
M=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O
M='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))
M300H```````,`````3_P````````.$))3004```````$`````CA"24T$#```
M```%8@````$```"@````%@```>```"E````%1@`8``'_V/_@`!!*1DE&``$"
M``!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@(
M"`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1
M$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%@"@
M`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'
M"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&
M"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3
M\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%
M-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&
M%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`ZG(_QD?4KIE]
MG37Y)I?A/=CNJ919M8:CZ)K9LKV;&;-OL4/_`!U_J1_W-?\`]L6_^DUXS]:_
M_%3UG_P_D_\`GZQ922GWO_QU_J1_W-?_`-L6_P#I-+_QU_J1_P!S7_\`;%O_
M`*37@B22GWO_`,=?ZD?]S7_]L6_^DTO_`!U_J1_W-?\`]L6_^DUX(DDI][_\
M=?ZD?]S7_P#;%O\`Z32_\=?ZD?\`<U__`&Q;_P"DUX(DDI][_P#'7^I'_<U_
M_;%O_I-+_P`=?ZD?]S7_`/;%O_I->"))*?>__'7^I'_<U_\`VQ;_`.DTO_'7
M^I'_`'-?_P!L6_\`I->"))*?>_\`QU_J1_W-?_VQ;_Z32_\`'7^I'_<U_P#V
MQ;_Z37@B22GWO_QU_J1_W-?_`-L6_P#I-+_QU_J1_P!S7_\`;%O_`*37@B22
MGWO_`,=?ZD?]S7_]L6_^DTW_`(Z_U(_[FO\`^V+?_2:\%224^G9G^-487UNN
MR\"U_4.A9+:6VT/WM+"UNVQ^$R[8VFW=_.>ST\C_`,&7IO1>M]-ZW@LS^FW"
MZE^C@(W,=`<:;F?X.UF[Z"^9875?XO&_6P]:_P"QJ`Z/UHW;OLNS7;]LV?\`
M@6S]/_H_STE/_]#JLS_QLOME_P!M_9'VOU'_`&GU?0]3U=Q];U=_O]7U-WJ;
MD'_UT_\`YI?_`&77@R22GWG_`-=/_P":7_V72_\`73_^:7_V77@R22GWG_UT
M_P#YI?\`V72_]=/_`.:7_P!EUX,DDI]Y_P#73_\`FE_]ETO_`%T__FE_]EUX
M,DDI]Y_]=/\`^:7_`-ETO_73_P#FE_\`9=>#))*?>?\`UT__`)I?_9=+_P!=
M/_YI?_9=>#))*?>?_73_`/FE_P#9=+_UT_\`YI?_`&77@R22GWG_`-=/_P":
M7_V72_\`73_^:7_V77@R22GWG_UT_P#YI?\`V72_]=/_`.:7_P!EUX,DDI[O
MKF']1LKZZ7&W/HP.A55U$#!87^JXL]S:/L5.117M?_2'6^__`*NOUKZL_L']
MBX__`#>]/]F0?2].>9]_J>I^F];=_.>M^E7S4DDI_]DX0DE-!"$``````%4`
M```!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`#(````!`#A"24T$
M!@``````!P`&`0$``P$`_^$ZK&AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z
M3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](C,N,2XQ+3$Q,2(^#0H)/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C
M(CX-"@D)/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z9&,]
M(FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX-"@D)"3QD8SIF
M;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@T*"0D\+W)D9CI$97-C<FEP
M=&EO;CX-"@D)/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z
M>&%P/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(CX-"@D)"3QX87`Z
M0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S/"]X87`Z
M0W)E871O<E1O;VP^#0H)"0D\>&%P.D-R96%T941A=&4^,C`Q,RTP-2TQ,%0Q
M,CHT,3HT-2LP-3HS,#PO>&%P.D-R96%T941A=&4^#0H)"0D\>&%P.DUO9&EF
M>41A=&4^,C`Q,RTP-2TQ,%0Q,SHP-SHP."LP-3HS,#PO>&%P.DUO9&EF>41A
M=&4^#0H)"0D\>&%P.DUE=&%D871A1&%T93XR,#$S+3`U+3$P5#$S.C`W.C`X
M*S`U.C,P/"]X87`Z365T861A=&%$871E/@T*"0D\+W)D9CI$97-C<FEP=&EO
M;CX-"@D)/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&%P
M34T](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R
M8V52968C(CX-"@D)"3QX87!-33I$;V-U;65N=$E$/G5U:60Z0S8Q-45"0C<T
M,$(Y13(Q,4$V,T%"0C`T-S,P-3<Q-$(\+WAA<$U-.D1O8W5M96YT240^#0H)
M"0D\>&%P34TZ26YS=&%N8V5)1#YU=6ED.C<Y-38T134S-#1".44R,3%!-C-!
M0D(P-#<S,#4W,31"/"]X87!-33I);G-T86YC94E$/@T*"0D)/'AA<$U-.D1E
M<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D\<W12
M968Z:6YS=&%N8V5)1#YU=6ED.D,U,35%0D(W-#!".44R,3%!-C-!0D(P-#<S
M,#4W,31"/"]S=%)E9CII;G-T86YC94E$/@T*"0D)"3QS=%)E9CID;V-U;65N
M=$E$/G5U:60Z0S4Q-45"0C<T,$(Y13(Q,4$V,T%"0C`T-S,P-3<Q-$(\+W-T
M4F5F.F1O8W5M96YT240^#0H)"0D\+WAA<$U-.D1E<FEV961&<F]M/@T*"0D\
M+W)D9CI$97-C<FEP=&EO;CX-"@D)/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(@>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N
M,"\B/@T*"0D)/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO
M;CX-"@D)"3QT:69F.EA297-O;'5T:6]N/C<R,#`P,"\Q,#`P,#PO=&EF9CI8
M4F5S;VQU=&EO;CX-"@D)"3QT:69F.EE297-O;'5T:6]N/C<R,#`P,"\Q,#`P
M,#PO=&EF9CI94F5S;VQU=&EO;CX-"@D)"3QT:69F.E)E<V]L=71I;VY5;FET
M/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^#0H)"0D\=&EF9CI.871I=F5$:6=E
M<W0^,C4V+#(U-RPR-3@L,C4Y+#(V,BPR-S0L,C<W+#(X-"PU,S`L-3,Q+#(X
M,BPR.#,L,CDV+#,P,2PS,3@L,S$Y+#4R.2PU,S(L,S`V+#(W,"PR-S$L,C<R
M+#,P-2PS,34L,S,T,S([,39$-D$U,S$Q-49"-D(Q-3@Y-CDP.38P-S8U,C$Y
M0D,\+W1I9F8Z3F%T:79E1&EG97-T/@T*"0D\+W)D9CI$97-C<FEP=&EO;CX-
M"@D)/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z97AI9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B/@T*"0D)/&5X:68Z4&EX
M96Q81&EM96YS:6]N/C(Q.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^#0H)"0D\
M97AI9CI0:7AE;%E$:6UE;G-I;VX^,S`\+V5X:68Z4&EX96Q91&EM96YS:6]N
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M+#0Q.3DU+#0Q.3DV+#0R,#$V+#`L,BPT+#4L-BPW+#@L.2PQ,"PQ,2PQ,BPQ
M,RPQ-"PQ-2PQ-BPQ-RPQ."PR,"PR,BPR,RPR-"PR-2PR-BPR-RPR."PS,#LR
M.#5#1#5&1D0Y1D(R,S8P0SDT-S,P0C0Q,S,P,#$U,SPO97AI9CI.871I=F5$
M:6=E<W0^#0H)"3PO<F1F.D1E<V-R:7!T:6]N/@T*"0D\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@T*"0D)/'!H;W1O<VAO<#I#;VQO
M<DUO9&4^,3PO<&AO=&]S:&]P.D-O;&]R36]D93X-"@D)"3QP:&]T;W-H;W`Z
M24-#4')O9FEL93Y$;W0@1V%I;B`R,"4\+W!H;W1O<VAO<#I)0T-0<F]F:6QE
M/@T*"0D)/'!H;W1O<VAO<#I(:7-T;W)Y+SX-"@D)/"]R9&8Z1&5S8W)I<'1I
M;VX^#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE=&$^#0H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T(&5N
M9#TG=R<_/O_B`Z!)0T-?4%)/1DE,10`!`0```Y!!1$)%`A```'!R=')'4D%9
M6%E:(`?/``8``P```````&%C<W!!4%!,`````&YO;F4`````````````````
M```!``#VU@`!`````-,M041"10``````````````````````````````````
M````````````````````````````!6-P<G0```#`````,F1E<V,```#T````
M9W=T<'0```%<````%&)K<'0```%P````%&M44D,```&$```"#'1E>'0`````
M0V]P>7)I9VAT(#$Y.3D@061O8F4@4WES=&5M<R!);F-O<G!O<F%T960```!D
M97-C``````````U$;W0@1V%I;B`R,"4`````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````%A96B````````#VU@`!`````-,M6%E:(```````````
M``````````!C=7)V`````````0`````0`"``,`!``%``80!_`*``Q0#L`1<!
M1`%U`:@!W@(6`E("D`+0`Q,#60.A`^P$.02(!-H%+@6%!=X&.0:6!O8'5P>[
M""((B@CT"6$)T`I!"K0+*0N@#!H,E0T2#9(.$PZ6#QP/HQ`L$+@111'4$F42
M^!.-%"04O157%?06DA<R%]08>!D>&<8:;QL;&\@<=ATG'=H>CA]$'_P@M2%Q
M(BXB[2.M)'`E-"7Y)L$GBBA5*2(I\"K`*Y(L92TZ+A$NZB_$,*`Q?3)<,STT
M'S4#->DVT#>Y.*0YD#I^.VT\7CU1/D4_.T`S02Q")D,B1"!%'T8@1R-()TDM
M2C1+/$Q'35-.8$]O4']1D5*E4[I4T57I5P)8'EDZ6EA;>%R97;Q>X&`&82UB
M5F.`9*QEV6<(:#AI:6J=:]%M!VX_;WAPLG'N<RMT:G6J=NQX+WET>KI\`7U*
M?I5_X8$N@GR#S84>AG&'Q8D;BG*+RXTECH&/W9$\DIN3_95?EL.8*)F/FO><
M8)W+GS>@I:(4HX6D]J9II]ZI5*K+K$2MOJ\YL+:R-+.TM32VM[@ZN;^[1;S-
MOE:_X,%LPOG$A\87QZC).\K.S&/-^L^2T2O2Q=1AU?[7G-D\VMW<?]XCW\CA
M;N,6Y+_F:>@4Z<'K;^T?[M#P@O(U\^KUH/=7^1#ZROR%_D'____;`$,``@$!
M`@$!`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*
M"PP,#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"$!;0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)
M"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1
MH0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U
M]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"
M`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2
M\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U
MMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,
M`P$``A$#$0`_`/W\HK^&8?\`!0SX[A'7_A<'Q'Q(23_Q4%SD9]#OX_"AO^"A
MGQW:<2?\+@^(^Y1@`>(+D+^6_!H`_N9HK^&9_P#@H9\=Y(BA^,'Q'PQSQX@N
M0>N>N_-.'_!1'X\!RW_"X/B+D@#_`)#UQC\MWO0!_<O17\,@_P""@_QU`C'_
M``N'XD_NSD?\5%=<_7Y^?QJ1?^"B/QX4L?\`A<'Q%^8Y.=>N#_[-Q0!_<O17
M\,Z_\%#_`([IMQ\8/B-\HVC.OW)].OS\GCJ:1?\`@H9\=U##_A<'Q'^9MYSX
M@N3S_P!]\#VZ4`?W,T5_#,__``4,^.\CEC\8/B/EEV<>(+D#'TW]??K1'_P4
M,^.\2*H^,'Q'(0Y&?$%R3WZDOSU[T`?W,T5_#.W_``4/^.[[L_&#XC?,-IQK
M]R/7I\_!YZBAO^"A_P`=WD5C\8/B-E,XQK]R!SZC?@_C0!_<Q17\,L7_``4*
M^.T,>T?&#XD$9W?-XANF/YE\XXZ4\_\`!1'X\%PW_"X/B+D`C_D/7&/RW>U`
M']R]%?PS'_@H9\=RB+_PN#XCXC((_P"*@N<G'J=_/XT'_@H9\=R9#_PN#XC_
M`+P8/_%07/'T^?C\*`/[F:*_AG'_``4/^.ZJ@_X7!\1ODZ?\3^YYXQS\_/XT
M'_@H?\=S&R_\+@^(V&SG_B?W.>???D?TH`_N8HK^&9O^"AGQW:<2?\+@^(^Y
M1@`>(+D+^6_!H3_@H9\=XX@@^,'Q'PISSX@N2>N>N_-`']S-%?PSK_P4/^.Z
M2,P^,'Q&R^,YU^Y(X]!OP/PIK?\`!0KX[-Y>?C!\2/W73'B&Z&?K\_/XYH`_
MN:HK^&<_\%#_`([LKC_A<'Q&^?K_`,3^YXXQQ\_'X4B?\%#/CO&X8?&#XCY5
M=G/B"Y(Q]-_7WZT`?W,T5_#,W_!0SX[L`/\`A<'Q'^5MXQX@N1S_`-]\CVZ4
MK?\`!0_X[ONS\8/B-\PVG&OW(]>GS\'GJ*`/[F**_AFC_P""AGQWB15'Q@^(
MY"'(SX@N2>_4E^>O>D?_`(*%?':3?GXP?$C]YC./$-T,8],/Q^'6@#^YJBOX
M:#_P41^/!<-_PN#XBY`(_P"0]<8_+=[4R+_@H5\=H8]H^,'Q((SN^;Q#=,?S
M+YQQTH`_N:HK^&?_`(>'_'?SM_\`PN#XC;L;<?V_<X_+?C/O2'_@H9\=RB+_
M`,+@^(^(R"/^*@N<G'J=_/XT`?W,T5_#*O\`P4*^.R^9CXP?$C][USXANCCZ
M?/Q^&*>W_!1'X\,0?^%P?$7Y3D8UZX'_`+-S0!_<O17\,S_\%#/CO)$4/Q@^
M(^&.>/$%R#USUWYH7_@H9\=UG:3_`(7!\1]S#!!\07)7\M^!0!_<S17\,_\`
MP\/^.XC5?^%P?$;"XQ_Q/[G/'OOR?ZT'_@H?\=V5Q_PN#XC?/U_XG]SQQCCY
M^/PH`_N8HK^&=?\`@H?\=TVX^,'Q&^4;1G7[D^G7Y^3QU-,D_P""@_QUD0*?
MC#\20``./$5T#QGN']_QH`_N721I]CH=L9SN#QD,?SQC\17X0?\`!R+_`,%3
M?CA_P3Q_X*,>';CX<^/-;T[0XO#UG-)X?:1VTNZDF%_&TDD9RA;Y48<`YC4]
MN?Q)/_!0SX[F4/\`\+@^(^02?^1@N<=,=-^.U<5\2OC7XS^-OB*+4/&'B?5O
M%.I1Q+%'=:O>F\D2,;BL8>4G"C>V%S@%CP#0!_33_P`$5O\`@Y+\,_MU6,7A
M+XIWGAOX?^,]*TNV#WUSJ;B+7+GSO(R%DB6.,ME'(60_?/(P37ZG^%/%-EXP
MTW[7I6I6>JV3E2EW;R++"^0"0I4X(VE2#D\,.37\#TL):0?/$7=B"JG`4Y]?
MNX^AQ7V3_P`$W?\`@N#\<O\`@FCJ=MI?A?7UUWP/+?07FJ>';Y?/@N(XX_+:
M.-V&8LQ@#*<?(G4"@#^RZBORK_X)5_\`!T)\)/VZ?$.F>"/&-HWPO\?W4=S(
MK7T\<>AW(CD#1Q1S,_$DB-C#*#N5@,_+G]/?!/CO2/B'H<>HZ+JFF:M:29Q-
M8W2W$1PS+PR^ZD?4'TH`_@:HK^SX?\$"OV-@CK_PSU\/L2$D_P"C29&?0[^/
MPH;_`((%?L;-.)/^&>OA]N48`%M(%_+?@T`?Q@T5_9\__!`K]C:2(H?V>OA]
MACGBVD!ZYZ[\TX?\$#_V.`Y;_AGKX>9(`_X]'Q^6_P!Z`/XOZ*_L\'_!`7]C
M4",?\,]^`/W9R/W$O/U_><_C4B_\$#_V.%+'_AGKX>?,<G-HY_\`9^*`/XOZ
M*_L_7_@@9^QNFW'[/7P]^4;1FUD/IU^?D\=32+_P0*_8V4,/^&>OA]\S;SFV
MD//_`'WP/;I0!_&#17]GS_\`!`K]C:1RQ_9Z^'V679Q;2`8^F_K[]:(_^"!7
M[&T2*H_9Z^'Q"'(S;2$]^I+\]>]`'\8-%?V?M_P0,_8W?=G]GKX>_,-IQ:R#
MUZ?/P>>HH;_@@9^QN\BL?V>OA[E,XQ:R`<^HWX/XT`?Q@45_9[%_P0'_`&-H
M8]H_9[^'Y&=WS6\K'\R^<<=*>?\`@@?^QP7#?\,]?#S(!'_'H^/RW^U`'\7]
M%?V?'_@@5^QL41?^&>OA]B,@C_1I,G'J=_/XT'_@@5^QL3(?^&>OA]^\&#_H
MTG'T^?C\*`/XP:*_L_'_``0,_8W54'_#/7P]^3I_HLG/&.?GY_&@_P#!`S]C
M<QLO_#/7P]PV<_Z+)GGWWY']*`/XP**_L^;_`((%?L;-.)/^&>OA]N48`%M(
M%_+?@T)_P0*_8VCB"#]GKX?84YYMI">N>N_-`'\8-%?V?K_P0,_8W21F'[/7
MP]R^,YM9"./0;\#\*:W_``0'_8V;R\_L]_#_`/==,6\HS]?GY_'-`'\85%?V
M?G_@@9^QNRN/^&>OA[\_7_19..,<?/Q^%(G_``0*_8VC<,/V>OA]E5V<VTA&
M/IOZ^_6@#^,&BO[/F_X(%?L;,`/^&>OA]\K;QBVD'/\`WWR/;I2M_P`$#/V-
MWW9_9Z^'OS#:<6L@]>GS\'GJ*`/XP**_L^C_`."!7[&T2*H_9Z^'Q"'(S;2$
M]^I+\]>](_\`P0'_`&-I-^?V>_A_^\QG%O*,8],/Q^'6@#^,*BO[0#_P0/\`
MV."X;_AGKX>9`(_X]'Q^6_VID7_!`?\`8VACVC]GOX?D9W?-;RL?S+YQQTH`
M_C"HK^S_`/X<&?L;^=O_`.&>OA[NQMQ]EDQ^6_&?>D/_``0*_8V*(O\`PSU\
M/L1D$?Z-)DX]3OY_&@#^,&BO[/5_X(#_`+&R^9C]GOX?_O>N;>4X^GS\?ABG
MM_P0/_8X8@_\,]?#SY3D8M''_L_-`'\7]%?V?/\`\$"OV-I(BA_9Z^'V&.>+
M:0'KGKOS0O\`P0*_8V6=I/\`AGKX?;F&"#;2%?RWX%`'\8-%?V?_`/#@S]C<
M1JO_``SU\/<+C'^BR9X]]^3_`%H/_!`S]C=E<?\`#/7P]^?K_HLG'&./GX_"
M@#^,"BO[/U_X(&?L;IMQ^SU\/?E&T9M9#Z=?GY/'4T1_\$#/V-XMV/V>OAZ=
MQW'-K(?RR_`]J`/XPHHC-(%4J"?[S!1^9XJ;[/&$RZ3(@?8TJD.N<=!T!.>>
MO3UZU_9NW_!!;]C=)%4_L\_#W+YQBQD(X]3NP/QK\$_^#HC]C?X:_LL_MKZ'
MX1^$W@31_!]E=>'K"\>STJ&0^=(S7P=]H#'E8HQP?X`<=30!^6A@C;:B+(6+
M@;@RL6!Z80=\>_7BK>EZ7=:_JMOIMC:S7.I74PM;:*%-LLC,0H4J!R3G'7/7
M.>*^[O\`@F?_`,&[?QV_X*-68UZS@TSP1X."0R'5->@DC:[A:9XF,$.T,[`1
M.PR4!&WYAN!K]]_^"0__``04^&W_``3$T6XN-2CT+Q]XVU*:"Y36;G1C!)ID
MD5N8Y$A$T\N03)(=Z!<Y&1P,`'X%_P#!*C_@@Q\?_P!M7XM:/J-K;^(?A)X5
MMY)7;QC=VLL2I)$R`QVY!3?(2^T8;JC]=I%?TC?\$T/^"<_B?]@'X,R>&O$'
MQB\>?$^[N,?O;QHDALML]S)^Z#YD^<3J&W.W,0Q@<5]56NFVMK&8X+>.!4!C
M`C3R\`\D`C'&3GCO[U-%$(8PJEB!_>8L?S/-`#J***`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@"O%_R%I_^N,?_H3U^-__``4(_P"5G?X0?]B,
E_P#Z1:S110!^O_PX_P"2>:#_`-@ZW_\`12ULT44`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>arrow_002.jpg
<TEXT>
begin 644 arrow_002.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X03D17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G
M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,3,Z,#4Z
M,3`@,3,Z,#,Z,C$``````Z`!``,````!__\``*`"``0````!````/*`#``0`
M```!````&0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```.N````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`&0`\`P$B``(1`0,1`?_=``0`
M!/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`Z+)_QF_5#I61;TL^I4<![L8U5U$,;Z)]
M'TZPSV^FS9[-J'_X[_U/_?O_`.VBO)_K5AYCOK1UAS:+"TYV200QQ!!ML\EE
M_8<W_N/;_F._N24^V?\`CO\`U/\`W[_^VBE_X[_U/_?O_P"VBO$_L.;_`-Q[
M?\QW]R7V'-_[CV_YCO[DE/MG_CO?4_\`?O\`^VG+ELW_`!MY-'UCOR<$NRND
M.8&U4/&R'0W=9^]])>>?8<W_`+CV_P"8[^Y">Q];BRQI8\<M<((^124_1'U=
M^NW0>OU_JMX9<"UAIM]CBXC=%;'?SBWU\R=(Q.J9.?2WI;7G*W@5/9I#NWO^
MBU>N?LSZ_P#_`#'^S?:&?M&9VZ^KZ<_S?J_1]1)3_]#U`XN,XESJF$G4DM&I
M3?9,7_0L_P`T(R22D/V3%_T+/\T)?9,7_0L_S0C))*0_9,7_`$-?^:%Y]U[_
M`!97=>^MF1FWV#&Z<]C=AJ`W%S0UNTM7HZ9)3E]%^K71NAT^ET_&;5N(<]W)
M+@-N_P!RU$DDE/\`_]G_[0D*4&AO=&]S:&]P(#,N,``X0DE-!`0```````<<
M`@```@`"`#A"24T$)0``````$$8,\HDFN%;:L)P!H;"GD'<X0DE-`^T`````
M`!``2`````$``0!(`````0`!.$))300F```````.`````````````#^````X
M0DE-!`T```````0```!X.$))3009```````$````'CA"24T#\P``````"0``
M`````````0`X0DE-!`H```````$``#A"24TG$```````"@`!``````````(X
M0DE-`_0``````!(`-0````$`+0````8```````$X0DE-`_<``````!P``/__
M__________________________\#Z```.$))300(```````0`````0```D``
M``)``````#A"24T$'@``````!``````X0DE-!!H``````T<````&````````
M```````9````/`````D`80!R`'(`;P!W`%\`,``P`#(````!````````````
M``````````````$``````````````#P````9``````````````````````$`
M````````````````````````$`````$```````!N=6QL`````@````9B;W5N
M9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG``````````!,
M969T;&]N9P``````````0G1O;6QO;F<````9`````%)G:'1L;VYG````/```
M``9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````!W-L
M:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU
M;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E96YU
M;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`````
M``!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````````
M`$)T;VUL;VYG````&0````!29VAT;&]N9P```#P````#=7)L5$585`````$`
M``````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A;'14
M86=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E
M>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L
M:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T
M06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E
M0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG``````````IL
M969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P`````````+
M<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_`````````X
M0DE-!!0```````0````".$))300,``````/*`````0```#P````9````M```
M$90```.N`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--``'_
M[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.
M#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"``9`#P#`2(``A$!`Q$!_]T`!``$_\0!/P``
M`04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!
M``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H`#`,!``(1`Q$`/P#HLG_&;]4.E9%O2SZE1P'NQC5740QOHGT?3K#/;Z;-
MGLVH?_CO_4_]^_\`[:*\G^M6'F.^M'6'-HL+3G9)!#'$$&VSR67]AS?^X]O^
M8[^Y)3[9_P"._P#4_P#?O_[:*7_CO_4_]^__`+:*\3^PYO\`W'M_S'?W)?8<
MW_N/;_F._N24^V?^.]]3_P!^_P#[:<N6S?\`&WDT?6._)P2[*Z0Y@;50\;(=
M#=UG[WTEYY]AS?\`N/;_`)CO[D)['UN++&ECQRUP@CY%)3]$?5WZ[=!Z_7^J
MWAEP+6&FWV.+B-T5L=_.+?7S)TC$ZIDY]+>EM><K>!4]FD.[>_Z+5ZY^S/K_
M`/\`,?[-]H9^T9G;KZOIS_-^K]'U$E/_T/4#BXSB7.J82=22T:E-]DQ?]"S_
M`#0C))*0_9,7_0L_S0E]DQ?]"S_-",DDI#]DQ?\`0U_YH7GW7O\`%E=U[ZV9
M&;?8,;ISV-V&H#<7-#6[2U>CIDE.7T7ZM=&Z'3Z73\9M6XASW<DN`V[_`'+4
M2224_P#_V3A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`
M;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'``(`!#`%,`,@````$`.$))300&```````'``8!`0`#`0#_X3JK:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@
M:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2(S+C$N,2TQ,3$B/@H@
M("`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@("`@("`@("`\9&,Z9F]R;6%T
M/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I
M;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@
M("`@("`@('AM;&YS.GAA<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+R(^"B`@("`@("`@(#QX87`Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P
M($-3,B!7:6YD;W=S/"]X87`Z0W)E871O<E1O;VP^"B`@("`@("`@(#QX87`Z
M0W)E871E1&%T93XR,#$S+3`U+3$P5#$R.C0R.C0W*S`U.C,P/"]X87`Z0W)E
M871E1&%T93X*("`@("`@("`@/'AA<#I-;V1I9GE$871E/C(P,3,M,#4M,3!4
M,3,Z,#,Z,C$K,#4Z,S`\+WAA<#I-;V1I9GE$871E/@H@("`@("`@("`\>&%P
M.DUE=&%D871A1&%T93XR,#$S+3`U+3$P5#$S.C`S.C(Q*S`U.C,P/"]X87`Z
M365T861A=&%$871E/@H@("`@("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL
M;G,Z>&%P34T](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B`@
M("`@("`@("`@('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(CX*("`@("`@("`@/'AA<$U-.D1O
M8W5M96YT240^=75I9#HU,C$Y1D1&0C0P0CE%,C$Q038S04)",#0W,S`U-S$T
M0CPO>&%P34TZ1&]C=6UE;G1)1#X*("`@("`@("`@/'AA<$U-.DEN<W1A;F-E
M240^=75I9#HQ,4-!0SE$130S0CE%,C$Q038S04)",#0W,S`U-S$T0CPO>&%P
M34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*("`@("`@("`@("`@/'-T4F5F.FEN
M<W1A;F-E240^=75I9#HU,3$Y1D1&0C0P0CE%,C$Q038S04)",#0W,S`U-S$T
M0CPO<W12968Z:6YS=&%N8V5)1#X*("`@("`@("`@("`@/'-T4F5F.F1O8W5M
M96YT240^=75I9#HU,3$Y1D1&0C0P0CE%,C$Q038S04)",#0W,S`U-S$T0CPO
M<W12968Z9&]C=6UE;G1)1#X*("`@("`@("`@/"]X87!-33I$97)I=F5D1G)O
M;3X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS.G1I9F8](FAT
M='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(CX*("`@("`@("`@/'1I9F8Z
M3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`@("`@("`@/'1I
M9F8Z6%)E<V]L=71I;VX^-S(P,#`P+S$P,#`P/"]T:69F.EA297-O;'5T:6]N
M/@H@("`@("`@("`\=&EF9CI94F5S;VQU=&EO;CXW,C`P,#`O,3`P,#`\+W1I
M9F8Z65)E<V]L=71I;VX^"B`@("`@("`@(#QT:69F.E)E<V]L=71I;VY5;FET
M/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B`@("`@("`@(#QT:69F.DYA=&EV
M941I9V5S=#XR-38L,C4W+#(U."PR-3DL,C8R+#(W-"PR-S<L,C@T+#4S,"PU
M,S$L,C@R+#(X,RPR.38L,S`Q+#,Q."PS,3DL-3(Y+#4S,BPS,#8L,C<P+#(W
M,2PR-S(L,S`U+#,Q-2PS,S0S,CLR-3DV13)&,S4X-T,W-T$S,D,Y-#$V03@P
M-C9%-$)"0SPO=&EF9CI.871I=F5$:6=E<W0^"B`@("`@(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M("`@("`@("`@("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X
M:68O,2XP+R(^"B`@("`@("`@(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXV,#PO
M97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@("`@("`@(#QE>&EF.E!I>&5L641I
M;65N<VEO;CXR-3PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`@("`@("`@(#QE
M>&EF.D-O;&]R4W!A8V4^+3$\+V5X:68Z0V]L;W)3<&%C93X*("`@("`@("`@
M/&5X:68Z3F%T:79E1&EG97-T/C,V.#8T+#0P.38P+#0P.38Q+#,W,3(Q+#,W
M,3(R+#0P.38R+#0P.38S+#,W-3$P+#0P.38T+#,V.#8W+#,V.#8X+#,S-#,T
M+#,S-#,W+#,T.#4P+#,T.#4R+#,T.#4U+#,T.#4V+#,W,S<W+#,W,S<X+#,W
M,S<Y+#,W,S@P+#,W,S@Q+#,W,S@R+#,W,S@S+#,W,S@T+#,W,S@U+#,W,S@V
M+#,W,SDV+#0Q-#@S+#0Q-#@T+#0Q-#@V+#0Q-#@W+#0Q-#@X+#0Q-#DR+#0Q
M-#DS+#0Q-#DU+#0Q-S(X+#0Q-S(Y+#0Q-S,P+#0Q.3@U+#0Q.3@V+#0Q.3@W
M+#0Q.3@X+#0Q.3@Y+#0Q.3DP+#0Q.3DQ+#0Q.3DR+#0Q.3DS+#0Q.3DT+#0Q
M.3DU+#0Q.3DV+#0R,#$V+#`L,BPT+#4L-BPW+#@L.2PQ,"PQ,2PQ,BPQ,RPQ
M-"PQ-2PQ-BPQ-RPQ."PR,"PR,BPR,RPR-"PR-2PR-BPR-RPR."PS,#M$-$(Q
M-#9%0C@U-#=&-S9&-C$P-4(R-#<T.$,W1D8V,SPO97AI9CI.871I=F5$:6=E
M<W0^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIP:&]T;W-H
M;W`](FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@("`@
M("`@("`\<&AO=&]S:&]P.D-O;&]R36]D93XQ/"]P:&]T;W-H;W`Z0V]L;W)-
M;V1E/@H@("`@("`@("`\<&AO=&]S:&]P.DE#0U!R;V9I;&4^1&]T($=A:6X@
M,C`E/"]P:&]T;W-H;W`Z24-#4')O9FEL93X*("`@("`@("`@/'!H;W1O<VAO
M<#I(:7-T;W)Y+SX*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"CP_>'!A8VME="!E;F0](G<B/S[_X@.@24-#7U!23T9)3$4``0$`
M``.0041"10(0``!P<G1R1U)!65A96B`'SP`&``,```````!A8W-P05!03```
M``!N;VYE`````````````````````0``]M8``0````#3+4%$0D4`````````
M``````````````````````````````````````````````````````5C<')T
M````P````#)D97-C````]````&=W='!T```!7````!1B:W!T```!<````!1K
M5%)#```!A````@QT97AT`````$-O<'ER:6=H="`Q.3DY($%D;V)E(%-Y<W1E
M;7,@26YC;W)P;W)A=&5D````9&5S8P`````````-1&]T($=A:6X@,C`E````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````!865H@````````]M8`
M`0````#3+5A96B``````````````````````8W5R=@````````$`````$``@
M`#``0`!0`&$`?P"@`,4`[`$7`40!=0&H`=X"%@)2`I`"T`,3`UD#H0/L!#D$
MB`3:!2X%A07>!CD&E@;V!U<'NP@B"(H(]`EA"=`*00JT"RD+H`P:#)4-$@V2
M#A,.E@\<#Z,0+!"X$441U!)E$O@3C10D%+T55Q7T%I(7,A?4&'@9'AG&&F\;
M&QO(''8=)QW:'HX?1!_\(+4A<2(N(NTCK21P)30E^2;!)XHH52DB*?`JP"N2
M+&4M.BX1+NHOQ#"@,7TR7#,]-!\U`S7I-M`WN3BD.9`Z?CMM/%X]43Y%/SM`
M,T$L0B9#(D0@11]&($<C2"=)+4HT2SQ,1TU33F!/;U!_49%2I5.Z5-%5Z5<"
M6!Y9.EI86WA<F5V\7N!@!F$M8E9C@&2L9=EG"&@X:6EJG6O1;0=N/V]X<+)Q
M[G,K=&IUJG;L>"]Y='JZ?`%]2GZ5?^&!+H)\@\V%'H9QA\6)&XIRB\N-)8Z!
MC]V1/)*;D_V57Y;#F"B9CYKWG&"=RY\WH*6B%*.%I/:F::?>J52JRZQ$K;ZO
M.;"VLC2SM+4TMK>X.KF_NT6\S;Y6O^#!;,+YQ(?&%\>HR3O*SLQCS?K/DM$K
MTL748=7^UYS9/-K=W'_>(]_(X6[C%N2_YFGH%.G!ZV_M'^[0\(+R-?/J]:#W
M5_D0^LK\A?Y!____[@`F061O8F4`9````````P`5!`$"!`4`````````````
M````````_]L`0P`"`@("`@("`@("`P("`@,$`P("`P0%!`0$!`0%!@4%!04%
M!08&!P<(!P<&"0D*"@D)#`P,#`P,#`P,#`P,#`P,_\(`"P@`&0`\`0$1`/_$
M`(D``0`!!0$````````````````!`@8'"`D$$``!!`("`P``````````````
M!!0%!@$7`P<P`A81```$`P8$`@L````````````!`@.2!#01(3'ADP42(A1$
M,A,0,$%187%R(S,D%A(``0,#`P4!`0```````````0`1(?`QP4%A<1`@48&1
ML='_V@`(`0$"```!RH1.O&\N2N"0GR7GU+S,&D6X=VU"**I__]H`"`$!``$%
M`MPU(W#4C<-2-PU(W!41'VU())F!ML)8N(:JAJJ&JH:JAJJ,XSC,&BFU:UG;
M?BV*(8HABB&*(8HSTZHYI*P14%%0G!X?_]H`"`$!`08_`N[TLQW>EF.[TLQW
M>EF,9O2S&XNNFJ>VF9?_`%4+N-IKB]A?()7M\VGS%&HBE7+$N\N)\&/HIW8#
M%.[`8IW8#%.[`8IG8#!D?*98D80G8T.]8:5<*V^6ZR^\=+U37]!Y'Y+#\-GA
M^KXBD9@(4C,!"D9@(4C,!"D9@(;M/;J[TTBN:-V4:9L^XDU6V'[K@F6VR31+
M-),S*R\^;&\[_5?_V@`(`0$"`3\AW?JF[]4W?JF[]4#P<`U+T<T+'9B]S[(F
M<67=P8;]*)PJ)PJ)PJ)PJAP@)DIH1&S(Q&Z^Q#ILN'R]W&V-"H/"H/"H/"H/
M"9FCX0&HQA.Y8Y3<TX[*ZERF[O'/35?_V@`(`0$"```0$/;]#O_:``@!`0(!
M/Q#LJ5*A0@!B1),-2UR`1;`[!"Q<!R-T3L'0B;EAD6)@VK<]O'CQXAX2O8!,
MUNXPD""12"/"?>4T0/(C88$$.O[>8[_[3M-FS9NR"(+AKJC;>%POG!"(U.F@
5,N",Z^UX03+/OVFR-^#*\>_SH__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>arrow_003.jpg
<TEXT>
begin 644 arrow_003.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X06\17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G
M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,3,Z,#4Z
M,3`@,3,Z,#<Z-30``````Z`!``,````!__\``*`"``0````!````>*`#``0`
M```!````&0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```2&````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`&0!X`P$B``(1`0,1`?_=``0`
M"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`Z3)_QE?57I>1;TPS4<%[L;TV-AK?2/H[
M*VM]K6,V>U#_`/':^JO[[_N7DOUJPLU_UGZPYN/:0[.R2"&.((-MG&BR_L&?
M_P!QK?\`,=_<DI]N_P#':^JO[[_N2_\`':^JO[[_`+EXC]@S_P#N-;_F._N2
M^P9__<:W_,=_<DI]N_\`':^JO[[_`+DO_':^JO[[_N7B/V#/_P"XUO\`F._N
M2^P9_P#W&M_S'?W)*?;O_':^JO[[_N2_\=KZJ_OO^Y>(_8,__N-;_F._N2^P
M9_\`W&M_S'?W)*?;O_':^JO[[_N2_P#':^JO[[_N7B/V#/\`^XUO^8[^Y+[!
MG_\`<:W_`#'?W)*?;O\`QVOJK^^_[DO_`!VOJK^^_P"Y>(_8,_\`[C6_YCO[
MDOL&?_W&M_S'?W)*?;O_`!V?JK^^_P"Y<UE_XVWT?61]V*3D=(>QC?2=H6F?
MTMK/[*\W^P9T?T:W_,=_<A65V5.V6L<QPY:X0?N<DI^G.G=3P>IX[<C"M;;6
MX`^TS$B8<DO%/\7?3_K<_J55W22^C#;8TY+[)%1;_*9^?[?W$DE/_]#U`XV.
MXDFIA)U)+0E]DQ?]$S_-"*DDI%]DQ?\`1,_S0E]DQ?\`1,_S0BI)*1?9,7_1
M,_S0E]DQ?]$S_-"*DDI%]DQ?]$S_`#0E]DQ?]$S_`#0BI)*1?9,7_1,_S0E]
MDQ?]$S_-"*DDI%]DQ?\`1,_S0E]DQ?\`1,_S0BI)*0_9<7_1,_S0N%ZW_BX=
MUSZVV=0RBVKIPK9M:SESFGW-</S?:N_2[)*18V-1BTMHQV-KK8`UK6B-!H$D
M5))3_]G_[0GB4&AO=&]S:&]P(#,N,``X0DE-!`0```````<<`@```@`"`#A"
M24T$)0``````$$8,\HDFN%;:L)P!H;"GD'<X0DE-`^T``````!``2`````$`
M`0!(`````0`!.$))300F```````.`````````````#^````X0DE-!`T`````
M``0```!X.$))3009```````$````'CA"24T#\P``````"0```````````0`X
M0DE-!`H```````$``#A"24TG$```````"@`!``````````(X0DE-`_0`````
M`!(`-0````$`+0````8```````$X0DE-`_<``````!P``/______________
M______________\#Z```.$))300(```````0`````0```D````)``````#A"
M24T$'@``````!``````X0DE-!!H``````T<````&```````````````9````
M>`````D`80!R`'(`;P!W`%\`,``P`#,````!````````````````````````
M``$``````````````'@````9``````````````````````$`````````````
M````````````$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC````
M`0```````%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``
M````````0G1O;6QO;F<````9`````%)G:'1L;VYG````>`````9S;&EC97-6
M;$QS`````4]B:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG
M``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI
M8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI
M8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````
M!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG
M````&0````!29VAT;&]N9P```'@````#=7)L5$585`````$```````!N=6QL
M5$585`````$```````!-<V=E5$585`````$```````9A;'1486=415A4````
M`0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4````
M`0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E
M9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'
M9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y
M<&4`````3F]N90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T
M;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S
M971L;VYG```````X0DE-!"@```````P````!/_`````````X0DE-!!0`````
M``0````".$))300,``````2B`````0```'@````9```!:```(R@```2&`!@`
M`?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``9`'@#`2(``A$!`Q$!_]T`!``(_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#I,G_&5]5>EY%O3#-1P7NQO38V&M](^CLK:WVM8S9[4/\`\=KZJ_OO
M^Y>2_6K"S7_6?K#FX]I#L[)((8X@@VV<:++^P9__`'&M_P`QW]R2GV[_`,=K
MZJ_OO^Y+_P`=KZJ_OO\`N7B/V#/_`.XUO^8[^Y+[!G_]QK?\QW]R2GV[_P`=
MKZJ_OO\`N2_\=KZJ_OO^Y>(_8,__`+C6_P"8[^Y+[!G_`/<:W_,=_<DI]N_\
M=KZJ_OO^Y+_QVOJK^^_[EXC]@S_^XUO^8[^Y+[!G_P#<:W_,=_<DI]N_\=KZ
MJ_OO^Y+_`,=KZJ_OO^Y>(_8,_P#[C6_YCO[DOL&?_P!QK?\`,=_<DI]N_P#'
M:^JO[[_N2_\`':^JO[[_`+EXC]@S_P#N-;_F._N2^P9__<:W_,=_<DI]N_\`
M'9^JO[[_`+ES67_C;?1]9'W8I.1TA[&-])VA:9_2VL_LKS?[!G1_1K?\QW]R
M%9794[9:QS'#EKA!^YR2GZ<Z=U/!ZGCMR,*UMM;@#[3,2)AR2\4_Q=]/^MS^
MI57=)+Z,-MC3DOLD5%O\IGY_M_<224__T/4#C8[B2:F$G4DM"7V3%_T3/\T(
MJ22D7V3%_P!$S_-"7V3%_P!$S_-"*DDI%]DQ?]$S_-"7V3%_T3/\T(J22D7V
M3%_T3/\`-"7V3%_T3/\`-"*DDI%]DQ?]$S_-"7V3%_T3/\T(J22D7V3%_P!$
MS_-"7V3%_P!$S_-"*DDI#]EQ?]$S_-"X7K?^+AW7/K;9U#*+:NG"MFUK.7.:
M?<UP_-]J[]+LDI%C8U&+2VC'8VNM@#6M:(T&@214DE/_V3A"24T$(0``````
M50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`
M00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`,@````$`.$))
M300&```````'``8!`0`#`0#_X3JL:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E
M4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE
M=&$O(B!X.GAM<'1K/2(S+C$N,2TQ,3$B/@H@("`\<F1F.E)$1B!X;6QN<SIR
M9&8](FAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/@H@("`@("`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@
M("`@("`@("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B/@H@("`@("`@("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O
M<FUA=#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("`@("`@("`@('AM;&YS.GAA<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(^"B`@("`@("`@(#QX87`Z
M0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S/"]X87`Z
M0W)E871O<E1O;VP^"B`@("`@("`@(#QX87`Z0W)E871E1&%T93XR,#$S+3`U
M+3$P5#$R.C0S.C$U*S`U.C,P/"]X87`Z0W)E871E1&%T93X*("`@("`@("`@
M/'AA<#I-;V1I9GE$871E/C(P,3,M,#4M,3!4,3,Z,#<Z-30K,#4Z,S`\+WAA
M<#I-;V1I9GE$871E/@H@("`@("`@("`\>&%P.DUE=&%D871A1&%T93XR,#$S
M+3`U+3$P5#$S.C`W.C4T*S`U.C,P/"]X87`Z365T861A=&%$871E/@H@("`@
M("`\+W)D9CI$97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*("`@("`@("`@("`@>&UL;G,Z>&%P34T](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B`@("`@("`@("`@('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R
M8V52968C(CX*("`@("`@("`@/'AA<$U-.D1O8W5M96YT240^=75I9#HU-S$Y
M1D1&0C0P0CE%,C$Q038S04)",#0W,S`U-S$T0CPO>&%P34TZ1&]C=6UE;G1)
M1#X*("`@("`@("`@/'AA<$U-.DEN<W1A;F-E240^=75I9#HU0T-%1$$X-C0T
M0CE%,C$Q038S04)",#0W,S`U-S$T0CPO>&%P34TZ26YS=&%N8V5)1#X*("`@
M("`@("`@/'AA<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*("`@("`@("`@("`@/'-T4F5F.FEN<W1A;F-E240^=75I9#HU-C$Y
M1D1&0C0P0CE%,C$Q038S04)",#0W,S`U-S$T0CPO<W12968Z:6YS=&%N8V5)
M1#X*("`@("`@("`@("`@/'-T4F5F.F1O8W5M96YT240^=75I9#HU-C$Y1D1&
M0C0P0CE%,C$Q038S04)",#0W,S`U-S$T0CPO<W12968Z9&]C=6UE;G1)1#X*
M("`@("`@("`@/"]X87!-33I$97)I=F5D1G)O;3X*("`@("`@/"]R9&8Z1&5S
M8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B`@("`@("`@("`@('AM;&YS.G1I9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO
M=&EF9B\Q+C`O(CX*("`@("`@("`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF
M9CI/<FEE;G1A=&EO;CX*("`@("`@("`@/'1I9F8Z6%)E<V]L=71I;VX^-S(P
M,#`P+S$P,#`P/"]T:69F.EA297-O;'5T:6]N/@H@("`@("`@("`\=&EF9CI9
M4F5S;VQU=&EO;CXW,C`P,#`O,3`P,#`\+W1I9F8Z65)E<V]L=71I;VX^"B`@
M("`@("`@(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO
M;E5N:70^"B`@("`@("`@(#QT:69F.DYA=&EV941I9V5S=#XR-38L,C4W+#(U
M."PR-3DL,C8R+#(W-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S`Q
M+#,Q."PS,3DL-3(Y+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S`U+#,Q-2PS,S0S
M,CLY1#E$.3,P-S,Y.3=%1C5".$)!,S,Y0CA#0S4P1$(W-#PO=&EF9CI.871I
M=F5$:6=E<W0^"B`@("`@(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`@("`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@("`@("`@("`@("!X;6QN<SIE
M>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B`@("`@("`@
M(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXQ,C`\+V5X:68Z4&EX96Q81&EM96YS
M:6]N/@H@("`@("`@("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^,C4\+V5X:68Z
M4&EX96Q91&EM96YS:6]N/@H@("`@("`@("`\97AI9CI#;VQO<E-P86-E/BTQ
M/"]E>&EF.D-O;&]R4W!A8V4^"B`@("`@("`@(#QE>&EF.DYA=&EV941I9V5S
M=#XS-C@V-"PT,#DV,"PT,#DV,2PS-S$R,2PS-S$R,BPT,#DV,BPT,#DV,RPS
M-S4Q,"PT,#DV-"PS-C@V-RPS-C@V."PS,S0S-"PS,S0S-RPS-#@U,"PS-#@U
M,BPS-#@U-2PS-#@U-BPS-S,W-RPS-S,W."PS-S,W.2PS-S,X,"PS-S,X,2PS
M-S,X,BPS-S,X,RPS-S,X-"PS-S,X-2PS-S,X-BPS-S,Y-BPT,30X,RPT,30X
M-"PT,30X-BPT,30X-RPT,30X."PT,30Y,BPT,30Y,RPT,30Y-2PT,3<R."PT
M,3<R.2PT,3<S,"PT,3DX-2PT,3DX-BPT,3DX-RPT,3DX."PT,3DX.2PT,3DY
M,"PT,3DY,2PT,3DY,BPT,3DY,RPT,3DY-"PT,3DY-2PT,3DY-BPT,C`Q-BPP
M+#(L-"PU+#8L-RPX+#DL,3`L,3$L,3(L,3,L,30L,34L,38L,3<L,3@L,C`L
M,C(L,C,L,C0L,C4L,C8L,C<L,C@L,S`[-3!%040T13A$,#<P0D0T,44V.3`P
M0SDS-4,Y1#$Q13@\+V5X:68Z3F%T:79E1&EG97-T/@H@("`@("`\+W)D9CI$
M97-C<FEP=&EO;CX*("`@("`@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*("`@("`@("`@("`@>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(CX*("`@("`@("`@/'!H;W1O<VAO<#I#
M;VQO<DUO9&4^,3PO<&AO=&]S:&]P.D-O;&]R36]D93X*("`@("`@("`@/'!H
M;W1O<VAO<#I)0T-0<F]F:6QE/D1O="!'86EN(#(P)3PO<&AO=&]S:&]P.DE#
M0U!R;V9I;&4^"B`@("`@("`@(#QP:&]T;W-H;W`Z2&ES=&]R>2\^"B`@("`@
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@("`\+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@
M96YD/2)W(C\^_^(#H$E#0U]04D]&24Q%``$!```#D$%$0D4"$```<')T<D=2
M05E865H@!\\`!@`#````````86-S<$%04$P`````;F]N90``````````````
M``````$``/;6``$`````TRU!1$)%````````````````````````````````
M```````````````````````````````%8W!R=````,`````R9&5S8P```/0`
M``!G=W1P=````5P````48FMP=````7`````4:U120P```80```(,=&5X=```
M``!#;W!Y<FEG:'0@,3DY.2!!9&]B92!3>7-T96US($EN8V]R<&]R871E9```
M`&1E<V,`````````#41O="!'86EN(#(P)0``````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````6%E:(````````/;6``$`````TRU865H@````````
M`````````````&-U<G8````````!`````!``(``P`$``4`!A`'\`H`#%`.P!
M%P%$`74!J`'>`A8"4@*0`M`#$P-9`Z$#[`0Y!(@$V@4N!84%W@8Y!I8&]@=7
M![L((@B*"/0)80G0"D$*M`LI"Z`,&@R5#1(-D@X3#I8/'`^C$"P0N!%%$=02
M91+X$XT4)!2]%5<5]!:2%S(7U!AX&1X9QAIO&QL;R!QV'2<=VAZ.'T0?_""U
M(7$B+B+M(ZTD<"4T)?DFP2>**%4I(BGP*L`KDBQE+3HN$2[J+\0PH#%],EPS
M/30?-0,UZ3;0-[DXI#F0.GX[;3Q>/5$^13\[0#-!+$(F0R)$($4?1B!'(T@G
M22U*-$L\3$=-4TY@3V]0?U&14J53NE315>E7`E@>63I:6%MX7)E=O%[@8`9A
M+6)68X!DK&799PAH.&EI:IUKT6T';C]O>'"R<>YS*W1J=:IV['@O>71ZNGP!
M?4I^E7_A@2Z"?(/-A1Z&<8?%B1N*<HO+C26.@8_=D3R2FY/]E5^6PY@HF8^:
M]YQ@G<N?-Z"EHA2CA:3VIFFGWJE4JLNL1*V^KSFPMK(TL[2U-+:WN#JYO[M%
MO,V^5K_@P6S"^<2'QA?'J,D[RL[,8\WZSY+1*]+%U&'5_M><V3S:W=Q_WB/?
MR.%NXQ;DO^9IZ!3IP>MO[1_NT/""\C7SZO6@]U?Y$/K*_(7^0?___^X`)D%D
M;V)E`&0```````,`%00!`@0%`````````````````````/_;`$,``@("`@("
M`@("`@,"`@(#!`,"`@,$!00$!`0$!08%!04%!04&!@<'"`<'!@D)"@H)"0P,
M#`P,#`P,#`P,#`P,#/_"``L(`!D`>`$!$0#_Q`![``$``04`````````````
M`````@$$!P@)$``"`@,``P$`````````````!!0&`0,7`@4',!$```8"`0,$
M`P````````````$"D@,TD01#$3$%46$2$T`R%!(``@$#`P4!`0``````````
M``$1\"'!,6&1,$%1<8&QH?_:``@!`0(```'*H`*83Z`<*``2LMRNC8`(Z>[F
MW0`(*__:``@!`0`!!0+KU7.O5<Z]5SKU7.O5<Z]5SKU7.O5<Z]5SKU7.O5<Z
M]5SKM7/6_6-^JPJ.*O:8C9$;(C9$;(C9$;(C9$;(C9$;(C9$;(C1G&?'/RU"
MV8]A"3(29"3(29"3(29"3(29"3(29"3(29#4%_F.6[1KUZ]?C^__V@`(`0$!
M!C\"YL#FP.;`YL#FP.;`YL#FP.;`YL#FP.;`YL#:3M*/8\)N;)?0I?[01^P+
M8TYT;$*NTB#ZD*LK#%65ABK*PQ5E88JRL,596&*LK#%65ABK*PQ5E88JRL,5
M96&*LK#'Q-)DHNY&-;9UC7K^")2OZONZ_6KV2GU%6)I"K$TA5B:0JQ-(58FD
M*L32%6)I"K$TA5B:0JQ-(58FD*L32%:)I#R/F/+?!.C_`%E-J:J.TB??T!(C
M0F-!=DI+H7X'_]H`"`$!`@$_(>H9F9F9F9GL"I;U87*M4>9<GX*$@L5+@J7!
M4N"I<%2X*EP5+@J7!4N"I<%2X*EP6TJ?T-K20E#3\1!#4DV&+ZB?9Z%!X*#P
M4'@H/!0>"@\%!X*#P4'@H/!0>"@\$-5_"+AP`[AQ#1,6-)F+(^+JO1^CQ\$?
M_]H`"`$!`@``$``&`!@`&``?_]H`"`$!`@$_$-GA-GA-GA-GA-GA-GA-GA-G
MA-GA-GA-GA-GA+ZF&5+2O[%A&I=$VA:,DVEQ9#Q=0B9WV&M^K/GSY\^?/GSY
M\^?9$C>NKL7[D/GE3(UZ(^QJ11$X:N$XX=^K,F3)DR9,F3)DR9/3MIZ]\.1:
;CRMJ8)"2[A*XHB&4))"6BZRK3U_1I^O]/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>AGREEMENT WITH ASTRAZENECA<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_AgreementWithAstrazenecaAbstract', window );"><strong>Agreement With Astrazeneca</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock', window );">AGREEMENT WITH ASTRAZENECA</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="display: inline; font-weight: bold">(4)&#160;&#160;&#160;&#160;&#160;&#160; AGREEMENT WITH ASTRAZENECA:</font></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>In January 2007, the Company entered into an exclusive global research collaboration and license agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. In June 2008, the license agreement was amended to include additional compounds and associated intellectual property developed by the Company. In December 2008, the license agreement was further amended to include additional compounds and associated intellectual property developed by the Company and extended the research collaboration for an additional year through January 2010. In September 2009, the license agreement was further amended to modify royalty rates and milestone payments. The collaboration is based on the Company&#8217;s melanocortin receptor obesity program and includes access to compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development. As part of the September 2009 amendment to the research collaboration and license agreement, the Company agreed to conduct additional studies on the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>In December 2009 and 2008, the Company also entered into clinical trial sponsored research agreements with AstraZeneca, under which the Company agreed to conduct studies of the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters. Under the terms of these clinical trial agreements, AstraZeneca paid $5,000,000 as of March 31, 2009 upon achieving certain objectives and paid all costs associated with these studies. The Company recognized $10,361 as revenue in the nine months ended March 31, 2013 and $23,996 and $62,705, respectively, as revenue in the three and nine months ended March 31, 2012 under these clinical trial sponsored research agreements.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">The Company received an up-front payment of $10,000,000 from AstraZeneca on execution of the research collaboration and license agreement. Under the September 2009 amendment the Company was paid an additional $5,000,000 in consideration of reduction of future milestones and royalties and providing specific materials to AstraZeneca. The Company is now eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets. In addition, the Company is eligible to receive mid to high single digit royalties on sales of any approved products. AstraZeneca assumed responsibility for product commercialization, product discovery and development costs, with both companies contributing scientific expertise in the research collaboration. The Company provided research services to AstraZeneca through January 2010, the expiration of the research collaboration portion of the research collaboration and license agreement, at a contractual rate per full-time-equivalent employee.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_AgreementWithAstrazenecaAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_AgreementWithAstrazenecaAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermContractsOrProgramsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term contracts or programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 45<br><br> -Paragraph 12, 15, 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Chapter 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 275<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471736&amp;loc=d3e54651-109401<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Chapter 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 35<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6407836&amp;loc=d3e58033-111643<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section C<br><br> -Chapter 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 81-1<br><br> -Paragraph 94<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 405<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471944&amp;loc=d3e56414-109416<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 6<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermContractsOrProgramsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]B,#1B8C)E-U]A8V(U7S1D-C9?.38U-5]A
M,3AD.&1F,&(S830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`T
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U5N,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7T]P93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]21T%.
M25I!5$E/3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D)!4TE37T]&7U!215-%3E1!5$E/3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-534U!4EE?3T9?4TE'3DE&24-!3E1?04-#3U5.
M5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%'4D5%
M345.5%]7251(7T%35%)!6D5.14-!/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1D%)4E]604Q515]-14%355)%345.5%,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?
M15%52519/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M3U)'04Y)6D%424].7U!O;&EC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4U5-34%265]/1E]324=.249)0T%.5%]!0T-/54Y4
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9!25)?
M5D%,545?345!4U5214U%3E137U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D]21T%.25I!5$E/3E]$971A:6QS7TYA<G)A
M=&EV93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-5
M34U!4EE?3T9?4TE'3DE&24-!3E1?04-#3U5.5#(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!1U)%14U%3E1?5TE42%]!4U1205I%
M3D5#05]$970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y&04E27U9!3%5%7TU%05-54D5-14Y44U]$971A:6P\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%52519
M7T1E=&%I;'-?3F$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3
M='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@
M(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E
M8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z
M4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X
M.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W
M:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#1B8C)E-U]A8V(U
M7S1D-C9?.38U-5]A,3AD.&1F,&(S830-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8C`T8F(R93=?86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T
M+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y'044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA
M=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`Q,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$;V-U;65N="!!;F0@16YT:71Y($EN9F]R;6%T:6]N/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I
M<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E!!
M3$%424X@5$5#2$Y/3$]'2453($E.0SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@
M2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`P.3$Q,C$V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UE;F1M96YT
M($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/F9A;'-E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XM+3`V+3,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<R!%;G1I='D@82!796QL+6MN;W=N
M(%-E87-O;F5D($ES<W5E<C\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<R!%;G1I='D@82!6;VQU;G1A<GD@1FEL97(_/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27,@16YT:71Y)W,@4F5P;W)T
M:6YG(%-T871U<R!#=7)R96YT/SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L.30W+#DQ,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^43,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#1B8C)E-U]A8V(U7S1D-C9?
M.38U-5]A,3AD.&1F,&(S830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO8C`T8F(R93=?86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T+U=O<FMS
M:&5E=',O4VAE970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%!04<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5;G5A
M9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(S+#4S-RPP-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L.#(W+#$Y.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R;2!I
M;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PY
M.3@L-S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPV,S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<W1R:6-T960@0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0X."PQ.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,S(L,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#`R,RPY-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<S
M-BPX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S`W+#`R,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q."PV-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@L,S,W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(T
M+#DY,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`L,S@Y+#,S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,S@P+#0X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&QI
M86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#87!I=&%L(&QE87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU.3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPR-S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A
M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S,RPT-#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M.30L.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#DX-BPR-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#<P-BPT.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8V]M<&5N
M<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,S,L,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW-#,L,C<T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-3<L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87!I=&%L(&QE87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#`T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Y+#DP.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-S8T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(L-C<W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L-SDP+#`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-30Y+#4X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q
M=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E9F5R<F5D('-T;V-K(&]F("0N,#$@<&%R('9A;'5E("T@875T:&]R
M:7IE9"`Q,"PP,#`L,#`P('-H87)E<SL@4V5R:65S($$@0V]N=F5R=&EB;&4[
M(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@-"PV.3<@<VAA<F5S(&%S(&]F($UA
M<F-H(#,Q+"`R,#$S(&%N9"`T+#DY-R!A<R!O9B!*=6YE(#,P+"`R,#$R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@;V8@)"XP,2!P87(@=F%L=64@+2!A=71H;W)I>F5D(#(P,"PP,#`L,#`P
M('-H87)E<SL@:7-S=65D(&%N9"!O=71S=&%N9&EN9R`S."PY-#<L.3$R('-H
M87)E<R!A<R!O9B!-87)C:"`S,2P@,C`Q,R!A;F0@,S0L.3`P+#4Y,2!A<R!O
M9B!*=6YE(#,P+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS.#DL-#<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S0Y+#`P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,BPU.3<L,3,T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0P
M+#<R-2PQ,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(U-2PS.#<L-#$Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S.2PR-#,L,C@U*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-RPU.3DL,C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,S`L.#DX/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL
M:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,P+#,X.2PS,S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,S@P+#0X-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C`T8F(R93=?
M86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P
M8C-A-"]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$583D%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H
M965T<R`H56YU861I=&5D*2`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W1A=&5M96YT(&]F($9I;F%N8VEA;"!0;W-I=&EO;B!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL
M(%-E<FEE<R!!($-O;G9E<G1I8FQE+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8Y-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.3DW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL(%-E<FEE<R!!($-O;G9E<G1I8FQE+"!S:&%R97,@;W5T<W1A;F1I
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-CDW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY.3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L.30W+#DQ
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,T+#DP,"PU.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PY-#<L.3$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L
M.3`P+#4Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8C`T8F(R93=?86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(P-&)B,F4W7V%C8C5?-&0V-E\Y
M-C4U7V$Q.&0X9&8P8C-A-"]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5$24%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E
M9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%5N875D:71E9"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%-T871E;65N="!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)%5D5.5453.CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,RPY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P+#,V,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C(L-S`U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]0
M15)!5$E.1R!%6%!%3E-%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DT-"PU.#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<P-2PV-C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#<S,RPV-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+#8X,RPQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W.2PQ.3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,T
M-"PX-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#$T,2PW-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#0W,RPY.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#(S+#<X
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L,#4P+#4R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#@W-2PT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPQ-3<L,3`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P
M97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,#(S
M+#<X-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@V+#`R-BPU,C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3`L.#8U+#`V,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPP.30L,SDW*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/5$A%4B!)3D-/344@*$584$5.4T4I.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT(&EN8V]M93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PV,CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#DU-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#`Q-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X
M+#(R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PQ,#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PX,S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-"PW-#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPV-3`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I
M;B!F86ER('9A;'5E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#`V.2PQ-C4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'86EN(&]N(&1I<W!O<VET:6]N(&]F('-U<'!L:65S
M(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PV,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN
M8V]M92`H97AP96YS92DL(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PU,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#@R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<L,#,R+#(W-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPR-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&)E9F]R
M92!I;F-O;64@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#0L,#$U+#(U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@V+#`R,"PW,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.#DW+#,S-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPP-C@L,3$X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC;VUE('1A>"!B96YE9FET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<U,RPR,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`V."PR
M,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.150@3$]34SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@T+#`Q-2PR-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@V+#`R,"PW,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-BPQ-#0L,3(V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3$L.3DY
M+#@X-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!C;VUM;VX@
M<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#`N,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,"XS-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@;G5M8F5R
M(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@=7-E9"!I;B!C;VUP=71I
M;F<@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`V+#0R-"PT-#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-"PY,#`L-3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.30L-S4T+#<X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,T+#DP,"PU.3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(P-&)B,F4W7V%C8C5?-&0V-E\Y
M-C4U7V$Q.&0X9&8P8C-A-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]B,#1B8C)E-U]A8V(U7S1D-C9?.38U-5]A,3AD.&1F,&(S830O5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4D=!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L
M;W=S("A5;F%U9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!/
M4$52051)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,38L,30T+#$R-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q+#DY.2PX.#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@
M8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@
M86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#(L,S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S,W+#$R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I;G1E<F5S="!A;F0@86UO<G1I
M>F%T:6]N(&]N('!R96UI=6TO9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0U,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@<V%L92!O
M9B!S=7!P;&EE<R!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T+#8R,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@T+#<P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<U+#,R.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q
M-BPS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN8W)E87-E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,#8Y+#$V-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-RPV,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L-30Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N
M<V5S+"!R97-T<FEC=&5D(&-A<V@@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8P+#0X,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-2PX.3(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,S@L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`L.3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S+"!C;VUP96YS871I;VX@
M86YD(&1E9F5R<F5D(')E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L,3@Q+#4P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-S@L,30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F5A<FYE9"!R979E;G5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#8L,3`U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-3<W+#$X-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PP-3DL
M-#<U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@24Y615-424Y'($%#5$E6
M251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!S=7!P;&EE<R!A;F0@97%U:7!M
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S97,@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S`L-S(W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H
M87-E<R!O9B!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-2PY.3@L,C@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I
M9&5D(&)Y(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V+#`V-"PS.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,S`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(
M($9,3U=3($923TT@1DE.04Y#24Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&]N(&-A
M<&ET86P@;&5A<V4@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$V+#4T-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R.2PV,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F('=I=&AH;VQD
M:6YG('1A>&5S(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!U;FET<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0L-S@U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O8V5E9',@9G)O;2!T:&4@<V%L92!O9B!C;VUM;VX@<W1O8VL@
M=6YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T+#0P,BPW
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I
M;BD@9FEN86YC:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,T+#,U,2PT,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R.2PV,34I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.150@24Y#4D5!4T4@*$1%
M0U)%05-%*2!)3B!#05-(($%.1"!#05-(($5154E604Q%3E13/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW,#DL.#4U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,#DY+#,Y,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-!4T@@04Y$($-!4T@@15%5259!3$5.5%,L(&)E9VEN;FEN9R!O9B!P97)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#(W+#$Y.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M+#@V.2PV,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-!4T@@04Y$($-!4T@@15%5259!3$5.5%,L(&5N9"!O9B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#4S-RPP
M-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#<W,"PR-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%,($-!4T@@1DQ/5R!)
M3D9/4DU!5$E/3CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T+#<T-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BPV-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V(P-&)B,F4W7V%C8C5?-&0V
M-E\Y-C4U7V$Q.&0X9&8P8C-A-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]B,#1B8C)E-U]A8V(U7S1D-C9?.38U-5]A,3AD.&1F,&(S830O5V]R
M:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3U)'04Y)6D%424]./&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS
M;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E
M;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/4D=!3DE:051)3TX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@:71A;&EC.R!D:7-P;&%Y.B!I;FQI;F4G/DYA='5R92!O9B!"=7-I;F5S
M<SPO9F]N=#X@)B,X,C$Q.R!086QA=&EN(%1E8VAN;VQO9VEE<RP@26YC+B`H
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O
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M9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M)SX\8G(@+SX-"CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M;F4@;W(@=VET:"!O=&AE<G,L(&UU<W0@<W5C8V5S<V9U;&QY(&1E=F5L;W`@
M86YD(&-O;6UE<F-I86QI>F4@:71S('1E8VAN;VQO9VEE<R!A;F0@<')O<&]S
M960@<')O9'5C=',L(&-O;F1U8W0@<W5C8V5S<V9U;"!P<F5C;&EN:6-A;"!S
M='5D:65S(&%N9"!C;&EN:6-A;"!T<FEA;',L(&]B=&%I;B!R97%U:7)E9"!R
M96=U;&%T;W)Y(&%P<')O=F%L<R!A;F0@<W5C8V5S<V9U;&QY(&UA;G5F86-T
M=7)E(&%N9"!M87)K970@<W5C:"!T96-H;F]L;V=I97,@86YD('!R;W!O<V5D
M('!R;V1U8W1S+B!4:&4@=&EM92!R97%U:7)E9"!T;R!R96%C:"!P<F]F:71A
M8FEL:71Y(&ES(&AI9VAL>2!U;F-E<G1A:6XL(&%N9"!T:&5R92!C86X@8F4@
M;F\@87-S=7)A;F-E('1H870@=&AE($-O;7!A;GD@=VEL;"!B92!A8FQE('1O
M(&%C:&EE=F4@<')O9FET86)I;&ET>2!O;B!A('-U<W1A:6YE9"!B87-I<RP@
M:68@870@86QL+CPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$)VUA<F=I;BUL969T.B`S
M-G!T)SX\+V9O;G0^07,@;V8@36%R8V@@,S$L(#(P,3,L('1H92!#;VUP86YY
M)B,X,C$W.W,@8V%S:"P@8V%S:"!E<75I=F%L96YT<R!A;F0@<VAO<G0M=&5R
M;2!I;G9E<W1M96YT<R!W97)E("0R.2XU;6EL;&EO;BX@5&AE($-O;7!A;GD@
M:6YT96YD<R!T;R!U=&EL:7IE(&5X:7-T:6YG(&-A<&ET86P@<F5S;W5R8V5S
M(&9O<B!G96YE<F%L(&-O<G!O<F%T92!P=7)P;W-E<R!A;F0@=V]R:VEN9R!C
M87!I=&%L+"!I;F-L=61I;F<@:71S(&-L:6YI8V%L('1R:6%L('!R;V=R86T@
M=VET:"!B<F5M96QA;F]T:61E(&9O<B!&4T0L('!R96-L:6YI8V%L(&%N9"!C
M;&EN:6-A;"!D979E;&]P;65N="!O9B!I=',@<&5P=&ED92!M96QA;F]C;W)T
M:6X@<F5C97!T;W(M,2!P<F]G<F%M+"!P<F5C;&EN:6-A;"!A;F0@8VQI;FEC
M86P@9&5V96QO<&UE;G0@;V8@:71S(%!,+3,Y.30@<')O9W)A;2!A;F0@<')E
M8VQI;FEC86P@86YD(&-L:6YI8V%L(&1E=F5L;W!M96YT(&]F(&]T:&5R('!O
M<G1F;VQI;R!P<F]D=6-T<RX\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VLG/CQB<B`O/@T*
M/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^36%N86=E
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I
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M9"!-87)C:"`S,2P@,C`Q,R!A;F0@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H
M<R!E;F1E9"!-87)C:"`S,2P@,C`Q,BP@,3`P)2!O9B!R979E;G5E<R!W97)E
M(&9R;VT@07-T<F%:96YE8V$N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C`T8F(R93=?86-B-5\T9#8V
M7SDV-35?83$X9#AD9C!B,V$T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-"]7;W)K
M<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY"05-)4R!/1B!04D5314Y4051)3TX\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I
M;VXL($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I
M86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!4TE3($]&(%!215-%3E1!5$E/3CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@8F]L9"`Q,'!T
M(%1I;65S($YE=R!2;VUA;B<^*#(I)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[($)!4TE3($]&(%!215-%3E1!5$E/3CH\+V9O;G0^/"]D
M:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF(S$V,#L\+V9O
M;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M(&%N9"!W:71H('1H92!I;G-T<G5C=&EO;G,@=&\@1F]R;2`Q,"U1+B8C,38P
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M9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N;W)M86P@<F5C=7)R:6YG(&%D
M:G5S=&UE;G1S*2!C;VYS:61E<F5D(&YE8V5S<V%R>2!T;R!P<F5S96YT(&9A
M:7)L>2!T:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!P;W-I=&EO;B!A
M<R!O9B!-87)C:"`S,2P@,C`Q,RP@86YD(&ET<R!R97-U;'1S(&]F(&]P97)A
M=&EO;G,@86YD(&ET<R!C87-H(&9L;W=S(&9O<B!T:&4@=&AR964@86YD(&YI
M;F4@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$S(&%N9"`R,#$R+B!4:&4@
M<F5S=6QT<R!O9B!O<&5R871I;VYS(&9O<B!T:&4@=&AR964@86YD(&YI;F4@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$S(&UA>2!N;W0@;F5C97-S87)I
M;'D@8F4@:6YD:6-A=&EV92!O9B!T:&4@<F5S=6QT<R!O9B!O<&5R871I;VYS
M(&5X<&5C=&5D(&9O<B!T:&4@9G5L;"!Y96%R+"!E>&-E<'0@=&AA="!T:&4@
M0V]M<&%N>2!E>'!E8W1S('1O(&EN8W5R(&$@<VEG;FEF:6-A;G0@;&]S<R!F
M;W(@=&AE(&9I<V-A;"!Y96%R(&5N9&EN9R!*=6YE(#,P+"`R,#$S+CPO9F]N
M=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C,38P
M.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG
M/CQF;VYT('-T>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^5&AE
M(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',@<VAO=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@875D
M:71E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@86YD(&YO
M=&5S('1H97)E=&\@:6YC;'5D960@:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!A
M;FYU86P@<F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@
M2G5N92`S,"P@,C`Q,BP@9FEL960@=VET:"!T:&4@4V5C=7)I=&EE<R!A;F0@
M17AC:&%N9V4@0V]M;6ES<VEO;B`H4T5#*2P@=VAI8V@@:6YC;'5D97,@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%S(&]F($IU;F4@,S`L
M(#(P,3(@86YD(#(P,3$@86YD(&9O<B!E86-H(&]F('1H92!F:7-C86P@>65A
M<G,@:6X@=&AE('1H<F5E+7EE87(@<&5R:6]D(&5N9&5D($IU;F4@,S`L(#(P
M,3(N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8C`T8F(R93=?86-B-5\T9#8V7SDV-35?83$X9#AD9C!B
M,V$T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(P-&)B,F4W7V%C
M8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-"]7;W)K<VAE971S+U-H965T,#@N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY354U-
M05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O
M=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U5-34%262!/1B!324=.249)0T%.
M5"!!0T-/54Y424Y'(%!/3$E#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C,38P.SPO9F]N
M=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C,38P.SPO9F]N=#X\
M+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4]
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M.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C,38P
M.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG
M/CQF;VYT('-T>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@:71A;&EC.R!D:7-P;&%Y.B!I;FQI
M;F4G/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',\+V9O;G0^("8C.#(Q,3L@
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!I;F-L=61E(&-A<V@@;VX@:&%N
M9"P@8V%S:"!I;B!B86YK<R!A;F0@86QL(&AI9VAL>2!L:7%U:60@:6YV97-T
M;65N=',@=VET:"!A('!U<F-H87-E9"!M871U<FET>2!O9B!L97-S('1H86X@
M=&AR964@;6]N=&AS+B!#87-H(&5Q=6EV86QE;G1S(&-O;G-I<W0@;V8@)#$Y
M+#`U-BPS,C%I;B!A(&UO;F5Y(&UA<FME="!F=6YD(&%N9"`D,2PT.3DL.3(U
M(&EN(%4N4RX@9V]V97)N;65N="!S96-U<FET:65S(&%T($UA<F-H(#,Q+"`R
M,#$S(&%N9"`D,RPS-#0L,30V:6X@82!M;VYE>2!M87)K970@9G5N9"!A="!*
M=6YE(#,P+"`R,#$R+CPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:R<^/&)R("\^#0H\+V1I
M=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE
M/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@:71A;&EC.R!D:7-P;&%Y.B!I;FQI;F4G/DEN=F5S=&UE
M;G1S/"]F;VYT/B`F(S@R,3$[(%1H92!#;VUP86YY(&1E=&5R;6EN97,@=&AE
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T
M>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^5&AE(&9A:7(@=F%L
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N)SX\9F]N="!S='EL93TS1"=M87)G:6XM;&5F=#H@,S9P="<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9&ES<&QA
M>3H@:6YL:6YE)SY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT
M<SPO9F]N=#X@)B,X,C$Q.R!4:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA
M;"!I;G-T<G5M96YT<R!C;VYS:7-T('!R:6UA<FEL>2!O9B!C87-H(&5Q=6EV
M86QE;G1S+"!A8V-O=6YT<R!R96-E:79A8FQE+"!A8V-O=6YT<R!P87EA8FQE
M+"!A;F0@8V%P:71A;"!L96%S92!O8FQI9V%T:6]N<RX@36%N86=E;65N="!B
M96QI979E<R!T:&%T('1H92!C87)R>6EN9R!V86QU92!O9B!T:&5S92!A<W-E
M=',@86YD(&QI86)I;&ET:65S(&%R92!R97!R97-E;G1A=&EV92!O9B!T:&5I
M<B!R97-P96-T:79E(&9A:7(@=F%L=65S(&)A<V5D(&]N('1H92!S:&]R="UT
M97)M(&YA='5R92!O9B!T:&5S92!I;G-T<G5M96YT<RX\+V9O;G0^/"]D:78^
M#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF(S$V,#L\+V9O;G0^
M/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S
M='EL93TS1"=M87)G:6XM;&5F=#H@,S9P="<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9&ES<&QA>3H@:6YL:6YE)SY0<F]P
M97)T>2!A;F0@17%U:7!M96YT/"]F;VYT/B`F(S@R,3$[(%!R;W!E<G1Y(&%N
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M9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C
M,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XG/CQF;VYT('-T>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF(S$V
M,#L\+V9O;G0^/"]D:78^#0H-"@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`R,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.R`\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&D^
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M/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;B<^/&9O;G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#,V<'0G/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I<W!L87DZ
M(&EN;&EN92<^4F5V96YU92!296-O9VYI=&EO;B`\+V9O;G0^)B,X,C$Q.R!2
M979E;G5E(&9R;VT@8V]R<&]R871E(&-O;&QA8F]R871I;VYS(&%N9"!L:6-E
M;G-I;F<@86=R965M96YT<R!C;VYS:7-T<R!O9B!U<"UF<F]N="!F965S+"!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@9G5N9&EN9RP@86YD(&UI;&5S=&]N
M92!P87EM96YT<RX@3F]N+7)E9G5N9&%B;&4@=7`M9G)O;G0@9F5E<R!A<F4@
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$)VUA<F=I
M;BUL969T.B`S-G!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$)VUA<F=I;BUL969T.B`S
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M=#L@9&ES<&QA>3H@8FQO8VLG/CQB<B`O/@T*/"]D:78^#0H-"CQD:78@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z(#,V<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I
M=&%L:6,[(&1I<W!L87DZ(&EN;&EN92<^3F5T($QO<W,@<&5R($-O;6UO;B!3
M:&%R92`\+V9O;G0^)B,X,C$Q.R!"87-I8R!A;F0@9&EL=71E9"!E87)N:6YG
M<R!P97(@8V]M;6]N('-H87)E("A%4%,I(&%R92!C86QC=6QA=&5D(&EN(&%C
M8V]R9&%N8V4@=VET:"!T:&4@<')O=FES:6]N<R!O9B!&:6YA;F-I86P@06-C
M;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*$9!4T(I($%C8V]U;G1I;F<@4W1A
M;F1A<F1S($-O9&EF:6-A=&EO;B`H05-#*2!4;W!I8R`R-C`L("8C.#(R,#M%
M87)N:6YG<R!P97(@4VAA<F4L)B,X,C(Q.R!W:&EC:"!I;F-L=61E<R!G=6ED
M86YC92!P97)T86EN:6YG('1O('1H92!W87)R86YT<RP@:7-S=65D(&EN(&-O
M;FYE8W1I;VX@=VET:"!T:&4@2G5L>2`S+"`R,#$R('!R:79A=&4@<&QA8V5M
M96YT(&]F9F5R:6YG+"!T:&%T(&%R92!E>&5R8VES86)L92!F;W(@;F]M:6YA
M;"!C;VYS:61E<F%T:6]N(&%N9"P@=&AE<F5F;W)E+"!A<F4@=&\@8F4@8V]N
M<VED97)E9"!I;B!T:&4@8V]M<'5T871I;VX@;V8@8F%S:6,@86YD(&1I;'5T
M960@;F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92X@5&AE(%-E<FEE<R!!(#(P
M,3(@=V%R<F%N=',@=&\@<'5R8VAA<V4@=7`@=&\@,S$L.3@X+#$U,2!S:&%R
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M;'D@,RP@,C`Q,BX\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VLG/CQB<B`O/@T*/"]D:78^
M#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^5&AE(%-E<FEE<R!"
M(#(P,3(@=V%R<F%N=',@=&\@<'5R8VAA<V4@=7`@=&\@,S4L-#@X+#,X,"!S
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M;VUM;VX@<W1O8VL@;VX@4V5P=&5M8F5R(#(W+"`R,#$R("AS964@;F]T92`V
M*2X@1F]R(&1I;'5T960@15!3+"!C;VYT:6YG96YT;'D@:7-S=6%B;&4@<VAA
M<F5S(&%R92!T;R!B92!I;F-L=61E9"!I;B!T:&4@8V%L8W5L871I;VX@87,@
M;V8@=&AE(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D(&EN('=H:6-H('1H92!C
M;VYD:71I;VYS('=E<F4@<V%T:7-F:65D+"!U;FQE<W,@=&AE(&5F9F5C="!W
M;W5L9"!B92!A;G1I+61I;'5T:79E+B!4:&4@4V5R:65S($(@,C`Q,B!W87)R
M86YT<R!H879E(&)E96X@97AC;'5D960@9G)O;2!T:&4@8V%L8W5L871I;VX@
M;V8@9&EL=71E9"!N970@;&]S<R!P97(@8V]M;6]N('-H87)E(&1U<FEN9R!T
M:&4@<&5R:6]D(&9R;VT@2G5L>2`S+"`R,#$R('5N=&EL(%-E<'1E;6)E<B`R
M-RP@,C`Q,B!A<R!T:&4@:6UP86-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N
M/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K)SXF(S$V,#L\+V1I=CX-"@T*/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$)VUA<F=I;BUL969T
M.B`S-G!T)SX\+V9O;G0^07,@;V8@36%R8V@@,S$L(#(P,3,@86YD(#(P,3(L
M(&-O;6UO;B!S:&%R97,@:7-S=6%B;&4@=7!O;B!C;VYV97)S:6]N(&]F(%-E
M<FEE<R!!($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:RP@=&AE(&5X97)C
M:7-E(&]F(&]U='-T86YD:6YG(&]P=&EO;G,@86YD('=A<G)A;G1S("AE>&-L
M=61I;F<@=&AE('=A<G)A;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@
M=&AE($IU;'D@,RP@,C`Q,R!P<FEV871E('!L86-E;65N="!O9F9E<FEN9RDL
M(&%N9"!T:&4@=F5S=&EN9R!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S(&%M
M;W5N=&5D('1O(&%N(&%G9W)E9V%T92!O9B`R-RPV-S(L-#,W(&%N9"`R-RPT
M-C(L-S`P<VAA<F5S+"!R97-P96-T:79E;'DN(%1H97-E('-H87)E(&%M;W5N
M=',@:&%V92!B965N(&5X8VQU9&5D(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F
M(&YE="!L;W-S('!E<B!S:&%R92!A<R!T:&4@:6UP86-T('=O=6QD(&)E(&%N
M=&DM9&EL=71I=F4N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C`T8F(R93=?86-B-5\T9#8V7SDV-35?
M83$X9#AD9C!B,V$T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(P
M-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-"]7;W)K<VAE971S
M+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY!1U)%14U%3E0@5TE42"!!4U1205I%3D5#03QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%G<F5E;65N="!7
M:71H($%S=')A>F5N96-A/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%'4D5%345.5"!7251(($%35%)!6D5.14-!/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+7=E:6=H=#H@8F]L9"<^*#0I)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[($%'4D5%345.5"!7251(($%35%)!6D5.14-!.CPO9F]N=#X\
M+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M=&\@9&ES8V]V97(L(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@8V]M<&]U
M;F1S('1H870@=&%R9V5T(&UE;&%N;V-O<G1I;B!R96-E<'1O<G,@9F]R('1H
M92!T<F5A=&UE;G0@;V8@;V)E<VET>2P@9&EA8F5T97,@86YD(')E;&%T960@
M;65T86)O;&EC('-Y;F1R;VUE+B!);B!*=6YE(#(P,#@L('1H92!L:6-E;G-E
M(&%G<F5E;65N="!W87,@86UE;F1E9"!T;R!I;F-L=61E(&%D9&ET:6]N86P@
M8V]M<&]U;F1S(&%N9"!A<W-O8VEA=&5D(&EN=&5L;&5C='5A;"!P<F]P97)T
M>2!D979E;&]P960@8GD@=&AE($-O;7!A;GDN($EN($1E8V5M8F5R(#(P,#@L
M('1H92!L:6-E;G-E(&%G<F5E;65N="!W87,@9G5R=&AE<B!A;65N9&5D('1O
M(&EN8VQU9&4@861D:71I;VYA;"!C;VUP;W5N9',@86YD(&%S<V]C:6%T960@
M:6YT96QL96-T=6%L('!R;W!E<G1Y(&1E=F5L;W!E9"!B>2!T:&4@0V]M<&%N
M>2!A;F0@97AT96YD960@=&AE(')E<V5A<F-H(&-O;&QA8F]R871I;VX@9F]R
M(&%N(&%D9&ET:6]N86P@>65A<B!T:')O=6=H($IA;G5A<GD@,C`Q,"X@26X@
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M=F5L;W!M96YT+B!!<R!P87)T(&]F('1H92!397!T96UB97(@,C`P.2!A;65N
M9&UE;G0@=&\@=&AE(')E<V5A<F-H(&-O;&QA8F]R871I;VX@86YD(&QI8V5N
M<V4@86=R965M96YT+"!T:&4@0V]M<&%N>2!A9W)E960@=&\@8V]N9'5C="!A
M9&1I=&EO;F%L('-T=61I97,@;VX@=&AE(&5F9F5C=',@;V8@;65L86YO8V]R
M=&EN(')E8V5P=&]R('-P96-I9FEC(&-O;7!O=6YD<R!O;B!F;V]D(&EN=&%K
M92P@;V)E<VET>2!A;F0@;W1H97(@;65T86)O;&EC('!A<F%M971E<G,N/"]F
M;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;B<^/&9O;G0@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#,V<'0G/CPO9F]N=#Y)
M;B!$96-E;6)E<B`R,#`Y(&%N9"`R,#`X+"!T:&4@0V]M<&%N>2!A;'-O(&5N
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M86P@=')I86P@86=R965M96YT<RP@07-T<F%:96YE8V$@<&%I9"`D-2PP,#`L
M,#`P(&%S(&]F($UA<F-H(#,Q+"`R,#`Y('5P;VX@86-H:65V:6YG(&-E<G1A
M:6X@;V)J96-T:79E<R!A;F0@<&%I9"!A;&P@8V]S=',@87-S;V-I871E9"!W
M:71H('1H97-E('-T=61I97,N(%1H92!#;VUP86YY(')E8V]G;FEZ960@)#$P
M+#,V,2!A<R!R979E;G5E(&EN('1H92!N:6YE(&UO;G1H<R!E;F1E9"!-87)C
M:"`S,2P@,C`Q,R!A;F0@)#(S+#DY-B!A;F0@)#8R+#<P-2P@<F5S<&5C=&EV
M96QY+"!A<R!R979E;G5E(&EN('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@
M96YD960@36%R8V@@,S$L(#(P,3(@=6YD97(@=&AE<V4@8VQI;FEC86P@=')I
M86P@<W!O;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N=',N/"]F;VYT/CPO9&EV
M/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/E1H92!#
M;VUP86YY(')E8V5I=F5D(&%N('5P+69R;VYT('!A>6UE;G0@;V8@)#$P+#`P
M,"PP,#`@9G)O;2!!<W1R85IE;F5C82!O;B!E>&5C=71I;VX@;V8@=&AE(')E
M<V5A<F-H(&-O;&QA8F]R871I;VX@86YD(&QI8V5N<V4@86=R965M96YT+B!5
M;F1E<B!T:&4@4V5P=&5M8F5R(#(P,#D@86UE;F1M96YT('1H92!#;VUP86YY
M('=A<R!P86ED(&%N(&%D9&ET:6]N86P@)#4L,#`P+#`P,"!I;B!C;VYS:61E
M<F%T:6]N(&]F(')E9'5C=&EO;B!O9B!F=71U<F4@;6EL97-T;VYE<R!A;F0@
M<F]Y86QT:65S(&%N9"!P<F]V:61I;F<@<W!E8VEF:6,@;6%T97)I86QS('1O
M($%S=')A6F5N96-A+B!4:&4@0V]M<&%N>2!I<R!N;W<@96QI9VEB;&4@9F]R
M(&UI;&5S=&]N92!P87EM96YT<R!T;W1A;&EN9R!U<"!T;R`D,30U+#(U,"PP
M,#`L('=I=&@@=7`@=&\@)#@U+#(U,"PP,#`@8V]N=&EN9V5N="!O;B!D979E
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M85IE;F5C82!T:')O=6=H($IA;G5A<GD@,C`Q,"P@=&AE(&5X<&ER871I;VX@
M;V8@=&AE(')E<V5A<F-H(&-O;&QA8F]R871I;VX@<&]R=&EO;B!O9B!T:&4@
M<F5S96%R8V@@8V]L;&%B;W)A=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G0L
M(&%T(&$@8V]N=')A8W1U86P@<F%T92!P97(@9G5L;"UT:6UE+65Q=6EV86QE
M;G0@96UP;&]Y964N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C`T8F(R93=?86-B-5\T9#8V7SDV-35?
M83$X9#AD9C!B,V$T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(P
M-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-"]7;W)K<VAE971S
M+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y44SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@1&ES
M8VQO<W5R97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&04E2(%9!3%5%($U%05-54D5-14Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@8F]L9"`Q,'!T(%1I
M;65S($YE=R!2;VUA;B<^*#4I)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[($9!25(@5D%,544@345!4U5214U%3E13.CPO9F]N=#X\+V1I
M=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C,38P.SPO9F]N
M=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N)SY4:&4-"F9A:7(@=F%L=64@;V8@8V%S
M:"!E<75I=F%L96YT<R!A;F0@<VAO<G0M=&5R;2!I;G9E<W1M96YT<R!A<F4@
M8VQA<W-I9FEE9"!U<VEN9R!A(&AI97)A<F-H>2!P<FEO<FET:7IE9"!B87-E
M9"!O;B!I;G!U=',N($QE=F5L#0HQ(&EN<'5T<R!A<F4@<75O=&5D('!R:6-E
M<R`H=6YA9&IU<W1E9"D@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A
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M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG
M/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF(S$V,#L\+V9O
M;G0^/&)R("\^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@8F]L9"`Q,'!T(%1I;65S($YE
M=R!2;VUA;B<^/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/"]F;VYT
M/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P="<^/"]D:78^#0H-"@T*#0H\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*/&1I
M=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX-"CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED)SX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/E1O
M=&%L(&-A<G)Y:6YG('9A;'5E(&%S(&]F($UA<F-H(#,Q+"`R,#$S/"]F;VYT
M/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60G/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#)P>"!S;VQI9"<^#0H\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N)SY1=6]T960@<')I8V5S(&EN(#PO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N)SYA8W1I=F4@;6%R:V5T<R`\8G(@+SX-"CPO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N)SXH3&5V96P@,2D\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9"<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED)SX-
M"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/D]T:&5R('%U;W1E9"]O
M8G-E<G9A8FQE(&EN<'5T<SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;B<^*$QE=F5L(#(I/"]F;VYT/CPO9&EV/@T*/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60G/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9"<^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SY3
M:6=N:69I8V%N="!U;F]B<V5R=F%B;&4@:6YP=71S/"]F;VYT/CPO9&EV/@T*
M#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XG/DUA<F-H(#,Q+"`R,#$S.CPO9F]N=#X\+V1I=CX-
M"CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[
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M=&@Z(#,V)2<^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^36]N97D@
M36%R:V5T($9U;F0\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I
M9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M+#`U-BPS,C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y
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M;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N)SXQ.2PP-38L,S(Q/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VED=&@Z(#,E)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S
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M;W1T;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT
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M<F]M86XG/B8C.#(Q,CL\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,S8E.R!P861D:6YG+6)O='1O
M;3H@,G!X)SX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SY5+E,N(&=O
M=F5R;FUE;G0@<V5C=7)I=&EE<SPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VED=&@Z(#,E.R!P861D:6YG+6)O='1O;3H@,G!X)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$Q)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^-RPT.3@L-C8U/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
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M;VQI9"<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[(&)O
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M:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VED=&@Z(#,E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60G
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED
M=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`S)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$Q)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>"<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F)SX-"CQT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,S8E)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N)SXF(S$V,#L@/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,E)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
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M.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R
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M+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM
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M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^,C8L-34T
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M9'1H.B`S)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L92<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SX\9F]N
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M<F]M86XG/C(V+#4U,RPR-#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z
M(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L
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M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M)SXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,E.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE)SX\9F]N="!S='EL93TS1"=D
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M=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,X,C$R
M.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@G/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9B<^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VED=&@Z(#,V)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[
M(#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT
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M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[
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M.B!B;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z
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M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
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M;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
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M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,V)2<^#0H\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;B<^2G5N92`S,"P@,C`Q,CH\+V9O;G0^/"]D:78^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
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M.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
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M.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
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M('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS
M1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,3$E.R!T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:61T:#H@,S8E.R!P861D:6YG+6)O='1O;3H@-'!X)SX-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T
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M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;B<^,RPS-#0L,30V/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L
M93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,E.R!B;W)D97(M8F]T=&]M
M.B!B;&%C:R`T<'@@9&]U8FQE)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^,RPS-#0L,30V/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA
M8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,E.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`T<'@@9&]U8FQE)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,X,C$R.SPO9F]N=#X\+W1D/@T*
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M;W1T;VT[('=I9'1H.B`S)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O
M=6)L92<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L
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M87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M-'!X)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CPO
M=&%B;&4^/"]D:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]B,#1B8C)E-U]A8V(U7S1D-C9?.38U-5]A,3AD.&1F
M,&(S830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`T8F(R93=?
M86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T+U=O<FMS:&5E=',O4VAE970Q
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-4
M3T-+2$],1$524R<@15%52519/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U1/0TM(3TQ$
M15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VLG
M/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&ET86QI8SL@9&ES<&QA>3H@:6YL:6YE)SY#;VUM;VX@4W1O8VL@5')A
M;G-A8W1I;VYS/"]F;VYT/B`F(S@R,3$[/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@:71A;&EC.R!D:7-P;&%Y.B!I;FQI;F4G/B8C,38P.SPO9F]N=#Y/
M;B!*=6QY(#,L(#(P,3(L('1H92!#;VUP86YY(&-L;W-E9"!O;B!A('!R:79A
M=&4@<&QA8V5M96YT(&]F9F5R:6YG(&EN('=H:6-H('1H92!#;VUP86YY('-O
M;&0L(&9O<B!A9V=R96=A=&4@<')O8V5E9',@;V8@)#,U+C`@;6EL;&EO;BP@
M,RPX-S,L,#`P('-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K+"!397)I97,@
M02`R,#$R('=A<G)A;G1S('1O('!U<F-H87-E('5P('1O(#,Q+#DX."PQ-3$@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@86YD(%-E<FEE<R!"(#(P,3(@=V%R
M<F%N=',@=&\@<'5R8VAA<V4@=7`@=&\@,S4L-#@X+#,X,"!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K+B!4:&5S92!W87)R86YT<R!A<F4@97AE<F-I<V%B;&4@
M870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,#$@<&5R('-H87)E+"!A;F0@
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M9"!B96YE9FEC:6%L;'D@;W=N(&EN(&5X8V5S<R!O9B`Y+CDY)2!O9B!T:&4@
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N)SY"96-A=7-E('1H97)E('=E<F4@;F]T('-U9F9I8VEE;G0@875T
M:&]R:7IE9"!S:&%R97,@=&\@8V]V97(@86QL('1H92!O=71S=&%N9&EN9R!3
M97)I97,@0B`R,#$R('=A<G)A;G1S(&EN('1H92!P<FEV871E('!L86-E;65N
M="!O9F9E<FEN9R!A<R!O9B!C;&]S:6YG+"!U;F1E<B!!4T,@.#$U+"`F(S@R
M,C`[1&5R:79A=&EV97,@86YD($AE9&=I;F<L)B,X,C(Q.R!T:&4@<&]R=&EO
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M('!R:6-E(&]F("0P+C`Q('!E<B!S:&%R92X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XG/B!4
M:&4@=V%R<F%N=',@=V5R92!L:6%B:6QI='D@8VQA<W-I9FEE9"!T:')O=6=H
M(%-E<'1E;6)E<B`R-RP@,C`Q,BP\+V9O;G0^870@=VAI8V@@=&EM92!T:&4@
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M;6UO;B!S=&]C:R!I;F-R96%S:6YG(&9R;VT@)#`N-3`@<&5R('-H87)E(&%T
M(&1A=&4@;V8@:7-S=6%N8V4@=&\@)#`N-S$@<&5R('-H87)E('5P;VX@<VAA
M<F5H;VQD97(@87!P<F]V86PL(&]F("0W+#`V.2PQ-C4@:&%S(&)E96X@<F5C
M;W)D960@87,@82!N;VXM;W!E<F%T:6YG(&5X<&5N<V4@9F]R('1H92!N:6YE
M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,RX\+V9O;G0^/"]D:78^#0H-
M"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+V1I=CX-"@T*/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T
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M="!L96%S="`R,"4@;V8@=&AE(&]U='-T86YD:6YG(&-O;6UO;B!S=&]C:R!O
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;B<^/&9O;G0@:60],T1404(Q('-T>6QE/3-$)VUA<F=I;BUL969T.B`S
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;B<^/&D^4W1O8VL-"D]P=&EO;G,\+VD^("8C.#(Q,3L@26X@2G5L
M>2`R,#$R+"!T:&4@0V]M<&%N>2!G<F%N=&5D(#(X-2PP,#`@;W!T:6]N<R!T
M;R!I=',@97AE8W5T:79E(&]F9FEC97)S+"`Q.#(L-3`P(&]P=&EO;G,@=&\@
M:71S(&5M<&QO>65E<PT*86YD(#$Q,BPU,#`@;W!T:6]N<R!T;R!I=',@;F]N
M+65M<&QO>65E(&1I<F5C=&]R<R!U;F1E<B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(#(P,3$@4W1O8VL@26YC96YT:79E(%!L86XN(%1H92!#;VUP86YY(&ES(&%M
M;W)T:7II;F<-"G1H92!F86ER('9A;'5E(&]F('1H97-E(&]P=&EO;G,@;V8@
M)#$X,BPP,#`L("0Q,#@L,#`P(&%N9"`D-S(L,#`P+"!R97-P96-T:79E;'DL
M(&]V97(@=&AE(#0X(&UO;G1H<R!E;F1I;F<@2G5L>2`R,#$V+B!4:&4@0V]M
M<&%N>0T*<F5C;V=N:7IE9"`D,S4L-34P(&%N9"`D,3`V+#8T.2P@<F5S<&5C
M=&EV96QY+"!O9B!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!R
M96QA=&5D('1O('1H97-E(&]P=&EO;G,@9'5R:6YG('1H92!T:')E92!A;F0-
M"FYI;F4@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$S+CPO9F]N=#X\+V1I
M=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CQB<B`O/CPO9&EV/@T*
M#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XG/CPO9F]N=#X\
M+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/"]F;VYT
M/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K)SXF(S$V,#L\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\
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M=71I=F4@;V9F:6-E<G,@=6YD97(@=&AE($-O;7!A;GDF(S@R,3<[<R`R,#$Q
M(%-T;V-K($EN8V5N=&EV92!0;&%N+B!4:&4@0V]M<&%N>2!I<R!A;6]R=&EZ
M:6YG('1H92!F86ER('9A;'5E(&]F('1H97-E(')E<W1R:6-T960@<W1O8VL@
M=6YI=',@;V8@)#$V,"PP,#`@;W9E<B!T:&4@,C0@;6]N=&AS(&5N9&EN9R!*
M=6QY(#(P,30N(%1H92!#;VUP86YY(')E8V]G;FEZ960@)#,P+#`S-R!A;F0@
M)#@T+#8R,BP@<F5S<&5C=&EV96QY+"!O9B!S=&]C:RUB87-E9"!C;VUP96YS
M871I;VX@97AP96YS92!R96QA=&5D('1O('1H97-E(')E<W1R:6-T960@<W1O
M8VL@=6YI=',@9'5R:6YG('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD
M960@36%R8V@@,S$L(#(P,3,N/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CPO9&EV/@T*#0H\9&EV
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z(#,V<'0G/CPO9F]N=#Y);B!*=6YE(#(P,3$L('1H92!#;VUP86YY
M(&=R86YT960@-3`P+#`P,"!R97-T<FEC=&5D('-T;V-K('5N:71S('1O(&ET
M<R!E>&5C=71I=F4@;6%N86=E;65N="!U;F1E<B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(#(P,3$@4W1O8VL@26YC96YT:79E(%!L86XN($AA;&8@;V8@=&AE<V4@
M<F5S=')I8W1E9"!S=&]C:R!U;FET<R!V97-T960@;VX@2G5N92`R,BP@,C`Q
M,B!A;F0@=&AE(')E;6%I;F1E<B!V97-T<R`R-"!M;VYT:',@9G)O;2!T:&4@
M9&%T92!O9B!G<F%N="X@5&AE(&=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!T
M:&5S92!R97-T<FEC=&5D('-T;V-K('5N:71S(&]F("0T,S`L,#`P(&ES(&)E
M:6YG(&%M;W)T:7IE9"!O=F5R('1H92`R-"!M;VYT:"!V97-T:6YG('!E<FEO
M9"!O9B!T:&4@87=A<F0N(%1H92!#;VUP86YY(')E8V]G;FEZ960@)#(V+#@W
M-2!A;F0@)#@P+#8R-2P@<F5S<&5C=&EV96QY+"!O9B!S=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O('1H97-E(')E<W1R:6-T
M960@<W1O8VL@=6YI=',@9'5R:6YG('1H92!T:')E92!A;F0@;FEN92!M;VYT
M:',@96YD960@36%R8V@@,S$L(#(P,3,@86YD("0X,"PV,C4@86YD("0R-#$L
M.#<U+"!R97-P96-T:79E;'DL(&9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N
M=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R+CPO9F]N=#X\+V1I=CX-"@T*/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-
M"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT('-T>6QE/3-$
M)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^4W1O8VLM8F%S960@8V]M<&5N
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M>2P@86YD("0Q.#,L,S4U(&%N9"`D-#<T+#0R-2P@<F5S<&5C=&EV96QY+"!F
M;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@
M,C`Q,BX\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]B,#1B8C)E-U]A8V(U7S1D-C9?.38U-5]A,3AD.&1F
M,&(S830-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`T8F(R93=?
M86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T+U=O<FMS:&5E=',O4VAE970Q
M,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14A(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]2
M1T%.25I!5$E/3B`H4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N(%!O;&EC:65S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYA
M='5R92!O9B!"=7-I;F5S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I<W!L87DZ(&EN;&EN92<^3F%T=7)E
M(&]F($)U<VEN97-S/"]F;VYT/B`F(S@R,3$[(%!A;&%T:6X@5&5C:&YO;&]G
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE
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M=&EO;B`H1E-$*2X@5&AE($-O;7!A;GD@86QS;R!H87,@9')U9R!C86YD:61A
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"=7-I;F5S<R!2:7-K(&%N9"!,:7%U:61I='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VLG/CPO9&EV/@T*#0H\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@:60],T1404(Q('-T>6QE/3-$)VUA
M<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93H@:71A;&EC.R!D:7-P;&%Y.B!I;FQI;F4G/D)U<VEN97-S(%)I<VL@
M86YD($QI<75I9&ET>2`\+V9O;G0^)B,X,C$Q.R!4:&4@0V]M<&%N>2!H87,@
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M<F-H(#,Q+"`R,#$S(&%N9"!I;F-U<G)E9"!A(&YE="!L;W-S(&9O<B!T:&4@
M=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$S+B!4
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF(S$V,#L\+V9O
M;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SX\9F]N
M="!S='EL93TS1"=M87)G:6XM;&5F=#H@,S9P="<^/"]F;VYT/D%S(&]F($UA
M<F-H(#,Q+"`R,#$S+"!T:&4@0V]M<&%N>28C.#(Q-SMS(&-A<V@L(&-A<V@@
M97%U:79A;&5N=',@86YD('-H;W)T+71E<FT@:6YV97-T;65N=',@=V5R92`D
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M;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K)SX\8G(@+SX-"CPO9&EV/@T*#0H\9&EV('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE
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M96YD87(@>65A<B`R,#$S+B!0:&%S92`S(&-L:6YI8V%L('1R:6%L<R!O9B!B
M<F5M96QA;F]T:61E(&9O<B!&4T0@=VEL;"!R97%U:7)E('-I9VYI9FEC86YT
M(&%D9&ET:6]N86P@<F5S;W5R8V5S(&%N9"!C87!I=&%L+CPO9F]N=#X\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;F-E;G1R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4]
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M=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,#1B8C)E-U]A8V(U7S1D-C9?
M.38U-5]A,3AD.&1F,&(S830O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%54Y!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY354U-05)9($]&
M(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@*%!O;&EC:65S*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!0
M;VQI8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<FEN8VEP;&5S(&]F($-O;G-O;&ED871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M;VYT/B`F(S@R,3$[(%1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N)SXF(S$V,#L\
M+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T)SX\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S92!O9B!%
M<W1I;6%T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P="<^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US
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M(&5Q=6EV86QE;G1S(&-O;G-I<W0@;V8@)#$Y+#`U-BPS,C%I;B!A(&UO;F5Y
M(&UA<FME="!F=6YD(&%N9"`D,2PT.3DL.3(U(&EN(%4N4RX@9V]V97)N;65N
M="!S96-U<FET:65S(&%T($UA<F-H(#,Q+"`R,#$S(&%N9"`D,RPS-#0L,30V
M:6X@82!M;VYE>2!M87)K970@9G5N9"!A="!*=6YE(#,P+"`R,#$R+CPO9F]N
M=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:R<^/&)R("\^#0H\+V1I=CX-"@T*/&1I=B!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K)SX\8G(@
M+SX-"CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P="<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O
M;G0@:60],T1404(Q('-T>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N)SXF(S$V,#L\+V9O;G0^/"]D:78^#0H-"CQD:78@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T)SX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R
M=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@:71A;&EC.R!D:7-P;&%Y.B!I;FQI;F4G/D9A:7(@5F%L=64@;V8@1FEN
M86YC:6%L($EN<W1R=6UE;G1S/"]F;VYT/B`F(S@R,3$[(%1H92!#;VUP86YY
M)B,X,C$W.W,@9FEN86YC:6%L(&EN<W1R=6UE;G1S(&-O;G-I<W0@<')I;6%R
M:6QY(&]F(&-A<V@@97%U:79A;&5N=',L(&%C8V]U;G1S(')E8V5I=F%B;&4L
M(&%C8V]U;G1S('!A>6%B;&4L(&%N9"!C87!I=&%L(&QE87-E(&]B;&EG871I
M;VYS+B!-86YA9V5M96YT(&)E;&EE=F5S('1H870@=&AE(&-A<G)Y:6YG('9A
M;'5E(&]F('1H97-E(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@87)E(')E<')E
M<V5N=&%T:79E(&]F('1H96ER(')E<W!E8W1I=F4@9F%I<B!V86QU97,@8F%S
M960@;VX@=&AE('-H;W)T+71E<FT@;F%T=7)E(&]F('1H97-E(&EN<W1R=6UE
M;G1S+CPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@9&ES<&QA>3H@:6YL:6YE
M)SY0<F]P97)T>2!A;F0@17%U:7!M96YT/"]F;VYT/B`F(S@R,3$[(%!R;W!E
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XG/B8C,38P.SPO9F]N=#X\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XG/CQF;VYT(&ED/3-$5$%",2!S='EL93TS1"=M87)G:6XM;&5F=#H@,S9P
M="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&ET86QI8SL@
M9&ES<&QA>3H@:6YL:6YE)SY);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S
M971S/"]F;VYT/B`F(S@R,3$[(%1H92!#;VUP86YY(')E=FEE=W,@:71S(&QO
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M=&EO;G,N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@4F5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I<W!L
M87DZ(&EN;&EN92<^1&5F97)R960@4F5N="`\+V9O;G0^)B,X,C$Q.SQF;VYT
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M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!296-O
M9VYI=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ
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M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE
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M+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L:6,[(&1I
M<W!L87DZ(&EN;&EN92<^26YC;VUE(%1A>&5S/"]F;VYT/B`F(S@R,3$[(%1H
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@
M<&5R($-O;6UO;B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E
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M($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D<R!";V%R9"`H1D%30BD@
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M:&4@4V5R:65S($$@,C`Q,B!W87)R86YT<R!T;R!P=7)C:&%S92!U<"!T;R`S
M,2PY.#@L,34Q('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@87)E(&5X97)C:7-A
M8FQE('-T87)T:6YG(&%T($IU;'D@,RP@,C`Q,B!A;F0L('1H97)E9F]R92P@
M87)E(&EN8VQU9&5D(&EN('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O
M9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG('5S960@:6X@8V]M<'5T:6YG
M(&)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@
M<W1A<G1I;F<@;VX@2G5L>2`S+"`R,#$R+CPO9F]N=#X\+V1I=CX-"@T*/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:R<^
M/&)R("\^#0H\+V1I=CX-"@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M)SY4:&4@4V5R:65S($(@,C`Q,B!W87)R86YT<R!T;R!P=7)C:&%S92!U<"!T
M;R`S-2PT.#@L,S@P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!C;VYS
M:61E<F5D(&-O;G1I;F=E;G1L>2!I<W-U86)L92!S:&%R97,@86YD('=E<F4@
M;F]T(&EN8VQU9&5D(&EN(&-O;7!U=&EN9R!B87-I8R!N970@;&]S<R!P97(@
M8V]M;6]N('-H87)E('5N=&EL('1H92!#;VUP86YY(')E8V5I=F5D('-T;V-K
M:&]L9&5R(&%P<')O=F%L(&9O<B!T:&4@:6YC<F5A<V4@:6X@875T:&]R:7IE
M9"!U;F1E<FQY:6YG(&-O;6UO;B!S=&]C:R!O;B!397!T96UB97(@,C<L(#(P
M,3(@*'-E92!N;W1E(#8I+B!&;W(@9&EL=71E9"!%4%,L(&-O;G1I;F=E;G1L
M>2!I<W-U86)L92!S:&%R97,@87)E('1O(&)E(&EN8VQU9&5D(&EN('1H92!C
M86QC=6QA=&EO;B!A<R!O9B!T:&4@8F5G:6YN:6YG(&]F('1H92!P97)I;V0@
M:6X@=VAI8V@@=&AE(&-O;F1I=&EO;G,@=V5R92!S871I<V9I960L('5N;&5S
M<R!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N(%1H92!397)I
M97,@0B`R,#$R('=A<G)A;G1S(&AA=F4@8F5E;B!E>&-L=61E9"!F<F]M('1H
M92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&YE="!L;W-S('!E<B!C;VUM;VX@
M<VAA<F4@9'5R:6YG('1H92!P97)I;V0@9G)O;2!*=6QY(#,L(#(P,3(@=6YT
M:6P@4V5P=&5M8F5R(#(W+"`R,#$R(&%S('1H92!I;7!A8W0@=V]U;&0@8F4@
M86YT:2UD:6QU=&EV92X\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VLG/B8C,38P.SPO9&EV
M/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;B<^/&9O;G0@:60],T14
M04(Q('-T>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T)SX\+V9O;G0^07,@;V8@
M36%R8V@@,S$L(#(P,3,@86YD(#(P,3(L(&-O;6UO;B!S:&%R97,@:7-S=6%B
M;&4@=7!O;B!C;VYV97)S:6]N(&]F(%-E<FEE<R!!($-O;G9E<G1I8FQE(%!R
M969E<G)E9"!3=&]C:RP@=&AE(&5X97)C:7-E(&]F(&]U='-T86YD:6YG(&]P
M=&EO;G,@86YD('=A<G)A;G1S("AE>&-L=61I;F<@=&AE('=A<G)A;G1S(&ES
M<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($IU;'D@,RP@,C`Q,R!P<FEV
M871E('!L86-E;65N="!O9F9E<FEN9RDL(&%N9"!T:&4@=F5S=&EN9R!O9B!R
M97-T<FEC=&5D('-T;V-K('5N:71S(&%M;W5N=&5D('1O(&%N(&%G9W)E9V%T
M92!O9B`R-RPV-S(L-#,W(&%N9"`R-RPT-C(L-S`P<VAA<F5S+"!R97-P96-T
M:79E;'DN(%1H97-E('-H87)E(&%M;W5N=',@:&%V92!B965N(&5X8VQU9&5D
M(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F(&YE="!L;W-S('!E<B!S:&%R92!A
M<R!T:&4@:6UP86-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N/"]F;VYT/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M8C`T8F(R93=?86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U
M7V$Q.&0X9&8P8C-A-"]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&04E2(%9!3%5%($U%05-5
M4D5-14Y44R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S(%1A
M8FQE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y38VAE9'5L92!O9B!A<W-E=',@870@9F%I<B!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XG/E1H92!F;VQL;W=I;F<@=&%B;&4@<')O=FED97,@=&AE(&%S<V5T<R!C
M87)R:65D(&%T(&9A:7(@=F%L=64Z/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K)SX\8G(@
M+SX-"CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0H\9&EV('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86XG/@T*/'1R/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('!A9&1I;F<M
M8F]T=&]M.B`R<'@G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.R`\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D
M:6YG+6)O='1O;3H@,G!X)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60G/@T*
M/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^5&]T86P@8V%R<GEI;F<@
M=F%L=64@87,@;V8@36%R8V@@,S$L(#(P,3,\+V9O;G0^/"]D:78^#0H\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9"<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,G!X('-O;&ED)SX-"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/E%U
M;W1E9"!P<FEC97,@:6X@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/F%C=&EV92!M
M87)K971S(#QB<B`O/@T*/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/BA,979E;"`Q
M*3PO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O
M;&ED)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60G/@T*/&1I=B!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;B<^3W1H97(@<75O=&5D+V]B<V5R=F%B;&4@:6YP
M=71S/"]F;VYT/CPO9&EV/@T*#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N)SXH3&5V96P@,BD\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A
M<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9"<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED)SX-
M"CQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT
M+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/E-I9VYI9FEC86YT('5N
M;V)S97)V86)L92!I;G!U=',\+V9O;G0^/"]D:78^#0H-"CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!C96YT
M97(G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XG/BA,979E;"`S*3PO9F]N=#X\+V1I=CX-"CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R<'@G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T
M<CX\='(^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
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M"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,S8E)SX-"CQD
M:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L
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M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^,3DL,#4V+#,R,3PO9F]N
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M('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M/C$Y+#`U-BPS,C$\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@
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M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)#PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I
M9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,X,C$R
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M;W1T;VT[('=I9'1H.B`S-B4[('!A9&1I;F<M8F]T=&]M.B`R<'@G/@T*/&1I
M=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/E4N4RX@9V]V97)N;65N="!S96-U
M<FET:65S/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@
M,R4[('!A9&1I;F<M8F]T=&]M.B`R<'@G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXW+#0Y."PV
M-C4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`S)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$Q)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,G!X('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;B<^-RPT.38L.3(U/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
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M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K
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M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,E.R!B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60G/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R
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M.B!B;W1T;VT[('=I9'1H.B`S-B4G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.R`\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!W:61T:#H@,R4G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
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M;VT[('=I9'1H.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
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M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F
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M;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!W:61T:#H@,R4G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[
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M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S-B4[('!A9&1I;F<M8F]T=&]M
M.B`T<'@G/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/E1O=&%L/"]F
M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,R4[('!A9&1I
M;F<M8F]T=&]M.B`T<'@G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I
M9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXR-BPU-30L.3@V/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#,E.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE)SX\9F]N="!S='EL93TS1"=D
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M=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^,C8L-34S
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M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S)3L@8F]R9&5R+6)O
M='1O;3H@8FQA8VL@-'!X(&1O=6)L92<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U
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M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B
M;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
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M9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S@R,3([/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#1P>"<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4]
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M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO
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M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S
M)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@<W1Y;&4],T0G
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M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N)SY*=6YE(#,P+"`R,#$R.CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@
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M.B!B;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z
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M+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$Q)3L@=&5X="UA
M;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`S)2<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8G/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`S-B4[('!A
M9&1I;F<M8F]T=&]M.B`T<'@G/@T*/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XG/DUO;F5Y($UA<FME="!&=6YD/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!W:61T:#H@,R4[('!A9&1I;F<M8F]T=&]M.B`T<'@G/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O
M;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;B<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[(&)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N)SXS+#,T-"PQ-#8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E
M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N
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M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;B<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[(&)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N)SXS+#,T-"PQ-#8\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE
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M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@8F]R9&5R
M+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;B<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,24[(&)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N)SXF(S@R,3([/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@-'!X(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z
M(#,E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#1P>"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XG/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;B<^)B,X,C$R.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'@G/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,#1B8C)E-U]A8V(U7S1D-C9?.38U
M-5]A,3AD.&1F,&(S830O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%6D)!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/4D=!3DE:051)3TX@
M*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R
M9V%N:7IA=&EO;B!$971A:6QS($YA<G)A=&EV93PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV
M86QE;G1S(&%N9"!S:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y+#4S-2PW.3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y+#4S-2PW.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E=F5N=64@<&5R8V5N=&%G92!D97)I=F5D(&9R;VT@07-T<F%:96YE8V$\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#1B
M8C)E-U]A8V(U7S1D-C9?.38U-5]A,3AD.&1F,&(S830-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8C`T8F(R93=?86-B-5\T9#8V7SDV-35?83$X
M9#AD9C!B,V$T+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y,
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5-34%262!/1B!324=.249)
M0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A$971A:6QS($YA<G)A=&EV92D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$S/&)R/E!R969E<G)E9"!#;VYV97)T:6)L92!#;&%S
M<R!!/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^4')E9F5R<F5D($-O;G9E<G1I8FQE($-L87-S($$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CY0
M<F5F97)R960@0V]N=F5R=&EB;&4@0VQA<W,@0CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/DUO;F5Y($UA<FME
M="!&=6YD<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$R/&)R/DUO;F5Y($UA<FME="!&=6YD<SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/E53($=O=F5R
M;FUE;G0@4V5C=7)I=&EE<SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q.2PP-38L,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#,T-"PQ-#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#DY+#DR
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3D],(&-A<G)Y9F]R=V%R9',@<V]L9"P@<F5S=6QT:6YG(&EN('1A>"!B
M96YE9FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<U
M,RPR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L,#8X+#(S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5A8FQE('5P;VX@8V]N=F5R
M<VEO;B!O9B!W87)R86YT<RP@8V]N<VED97)E9"!T;R!B92!C;VYT:6YG96YT
M;'D@:7-S=6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q
M+#DX."PQ-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-2PT.#@L,S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPV-S(L-#,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L-#8R+#<P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C`T
M8F(R93=?86-B-5\T9#8V7SDV-35?83$X9#AD9C!B,V$T#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q
M.&0X9&8P8C-A-"]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$50
M0D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%'4D5%345.5"!7251(($%3
M5%)!6D5.14-!("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`P-SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9W)E96UE;G0@5VET:"!!<W1R
M87IE;F5C82!$971A:6QS($YA<G)A=&EV93PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!C;VQL86)O<F%T:6]N
M(&%N9"!L:6-E;G-E(&%G<F5E;65N="!W:71H($%S=')A6F5N96-A/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5V96YU92!R96-O9VYI>F5D('5N9&5R(&-L:6YI8V%L('1R86EL
M('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS-C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,BPW,#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N
M92!087EM96YT($5L:6=I8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#4L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T-2PR-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YG96YT(%!A
M>6UE;G0@16QI9VEB:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.#4L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#4L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8C`T8F(R93=?86-B-5\T9#8V7SDV
M-35?83$X9#AD9C!B,V$T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X9&8P8C-A-"]7;W)K<VAE
M971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$576D%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/D9!25(@5D%,544@345!4U5214U%3E13("A$971A:6QS*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!E<75I=F%L96YT<RP@9F%I<B!V86QU92!D:7-C
M;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V+#4U
M-"PY.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E%U;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',@*$QE=F5L
M(#$I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@97%U
M:79A;&5N=',L(&9A:7(@=F%L=64@9&ES8VQO<W5R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8L-34S+#(T-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@<75O=&5D+V]B
M<V5R=F%B;&4@:6YP=71S("A,979E;"`R*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H(&5Q=6EV86QE;G1S+"!F86ER('9A;'5E(&1I
M<V-L;W-U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VEG;FEF:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<R`H3&5V
M96P@,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!E
M<75I=F%L96YT<RP@9F%I<B!V86QU92!D:7-C;&]S=7)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y($UA<FME
M="!&=6YD<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&5Q=6EV86QE;G1S+"!F86ER('9A;'5E(&1I<V-L;W-U<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#`U-BPS,C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,T-"PQ-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO
M;F5Y($UA<FME="!&=6YD<R!\(%%U;W1E9"!P<FEC97,@:6X@86-T:79E(&UA
M<FME=',@*$QE=F5L(#$I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@97%U:79A;&5N=',L(&9A:7(@=F%L=64@9&ES8VQO<W5R93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,#4V+#,R,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S0T
M+#$T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36]N97D@36%R:V5T($9U;F1S('P@3W1H97(@<75O=&5D+V]B<V5R
M=F%B;&4@:6YP=71S("A,979E;"`R*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&5Q=6EV86QE;G1S+"!F86ER('9A;'5E(&1I<V-L
M;W-U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36]N97D@36%R:V5T($9U;F1S('P@4VEG;FEF
M:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<R`H3&5V96P@,RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!E<75I=F%L96YT<RP@9F%I
M<B!V86QU92!D:7-C;&]S=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E53($=O=F5R;FUE;G0@
M4V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&5Q=6EV86QE;G1S+"!F86ER('9A;'5E(&1I<V-L;W-U<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#DX+#8V-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^55,@1V]V97)N
M;65N="!396-U<FET:65S('P@475O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R
M:V5T<R`H3&5V96P@,2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!E<75I=F%L96YT<RP@9F%I<B!V86QU92!D:7-C;&]S=7)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#0Y-BPY,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E53($=O
M=F5R;FUE;G0@4V5C=7)I=&EE<R!\($]T:&5R('%U;W1E9"]O8G-E<G9A8FQE
M(&EN<'5T<R`H3&5V96P@,BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!E<75I=F%L96YT<RP@9F%I<B!V86QU92!D:7-C;&]S=7)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E53($=O=F5R;FUE;G0@4V5C=7)I=&EE<R!\(%-I9VYI9FEC86YT('5N;V)S
M97)V86)L92!I;G!U=',@*$QE=F5L(#,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@97%U:79A;&5N=',L(&9A:7(@=F%L=64@9&ES
M8VQO<W5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]B,#1B8C)E-U]A8V(U7S1D-C9?.38U-5]A,3AD.&1F,&(S830-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`T8F(R93=?86-B-5\T9#8V7SDV
M-35?83$X9#AD9C!B,V$T+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15-/1$D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3
M)R!%455)5%D@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^
M,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;"X@,#,L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$R/&)R/D5X96-U=&EV
M92!/9F9I8V5R<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6PN(#`S+"`R,#$R/&)R/D-O;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6PN(#`S+"`R,#$R/&)R/E-E<FEE<R!!(#(P
M,3(@5V%R<F%N=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5L+B`P,RP@,C`Q,CQB<CY397)I97,@0B`R,#$R(%=A<G)A;G1S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3(\8G(^
M4W1O8VL@3W!T:6]N/&)R/D5M<&QO>65E<SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/E-T;V-K($]P=&EO;G,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,SQB<CY3=&]C:R!/<'1I;VYS/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;"X@,S$L(#(P,3(\8G(^4W1O8VL@3W!T:6]N<SQB<CY.;VXM
M16UP;&]Y964@1&ER96-T;W)S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^4F5S=')I8W1E9"!3=&]C:R!5;FET
M<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$S/&)R/E)E<W1R:6-T960@4W1O8VL@56YI=',\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CY297-T<FEC=&5D
M(%-T;V-K(%5N:71S/&)R/D5X96-U=&EV92!/9F9I8V5R<SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/E)E<W1R
M:6-T960@4W1O8VL@56YI=',\8G(^17AE8W5T:79E($]F9FEC97)S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^
M4F5S=')I8W1E9"!3=&]C:R!5;FET<SQB<CY%>&5C=71I=F4@3V9F:6-E<G,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,SQB<CY297-T<FEC=&5D(%-T;V-K(%5N:71S/&)R/D5X96-U=&EV92!/9F9I
M8V5R<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$R/&)R/E)E<W1R:6-T960@4W1O8VL@56YI=',\8G(^17AE8W5T:79E
M($]F9FEC97)S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^3W1H97(@17%U:71Y($%W87)D<R!.;W0@4V5P87)A
M=&5L>2!$:7-C;&]S960\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CY/=&AE<B!%<75I='D@07=A<F1S($YO="!3
M97!A<F%T96QY($1I<V-L;W-E9#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/D]T:&5R($5Q=6ET>2!!=V%R9',@
M3F]T(%-E<&%R871E;'D@1&ES8VQO<V5D/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^3W1H97(@17%U:71Y($%W
M87)D<R!.;W0@4V5P87)A=&5L>2!$:7-C;&]S960\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K(&ES<W5E9"P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#@W,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@8V]M;6]N('-T;V-K('5N
M:71S+"!N970@;V8@8V]S=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S0L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#<S+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#DX."PQ-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PT
M.#@L,S@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y386QE(&]F(&-O;6UO;B!S=&]C:R!U;FET<RP@;F5T(&]F(&-O
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PT,#<L-#0V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0FQO8VME<B!P<F]V:7-I;VXL(&1E<V-R
M:7!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y4:&4@=V%R
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M=6-H(&5X97)C:7-E+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YC<F5A<V4@:6X@9F%I<B!V86QU92!O9B!W87)R
M86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPP-CDL,38U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!P
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C@U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,BPU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3(L-3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"P@=&\@8F4@86UO<G1I>F5D(&]V
M97(@-#@@;6]N=&AS(&5N9&EN9R!*=6QY(#(P,38\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#@L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC
M=&5D(%-T;V-K(%5N:71S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(R,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(')E<W1R
M:6-T960@<W1O8VL@=6YI=',@9W)A;G1E9"P@86UO<G1I>F5D(&]V97(@,C0@
M;6]N=&@@=F5S=&EN9R!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#<U+#,R.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-S$V+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S4L-34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,#8L-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PP,S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@T+#8R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8L
M.#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`X,"PV,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#@P+#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C0Q+#@W-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3<L,#`X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#@X,RPS
M-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(P,RPT,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0W-"PT,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q.&0X
M9&8P8C-A-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B,#1B8C)E
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M,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*/"]X;6P^
M#0HM+2TM+2T]7TYE>'1087)T7V(P-&)B,F4W7V%C8C5?-&0V-E\Y-C4U7V$Q
...&0X9&8P8C-A-"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">(3)&#160;&#160;&#160;&#160;&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Principles of Consolidation</font> &#8211; The consolidated financial statements include the accounts of Palatin and its wholly-owned inactive subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Use of Estimates</font> &#8211; The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Cash and Cash Equivalents</font> &#8211; Cash and cash equivalents include cash on hand, cash in banks and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consist of $19,056,321in a money market fund and $1,499,925 in U.S. government securities at March 31, 2013 and $3,344,146in a money market fund at June 30, 2012.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Investments</font> &#8211; The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet, based on the contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&#8217; equity.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Fair Value of Financial Instruments</font> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts receivable, accounts payable, and capital lease obligations. Management believes that the carrying value of these assets and liabilities are representative of their respective fair values based on the short-term nature of these instruments.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Property and Equipment</font> &#8211; Property and equipment consists of office and laboratory equipment, office furniture and leasehold improvements and includes assets acquired under capital leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under capital leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Impairment of Long-Lived Assets</font> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>



<div style="text-indent: 20pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left">&#160; <font style="font: 10pt Times New Roman"><i>Deferred
Rent </i>&#8211;<i>&#160;</i>The Company&#8217;s operating leases provide for rent increases over the terms of the leases.
Deferred rent consists of the difference between periodic rent payments and the amount recognized as rent expense on a
straight-line basis, as well as tenant allowances for leasehold improvements. Rent expenses are being recognized ratably over
the terms of the leases.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Revenue Recognition </font>&#8211; Revenue from corporate collaborations and licensing agreements consists of up-front fees, research and development funding, and milestone payments. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. The Company estimates the performance period as the period in which it performs certain development activities under the applicable agreement. Reimbursements for research and development activities are recorded in the period that the Company performs the related activities under the terms of the applicable agreements. Revenue resulting from the achievement of milestone events stipulated in the applicable agreements is recognized when the milestone is achieved, provided that such milestone is substantive in nature. Revenue from grants is recognized as the Company provides the services stipulated in the underlying grants based on the time and materials incurred.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Research and Development Costs</font> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Stock-Based Compensation &#8211;</font> The Company charges to expense the fair value of stock options and other equity awards granted. The Company determines the value of stock options utilizing the Black-Scholes option pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Income Taxes</font> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>During the nine months ended March 31, 2013 and 2012, the Company sold New Jersey state net operating loss (NJ NOL)carryforwards, which resulted in the recognition of $1,753,208 and $1,068,233, respectively, in tax benefits.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Net Loss per Common Share </font>&#8211; Basic and diluted earnings per common share (EPS) are calculated in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 260, &#8220;Earnings per Share,&#8221; which includes guidance pertaining to the warrants, issued in connection with the July 3, 2012 private placement offering, that are exercisable for nominal consideration and, therefore, are to be considered in the computation of basic and diluted net loss per common share. The Series A 2012 warrants to purchase up to 31,988,151 shares of common stock are exercisable starting at July 3, 2012 and, therefore, are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 3, 2012.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">The Series B 2012 warrants to purchase up to 35,488,380 shares of common stock were considered contingently issuable shares and were not included in computing basic net loss per common share until the Company received stockholder approval for the increase in authorized underlying common stock on September 27, 2012 (see note 6). For diluted EPS, contingently issuable shares are to be included in the calculation as of the beginning of the period in which the conditions were satisfied, unless the effect would be anti-dilutive. The Series B 2012 warrants have been excluded from the calculation of diluted net loss per common share during the period from July 3, 2012 until September 27, 2012 as the impact would be anti-dilutive.</font></div>

<div style="text-indent: 0pt; display: block">&#160;</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>As of March 31, 2013 and 2012, common shares issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the warrants issued in connection with the July 3, 2013 private placement offering), and the vesting of restricted stock units amounted to an aggregate of 27,672,437 and 27,462,700shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be anti-dilutive.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001387131-13-001759-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-13-001759-xbrl.zip
M4$L#!!0````(`).&K4+90#.C[%8``#0;`P`0`!P`<'1N+3(P,3,P,S,Q+GAM
M;%54"0`#E5*14952D5%U>`L``00E#@``!#D!``#L77MOXSB2__^`^PZZ+&XP
M`[03O1_IQ\)).KW!]"39)#VSNQB@P4BTS1M9\E!R$L^GOR(EV90MV9(L.T[B
M!F9:;5%5/Y:JBD6R6/KP]Z>A+SU@&I$P^'B@',H'$@[<T"-!_^/!M]M.]_;T
MXN)`^ONG__XO"?Y\^)].1SHGV/>.I;/0[5P$O?"]=(F&^%CZ@@-,41S2]]*O
MR!^S7\)SXF,JG8;#D8]C##<23L>2=JACJ=.I0/97''@A_79S,24[B./1\='1
MX^/C81`^H,>0_A$=NF$U<K?AF+IX2NOZ^/?/9U^Z-^0O3'\_]0D.XNCW:^2C
MF`2__^ODYNOOJJQHLJ8IOX_B@/W-_GWXU(->GJ$8*+!_'\G&D:+=*<:QHAQK
M=D4D,8K'T12)_"2G?Y+'/SS=4Y\<L_]+\)*"Z/@I(A\/A,X_:H<A[1^ILJP<
M_>N7K[?N``]1AP11C`(7'V1/^23XH^@YQ7&<(WXW:[K0DC'/>&A'[/8]BF:4
M&<`E[1>0P%TOGCX@-C:.DINYIJ2PJ9DT)5E3#\^UB[![V`\?CN`&M%?4CJQT
M-"5K3G&O%+)Y!'>SAB0*=56QEO4O:9$],(XZ?81&TP=Z*+KGC=,;!6#@#@U]
M'!4^P^\4/!2$03`>%N/R8GH43T;X"!IUH!6FQ)T^M_JA_`.`@?U<C([?*4!W
M?7<Y;3]*[`AL<WB4F=%!9AE,FXXCKK,WN"=Q13P>\-<#EM;)VA\^1=Y!>I?Q
M_'@0$>9-#J2CC%)B*&X8Q/@IEHCW\:`;7?42:&9'DS.6TZ9@Y"2>3'^=_DX\
M=J='P&5Q8#@GKTRO3B]^/OC$[-11%%4Q/QS-/SQC=U3(+^4V`EF'7@$*;C;Q
MIUD'IBS2._/T<Y2R'U-YK!22UI&USNR]O#PAI1W8C)#.:3@$8W<ZL@5Z'H?`
M3WZ16@5"H3$;L3[-NI-1FMU;>`P&W_2AK-\S]E[ND3:5\?LY(I2/BQ?!:!Q'
M7_$#]I5?\/`>TV>3^TR4N#_$@H9-;WD`YFGD$Y?$"5;)(]`RB:W24>!XVK63
MR?3R'\`'47<PX1WM/I'HX--"^T51?#@JY"HB/BJ&O-M&5T$9U+TRS(GB#2N#
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M?W["[C@F#_BJUR,NIM'K,)(SW,.48H]9!]Q#,=SM,G/H<]/YC<2#B\`C#\0;
M(_]V@"@^01'VKM&$W8Y.)G<D]D$FLT8SZRH1V0X$./57.*QMKHQ.=6XX\L,)
MQJG@OO.YZ-6(O:.]]JW4OKSP5FM='>#=1T2]N\D(YY<,%E[07M>KZOIE&&1O
M[(Q0[,8A+5#[O===J??E@MRV">S]_?*=`S.S@32F*8LQOM_@**;$C;''I?LM
M('%T<_MM;PL;BT!:,(2E+^U9;2)5O7HVH6QO\>'E3DXV.H,KWT+_?DTS(^(3
MVM?A&"INTQ3V_>6-.<^4?3&G.MTWK#K=O>K42G38J\Y.J<[NY6[,1O47F!>3
M']6WD8UJ=)07O"Z;=F#30N*.YQ>PR,DOB/Z!X_-QX+V218%3%`VZ@<?^8K[G
M`?F+;J>XY\^X9[&-3.WTT-+^M>_.:]_B.;+OWV[O*$;1F$YN839/24SP&WKU
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MDV^W9PLO?L@WU?&G]/.'Q]`F(Y;=RK-@U$KH\^@R*F61"H$W:LP#\%V7\.'Q
M:X%LV;.7[&.(['.FBPI70P;S&(NH"DS/<!`.2;"*[6JYS/,M(IS=STFA@D!!
MCUQ0\15O;027S?7BSS%B)1MP.1=FP=&?O7@MO6#3K%>C%4PBK$-;T(B%NAI\
MTGJ-Z!7E%3D\GN!RC2DW/"EU,C?LXYYSW^:4&%E^0[!3R<,N&2(_^GAP<7D.
M`\4A<XGUF+8'-?ORT3-!31AUQ_$@I.0O[%639@D\)?W&<!G$>6;K0UN4WA:A
M7431>$V)Z8YC+8>4,%D/3F4IZ69[<*[&,<OR8A_[WK"(!$XM`&M16$N`"1^4
MV9)CJ\"Q)9!KN+3U0&[$F<F%Z%;YBYJH*BN=VBZJ%ER8ICNR;#C%+W&9TZ@!
MIK)X--O1+4=1UP?3EONJ()YJ;J)=YU5!4`6P/$R./_/YYPWNDRAFGTJX1,.\
M%UCV><?K[M?NW<6E=/?Y]!^75U^OOEQ\OI4N+D\_')617F1]"M,#BOR+P,-/
M/^-)9=[B@D`I-9'=6>B.V12<3>PK<U'DSC\3^N+C162O^8SY<S*?KDQ?7+PI
MI2:RZ\)=C[4X]U&_,IL>J`I...0(B)1/QS#>P<\D<I'_;XQHW;YTLJ.XRZ@M
M*L!OV/=_#L+'X!;F(&&`/6[2M#+;RU!4@!)JBVQ_#?UQ$",Z.2<^IE%#=G-4
M"M0[D<,-'H4T!MMC0^"X.K=_LTG[*FJ+7#F:4Q!W/Z353>H6/`H\)TW)2VS;
M#P43$4*.=)$A)*\\4>!S^*UZ9_^IY8U@@5(Y.Z9A]9BQZR)V4TH+SKOX'$E\
MBBB=@+!X6%,YRA-=N,P<N&HICBWX[RK<6H-8&./-050U0[-D0WLNC$H%,2JV
M;3JFYCP71K6"'&W+DE5]78C=*,)QU%3=#,V6=5N?84C(56=216$T&<(233-6
M<>%KZ\FMRS!P$Q?7V)!`M(X0!Q42;XR@2K<-6].LF@"2^Z?K=5VW--,6=3]'
MM3;+:J]85C7'LBORA%GU"!'O\Q/+)<&@\X)PUNR\H4'#_'K0*E8MH:LB)]VV
M%=M8"UW7=4,(-:(;[&+P$?<^_D+#:%VQJ9:I"9.9Y4S6AU0BJZ>('`?$_W@0
MTS$^D([F&7TEZ)[X_%1F8[]@Z(YAF[.N"C1KLJLT6%HP3ZS(+LNQN@&AG<+?
M)%[?#5JJ:0E.:!F+=>%4TG_=,O5F<`3!K:GKFFY8N:661=+-F%=3"%V#_^HP
M!_,"<_#:$X!JR:;NF#ES+^:P%I0JXH!8UU1UN0&4[`M(-]AGBXGM24?7V)\9
MHI6,6D'6T"-FKO<:39C?75<Q'-UV],5A($^].88J&F%IFJYK=3$(0H91E"]W
M#4+?@ZEXDJS16H"\BE$;P)H%U761M2<DQ=9D6YRTML6\FD,U(-`7YU&KN=_@
M&)$`>Y\1#6!B%8&.C8=C;JTP)+'\G::BZ$`8K(*'%X.\U=S:P5=%6AW5`)6V
M=$59!U_7@Z&:A`'RKR%ZO0A.T8C$R&_L=G394@U%%0*5$@YK`*FD2[9J.):B
MZ;6!",OLZZW_L'T%862>I]N$;R5WPC<.JO.=I?B+)P*J+KHMG[W"%$ZTYD).
MS?$4Y"\N'X\44Q.#Q;;Q5"QPLGQ.8Q@;1%BQNL;2$4(V37V#+[5^;8<5JQGB
MRLTVY-D<K*V;JKI#DBT]@[74\9JV96Q4XBT=.%[Z)F13W6PG6CHA^HR=:.](
MW_*`0MFH/M4YA+5T=F')LKU=M6\"4[%MF&EL6;6;`%5E31>G[MO0WB8X=4O7
MZUO9S$Z*=XJ:+XGF,X]6\6D#5\/E#NX@DE2?LS&%R4JR*9R4QN,_GX>4L2_7
M,G7V37)96Q&+P[Q$U\VYF645]A5QBZE+C8&79B@9<QEEU4%L'/YW87ZQ8"^E
MN4V6MKO]X=^(_`VQ(]%QY1XICFTKAK+#73JIVR5#A\'";N4M<0!7O13!%;TA
M_4$,X0!U282OP>/@Z<THO5OF`RN\H^G1CA6IK`U`;:5CI6]JBQTK'L>$.@$G
MDX7:`'S03&>27SCUBR!1$;Z)N"I<X-<P#*\.$\M2;VU#7CV_7ZL/NR2F=&\B
MJ_<KS..K"DRQ5>/M".PR##*9G1&*W3BD!;*KK&V*\G*$EP2U%P%$=SPO+N*A
M[MT`!87,-V^I:DNRJ]FQ71(H3WY+!9HFPI4)M/*:4HFX%\+'+8N;'4W\"OT)
M(@@:NGV*.9,NRR'_#PZPBPKD(SN"PLE5]O>R8Q<KN:T%RYS!8A>K=]3D1KAN
M\`,.QGBQ_:E/`N(B_XX28%%Q26-%%JC#,@AJ<&T):-W]!$763.4Y@-;=:#!5
M2S8:`_V%^&#N88!3R_OLDS[A^\&-=U85W5"-F18NX2`".05F`)F=76@-B9T#
MLHR#B.3$!Z^'Z34-'P@K['"&(Y>2T?)%J/PL^]/=`$N/:=0KL8-QT?C^_R`*
MD.)00M)]PD$:92S8U0"@\*1YG`;/4MB38I$.2?Z=;%%+*/`DPJB#]_8)BG$D
M/89CWY/NP;[9]BOR_8D4/@82"8"FBR%X`8K.H>/\;T8Z#MFN9S#FE2S@M^28
M/[MR^41;BM@(D+5VDVQ^J1?Z?OC(H$9C=S#%>YB(>8GXZBS+7.)'?F>),==8
MDC'FC\E58EUKLKP&X%96+A90LY=Q_JLX5N(6@ZVBY5YU:FOS?%O!5&,.4N3/
M[8VB:QKP%^5>5@1:%*AM]`6;LH"LB'LS?)L(3HOR\ZJBG^9PP'CA$9_#F'W7
MY?.3ZX\][#'P+*(=QSR@O>IE>3#9T>3ND"6@5=VWF)X83Y:;*D]N+--2=7';
MN1746Q-%T=9(8U'H+!:2-RR*"^@#L(]97D\[B2OB5H%(O2[GVI&C*:9_+.-<
MO$&3C#X7@<N^?83/</)W*\&W8\F.+6X=UD'0-OJZ<NW`-,QQ-$=N!_XECMES
M/*`"M3V9?(.)\D5P3@(4N"S*=T&_%T\;-!2]IFN&HFN"2E;GWR[RVF)7'5,Q
MVL`-C[@8>Q$#PF(J:(^OZ"UBE6@+LDX;2UJ7P7T+&_FK^;:#M()D5^VH9A5Z
MTV3UN_`./;%JOFQR`K(]#^GF4OTTW<H=AFH(99-=:D'")>I[$3R`DV[=[#NF
M;.J:L]KL"_BWB[R!M\TE6C;'G2G`7=AUP78H!AHC3./)M0_1-[AO9E&CX?PA
MA882MV1+S%RNSKQ=V'7%K>2WO=:`+;BNQ&%M5-P0&\K%GG8%\Y9QUY6W;LGM
MX"ZQBZL1*P?8OC^Q#<O*G5FMSK]=Y$VB-\/1K;6@LTGF?%QW$7P+,$PQV+E%
MOD[;5-!E(T=SIK5EI)M*MNB\FN/B/&;^B<73>ZWHH*+8X*Y4<8ZSFG-;:.O*
MU+!L1=<W@%4\!M>*)]5L0TS*7\FT%92U)[<P!5LES7H@TT/WV>'CPL/W[81B
MIJS;\C+L5:!LKD-U7X6J&+:SU`K;Z<]B/8%67L=<C8,J?-O"6G_L4O2*MED.
M]@R/*!#E<QNX]C'?KP^\[I!5=?JKM6F<K6JFH.55V+8%M?9A+LU2U#6Q+D3*
MR8QDN)#JW%"<AN/8JNTL"<T%ANN":V,%@8HE4M<Z_6CD(N0%L@TY5UN\K<4Y
M/07ZE9GBU;U/^EQ36BA;I#B.G"L)M8)/*\`JY7O`4-8^KG7K%:BJ6-UD.9/U
M(56LCI:K"EH+4ND<$"8NC4]W*+8I%FM;QF-=/-4*%UCRW`R^,I[;`;CE.TR'
M95YMN5Q6GBZI2+ZJ%[?T7/K<(O%Y`+]AEE:-O>X#3$C[^)+G<USU^'*E4+?U
M!$7$!5&=L2VQXIWMY>E<I;6135W5<]4WFB':7+^6#Z8E_6*+`+HE#JD[V*WY
MDWI-:A#O6K>61Q=;[M;\KC!OWB@5LJSH>4<^E(6I:B'#QJA6AI%+4"G6!E$M
M4=SG0K4RJEV"2JO[!F&<@ME9.,1?2XX5U$VM[>BR8JB&G5NWG+&HS;_^<INI
MZ+JBFBT"6*XDBWM8*HL2VN+?8/;MP/`]M^A=#B"Y<X>>TO6.$YZX6;AK4$$7
M5D4I-;C5?_.L^(IX)+V$V7J85BE#BQ)HL&E@VJIXAKR6!)AV).E(+$5Y#+XC
MW5N`F/\$]T(V'T_)X>@,+J*XX1BTTF>L`6C#?6N@E;;#RL*]D,ZMZ>MVMV_U
MC4D#:U*4S6CE91B$V<9=TCRUT#;LR39RPU\9J[4PU;8#2];47.W0C>&JI<*&
M+=:RV`RFVEL5IBJ6,ZL,*DN>;%&5%$7.#2<Y!@WXMY.7NA;_6NK!JD.VR;^=
M[-A2_MGB3*(F6?,V%,$QU=R.3C&G=1#53L"S9'$2MB%(]9R)(V8+;P)1;5=B
MJTW>VU7>W[0X.50U2ZQ(6\"H(9;Z@9EL@W&)FW^M@JD=2)F&F(G7'I8F@8^C
M:TY#,*EO:D5?RM4EX]((1OU3N+9EZ*JR`1RUM,24#=E0M;9AU$Z^U!3#4L2H
M?R6.+S#OI,AGF]/>D`3\6VKL/$R;D8IL.8JHM"MXM@"Q]HBEZ(HE5DS:"L1Z
M\8ZFZ[:Y58AUU4_3+<T1C[74A'B#(XRHRT["G.$'[(=\PZY%350=73=L01.7
M<EP;7NV4;TO33$O>(KQ:&JA;LF&:ZK;@U=4^Q[0U16D.KSS]M875U353>HM*
M3\R3KLFRUJM/RW*LP[)AW8HREL)'"^M_]=2`$+/*^?KLJZ?5F"T,\;2/@C3;
MZS0,HM`G'DHSP:[A45#&]&1I>N8,^?P+QGP/_XQ$KA]&8XKO`#\OFE!5=S[]
MX,?O/?(@1?'$QZ"2\$R'!!Z0/9;D4?Q>\D@T\M'D.*DT\5X:(MHG0<?'O:Q%
M^@ME.Z3I3YP,\DD_.)98RX,?^O%[QJH'L#)>4\HD\$F`WTOL)O`)?4]2@(QT
M1X:@'Y?X4;H)ARC@1'Y4?OH!#4?O_Z:8\OMUKJYNOG0O+_[3O;NXNCQFT(X8
M^PSG$<B$7_]-T=+_[9R@2F4D='>]?FGFCG5L[GEVW>'70"(&;JZ`-J')G[M$
M,1@'JSUR,H[@QRC*"49*!&:KBO)>ND8^"X*E.^P.@M`/^P1'[R28,AU*/V;W
M0LJ+F*2?)/U)(A&KQ$+"$9CY$+EX'+,*.=,B)UXRHC`?$X.D<(R]=Q+%+A[%
M(>U$(W`E/>)*(_@W\3`C3=&($XE`(@FOF&+$I_RL%]!'ELT528\D'D@1")D1
M0'!S'`QQ+`VQQP$$&'N\N`LKP<(JJ\!OHS`&*G!UF'5UVGOK?<2JQ_0I&B:5
M9N[9^40I#*1AZ&-W[`/'>("`?NCQCW-P9"@YL3+)2KL,L8^"T.6?;>7,`Q13
M`O*/A3YFO9>B201>+#J4[N8?3>XPV9+@(?0?``DC*/E,A)PPJ"VF$!#,BLZ,
M!I.(\)?F2KUQX/+E_'>\L2!5"?5Y7E7:#?Y>!L`GY3A$$VF`'I+>3<7%RNWP
MEP`0'A`E..DQ^-GDZQQ1"BEY,^\`*RL-P"O;X*<Q/.]-H@S2.RF\QQ&3&7N&
M)H=$V;,A95^,>2>-2'^8N?S9[TF=GJ#GH^&0W^H(CW*VB1@K"!PZ&#&Y81JR
M#]4BZI'P`47PCA%=3W+W6!I'N#?VV=O*:2URQZ`R*(H'0_1.&D"\%4L]1'Q`
M"O^<L!0\5FLJ3+0F9&SGD4W[N7?8+Z)?V?/$^WAPUSV!*"ZEE,/$AIEI^VGO
M[V8>=LY#0>!%)\Q3>6,W9FKFS4)VYB_N*4X\"=?\0@_:PQ"\X0+3E'X\OSW[
M*;&CE+L$85[(#<:C8P@3603G\2)90%ED/?6=C&5JX>\DS"KX$&"6<P"CL0_!
M(>O'S&64*/L[8`+#2ISZM:GSSWF#4*"41\^`(UZVRX?!#]Q:WP_OH=,TG?*`
M"_-]=!\FFY^<JL^KOH&M9D7?DH%&K##8/9%^%/[]$W./LU&&_)64^`K'@9>.
M&<G(EW?QF5,J&>:F(O0(NL=QVN7,Y\%`!Z@!*GB?P(,0%[S(_[?WK;UM(UFB
MWR]P_P.130,Q0+OU]*-[>P''<6;<DTX\L3,7NU\6E%2R.$V1&A9IQ_/K[WG4
MDZ)DV99MR>$".QU+%.O4J?-^%8%9/:489Z*)H9I;%XCK*"EIKXT4V8Y]57Z_
M@NSXF[@-1,+>D;9+ZF3)0)F#`46;Q-6M4MNHPU"YX92I0AN"K*W%=U14.%,/
M*%YQ?\7&0NIWE::25/+70&"FAEZ<XO2^)(EQR@;3]0ST80I:?A+/E&%7:TYB
MBRC\=AP-L7%3&V&.&`KA8-(2OB](L0*V_A2HJ<-`HLA35@I8"(.2&![-)B5*
M':9AGG7$",A5:\?^:B#FT8`@UT8:7W,OJY>1M$,:!8@#X<=)=A-<40@0>7L,
M[+SPT.:DDYP73P@>0JVL"(VY)^!X0WR#//C9OND'9+J'>F?:)PN^QO)/.KE/
M\;_*>(3VL;^`XZ95-5S,;3_@;8@KBAM;NI),3IFI[P&/";B.B!7_,6.-C`OC
MFY#!X4Q&H6'W82%9O5&I$#$^/T0F+@`R+IG79#G```^Y"V-6?:05L:N/UX/-
MIRE`J9G$90TQ!BU8@/8^!@@G:MHF>UC*DU11*A4=0C[1P2#`N8X&A1[;*NT?
MV0L584V^OS$BT?@'V0#==AA@6$@9%0J7$6"S"!),21H%/0&F8[<.#@T<@;28
M`,X0895756PHP,HPGBF%C._'S43F:D-:A96UQ2B"&*&A4B9D$$A$.OX.Q!9B
MLTZPP+(@68>3&+[##\=`>CR8U4,,G&Z2P09@6R0\2%``[J:E+'`6*<XX!2<F
MN5TBXSWM$&LQGF>S3-HC1KL.?$0\;/M:SR"1!?B)ZM?FPX+&ZZ*CB#=C`@ZH
ME1*MGRL\1C3WHAD.?<71O_A+#V9'`]"7K`1XQNK=$//)%2`5[+I`R&":P<\]
ME*)6F(`H@B7!L@6]"+!:IQ%Y,$6',(43D;+,4=G-:Y:;.$GP*>I<+A8<'AYY
M!!N0?%$HAB9B]++!K2Q0D3:VW';LZ_YJY;A&3(4+C0.4^B'+?N'<_T0<@NUO
MNV"`33&B9+KK;I!0WW:.]OI3($1T"SS!!9::4)(<["7B>_$]IO%/L`S?]0H2
M*BMS-.103+(9@_9:/D.O"BBYS)'#&(R;+/_3^;$;*:*AIIX$T&*-A=2\8PO.
M:N@)$T^(N/(1<$@*2,6#:OVPW;9>[WXO/?^TVSTZZAE@6:JL]GNVT`!1Q1C4
M6F:%T.:::IL6%O\C2B.^_P#$:(*R<]Y^]YAD"0$;83P"]B'O(B-3AFF3>X9!
MVFL[QAI57L2S'$SC@E?0U@^<:P'TEC"/S.)KFA=^/L%!F5VC`S'("D!_V[O8
M"SYF&4>O/Z!#[U8%4)CFP_&.LE;`A-"Q2.`R_2Z4$7E67DU00R0BPE(\E`:C
M*`]N!?P/&RD:@HKF1=*L93?&D-*+7NS=,68L/HGT&<N-BMJ.?3V?YW.2@4&4
M%MHM<?P;/S]5>4[9R'6<'?&D'0J@._Z.NC$@IDL#E)UF`FDYN%U@\YG$,KS?
MW)/"<L3<..#H17:(7+`P&P*F(BR";U1QVCBAL:%@K)&T7Z*>'9WL:>`Y]:YX
MJOJ*7#A+\LLX992QGR)NM1E,\DS.T)%"TW9P:[)*8P\'<5'JD"CX=@+->'H[
MBCH44<%5=BWRE`2O-#.A47"QKW27AZ0-Y=6=JDX(=-NB.Q=R73]!]@MYN$X`
M9+&L<>K]UEQS4*UIP%95^66LI@15*RQ>55%"YU%%"<'[XXNSB^#+Q^#\Z^G%
MZ>?+IBAAB_;UV!R7%]TITPB,%S7+8'F<AW/4`R$HO3&+<I4@A]?E(_*TR6<@
M4TJY)"`8X6LP]3&V8]D2Q":\?)8H_R6F(/74$X;P^=3FATSLEC4%)XM1(X#D
MFP*J=O^^9X_[F`""=1*.P-P&HRP`F\J$V@$N':.O+C3.L@(>%7C>2MQ(+R8Q
M0*%/H@JQE.76WJQ#V5YPQJH3@]@J]CTUQC-!Q_6%=V`>Y1AJ4(0\&OVSU*[D
M.Z7I*$0UADW"7M`8M.$N\^P.:\61X)@EAFXP&5AD>C^8&L_AP!9I>@L8N)8Q
M8ZS64]:7^W`8C1YQ3`/]K1LMO7>HCQY"8<Z*NWZE![P6ZPF04C1^4+,/D$JP
MO(6"O(INZE?DV*TB#(XJPH&A[1_2+4:S8CX8Y<1[*4R)02?'QO=BH6,@RHA?
M&*C`Y.\E;*G;4A'05R;I7KL$?X3<OEMFR(FZ40OCJ"2IX3?_U%4'1J*N+OZ)
M@S+.U8$488*EVTB6.@AI6I),PH@+!E6UR/Z;(6M-S_`BEYS!]AS'B7"DO[T'
MA8`Y_3Z<X$6,N.XTEE3)\^[B]&0G#&XF,?"U@D^NLCGB96]Y+63:2C,`C!B/
M5A+`X47C()&DV:7MS/@ZRYI=K6(ISUFR<V.[K(BP#YUC<0(@YP<HRNT^SOZ]
M^/;''\=?_QLMX(NSOWP^^WAV<OSY,C@^.?GR[?/EV>>_!.=?/IV=G)U>-$;Q
M=NSK,4;Q0Z,IY]:,!:'@>;2+RWTO)ZL8?-I4U=G84M65Z()@;47=3#(PLG>S
MFY2D,)7&TH6-8.G%8-_M!<=@@;@&!1G;NE#8O)H"`WF4RDC9UM;6%TD\A3>K
MV,;0W65C;VS'OIXOP/B-K_X\!9=DBJGWY7S`;F2DJX)680M\"%TVS-`^P-U4
MKIQTO#"TO*?1GR(0&F@NYI&RG,Z4HXE&>S0>ZY`D&S.X"-\-A[7&-@Z:.+/U
M5?&3<B75)M5-K@M_PXM0)9.YO705XZP&-.E%[G1]";7TCN@63N='A"HR6T!J
M#`NVVMC-&9(I.8H!!;FNE<+,AT%9(PFV8U_/F&K0@7/ZAW-QW&*1<+(PUJ[5
M(7T!PF)"$7+Z"T3"($K_5$P+RDZ5AR14TN4GWE%>1)@<'TZHT62*;3JJDR3!
M@C!@]%3%"SA,L,=`N;`XR86W[:.PU=\/NYTV=8K,!_T1J+?ML'=T%!YU^BJ,
MOU<?QT?&KPESO.V&W5XO;/?V%ZU1K.I@O'@B^\=E!V<"\G*=>&)ZN+!P!.L4
MV0C$VBM09*@4AGBU*-ES6G-R9:&E=&I1&!0L\/DJ/9_."EUOA<6XBA]4L;LJ
M5Q>2J[<T'#I\5[`7/`!#%$.^<B*`#E$Q[04?<$EWG=S"BAH)K$J1C':+;-<P
MWLU$>*$#*A_DP&Q!*A+I6Q5D@9[&Z^SH:V<54M_\NGD0T&OG6("[R"B#KS#.
M9[JNU'+P]-QJ]O4U&XJNHSC!.K+=,7;6@8C8"_Y:W60%);G`^#3_7L14C>)4
M"@$(299>J3\8.1ZR0]LEITP#,-Q979L5R78@W&')0$%F`YHP?,4#17MDL8?2
MYD]L:DA\A)*U@]UX6,S`9X`'I^TH+L!6L1M5:43%DB))E$4QU1$1O$TIH*W,
MXP[`5NUJ7E2'4:2M&`Y+!TB3NMVB3'-!]9"CX"J*54A957,B;L'7^3<[*T+-
MLE5T80L3:<OSC($D<0?!(H58T%<A"+.I893GL;,G)</=K2'*EFPOI/)8M`FC
M[^%<],WC5#8UIV!A3[#'[1I)'(?P*"97Z,6N1^P41TH7N70"=PH[C2YYXJ"N
MI6YB(5O/C;X,NNZ6.JDA0BD%*B+X5YE17Q+3$7#G4+=B:;M\5'W_`LF(5;LY
ME<W6O9-:W+3,D?$TQF:QXG;&<8\ZR8'\80F37]:X"-NQK^>SB3XB;?Y#TZ8M
M!SJSY4`KV4H+TI1N59$VVFW!CJH-<DW[T,;#<G/#E//AC&];"]T:.RKT`_CM
M/2>H5I>41Z(6H`R.84I.`B\*!K`V--4Q)@4)J(,/,7>(GUDVE[YYX%@6J1E*
MP"LZ^&EX<SOV]7R\J:^HX42;OI]F,3MZSPOW$EGD.TZ4C\%E80-$M?]B4XEY
M-M0/C$NPVDPG"?$76>+Q%-M/G'B72>]IWAFJ.@WPBJF5W^%08,L%(/HF>:%,
M8_>6--1_CF')G9K$7*#G\,QW$RHL$,4D`\8#UYZ^M4I8S2=(XFLA;04!%T,R
M[*$3PAPC0W->$96T@RO5$30K@9]=Q$D,\#D_J46DLV,5*\20!X^Q('>0'(ZQ
M^H:$&N_#0#_FFN3Z$]D+O(OKG)#HLE/A:1O6CAVY:%>A2A2HY)^1#Z3L5Y!W
M+!S50V1\FSXR,&P2]=6(,*`$,#"E4)MW=X7`I@ROLM0)1CSM1C)NQ[Z>,9(S
M1>+3W22?T%?_%..P&+[J<[7H3BZN8W$C*7!#[GY"KU`L0T5Q=AD,D@B4*LCF
M!4V!X,('3HC$^;"<HMM`ICJ7*HD:@\,F*RB@Q$OIBJ<!%RO=DJ##.X<&&,JX
MS*S+8;]1_7%CK&*NP!ZZB14;28(=4)S#%XNJYQ);N2696%295LPUTAIPB3EM
MH);+R+S=[05G8Q=UL<7(B'NXJA`'-[I,Y@:\&!`/P0@[8:GC7=M4>\%'ZT;-
MN6$XZ\*,>""TZ!@`^T]^D6&AO*Y(7U&K5E?!%AR8`Z+5;6ZI=\F<94(MJ74E
MGVM:SN/;0:\Q%?&"U2PEF+FW<X81`O[;)L)^:&&XT@X[Z]ZBK5FIDU=W2,08
M_Z$O)B;8OR)YT`9C^WK3`!+78"76D8HZ9\M<,*#5^8ROF2<)1E=*QNH27VGM
M(N0=Z5D:0%@(G(8TR*NF(X6W*/LHT`88B.*&RI`I6QD/^0<S=0^LL6^4P'-,
MMTCRH\IHH!Y?6MJWY%2O;X2]#EAQBUW7*75<)<`V+&B764)?G3748#.!2'(@
M`;0!=]T25@B"A9CY@5ENB_;U?/:'&C8*1$;$1%K%?[%C<^B'28_:_F!O`I,.
M.N"0$]*D=LR)RX/E;!?>@G7B`B/19IH3E3@X+;9J-`M'2:9@A\L"&Z(T=^X%
MGVF.'#Y&^L5[+S'+2,L!BIR;G`5-!.#M&%FBO2B0!*1C43KH&@;7WK*U':0G
MYYX.(O,-_@5FE:H@+?3#TK2QN9M5LP@Q4L/NC<K5`399>6I<HE"(IX,REPJU
M+"$7X-!YK>>>JH"J@G*NEMR`ZCF8=2!ZDJ8.7I)BC&PN`D'*L-883TS01K`]
M966A`K9G:OB''BE2MT;%L3;)0/L^''3):XU"K5Q&ND<0$.<]::+GE.U0\:X]
MGP>N\FA^877X!HV\CE29QOR:+*[Y/1$Z$[(^U6N]T!OE5SGGA/TMV..K'=1&
MJF_'OIY3JCNBP)D(#D0I[W(J,6*E"KU6DR?@/>97+%&U)>1$3US?HU"OQ[?;
M`%(U=Q1+FKB2`)FG'*/6KIT4#:EOQ[Z>C]1I0/GN>Q*5*'*!_M@W7MB.[FIR
MIEWITFXQGT?%)<`[L>8-3_U0*?_H)LI'DH6VJ%@*E;J;!:_DR2R:0]XG$>SH
M8@BN`#HZ]`PYZOC`-!N)9,_?*7,LLA&EWW=9;RBP>!1?GI&/$&!1CRXU0/>#
M0AG4MD=&@%1SBN;]EX;QMF-?SUF#1A4@=,/D:F%*W69@&PJH):M2CRQ&-'Z(
M`D=<T"UV=8<!%1_IVI,B^@XZ"C1#2IVQ^C.EE52>5;5/.N8TA_Z<Q.BMRK5@
MFD:Y"OCJI2E48^S9WDQ24?A#W`Z(!L&C,0L>5:FG@]FX@S2!!VX`FRO#KD8C
MY1V5X7-I7`2&F-<=J('1%>P"I5\@M#SS@M:"S9#06!T34Q%A*;I.8PGL&5&_
MRLE!,DVL.!D-K'8JA8.O"1_J()4!;)K?M#&`E6"`"O0R:3RPQ1QFI5;?CLGL
M:$`&)OR,]C6(35$4B1;=@BOS<7+Y"DB@N+5J',1]F(W'U?*QJJME\HT45D7$
MT:%S\:/+-I-(.BG%P`:'3?P(G""L[2K45,%YJ#U/8@(^..;_L$Q93RU\,D>B
MJ<_2Z/Q@.R16;DCWAV%B*)_@^!WO#=#2D(KX?&9X]_GWX/.73SL>%^@V5G;`
M+4WF3N2'JM##@WXW[+0.=;EY:_\P['2[H2-:U!`9$C!\FW=C(&S)OI[/0/@,
MA$GW00)Q!GR;4$`W"2T.,&*G\E"U.24E$JDNNJ67#/DE9.4&[T[/+W94@CT9
MVEA*=8((I[*RZUCJ,4^V-LP9[G.!5QN1MGB?P7^"=Q^/+][OU#]QDHULP?R[
MXXN3G>`RFP'DG?U6:,R?3NO74Q=ZVGMHOH7M5OK*K\IXI*.(&!LD<<$3Y8"#
M*28$;"=E:9HG4U'IO_^]!`W;51WGX#-<T_Q&<"AT=&U,`[Q#6UPION-$6$GZ
M&(V9-,.BW\3,]S#33$)VS_%N\9#+,DF1.G-`8EU#CC4E)G\YF#M3,Y6W>J:L
M]RX`1,#&,6]"[YR<%-U;4,[P3Q"71X>'8;O?YI]+5:9,[R,'J[I!D)C<F49=
M+@ZJZO97K8B^$<B<J(,Q;WWE7MSB;@*@<&[E*J4^+$0*?G(/?%AXX1,7W@U6
MU)LV7=*AJ/=W4U0_[`%%=0];BRB*QI4Y-&\;,'%L&_`FTQG_F(8-"2J%+CQR
MJE+#8@I`V9-X5@`7D\)["""NM3?#E(T_HC.E)!%+L*5SKC:S069O6RB:L=.5
M"+ISH+CBG10$NPCV=W@NG"99D+WA'7LW$J+*1UI<VYD_U)4B@!Q2-7JH+GFB
MVE/T=46$5PR`2&R6"&%GJI3#6/"F%`.#^+L$.>#-DS%5BG#ZU+\KH$V6P@6;
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M?YQ^O@S^W]GE7X/CB\NOQ_]S^OGTY+AF]L[K\>I>N[?ZD$$\9V`S1VF)L<-.
MJW7@QU)PY"+[+"R\UGR_&$5Z)848PR57<#S_)6,T0Y(:_`$GAZJ(=7X_V'LZ
MY="4G<SFC@BWD*OQ)AG6V3-"19((;B&>Z28)A0(N<77.@<#Y`%MDZ^<.D,9E
M3HFW9P%-S3<IU%(4*:LE"3P75'\6`IK9IL>W6QILMVB[CK77:AW=<[]3##V`
M$Y#=1@D`GYL),W6U49S.=V&-*['@NC+,6O(S5WZZER38EAFZO$5?%X3(AQT-
M<KQGE"Z005^@>F^+O8D,EJE?DZ["TWQT6ZU#H)N&\!(O[3'XB&6LZ9D\2\ZO
MEJ5]:4$?C]30<+H,QSEM/?Q?H92]#S(BZW=E;LRUA$I41,Y.$?TI_/M5.==L
M.1E38E-,*S<AURW9U_U]D(I0/%+^AY:.WLV>GB:K7+]BI\3;8I[%U\Z%*DTZ
M/^)BGOX-T8^?F^B#;[5UASCYV-^\W6GHZ>99%(^"M_VPU6KA_]?,'0:$DS_'
MQ8(4+%'5FAG=)$"==W1+#+X*&^NY!,/1-=KQLA=Z[%5:=DQN\&V[%7;WVUQ.
MSL6%>M[%*GFBMYUN>'2TS_\F'ZM?3=7,OWGUD?TV=3Z/X:7DU4BG[0F0SL46
MP9XQE=3*GN#D8,NP3?7.AH!Z+,707,MY7Y7K<O9B5>Y`BR82<Z!G?3FLK49,
MVCP&!3-&//*=+E+FL@UC/"GSF:PKYX*YZYAGRV@A9FMP022Z]U;X=V]A(>,-
MCKR\BG5Z9=Y,@U=@$@US!12#?MON]<-.GQ&M9M3P%X?F<W?N7U:I(4^]6_8J
M.RN<^3_^.RI%V#AK1BJ'A`?/:PS[*@CV:/9')?5$0+`L:0N<GH;755[A_='P
M5.&@%H-HD9IV2CJ&0MC"O<?/NQ(5&\=8TJ#4B57I#MW&I*]L=7RK2-U3K2^J
M7&1$LN16>!Z`VG'NJ:5A2'3/+)[],(;'Z?0]RW4QE?O$8,K-S<.F%MRGH5K'
M0<<)9[$EY"7\10,8'\:%(8UV\@9!\25P.*NQ3))=+$3?M7,N`C&=)=FM6"F8
M=K^P6#6HAFV3-.##/OLC3*?N/RXB]O'X[&OPC^-/WTZ#/TZ/+[Y]I?!8,XKZ
M9?9UMS(F"/T"Y/O<!UD9(L9U>1%(8E"!(`)0$,493EA"T]/$`N)T5J+$_822
MD2!HJ\_HA:II6'4+ORM3O@I$C':XXH+*#;FE6/6;(S+Y\D2N0,/^1ELVIQ8*
M.@L782R@XZ`F1"VHOYM?GJZ`H9>:&H=L@++6E#C8,E`'*C"3U?B\40Q:K$AN
M"01ZF_[$B&;5/0U.3IYI<1IR!;8W<XLK0\$_<,=AU,T4T@CIN@@I4PLX`:.^
M,Z=FN^/]/MJ;U!LX3#4(&#OB8LTEDX+=)O5C!U"-+8+"8,R_VLP?(XGZ--;U
MAIKT*LWN;B`JR6Z`A(%O$`NT3U4E*;UYXQS)J;*(VA@A<JO9_Y5(L27;,-4E
M+[2E(85+UJ>=-^*<EFQJA=C4`\!WZ$-!\M@-O5D"P"90_',-<,RPIIMR^VKD
MA],\JH=\5"9_D@Q\`G-N4TNW5R!*_T%&Y5`DR0R=V/3JMS>M-_2WG$5#_;=Z
MU4T\*B:_T#V5WB$7=,@I''*.AZSRUQ+,*'Y`?3".P%R!;58>KP"4^W^.%C,7
M%8Z`':4_!1>UR*:_!FHGN_SW+T%G]OW>=%L+HS\BQ*>H8K0`[I>#<A4@\=IF
M\,%_>]-Y<Q?``^RRR`V\`VS%0Z@#:E!:3G\OK:@68NN2[JJNC(JLNVWO#AE2
MC]TTN\FCV6]O^+^/Q/`:I/'CZ64---+0]S/2]]\][S2N#C!YY-LK[F6]0ES7
M8N_8#6SO-*S8L.(6LN(7BJ!P).=G)^S"D8M-=Y8>R*V=AEL;;MU&;G5JF[U@
MX^MFU^ZSL.N\*[<!SM#/RO-<AP_ZG#2_-GGF^SMW!4V62KG[X>FEY=H&0_M(
MQGHY/;?!.&THH*&`A@(:"F@HX#DL*;W>`)R"JQRKFW<!^5G^2_`?PZ$0X_&;
M1U+/KX%*2W3W?]I.NXON&>4;`H./@*#GL+PLUG[:/&=8YYE^>B*,OUTCC%4@
MB5S6`J6]\O8)9,13H_A)%49#O`WQ;ASQ-J2ZI:1J2O4Z3V&,-;3:T&I#JT_E
M0]Q,XD*LTX-8$HK>,K?BV][%7G"%C3TI-?/8VX.?V;_8B.C^O03,]J<374ET
MG]VL3U(=A+VCPW!_O_^T<FI[CNI!G+-Q:>'7>#*;S43[X5&G8:)5#=>&939B
M,R_',D\:67^-9]7PS(9LYO7SS.;7_3PX6[5J;FIM^UI'"\H/'.YY,@Y^71RZ
ML;AN:+:AV6W#=4.S#<UN&ZX;FFUH=D-PO3DIH=Z6IH2HV7D>S\^<_>EM8_8'
M@`Y&63E(Q);DG^^UB_4)H\Y^V._WPJ/#_1<(OSWY(;UPXL?NKV&@5\U`W;#3
M:QCHL0'LAEU>/[L\6T%4PR^;`'O#+]O"+W?G>E[`#VAR/4T\IXGG;!NN&YIM
M:';;<-W0;$.SVX;KAF8;FMT07+]4KF<KTSIT96FWQ7>2/<O<ID9D-")C<W'=
M4'%#Q0T5;Q1A;!1F&RINJ+BAXH:*U^2$/,$<L]=3<O;2P\TV(NW4I#>?*[W9
M#;N]7MANBF>:ZK.&?QK^:8II-O,D7@FW-,5G#;\T_+*!_+)1Q6>^)_DSW;@Y
MY_PX__[/GTNY>Q5%LU\^1G'^#[R1\$,LATF&]SC+2]C:>_3J_NO__I\`_N\_
M]<,7!7PXR1(X6'GZKS(N;C]GA?-+\\-@"$#"'U_%^+<W'V$KF#;:;1WLMMI%
MAE=_[+:ZN]WVF_^ZIYOY9FY3=):;Z;`NO[GXW?Z.<[`K_BNXN/QR\K>_?OGT
MX?3KA7/_=W#Z]V]GE__]!+?0ON@EONNZCALO_-VHC55^C__>I7_#*PI8;>A`
MR^^DWYUDTVF6!L2&P64>I1)O1\Q2?]QB8`BC_>"5%J#^2QK\7B:W09<3P2'=
MBPQ0S:+T-D`AP#?*1W@9Y'54B`!>/*2+X8-L/!8YWG\:IYA3'TZ\WTK@E1#0
ME@?1U54NKNBW>3848D07I;[M]O=:P31.$MAN".L?'G3#5JL5R$D$$@L?B?%N
M9D:01`2%P04L"-\=$ZS!390#QN"A(@MF93Z<1%($Y0S_[+;#H\/#L-UO.^_S
MWQ6E(_V^]W>_KQ_VX'W=P]:"]^T%EQ,!CYMWP$.!^"[R82SI!K"H@!7U)X+O
MUB0\M/9:[6`F<GXQPR6^SV+X?2'2X%9$N0S&('$)O2/$(^)&RC)*AX+6#90$
M!W*_M4O@XP8<.L-A)">)D#(81#*6_%,/8%D._BF&!>XX8J8"N.C*;`FGA/^:
MQ(.XP$,WRP`PWDHQ_\T@T6[P'*/Q.$YB`%X&-UD)8G0@4C&.AW&4`/5E-RE2
MD?@^1.C@C4=[1T<_Z5<7=-UN6DX'\$+XK/X$]-.:`.W-W[($VC3POHL83P,X
MD]$_2XDWG<)^\:<@&7CH:8&$6TP0)F=O.U6,)3+3%XK#<W#"ZGEQS?P!2-30
MG`"_Y0`1+(8!S0@Y"#;EL#P!-@*<I/",O[#<\?D2P`^1H&BM1/#/_7-0^`]Q
MF[D`S9[S-N$_0DP!]"1`U@QFL,_Y7TM%KM$T*U.T82R.@)?A%'-S-A.@4;[*
MU=*T`ZNCTF3EN'*^@YV7,`P`1E=,B^%&,[K]$KZ36;JW$:H0"28>W]:)U*U6
M8._%,"I9:,`9W.#_I!F\K1PCDR(Y1V4QR?+XWT`*B@'AD(8X*IBH"<\R*PM9
M`,<CTRT0K8JPEV@3OD<;50_\%0;`++#"\<5)<-CNAT83=EJ_?A#TDO@:ED$Q
M\U<QNL*?F$?:O_):BTA\`,!;(G;VE]"UAE7Y<@.0N:P$G#5,(BGC,;('?!D%
M(.$&(.:*6P((+PBGKT"<@%&N[@G/TH7\,8@2E.F`7R$*%C;.#W%]\&"&91*A
MS!J`'"B3(IXE=`DYOG-.1!+R[/<+SF0%1*S$T0`1/J>.SHJ#JAX/2`>QP+U#
M'>ZM1->[XP@,"?BPCK)]F4V4;8_).<!BDF?EU020-"L$X;%SH(PB3_+`:2IK
M!Q:S6'-/V)?$=C6F(&?-.`4ZDHX/YGH`@OPQ,$`TWK1*G:'.B<RYQ.D09++$
M?[AG-V>=>`]:<$,F72`7H*:5SUJ]"\^9;!,XMW[+D>*`I:JI@CP#CQTXQZLV
MA_^L;"XD8C@(6_M'87N_'X`M!@P'>`;\81Q",5R:I;L9O"Y2-LE,I+"_L=(M
M*5!(`#`7$QF(%'_D7U?9J)3G<?:0^(Q!'8$%P2)?'].\,E!&E62KJG!^GDMP
M*D"L*=E&W\&"T976(L'?_W$9?(Q3H#BP+8-/YR'0#HBWH<B+"`B?MHV_+N+$
M=7T.0Z3II"3EI1Z"MXWC7!9`=.-2PMM0JL\BC"3%LXB4"O(<>COE0`*_(@B*
M;6%O(S&`33(HJ,K4KD9V5[P3M'[A@P3XJ0!0C-WKJM-EEJZC%"*ROXVTFXAD
MI,4RKT7R3XO=$<N%FJ,ATQ9#/H`R:7$G9`&"&E4N:?Z4%H$GDXP5MUT'?QNG
M)3$]LG8@9V*H-"59?(1=ZY[D\PY![2^J>%G@C;TJQMZT(([^?3SZ[<WE\?NV
M";)Z,*$XLM$]?19(;RGY"BH4H-P*3<M$GV^[O;V>C0U$8W0X@''*(8EY8RHJ
M>2^!)V_)R5:DKE_&KK1F:A8UM<N&R#7T7^-H+_9O09U9#TW#\@049Y`WR(.?
M_6*7C=(+*Y!+C/^@(!=!^V5F8UQQ-<`5G*F0U'P\Z@I/`'#?.>Q3J"CC]^!A
MHHT)1S8L23AEZ+60KF@?=L)^S:/369+="B$)'J23=KOV030P],.`0[`^BBQW
ME4^=I020MU5,[RS%^]81IG.P[5G>ZNW$$B4;:)-_`P$1((5O\3/I(0TJH-`F
MPAW!YD/X5^N0T(#@OSU0GX(TG`D2T0F0,[EG^-;>H6,((3=H%.][,!$4:&)=
MI61$ONWVPWY?+=%N[8?[O:.Y-<8L='<'D62[$[F2U:.VR'+!^HG9SMG1J,PU
M;X(!#CB&E0B(I[;=7IHK%D?"#;N_D*)`@A7Y^O(B&Z&+[[^I9]S/ZS/]'YBD
M^*H,3.!V%I_?4A#""W,AJZB*#HOUW+Z9;>@2W[Q8<SR!A`\62?<%L)&PWV^Q
MIM-RO--;(,=[_LJ>#(=W=`]8AA_VPGU`R3I$^`*PZR3ZEGCBFY?GW+1]57Z_
M@L%/+`J'CQQ3SZ+`GD3CJ[*HX^X_F$G_&B7C.QGP6E!R*-,[Z'`XD`@:U\S%
M-(H)`GQ2.KPYEZZCO3*'TC_YBWL*@UZ7$15C*(Q"Y2Q;$,:J?""0*`H+[DDV
MTEY,!&[,:+&DZ.R'AP=])2E:("GZ&R<I7.#XWYU>&Z&N0JJC2RN_NM,(H>W8
MU_V%T,4BDAUFLK@_I73I)RH6IQP9BC50Z$^M$Z=`]"6**1,SX'1F,8DX=C#_
M@D6,(N0PCP<8":-4#>81WO8/0!@<,@>TNF&OVZUR`#MMA]VPVU>LTCOHA;UY
MIEXGJ]A"M)5KRZI%:9^C`K[^,O["@7U$SCJJSUZ+D<SH04G\OI3PH5QB()]'
M":9&@DLQG*19DEW%0H:H#?>"=_J[S-.@.V2T!H,XFTVB?!H-14F%D\0WJ"]&
MF!/,9B2Y`5,"B!7I:2AF19;OJJ#M$/0.T/6($\K1C%XB+:%A$8$.V,,>,2LE
M@YL8])8$).,+(E+O4U$$4S$B`%*!#)!R9@N#<_#9+,.*#?C7GMZJ9P',\@S4
M[92+6Y@M@>FG60*V1*+3"]-L1-%S5I#(%!2_9X4Y!5V69D/4LRES1@0<"O@O
MG#WJW0?R%BR&J:JL\7[*WR!NX_0Z2ZXY@A@%":*07@QD"XSB)G%GDUL9TZ$-
M,:K.A6&A-C\T5@,PAE#&J&VP1H5UU(I8ZD()$$Z%*W21;L9#`!"NHSP6O&-@
MLU%LQ9$^&3<U(L7W$GX_NI4:)#`*!D+JI+=6_O!;JA>&'\_B*RIW(8EK/N?2
MH'2<1-,I?;7K_)26932N@'#*#@+>1)Z5F"//1W%V'4E,BN2/P]Q`!*44XS*A
M>*]+M1%8HW!PLIA,HS"8B"BG+']28@W7Y!9$%Z":JJ9P59;\%<C,/E^9?G[M
M=L=#\QYU/LHLC^'7MRBI,+V!9*8$+!$:FOK@9I`D(<JOE:!C<$024<.:P;N/
M%Q]V?'N?4GO(,*.\O`*2!(X?45T>92SMTD9VXI**P\-`8`0\AL4\`3`K$S`6
M<!]69"P@]A`6`;52*+EFA+\G#3+G33[T"#C548(\DNC/7279`#8-!HT@"V68
M)0E826PXT%M!D9);8K.;I&B.P=2*_D>D8A@%Q^^#=\[?.US:I+4,^$:D_3+*
M;'+REC2?+^*U4%J@Y@P*1W$T$(60GK@$10=0`Z@@?=(16#@@10C,ZBG%6(8I
MAD"QI!0%NH^TUT:*;,>^[N^]_$W<8IDGNQ)+"G0&RAP,D)(+<76KU#;J,*K3
MQFB*-@1U=A05%54+9YK[*S864K^K-)6DDK\&%%+G`G"LUTR2&,M\I*F22$'+
M3^*9,NQJS<F8RPC'T1`KI+01YHBA$,,])7Q?D&+E2E.JII`H\I25`A;"H-1%
M?EJ4.DQC"BZ<P*RU8W^U=1U4?(`5#!I?<R^KEY&T0RI^B^0D&"?930"V!;HO
MP-LF&E1W:'/22<Z+)P3/EL,:S*WBA,W[4E5OZU,,OAE8?;=-U\]S&@0/]?ZT
MSQ=\C>6?1!GF`"L3OQTWL*I!02Z4.9:QIMB80>4\FFY5\#*SOC>L-Q3$#/B/
M&6M\7!C?1#&_$;J`6IP,"U49;`N`^"%=,C$NF9>Q9JJ(V!WAHB'6NK,$M",S
M'VA7K(;73.BRGAACB3Y8!\<`X40U$+`'ISQ5+IM*Z1)DYD-3%291U!"S^2%I
M95W`*\JIJJ@:45%2H<J2:V*1!I<1%;8`!\D'1)0J-EJJ2LR$/BL*]X[8.8,-
MX"I"^ABMUG'*F4H189E:(6L%%RP+DGLXB>$[_'`,I,?%JAYBX'23##8`VR+A
M1(((<#<M)=:(#[%M`YRDY':)#O&T3ZS51)[-J,=(:Y60?%`\;/M:S^"1!?BA
MZM?F0Y#_8-:B(ZKJU%25=BZN\!C1G-2%I?Q+#V9'P]"7JIV!VD;NAIA/CHJ!
M_48+0*N/4M0Z$Q!*L"18SEQ39YU2Y,$4'<X43D2"&.::V:KFNHF3A'I7L-ZI
M6'!XW.XCX70B:B>A?A\N<L+:OJ2Q%;=C7_>W%8]KQ%2XT/A`J1^R[$?2!?8@
M`X0X9`+B=1<,O"E&K(0LE&U"]7F=H[V^*L^K)+S!7%"2'.PQXGOQ/>9,U#":
MH6)#"965.1J**";93$)[,)^AUT;EJ,AA#,9-EO_I_-B-1%%;@2<!M%AC(37O
M.(,S''K"Q!,BKGQ470LZWE3KY^VV]7KW>^GYI]WNT5'/`,M29;7?JX8H`&0,
M:BVS0NC'+3^\+U/]8=/'`Y&@[)SW#SPF64+`1AB/@'W(>\G(E&':1+,@+4#:
M:SO&&E5>1+4<3..B4%7>;/W`N19`;PGSR"R^IA;(<ZK2[AH=J(I8O^U=[`4?
MLXRCXQ\P8'`\F@(!D1_(8:`/QSO*6@$30L<Z@<OTNT+3_V(JT8<H#4913BVH
MRDC1$%0T+Y)F+;LQAI1>]&+[CC%C\<E=4X3E59R;9:Y+U<TYR:@$@!&"MO,)
M*.JX("OZB;R<35(=JS>D.VB2U<9SFV2J/!<O;FH#6T8HG>(Z%:K3.*9F8]M@
MP$9W#J<"AI5MXW"3J<2LIE/943[L=;A@84J#CIG>J(*M,7`D^@7`'O3`8AWH
M*#Z_2K:J0Q7A5E^1"V=)?AGG?3)V!L2MMC5):,@9>BLY]_;IU-#8PT%<E#JN
M"0Z40%N9WH[R!.5`<(65(.F4VYA!`@&/80CUXXH=4::V9?54<`A$R#TK.?8]
MET(9">1&.E&,51AZ"9/6\+/R[.#1<XR<WCYYV&(C&/HY@PWGX'>"'YIPAXV'
M\L4Y9V24._UN$YK4+KMN\-%9:3TXX&:2@8^V"PX^L4[$W4<8.P#)'^6W>\$Q
M:!A7LZ`-FNMLM7DU$;8S8(.3HM12"%8`:,M(\>;0W>5#[2IOC-!:R&HS'*4G
MW%>M-%C(XE5Q\$V*+^-3$)!3"IH\1@!LZMD]D(>_<0^3P<URQ@5'9!8IJY$+
M`N[D8WP(S+TI=3BCXT7VJ/+K$F)!;*D>:5Y4O>%:L"CC4+IUG:#)I]&?X#N:
M`Z40N)3E5+?GH!$0C<?:!@"PP2DRO8*4H;>&AV[!UD&<D;$7U281*.I[7/";
MPJOF+%:2<+9,U`-->JI21TVIC<TIB.0?V0).$'/#HF1CN4RHH1ZGJ(QB[#_3
M&0:TYPW*&M'U@J++%T=SM@M8BL?I"/]S:NW%=1HQFWJ(#_5*M(U-_W!PMEB8
MG2PTR[7E05^`F)N0,4U_@3`;1.F?2MR`7:'"M0DYFGX@#"5=9'JG,6I<H+E-
M=51JP`75>:(=S>;S'@/EPN+X(6_;1V&KOQ]V.VVJ#)OW#[B>,^P='85'G;ZR
M^/?J37X4676%TV96[Z(UBL"[&6H#`TO/:X.LPJI5_CXS=-+P]$*>MDBZPR0Y
M,86G&(W&Y"<[#9C0`3L"=;(>J3(TA@NG*RV[4EW5H'#*M"O,4N@D#E80F($(
M5*&C:FR$Y)20AD/%&."WE.KQAO>0J;`7?,`EW77RZLP@G-"P6V2[1GK<X#"9
M:DZ2Q[S0<#*23"K+HV<K4#&Y786L)W[=/`@8F)N?UC?*<$AI5MA24;4<#@FK
MKF9?7[.AZ#J*$TQ.[8ZQ'!CX92_X:W63%92X,UU$3"%N)_T`(.!\"?4'(\=#
M=FA+>Y5E!HX>6TMF13+="'<8ARQX6$;A=-!@)\">NG."<FLN0LG8Q!)BC)#R
M&=!H#67&<M6(GF;"Z0O*P(HD40;=5(?(4@RFTE;F<0=@JQI;BQX%LC4B"V]V
M#ZFA,LT%)5E'P14-["#[E5/$3GL/3MB+\A16D(HN;+:3MCS/&$@2=Q`L4H@%
M?16",)NJ#LA2BLC=&J)LR?9"RKFC21Y]US%U.YS!XU0U(P0<G`D6YE[3/*1L
MJIE<H3?VQA'5S&/ZL13BB];+^NUQ3KD(.I48]+%T2O5<2CU0^/1?949EE<YD
M0A7#U0[2J/K^!3(2BP)H&E[M.ZE"5TL?&4]CK'4M;F<<,:N3(<@IED3Y98VO
M]H(FWD)KK6K6F<G:7\8F,W%F$Q/\Z\;$LR8>(BSXAV8PF\UQD+:2Z>?E6\:U
M22'M2-E\BTKMN.Y6:,/!F,2'CT$M.1^J,4*AFX>D9"C`/X"C88L/K80E*614
M:E1[5FGL711:8N6.]>O4(G.M?P*HLUUZCJR2OK7C&$JI:0SC%1W\-`+F!07,
M2G*C*FS.<\R6%K?8KUZ`!XK>YZQQ*>](5S'.B,D,PA:+&.]YH9_7LH0T.,\#
M8:[EMA(L)C3/AOJ!<0F&M:D@))E!SE(\Q;)#)R*L;%2;%Q^JFD&>9>!)'1`U
M"T#TO:9">2\?4(X,8S69T+/]N0.`NX[S"(]K-Z'$KB@FF3,_P%I'JN\MH?FZ
M*NBM\_,,>^@$^<<HI-2L<G38+*Y4)>BLQ"%N#N(DAL"=G]0BTMFQBJ9C:,T9
M/TT^X5A]0X*:]V&@'W,M2OV)[`7'[``:#V&54^$N3NMJC%RTJV`^*@ERH<E-
M52X&R`$]&)X>XGF-NGX8+,Y$?34B#"BE0E/)1W.[0F!3AE<Y4P0CGG8C[5]0
MVJ\JN.>"AE.D#WSP2_X!(,K`5?XR_I2E5Y^`MT;'1)@_DO!_SD('BWSD*T3Z
M+F$]8+2O%J#,Q74L;B3%'BEBE=`KE$A!*13;93#.)U#JTF4!U'TYG$3I%5?U
M#^-\6$[1WR4?,\4.^$+4&)DVW4DQ45X*.Y<Q<C-`<8K2&14!K(7&+57\&U_9
M?J/JQO'.@BKLH9N:M<%0V(&:9^$YU=R+@"U4DLQJZC(IYAI,#+@DO&S"A"HG
M_=WM!6=C%W6QQ<B(:YNK$)L[)H(;<+_Q&HT1=HA0IYFVH_>"C];_GXL?8(^I
M::TDM.@PEII5'E/.6W69ZI'@"O]#O;J*%V*C.EV'8HL^ZV,)SC*AUF3*-?!G
MB\_AVT&O<0]P0'>6\NTCU/,PPR`7_VU3Z:O493U$-E7EVP<Q%JCGOG+J^ZFZ
MS3:MW/BA$DFC*_B*A[^HL^NA;U^@4A?YW';$NK*`]*TG*-1RXDDU6UY:4Q+9
M27K&&86=U;;RJJ5-`5LJ9Q!H,@U$<8/%65S^$`_Y!^"A^\452OXYEB[-V$=!
MI:91<2N,9_2J=I@(*Q63A,+7-,L:HXK9#<O<94;C5^?]:K8(S>-RH`!T`:/=
M+L?&"IQW-]=4^4P]^95A^=&J(^\]<)*0%3C86MQ%J1\F_67[5;R)`SK`@TV]
MI,%L6Z]+[.5L%]Z",_`%)C',]`(J3G):/E0K,D>DIN`?R`)KAS4;[`6?:6X*
M/D9RW7LO4>9(,QPE74RZBSK4>#N&1+5W!RQ'N@W94%<?N7:.K<HB_33WM)X$
MK_XRUX/%A7[8CI1W-ZMF[\3"G;X9S6:`359:&I?(@?%T4.92H9;%T`(<.J_U
MW&9]%0U#.==H9T#U'-\Z$#W6KH.71`8CF\NWS+497/U*'7S:^+2GK"Q#P/9,
M-:/J%M>Z-2H.O\DCV_?A8"=>:U2]C(`2V]Z3)MU"B3(56]SS>>!*3T2OR%\/
MC?8J!\RIYM=DZ<SOR;FJ1KW6"W-2:I[3E3AT`'M.M..\BAB]4RC.2U&F)G#@
M/EA:.F69OX9(_ZN3HP[S.0@#,I!WN4\8NU)%D:MQ,/A)^17+,*WDG3B*:V47
MZO7X=AM*JJ;W8DD]MPD05LH1>.W$2+$:<=U)*W/WKF*.^3T2^(DSCI#GXL-K
MS+A2#"*L([&TZ>3VG+X^#X,DY`<N]A<W.[G*CXE/NL17S.>JYR8[<N.F*K"@
M*:Q2#\#=6U;EM."5W%RK2?P]7L6\>S$$4Q4-<'J&?$I\8)J-1++G[Y19CH98
M(B&JB94*+)[6DF=DPYHYLG2I$YC'0SW:E?6F7&A?KS0B\OYL,%]KAT4<E]'W
MQLI=4FI'A2Z`I+O*_]V;4S`28_ML@C%&I_VJ=S&BUFT*+G#;@-C5C3=48Z5+
M;(KH.TAWD*F8/3TSGREYKO*O^$:@2,?TX_"0DS"]5?D*QX_$5R]-K1K#1!=H
M*>&./\3MT+5-U'Q:\!@A/5G!.J/2>*/T^_EB_VK$2M[1?S"7WD5@B&O</DET
MMW&:"/T"H>561EH+-D/<NCHFIN!SEKE)!0ELI5*_RLF8Y^$MS-QH85+%'WQ-
M^%`'J8PUSMHX]_YBP1N@`CTB&MUF,8>9G=6W8[(C&I"!"5&B+9CCW:Q%HF6F
MX/X/G"JY`A(HMLDQ5MJ'V7A<K9*KN@4F9T>A-T0<'3K7>%9GZ]BT7&`#B":P
M``8[EK`5:B++/-2>U3L!?Q%S:%A2KB>^W&7TOGC#_Z8*S8?8&!]L1\Y*K;/S
M%U%@X)<@^AVGNVJY2%6+/EN\^_Q[\/G+IQV/'T+%8>PV6NK,G7@%]0Z$!_UN
MV&D=ZB:!UOYAV)D?":WHGN]:6U86XI9'U2O8JB(^5:6EYR(GM=[HX\43G.'T
M/^&9XT68^@IXN@]S8>P)C"0<6$N]:TF)E*!+>>DE^O([>LF[T_.+'943-C<#
MQC36"B0322%36VLN]Y9^B=:Q[=6[P+OV2#B_S^`_P;N/QQ?O=^J?.,E&M@S_
MW?'%R4YPF<T`\LY^R[N\]]2%GO;NW=NK`D9:[EZ5\4@'F#!L1#S)PR_TO6RA
M<S$;D%JJ;L4V&W5ON5]R_7!H"S7=V]O1=D@S+"5..(XW$G;":,A^)#R#I6.Y
MT)<#J^<LUW(9A$DI#>;.U`P0JYXIJQEU?^]Q<.=U]>WPZ/`P;/?;BRY+KVX0
MQ!*W&U(#D(.JNOU5ZZQO!'(:JCQ,)5ZY,ZS=34COYL92ZL-"I.`G]\"'A3=+
M/7@W6"]N6F;*H:CJC=`U%-4/>T!1W</6(HJBH0\.S=NN6AQ^@7<`$YWQCVFT
MD[YDW"6G*C4LI@"^P=55M5S3J>].J-Z6K,W_!=<E._%'_Z[5M.9&Z."=%`2[
M"/9W>+J&)EF0O>$=>S<2HLI'6ER37#$1Y8$`<DCYXLO:N+IJ>M&3VPFOZ$E+
M;,'`&]3M?=ML,)OL.,9W=PERP)LG8ZH4X4Q+^*Z`-@%L%VR:YW\7\SI]SFHO
M]"Y/[O#QUJ!>MT/!F2_>RE-)@>86UX53YAS[UQ?ZAO[ILF\@5+SG0-&*T6@G
M]'$1XW/GN?:+*%3']K1['ZNK1MP@FZ'6=_ZMKS5WM]YA(G27F`@[9F:C"8YQ
M\+KNZA:.!RBG&KCZZBK'D:NT#2#I_8-.V%-WL\&?O?U.>-!J,>)\VYVX4PI]
MO;H*,]R#+3UV5&]Y%"M9%^$.TW]A'P77C1RGHT_63?]#A2F^I%^%&GP*#WS.
MTES_B::PO$2*>M7.!75`91@WX*M6N/3(2:;I8J-*$QU%C'_97#-HW6A>H>C3
M?Y!1.11),L,A=.G5;V]:;^AO"7R@_U:ONHE'Q>07&G'EG5A!)Y;"B>5X8OS=
MK@13@A]0'XRC:9S`-BN/5P#*_3]'B\LT248"8^M/!UE19--?`[637?[[EZ`S
M^WYO(JR%T2B\8)ZBBM$"N%\.RE6`Q+&*8"_^]J;SYBZ`!W15C8%W@'D6A#J@
M(/AR^MN(^VOKL'5)LR0K;4IUXZWOD"'UV$VSFSR:_?:&__M(#*]!M#Z>7M9`
M(PU]/R-]_YU+:W5-;;6@ZY%O5P/HN'!7!O4*<5V+O?N$]01!>Z=AQ885MY`5
MOU#5`]>Z_YP-L/Q+91-G9:4LZ*4,R37N5G%KI^'6AENWD5LOO*LW?Q1V[3X+
MN\Z[<AO@#/VL/,]U^*#/2?-KDV>^OW-7T&2IE+L?GEY:KFTPM(]DK)?3<QN,
MTX8"&@IH**"A@(8"GL.2TNL-P"FXRO'6X%U`?I;_$OS'<"C$>/SFD=3S:Z#2
M$MW]G[;3[J*YPSQL,_@("'H.R\MB[:?-<X9UGNFG)\+XVS7"6`62R&4M4-H1
MV$\@(YX:Q4^J,!KB;8AWXXBW(=4M)5536=YY"F.LH=6&5AM:?2H?XF82%V*=
M'L224/26N16+KT-Y9O]B(Z+[]Q(PVY].="71?7:S/DEU$/:.#L/]_?[3RJGM
M.:H'<<[&I85?X\EL-A/MX_U6#1.M:+@V++,1FWDYEGG2R/IK/*N&9S9D,Z^?
M9S:_[N?!V:I5<U-KV]<Z6E!^X'#/DW'PZ^+0C<5U0[,-S6X;KAN:;6AVVW#=
MT&Q#LQN"Z\U)"?6V-"5$S<[S>'[F[$]O&[,_`'0PRLI!(K8D_WRO7:Q/&'7V
MPWZ_%QX=[K]`^.W)#^F%$S]V?PT#O6H&ZH:=7L-`CPU@-^SR^MGEV0JB&G[9
M!-@;?MD6?KD[U_,"?D"3ZVGB.4T\9]MPW=!L0[/;ANN&9AN:W39<-S3;T.R&
MX/JE<CU;F=;YO4Q%T&WQE0#/,K>I$1F-R-A<7#=4W%!Q0\4;11@;A=F&BALJ
M;JBXH>(U.2%/,,?L]92<O?1PLXU(.S7IS>=*;W;#;J\7MIOBF:;ZK.&?AG^:
M8IK-/(E7PBU-\5G#+PV_;""_;%3QF>])_DPW;LXY/\Z_[56RZ[\;MGK[[$DD
M)_C_I_\JX^LH`0\25[F89'EQ*?+I68J7^N+X..G=*GLLOXR=FV3I>E_ZXMO%
MAS?!2`SC:91(O#KTOSI'_6[_X*AK=[7ZFE5H_Q+%Z:=,RB_I!?SNR_@\SV9`
M#+?G2906^+H93;JKN?\6(&U7[[^M0/U=QK^D<0(6<UZ*-\'/ZUN\[O+=92CK
M[7=:%EVKK;M6:`VJ.BM`VSYHO2"T;0>WJT#;6P.T#A-:#AW]LV2J?2+RN_^B
M]R6[W8/6_E%[OV_1LWS-M4!X%ZFM'RTK4,Q=BWX5L^B6)-27\:<LO4*Q=1+-
MXB)*/H%4%E\&H'HBOHI]#0<#9]([L*=RC]77#/A]F:USM-_NKP7PDRS%R\YR
M^O9K+/\\%SE^$%V)]OT9;L8_=J$]^_P1$+WG"H=E:SX6ON4D\`3P5?1M<:)N
M/":&6:+;_Y<"N!R_Q?`MF!W3@<B7T^M1J[_?[;1]E;]X^<<#"^C<W^VV'@)L
MM]OKM7O[SP>K1NRWB\N<3+C;"S.9=Q7D]HZ.CCK]A\)[E@ZSJ;B,OH/1"/0#
MHI/(A^XFM7*SEOM74&(5PZ#?[;0.+:0KKKU&D.]MR[3V#SO=[CI`S@5^$R4G
MV72:I1>3*!=P-D4>#TKR`"XSX-\"C@F>2F[/I"SQ4WYN18GQO^>Y&(L<?("3
M))+R_1SU\-OFQ$BWWSL\[!ZVO&T^!MZ-V/[QRMMO'QT>MOOM)]L^<B1X-!7&
M-.;)AU@.DPQ]MP?[5/O]?N_HL"*T5EKR*6#]7_/X&=V-2E>)ME>09;B/;J<J
M?#=K'YWZ?=QE(CX9/-T7A&=MML#S'_&Z+827(]('V@T'*##V^YNRB_IS>+`D
MV0XR>_#V-H0$'["[EQ"?#P#S):7J8H9^,+T`L^_/.0E;P>POJ6[O>1`O">KK
M).T'@DI6^'D>#U<WJ,\7^`:MO0-'A]@7WV])=E:ZJR[9;ZVRY/$0G!1T/H^G
M65[$_V9'=(P'D96<0P&':!J74[DH;?/0?(3K*ST,C*?;S,/"N?_Y\_=!GL2_
MX/_"G_\?4$L#!!0````(`).&K4)VC*AEW0H``+![```4`!P`<'1N+3(P,3,P
M,S,Q7V-A;"YX;6Q55`D``Y52D5&54I%1=7@+``$$)0X```0Y`0``[5U;<^(X
M%G[?JOT/7N9A>QX($#HSG4QGIQP@&=<28('T7"I54XHM0-M&8B4[E_[U>X3!
MX6++,I=8J=U^:`+HR-\YWSE'1T*6/__\//6M1\P%8?2R5#NIEBQ,7>81.KXL
MW0W*]J#A."5+!(AZR&<47Y8H*_W\C[_^Q8)_G_]6+EO7!/O>A=5D;MFA(_:3
MU4%3?&'=8(HY"AC_R?J"_%!^PJZ)C[G58-.9CP,,7T07OK#J)Q^Q52YK=/L%
M4X_QN[X3=SL)@ME%I?+T]'1"V2-Z8ORK.'&97G<#%G(7QWWU+NY;S1N[3[YA
M?M_P"::!N.\A'P6$WO]VU6_?GU9K]6J]7KN?!52^RO<GSR/0LHD"Z$&^KU3/
M*K7ZL'9V4:M=U#]I(@E0$(H82?6YNO@7B7_V"?UZ(?][0`);0!L5%\^"7)96
M]'^JGS`^KIQ6J[7*;[?M@3O!4U0F5-+GXM)22O:2)%<[/S^OS+]=-MUJ^?S`
M_>4UZI4EG+AG^)8HVJ\@$>1"S.&UF0O6E=Z7>1DKM85\5UXV*\N/RK73<KUV
M\BR\TM+X<PMRYN,^'EGR%;PHONHL(AD<9UJ1WU6`GW`*_-O4:]&`!"^2+#Z=
M8P7\\\XF'(\N2^`)Y:5;R`M^IR,:O,P@E@21H5"R*KMAO((/P)R#"<:!N*,A
M\DB`O0QT:J$CXNHA#D:9X("XR-\)9&(/!T$LHP]+SD1WU)W)Q`5<B0R0:J&#
MXVH@,;GVV5,>6%LR!T'5Y6-$R3>=6$AJ>B`?$P04['$L0%4=*`J)PW`53J>(
MOW1'`S*F9`0^"BG`=5D(.8".>\PG+L&9Y.7JY""X[3''<W_YE0036P0<?8.Q
MVT492+/$#H+M&A$^'Q%O,1(AC]PZ`YA2YD!1R=RO$^9[4+^T_A-"AL\,R32!
M@\>CII^I1-XP&@X:%4?1(]&;ANC!SP2M(7EP]ILX0,07'<3E:/2(<WA!FN@;
M>D-.]/MU>M3<F5.3O-T<S[,75]S%M3=$CY1I\_J(=@<JO%!NNJ$_#Y,VO%^3
MP,\!S$E?*VB)>[]I!7PLNX"Y7\TJ6TN)U3]A-FY%XM::_+%09\P98KRG`#(N
M/^'O!M3#$(8>?.)9BTZLJ!?K0]S/]\LIVA*XS]PUL+Z<(S*^3O4"ZWPB.$+B
M83X;#$5YC-`,9H6UTPKV`['\1'K%:;E:6TP*OUM\_*<M!(!IA%S.+)87\-$#
M]N>7_;,W[&PTJ10'5E;SX#CR1?KR(_)EW-E!`WSY!5+>/"23E=`4W51NQ85L
M[EJ,0QQ=EFK5ZO(JB+MKKK,]-U^TJ`B9K65'9>!\NI0?<39-L_3"JBRO$JML
MP-5+UA,FXTD`N`ME;S!A/!AB/G7H(Q;!6EFZ3E9R2SUN3@OB1J6=<50LJ@31
MQRX&-X*2[(8SD9$&,F3TZ*D71(^>QL81U0=7XL2%02(Y]I.IRI;2(^MC063I
M:FT<73V.9XAXK><9I@(#\&XPP5QCC-42U"/MK"#2<NAN'&\12E7Y8T9ID)38
MWH6!>YS-,`]>>CZ*:G\(YID<(SLX-2)4$B;4`HDQD*VF<=RLQ&F'45>5IE*:
MFC#T)["A5,PX&MH$/1"?!`2KAXJD=H7.R68D0'X;(X&[#SX91[\"*57(DBDV
MU:83L385TU';."=;EL$]]")K8*V"?[-ML;E7BQVUFL:QTIK.?/:"<1_[<J5(
M-Q-HB!6;F;6XTE;>.-K`RWBH3Y>B>;'3,=V04BMK'#TK4#-'4H/&G`3;OR.C
MIXR+686EAI@QPXY^-?`.JLXF'F%`Z/4!9`->29!%E5K"F`$G@24=78TC*'WK
MQ,::>4*[8E?"(F//<2E^F$EL6&PR5NQ686K<AOI0@TVGC&8QL=VJV)2K14.:
M:L9Q8'N0;T!?Y/<0\1RZ&#)22L6TQL6F5RU&,A0UCIB^W`]!L=="G!(Z%E#H
MAM-P/A>!`8.X)&4<U)$KMJ[7HDM??>.86QGM;>KI#I394L9,!91:)<\/\I%5
M6`VMJUG6QM$T!3]7-O5KP_LWW1V4O%D_WBI4WVVKD/5AK=_OC[?G*6-W?ZS(
M1Y4BKYU8;&2]=B-50F'ANY\6@.AX\:MERD)!0K-B]P1@\'OYNW@3/V*?S7]A
M6D!+W1"@$BDVX:62L+XC(%MGXP:HZ!Y`'T#;WI10(C>VRBV72JXRA8I-XCIL
M:>IM'%^Q;@Z%-(C;3&0EA-6&A::$1TS#M/3U^JTA@;YMWK507]?%Q$I&3Y/T
M4-E6J5RLYW<89>LZ*7.4HGF!2KSNO(PP.33`'#Y)UB&]=;%1DDG%BH=E:6Q<
MAET"5'K75J-B@ST?(8GZF1?P*W.Q^&86V_MW&'E3YLPY4:;8Q:D\-.EI;UST
MW"!"Y5C3I0/D8WDK[\IVLWBO64I9J2E;[))5'A+S6<,X,E]+AVNP`,R:0><0
MU'Z=)%_A$>,X:C=$SU@TX0\!\_ZTM+E'A\6.>0>P15+=E5"=&5A,'E;Y[`@R
M+1`Z.,B:;VTT*;A`2\*[5@/LSZ=I',58%\YT!3/\4=HO(ZF-"Z[CM'A+U3&C
MAGO3%6?U$2?QTNR9_M*L[,6:=V/(TBRP)3'!H/Y(P"Y7+W<">PZ-<[OM!N11
ML;DKC_S_DU^>(,I)R^K8E!B!IN6Z)IYQ[!(4'0HACVJ3IJ6>/64\V#C*9W-K
ME(YDX5EP=P+SF,8X7N4.U@CP"MKNJ$E$M%D<].AQ/"7A5&3>H;QK7P5/D??A
M?C_SF;<"\C\PF=Z'[KUGUP73.Y@@CJ\0:"S/VX1Z3I&WT]H6>\/M7O2IU3<N
M-Q>W'/F#B>SMO#Y9<-!!=<?E'O@FCEX=NGWN0NJ<44-2C](?3:0TCVG>`[&+
MV_V7>^H3;_O7I5JO+SWR/[T/\O.8[SVXP\8=EWF#/!;3(_G\?9"<8A3C1M]$
MY!MW^^5@=$M2>\GBO;":8IL#$KMUD!]`2>#ICF+$J;RE2;4!2$=.DR,CUY7T
M[6)<Z*7H'<V@=U_F3)0O]OP7%V-O_HM(PGQR]:B49#US=6#D$JF"TO439/(:
MRCB?AN$N.NN7V2Z`Y3@OUSGDC5Q,U:0ZMYG,*P2W=,A<.55+&+D^NB.=[V(5
M-$7E:T(1=7<??Q+E"]T@/5O0TQVU&1W+@SI3;MI/UC-7!T:./PI*UW9?YS:4
M>4Z]#,7%D3)#-D3/\F1Q>2,9&.":\3RKP[OW9N3@I.<'^YK00*=8J:P<(4)Y
M@UV71S66ZGY1'3DCARU-HK7-8ER=F7PX;`]SPKS-*6$RM_EZ*#:M[Z+M^MZ+
MO!-L`_=*'L<(J@)O#R,<*]Z/8P15NC#G7NO$YVG%&]Y^D`^)(,+UF7PJ![SI
M]F_LCO.'/72ZG6,^'B+]R5HQMA\WL5W9`V=@=:^M7K\U:'6&1P:9\\E:,>Y/
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M9M'%48^#T7Z06(Q_:^Q-&BG2"5@4EO(_^5QC^.2_4$L#!!0````(`).&K4+_
MUA.KF`L``,F.```4`!P`<'1N+3(P,3,P,S,Q7V1E9BYX;6Q55`D``Y52D5&5
M4I%1=7@+``$$)0X```0Y`0``[5U;<^(X%G[?JOT/7N9A>Q\(MT[WA.GLE$,@
M[=H$6"[=,U.IHA1;@#;&8F4[@?[U*]E@;I*QB2_*+/W0(49'_HZ^(^E<9.?+
MKXN9J;Q`8B-L71<J%^6"`BT=&\B:7!>&_:+:;VA:0;$=8!G`Q!:\+EBX\.L_
M__H7A?[[\K=B46DA:!IUY1;K1<T:XU^4-IC!NG('+4B`@\DORC=@NNP*;B$3
M$J6!9W,3.I!^X=^XKM0N/D*E6(S0[3=H&9@,>UK0[=1QYO52Z?7U]<+"+^`5
MDV?[0L?1NNMCE^@PZ*M;?VS>WJD]]`.2QX:)H.78CUU@`@=9C[_=].X?J^5*
MK5RK51[GCL5^LM\O%F.JY2UP:`_L]U+YLE2I#2J7]4JE7OLY(A('.*X=("DO
MRJM_OO@7$UG/=?;?$["A0FFS[/K"1M>%+?U?:Q>83$K5<KE2^NWAOJ]/X0P4
MD<7HTV%A+<5ZX<E5KJZN2MZWZZ8'+1=/Q%S?HU9:PPEZIM\:3B"PW?BRY'^Y
MW12%=+T%VD9UV]/D'NN4"&:H1Q$IPA;LM^*Z69%=*E:JQ5KE8F$;A35/WF`3
M;,(>'"OL)S6XX*YSWQZHC<U*[+L2I=*=45-1+:-I.<A9,E[)S,-*\7N=30D<
M7Q>HT137%L1N^%,446<YI]/.1FS6%)32:1AOZ`4ZG/TIA(X]M%Q@(`<:1]"%
M"Z6(JPL('90I=)`.S)-`<GM(!#&;J)!Q9G?&G3E;XRA7]A&0X4*)XVH`>]HR
M\6L<6`<RB:#JD`FPT(\H<X'7-"$;LQ%5L$N@356-`B5$(AFNW-D,D&5GW$<3
M"XVIC=(E0->Q2]<`:]+%)M(1/$I>K$X2P:U."/3LY3MRIJKM$/"#;O,Z.(+T
MF%@BV%H`$6_S?(#`=HEOUD>`A<HD-"NQ_CS%ID%=G>9_7;K"'YV2(H'$YV-$
M.PL3R7`V)#HK4M&#:TT#\&0>!1U!,G'V;Z$#D&FW`6&[T0N,804BT0RM(2;Z
MMW6:ZMH94Y.XW:1GV:L[GF+:>Z(IK;1Q;21R!V%X`='7D'F-MQ$(8I1UJ,2"
MDTL/V91V073W"18-1,?/]MR1U8VVQR3H!5E.B38MK=J4N!VDCSNX6='`,X!B
M@CZ4S@"Q=Z?B#,Z>((D)=U<T?:S`-.,A]`32QV5A1XT+;2V3J4W",7!-YV2C
M7(OO8J:7D878+GE/?]W!#1<.M(Q-`,TZ?%M6@5YF793+Y8I25-82VQ^!92B^
MN+(CGQ+H(QF#`&Z58@R"3_JY0:-AN@D;](JAK#I1_%Z4#T$__\@8-S^)$"A1
M.TT)Y<-.O^DI=23I$.CQ,4R/32<*'BN;;IA&P$V9EO#\1*#`970%6"^*UTTF
M"G!S&@'N3VRF(ELW,?.,Z"^=WIW:UOY0!UJGG:*MBY,;`;3/^]!NU+[65SHM
MI=MK]IOM0;H88^8V`M@_[\/N#Q\>U-[O#'A?NVMK+:VAM@>*VFATANV!UKY3
MNIU[K:$U^ZGI<C3[$:"_VD>OWO6:S0<ZVLIW;?!54?N#GOI'L]ULJ*FA#4^)
MK*%6ROM06ZK64[ZI]\.F\M!4^\.>ASN]40W)DP0@*P?6,.@T_O6U<W_;[/7_
MKC3_/=0&OV<R]X466ZF&K0%TJU@)IKC&GI8P"12HG3[ELE`O2FHET.5C1*M6
M/O@]9+-Q",/0`/=EN!&M.E""'O*VIN,:'6R-<:R*H^]*V[6^)M9WE#19:1$3
M;DSAQ0)C8#]Y`8%K%R<`S&EP4:F6H.G8ZRLLF5`MEBNK6N)/J\NCP/^@(PLU
M^C&P.Q,\0=.[]Z@[://:E22`[5GZ$<BK-OMP-U:EDC7P52`5,5KUH[>ZCBV'
MVF'3].Y&(T`X81_6J,8$ST+'<35F6(A\>U`I@(*""=U8K@N5\@8#-45H7!<<
MXG)4S9`9YL+2H)#]8!O?"S#9DJ8ND,"PPMHGRA@WRQ3&T.[@XTB(A4SERDD/
M4K\.Z326X&/G7WU8Y8IXK+VMQT1Y/4S$<4B-P!E.2#F1"53+9QL(>AQ5.*.1
ME!FL4U\G+,^9V8DW`")3J>5K*@_8@LL'0)ZATW(M(]0(^&U'B;.[F[[F,)?(
MI,41]))SB1_V!\0+(99]J+N$CC,,Y4W</H6IF35Y1Y03,I@OA8'CX2<,V$%4
M:H2ASM,1$3G]ITAZ<O;/7,G9PWJ[XVKLDB)HFKW3$VV@\3'@DCHT;V5$5A<D
M$=9D=B^ZM"]("%WK36#;:M@NQ6TZNLQ^@PJ?&C@"8!$9E_EN.KN`;Z*3L6HZ
M^O1>R-@&+"+C4[YD[(<=3@,0LD36Q$L1B_,G8IG15?;T1$IQ18`M(BG?U4NS
M=#R#`[#H0;JJZ\A$7A:\XTPA48W_N+:S4Y/:)2NBL+2LQ<$OIQ]'-?"K+,"D
M"\@,6_TI()#:'XT_GER'N:P#W,!>/8"V,I>:;;OLJM].2.M;.I69[C?K)71"
M<C4#E6(VD.FR\LLF1FPN=-,UH-&B(\6V%]<_?]`9-P&QJ(YV%Q)/-77&2D9\
M8TBD:VE-(CGM1(;Q<:OZ5]K3FR)[SO88Q/%:X,%9%/&QB$QKG9&.-@=:'!Q-
M$=:65UV<BY;GHN6Y:'DN6OZ?%*S.1<NS#<B:,3P7+<]%RW/1\KV3]SZ+ED&4
M<;,,/GY%D%"(T^4]?(&FV(N**BNG1Q5/<]GR8-SH\%"/L*I:S"ZR]Y]B,L2A
M-L[@2.<\94VQK.Y1-F8@LV\48-:LN>O8GLZ5L(TV1&#$TR7EG?:T^<@A4J".
MD#9)UN@MV-6XM%7SJ].F05LU2A57/MIJ<6E;">11!TB#MFUU1+1=Y4L;WUT/
ME-DDQ^.D!#GBH\IG26L[,56(4)_/L(`3X_TH0='CX(E6WA.8YP>VSK6//W/M
M0WT%Q!C0NX@#];TF<L;C7#UDRWAY1?`;0)EG97*J+O"'C0!KXF^T-\M-FRY8
M>N]889IMU+.,K@DL]E[>L-`MG3ME'\3S:<4IZREI2/^^S4?6!$$>)B9SNL!S
MI3ISIF18V'+0+(\8,]7ICX_H*FD`N@4VM)QRV&Z41VB2.8/;RHHH_)POA9O:
MDH=[2,??[O6'T2K;'!&ZW/QIF8V@N-@?/]4=/'@_)P4R\LY!^\&GIT'H[!,T
MSB<]D`U3H2H+.?I\?BSS_%CF^;',\V.9Y\<R4\U_^T]XL"TT;-LZ:);'T9NH
M3P#RP0IWFD2=`?\)T.\L9VPYH2-ZV'#$F\2RC*D`KG`]2GY4;Z*.ZF[#/$K7
ML4:5`U>X6.3K%-VNGZSENXOL(1K-,M`+,EQ@'GB.U)L<L"),9[QI)/:FTKJ7
MG&Y8NB,KVW-X!V"9?CUH^F]QGJ+Y`#>]]X.'^1&Q.\G>YTN957SZ6$CJ1N9A
M&+*ZGK(:3SK>+'?;;RZ@[CUSVAF/D0Y):&9%T#B/]X:<.AUQ)&5$8W_R.T7X
M8S^;FW@)PX_F[S7*HQ20P%ASE!#F^!,=XS:VUC>_103J5"ITN,7M\TCAOWWD
MC^@CS-+GG1JD@25[YP$T;EW"WB`-"<*&=UJJ#5^];X0IP@BBHVH.<6#$`R^1
MX8NXDZ#&>:B`_^**T[C;DWUWY''Q"W,E\K+G7V]AP@XRGL#@COP[99&C@YP)
M_+"%Y'0B#\7?'8\B%>2,X[WT56>\RE]U2`]-I@YU78F.;-@EU'$-OK17WXI>
MK7!"3_*2>[HV(IX_)NEVWM"FSY!T"7Y!MO>W/&R=H/GV'UW:92=$0%X2CH(6
MQE&YSJE[!)Z0Z3T'')S!W[QDC<]/N(R\%$7!+8S$\C^2Z<WDD(.4WO?RCOX^
M1F&XE?](AQU2$9U169WZNO-66<WR]]<[@FV1?Y_\C23G/@UE149TE>0&UOJV
M#6/SK-#>`W9[K>1E@X]4&(1)?AI=9#I^452S;(=X?P?6]@Z&#:;`XAI5PK,T
MYMWE-99L1T!HA(DF0EO?>,<Y1=.:UU9>OL+P"D<WY_"<:V)Q)J2\=(3A%=*Q
M%6:+'FY=76?_/='>Z97_`5!+`P04````"`"3AJU"8IC7$GHH``!-"@(`%``<
M`'!T;BTR,#$S,#,S,5]L86(N>&UL550)``.54I%1E5*1475X"P`!!"4.```$
M.0$``.U=^W/CN)'^_:KN?\!-KFIGJNSQ:S>7F60O)<ORK"X>29'DV3SV:HLF
M(9E9BE1`RF/M7W]XD!0?>%&2R7;JMBJQ1NH&/P`?@4:CT?C#'Y]7`7K")/:C
M\/LW%^_/WR`<NI'GA\OOW]S/3GNS_G#X!L6)$WI.$(7X^S=A].:/__WO_X;H
M?W_XC]-3=.OCP/N(;B+W=!@NHM^CD;/"']$G'&+B)!'Y/?KB!!OV373K!YB@
M?K1:!SC!]`?QX(_HZOVW&)V>6A3[!8=>1.ZGP[S8QR19?SP[^_KUZ_LP>G*^
M1N27^+T;V14WBS;$Q7E9DX\_#6X^]:;^KYC\U`]\'";Q3Q,G<!(__.DOU].[
MGR[/+Z[.KZXN?EHG(?O+_OW^>4%K>>,DM`3V[[/S[\XNKN87WWV\N/AX]3M+
M)(F3;.(<R?GS>?J?4/]#X(>_?&3_]^#$&-%N"^./S['__9M"_;]>O8_(\NSR
M_/SB["^?[V;N(UXYIW[(NL_%;S(M5HI,[^+#AP]G_-=,M";Y_$""[!E79QF<
MO&3ZJZ^1+R")_8\QAW<7N;1U&?N,CT%*"?:OTTSLE'UU>G%Y>G7Q_CGVWF2-
MSUN01`&>X@7BU?R8;->4T;'/"/DF_>Z1X(4<3$#(&=,_"_&2=K;''O2!/>CB
MM^Q!OTF_OG,></`&,4G*4V6]/I3*2I7.V@8[P<2/O$&X'^JJ=D?PZ;M#D@,J
M4-1OO0KS*'&"O<`7-5N'/<+[M?A.K_V6IM,-WJ^E"YIEV`'[\HY^*@''SPF=
MI["706=E:08X_B@^[J9EYZ5';JG<@`V6$9&V""]RX<0/O-Q-?+ITG#4M_^+R
M#`=)G'USRKXY/;](1\??I%__?.OXA,\]PW"]2>([_(2#B\]X]8#SQ_&Z?O_&
M2N.L6A.FVR-9=1SB&MHDE3AS(SIAK)/30+2^4%^0:&4))&V^R$K\Y^`A?X9H
M<0I#49F2&,$QMR0:=7BQ1O9MFV)<!52'66DX/+V?O?GO/V\B2E2T)KZ+8^2'
MR'$3_PFCE4-^P4F,WO(RT,6[/YSM'@B`;M?;_.,//K48B?NXY5![SWYL:AV#
M<B<DM*J0E(]:37C4M(%;92G3$";N"<J5T-^9QO\"(V;AS;ML/`Y>0AD'+YN-
M@Y>O8!R\U(Z#X^21KC'_R4?#L^@AQN3)>0@P'1%9`=DP>`EM&"S4[ZHQVZZ@
ML.VJ&=NN7@';KK1LF_G+T%_XKA,F:!,JZ78%A&[]:+6*PED2N;]H22:1:Y-:
M2IA%0M6$P-!(A:Q*'B&'N"`,?C`G%%[A,!G\<^,G6^:IBT+F!-,88P:=-GEC
M!;_((:T"&#[9H*QR2XBBG>R1C*QU$IYF/E!.G<E\]',_<.*X]Z-#"!T'I0.+
M4JH->A@@,D(H1#JG@!Y7;3;"Q*>+OQ[S0E^B5"-^N2Z_MNKRJE2K72Z'6.KR
M:Z!=+L6EZ/+K%KI\\(S=#?,IC!?4XL$D5G:[4K*MKC=`S;I?(0:"`GILM>$^
MDT:9.`R#X@8O,"'88_,0#F.^T]-C'%WR">U'/WD<AI[_Y'L;)Y@].@1?.S'V
M)LZ6_1Q?;^=^$M`FV`EI+)&7>EB;)LS+-EC1]GF9)W7^[K12O>KKQV51M$`[
MZ9>TMP:K=1!M,=:,P%6)UD9>.;1\Q"W_W#E;U)AJ(VPF!6-@Y8O&\9JQ6KN2
ME\BUNR)3P"ROPBI"G=/"A*QFA3$Y)`1A\*/WU2'>G#Y%,U]69-KDA11>D1,E
M`3!\D*&J<H'+(";TDE/`*`JS$>G&)]BE6NK90"?<UL1@!IS-$6K)SGE@!:]*
M"*IPFFF@7`7&,%$8X.3TT0EV-)%(:*.6ZIPR1FBZN00(2Z8X3HCO)MCCX.Y#
M/XFGLWLM80PZ;7+'"GZ11EH%,(RR05DEUTY';#L@K@6#91.2+=FX]TO++H5L
MFZS2PBVR22H(AD4Z=%7VY+*H'X5/F"0^V^KDBN@:(HEZ#4C4ZYY$/5L2]4"3
MJ+<WB7HP2/0Y"O'V,P^<N]V$GMXR4@FW22,]X"*/Y))@B*2%5V42%T9"&G%Q
M&/3I._%C+_38'[8-^^0$ABUTG4*K<1=&X*4`#*4T&#H9(=9",J@D<D(Z-K$/
M!1U0,8KWLSG!3KPAVQEV-\1/?(4KV$:A38*9@1<)II8&0S`CQ"K![F?H4T1G
MO9#M,J"=THLXB7@LI(@$X5XIM8=(*=F6>\@`-?,-*<0ZYX,9FSQ.-0W3$?)H
M%#%*K!WB)#C8HAL_=H,HQMZ+D.,F<C>,A'1\'(0)1<%.(Y*5V"A[H,M$QTTD
MM;13:XLV32J1<<A&!P2A&@"MLBM31507"654T#[F-!9C]_TR>CKSL"]F,/JA
M.G'1KWX6**9XZ3/D8<*.O58JK19K@T\FD(P_*IG.^6(`5MO-%)38R?)3R-W1
MHD^Y2IQ@&'KX^4]XJZQ<3:Y=8BA@EIE1$0)$#3DR!3=28<2E$17O@AW9.,:V
MTR35*O_<%A=DH#(*%'\#T?,20,K)@LETV<OY<7*62T%3EXI<V_TNA5DE0$D(
M%!-DR)24$,+4A/!X@HLNV-&C0#P&YC9PEI)Z57YOBPU26!D+2C^"Z'T9HEKH
M0B:#F%`7?=W?$,(PTI6/$_P5.T0]&*A%VV*`"6Q&!I4<"%X8P-4<9$(<"7G$
M%#H='(2Q\B,.@C^%T==PAITX"K$WC.--S=%A(=^N.6F`738K%<(@2&2#L,JD
M89PM3!W$-$]_8:HHTT5"^8_=D>I+%&S"Q"%;GK:JZKO7R+5+(@7,,GDJ0H!(
M(T>F(TNN@;A*APQ)!\,I7D<D\<.ER.&E7GXIQ%M>PVI!5Y:R4EE`[-$"5)+H
MFQCE&FGB-926U"&;.)O[=!Y=1D3M`:E(M<L=*<0R94HB@)@BPZ7P?*1I"E/9
M[@@QV3P$OGL;1$[5$:^0:9<,$GAE*A0$6B7"NI*5SMQT>CX(0<0E.YQL=ED%
M^'&E>+Q)>%Y..HBIQT>M4LL3CT4%*M./1@/0T&(!4^5C+62`.$%"&16TNW3&
MB16>\/_<TN]D=HU&MFVGG!)NU3%7$P3!)!,ZI8,N78BG?CJNTCUKF%O`CC,%
MR6X84X,JYTLN!I`M56PFKG"GS=&9<H2L,^/%K1\ZH>O3-R"*?4TD0C/53G+0
M6%1&FHI&H]<Y]_8`6S_>DJJRX]*Y,LJTT=\S?2"Q=KTXQDELH&%5J-6CE%*`
MI;.4)0DP))+"JFU)S&:#^0P2%5)'@14C:K+M$T,!M\Z/BB`PFLC1J78G'*[S
M$09M%$'(2=\A9$N-?)YQ4%%Y2UT`0>+RZEC$BY<5P="N"5IE%+G+/N"=.@Q"
MSAXCDLPQ60W#)QPG/-^):J*7BK9J3VG`ENPGB1P8,FG`U>PC)GJ:4%GD[X1A
M$*?GNM&&HIEB%_L\S^DG$L79V*P:OPU*K4Z)5A4HS8U:#3`$LX)9LZU2)41R
M+1@\VYU2EH_"BD8PJW5SZEQ?"?G!<[D.&+Y9`M4</V<*,-@V(7CM^-[@F>4)
MP[0N_&A&R>Q4M(*59LO'B6VK4CE<;%(#PSQ[K)*#QTP38:$:<PLMXL=PW-*Z
M`08M;0C8(=6,I.J./DGA7B1SLZE2^K%"0!)C0J(U)LEV0O'RLT%TV%TS*W&$
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M"I@6BG9J,-B6.6LGSI8Y:NU\[E7A+GSM<L`R'WM9$@R;M/"4/O6UD`9#'K+!
M7GWP55=9)=\RA?2P*RR2"T,BDA:AA$M,/G=8PN!2ELIZB@-^<;TMIRSTVN26
M=36*'#,J@>&:+5(5Y]S"M2DP>&=-M*Z994>ECKEC=$98,Z;L*"^8Z3!HH[`%
MC3Y-"ST`MKK>UVE4:I5R3Y@\1#'6D<X6\"NSW;.[J*:T!GWZUT^,]-.K='$C
MF0Z\[%XQF3R8Z=$"9.T419:VFLG`X%5AC#:/XIU-@H;9#^RTIYWOP,USC?WO
M4#SNS7SLK\"KWMB/7E3XAF\&)UL@/LX\63_'J(M4ETIV<I5"':KT(H6=&!CF
MJ+&I+U&(^34NT0+]Y_OS"[1V"'IB>N@4.9OD,2+^KU3HXOSD_)S_#\7\D/'O
M47Y7=.$6AM\CGR7=\41DU.X8,OKVY+<?_BM514[,'O>9MM$CNKHX83</7W&-
M;T\^4"GQ\_]L0HRNSOFOES"X7#BFK3UR41-KU<Y7@"R9]149,/Q5`*M9Z^+4
MNQ5S+\_KU%60].IW)Q^^_:^3#Q>71J9>4:K20K_[<`&7KCW/XR<BG6#B^-XP
M3-<X*M^B2KI5?ZT><LE;*Q<%0V4]OIK7+)=&+,3TU`^1*Q1@<&F*$\</L3=P
M2$A?E;CGNIO5AGL&Z;+&=WV5D6BCV&Y0O6U%RF'U)BTPO+.&*G'<9H+($Y(P
MN%<WAZWMYJX7(G8+$%@+6"4^^3HVEJP]8/#&%)RT9TP3K'"R?<+(8/'-$JW1
MB\+M,KAL+"_-)@X9$Y[)PN.&[@03GKS):EVG5NYNN6RJD'H%K=($,Z,V@FM8
M9Y_LEBD0:2D2B/7RU9-5B]25NJ.AJ@)J^E4U@-).`=-(MVPAFRO"I1W/U]R$
M<IE"UW0K`S=134B#IED)HI%B,D=@3CSA:H%+.G4.3&NMKNFGR()IJ0*:B.8\
MF,W8&+U,9LRCN)0;FH16FATYGIL8@Q9J8"AJCU7GL09G`];2SQH-0*U&1Z2S
M,?TTXA!)9FGTE<D%U.*K54MK[BFE.R67VM!3B,(EE=;$DQ(*DB77()6YG4JG
MM#(8<*"3F#<`:<4R<!;:,'2C%<Z3SAIBHI32;1+,`+G(+84H&%KI\=7N9^'2
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MD*8.54J;G1A0XM0`UC([T9\0:X2,/F".4HZB,"I7(\L$JS?-+?3:I)1U-8H$
M,RJ!F>-LD=9,]_D/@RD:COKCSP/T-C7?WP$QWW>Y^T65AF&":<.I?4DJ\7:=
M27K096^27!8,K0P`Z_ZD3!SY7!X*CP1JO3E>DVJ7-5*(9;*41-KAR`?!D1`O
M>5(3+55D\.H,$5*9;02#((60VEO')WR#NN?]8R.XK*BP2:FCJ&=-!10QSQ(-
M,`.0%4R)6YOPO!1^B!94*SWF%BW05X<0!\SM+I\</V2&WSB<.0$>+TI9K?.4
MUJI5K:5RJTZ$1A4J^1*L-,'0LA'<FF>!*J,H1)X?K[-+&"DWX\UZ'61Q^7F"
M<AA,59J73<U1($9_(V,?UIK2!%/AE."IRX51AMZFD^\[0-GO=ROD6]J%_2BD
M]=O0*H[SY?`U7D0$"[FY\XSC&_HA3GQ7NQ6Z9XGM;S\?5/7Z%O5>Q<%B^N$5
MD7I9'KA2]BXD3`W2*T#KD;[0USC$"^5!8:5T^]150J[3LB8*;QFC@ZD(H*`D
MHK3B@C"H-,*)T<M;D6EU7I;!*\W%10%8HY(,6I46H\$<W8UG0&Y1SDZV9R'7
MUTZLG#05LJWFB=7!+>6&E0F"62+HT%7YPG\36]M^L&$)!:A=A@(V6ZW996EI
MX!\K!@:E?L3^\I'B[#W1J7B)1YO5`R;C!:]H(9"1UXMM\XM:*5IJW\+:).5A
M%2ZR=K^2P-#Z(/A5WF>%(4>4AD)>'%L-%SE?BG)%FY@JL'POT6J]X?NL#Z_M
M]<D#+L<+=BOG;1!]-46ZZ57:S=IA!E_.WZ&6!T-K"Y#U)()9U"RE*[^`G&N!
MBZ&E!@M#-R'1D^]A[WI[3U^@89CO3??<Q'\2Z20,.[I[%-2R5;EG12NF9\-2
MP)!X;^BUDP:]V0_H]F[\XPS=3L>?T2[`L]>?#[_P"ZBT>\1PU@Z7D'I'@JNV
M=$AG+AACQVZK)9Y'4\RZQP]PJ2;SZ#BCR\L\JMUD?"_76.5,?L=_#IBWY`4K
M5\\AF#\*)1$BV<-VUB/]EGUVV>2>F9V[\#XG?Q"0>)D;O*:5\+EOE'X.,/O`
MPEY7$4G\7_GWBF:W4VTW"[Y]9<K9\,UZ8-C>`&P]._Y.500I%W1@\)%=;2-J
M5(`V7MSXL;BRBU9T0O#*WZSB7>20\C;;/0MK^_JL_2M<O5NK>4G0G.D'U4)U
M49*?A1!52<_VU->BN#,O?41'1NJ+!T*T9-;:=W5#W*J8B)@J0P^&R-RYV.L7
M[NQ2.184PJUZ;+2`2[X:J228Z5(+3WK)P^D#D[:^7.TUA>B!&P(L\;[6:+T,
MYPT6?PM+CC17N3G7@74!+6_B-ZQ895_?4AO,,-(8<LT_]DC_Q5*\E):#<8P3
M,6'!NSJ[7N7LWERZQL;^$[LYU[JU9*K=$E9=&3U5ZWK0!M4&F)4W(Y-<$BH9
MZ2J`7>.0W?B6G5T*O3&+6^SQ-\NZ@>P*ZY:P32JLI[!-2?!)W:`6DHR63#4_
M;7N"V.J0^"[;".:N.WYO#0^`%6,TU+>@<N]YXQ$AUX,Q&%>J83<2ITK0[DFU
M!?PZ;J>7UJ9R4WJ3AJBI=DY`166,'*SH`399E6!-E]J?E%;#:4*5(]ZTNDY"
MQKNK\ZN4=9/Y2(+_/L0."=F%L-(47[9*;3"M6048Q^PT.F=7(YA57F5BE#1"
M#L;89A\$<7`4!=3PEL/"6L"%6S?#+0NH,&[@@J:NV!HY0J26MB``5+:HJ`6E
M-:5T/N`>#-T4J34<?1G,FD1JM7F;1.1B[/'#7)(](KK6,QUY;E1"N[=,-*Y:
M^<8):W4P#&Z.N;YN%R6(M$>O8>./+O72P*2>2Y$1W)C`#0IHE;^-*U:BK[4V
M-#]48^0U#E-0C]1HYE<:KU/E5T%=<\"-7J53>AJ"9W3RX"EH#H0ID<[?B<-@
MFKUI<[!M!-5H/<Q8?17K+S5NY?IKG1:!'K8I:U_1&NS6#YW0/<(:3%L0`#I;
M5-2"UII2P%BP>T,WK<%NAZ/>J`]R#3;%ZW2^&2_NHG`YQV25ACS<,>??^"'P
MER*WAJ+5&I70;K+TQE4KITZW5H=F0C2'7K,H4GT6@>D*313PF*QHIPN#P1G4
M*0Y8N\RCN?/\HY\\LCNLZ4M[&Y%&X9G[%]>%`;QOI67&<=.RH+'^P'HH7@$>
M=K@K1:0'0D0\0YP2RF,+^$5,:!/Z4$SOHD^&W5=&YS$\)L([(^Z&MW#FJ!2[
M\J?I*Z)RH\FUP-@>UE#U3K/D$>>.,[=P.Q@D4MJ;60?;:5`-Z,,,YU>Q'E3C
MMEH/ODTWY]ZA1580N)4AJW8O]-@?]HH^T?>.A?]@XD=>=1-=T7C-BFCUCL4]
M*E>Z<[&!/IA1>`_0LDQ?PU%_.NC-!NCMS4!\>D>_0WQ9V!O=B`^#/]\/O_3N
M!J.Y-BM8ZUW<HZ\S(5OZPO'S&O9]6U%L.='"FG?2+'%(HANMFD&7+NQE/7B"
M'O#2#UE^+^[XYV#^-;OUJH-N'81:R[\9\`:=BEF<L$UWMGC6D&V'\BQ#3I`E
M)AJ&BXBL^&+&E#3*5KO5TXC-JE0ZGFBG"F:":8:W=H#Q?C*Y&WRFW.S=H=S)
M2*>6V_'T<V\^'(^`>!6S2QTFCJ_*\5<6Z>)FC2(XV;4:['<PQ)&`JHUCW(9F
M!Q\HG_)#\3`(,29+)TQ/Y?>C,(X"WW/2U!83"I.]$"(50+IN<((\FYKQRM?C
ME-WJ=6;';([2!6C'*!@,Z8]9F]H]5X6R3U"I=!ZN42R?V0#Y$W:78\/+['=0
M@[$D'$$4;PB>X^?DFL+\Y27Z1?J85_/R:1KI:.^AY!G_&J^DNF*UMW/ZJ3<:
M_HW;-#!>+9:_-AXOTN-;=%&A:"")7)OD5L(LLK,F!(9>*F2U_-B]V7"&QK=H
M,AW,F#T,AR@[[!/Z<K@6>0XU"BWGJC(`K^2C4DB#(9,1HN)L)G/B9!K@IOB9
MOPS]A>^R<-1:_4P3MZURJZO_1A4J+?ZM-,'0L1'<^M+_\^?>]*]LR)L-/XV&
MM\-^;S1'O7Y_?#_BQSLFX[MA?S@X^(H)Z6G-WI)@/H>S#?4>>R%^Q2%V'<70
M9J?2UDE-6_#9.4V3?.>,:@"R-L1E:HCIH8(BC.$M#U>*0EZ->$PF)%H29]5@
M?=*TD%8OYMRK@J4L8(U*Z)RL!\&NT??3=,`=H.C'X?P'U)O-I[V_#4:#?@\&
M??,T9[LJF<P_O4J;U+0!7R2B3AX,[2Q`5DG&5!#7004E<):@K&:FD=&@TS7;
MM..>5@$TWTRCVFUO.$5?>G?W`_1YT)O=3_D0!^6R,!Y]9AC$JD*M7@\F!5BZ
M%ZPD`88J4EA5;@@A<(,/SZ7*8F(QB07$491@>Q.M@7Z[5QDUK%;Y7B-+93`,
M;(JXMBJ=C_M_^F%\=S.8SK[AH1/SO[[(^K/H=C:XU<SB;:T[;4!G:TZ=;.=T
ML02HVV++'6HPAJ^1DU!ZCQ>[FX,5;XA,L-688B704NQP3:ISSABAU0(GN2#;
M:KW>Q'Z(H=QX=.?3@=&C0V,#_X-6I55O@P7X<H9QM3P82EF`K.T7I91"4S_^
MA>_OYX7`8%F?]25SC+!7A('L$TS1L4^*5M!JM!HI;H9>BC)5BX-AF!EC+?BJ
MJ''PR"6U@6:;U<HAV_%"NY%@81WM6U!;=M-A%<TLJOU*Z9R"!T.OV>BB,#1>
MH$)Q2+;7"<M&*X67<&A;T\2K5VEY4#2"KXR*2OG..=D`9/UXHA^Z_CH0N6E*
M!<!@V7W,3EC&B;]R$N6)PZI0FTR2`RQRIRP!ABU26+6<L3$W^7,Q&*10G`.S
M&X/L=`&<Y;,8E6P4P1"N"5II\#Q;%_`/!748A-SE`+,CH4:^W:,6!MCE<Q<*
M83`$,R&L7V0%+!5;OCE5",\=AM1\W*QVKXII8TNOV\D6HDUUI%N).D4PM&N"
M5K.773K$4-"'04UEHDV[`<]>O>6T)8TJ54E>8J4+AJ8-`4L2F>R2I>:Z,,@Y
M7*WI>\3PC,F-'Z^CV`E$:JT[_PE[XC8BRYEYKZ):G;0/J&QI/M^C'#!D/@!\
MS0K(BV)#,"OBE)>!>H#NGLKNV4JO^+#?Z[!1;/>6>-N*E.^(-VF!8:8UU/K]
M\.F=/E,PXVI:AREVHV7HV_OY+/3:S31I68UR?DF#$AC&V2*M$B[50P5%*+2+
M,6U+YBRXH1B#B)L:Z16#VD60E6:[U+.N2IE\1C5`]+/%6B>@T.0F94$7]:,8
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M\>S4;&=?.$M\H6HMK4JGYPLDX+4'#`KR<,AH!JERIZ]S2>1APG<2^=T?/)?+
MWP#E<LD3_W'S0N41JPBU>]I7!K!\I+<H`88]4EAU#V$JA/[.Q<"<'$]AW?DA
M'M*/JHE3)M@).VI`I0S)I>"QI`I-PQ0FBK@L$+K876,@F>IU2FW;6<WO8=#<
M8P"%7E8PI384AA=>G3K+V59UZ-+%L]B721XQZ7G_V.@M?&OM3C8S[*HDW=O0
MJX(A8C.\-9_T^(X:])2YBXA\=8@7HS@*O!-VK]\FX.?C_)#=^H<>J&FU`'.+
M&K^.*+U(@CO2N1^=OH4)\1\V"7?H1"S7&JT!E0JV_%8Y^JV04S?E8:6V3/%C
M-$&%^H<4">F5.$(]:G8"_Q'YJ2S:K-GUL!%=[9(X39/_E7EOZ,MVPKZ/?;I`
M$;=D/F#V1?ZXO`P8+U./(O/\8,/<3C/F&>7.T\&S&VP\[+$[&=D6^R9+;5[=
M_.JMV%%:15<<J>Q6,T$?LSE*2:./43"8E^R8M:DENBR4+;9(7R:I@"J-;`-?
M>_,BND[\:^N#;ZK?.3,/`&V?*/CXGGHI,^]\%],9)%SF2`H.+DF]#?)M<<X*
M=D8PK3`(-MD@5(9=NE%`BXK([E:=@!>'D9.SZVO.KN.X+J5<2EVG]<KTJ:;O
M.L&<^$Y0-8H;:;;%KX95R9AFJ0:"<\VPJMSD1$2=_TKMSTU([5#DIMJ(<LT/
M4+QFR2B8>4KR,.'L02\SUW[V`QPG48C3J^4'@;_T^4Y]-:37*-T6VRP@9PS3
MB,*Y,=0.:)52N09*55!!YT6HLEN:67%%+]X666Q`9VS1R<*BBP5223*P5.4E
M"/.2*4XDV:LUWE]+_>Y3G6BJ94YW(E'N?)K<%[')'7]2B.="7JX-@[+\R`-S
M5&'O9L-BU\3%[+RF(_R5_Z+>3+32;3W7M&UU:GFF38I@*-H$;7T@Y2'B,2N"
MNPPQE%NXY942CIH]N5A3!D!&184LV%C1A$Y'.5P+/IZ@^"C>N19X*;Z_C0@;
M]?=IGDH!8/@IK9@U1TO:KX.G,LBUS1I'A&J[1<YN0I]-\B%.Q$\Q^]<K(#"?
M+0[@KTP?`'W5U;*=[U\5>96(]^4N#,[V`R>.QXL?Q=;GF$S]Y6,R>,;$]6,\
M(;Z+\Q_C]%=EL/A>1;6ZP#J@LJ6UUA[EP'$,'*$65<ZG8@BGVFC-U%_$N\1/
M^6!V_=Z3'_-C&[%+?'X(7>(`T4JWY5NR@)RYEC2BG0^0=OAJMQ<(#<J(5.4$
M>3LE&(.@.`7,**N:$PH"K6>=*`&K)9/@O\(;7&K8I/$XQQDG7C*928\-;$N^
ML7*]W8FDKM$>"[H3&3#B3WR@'(;"7/A$HEBYAGZ))W6?#.4H365.EG+08SH?
M1%^^;M)D*R@2:FC)]`[W1,ES%GPI@L.>9/ZHB[26C4`!+D\]4/F]<Z9H0$F3
M"CQEB7(K77V2AC`ZJX@D?$LY>J+S\;>_0W1YDCS&"(<>BQ3^GTVP1;1/?_O*
MAV-Q%V`A1S"/I9X_.J'TU3GV^]GX\:]BX-ZS48\RFC=\=N<O;D<5ED0R)=2Z
MHB,`$E/`/?-!O/`$L'LH?R9_I'1<DPNV-QGH@.ZF!)E4Y_PR0M-/#V3'BX)O
M:C=;5.:)RV_%/('8L7`V3PCS7\>?U@<P^^'FY\M6NX\VX$,48^-"28U3;LT]
M\-1YKF7JO!=ZB?@Y#0KD!HN_P_`^Q`X)\_2^M1?*K/&S%[FM]0Y]%A]?2QPJ
MO&36<*N=-'_$W-7K/K*A'GG<C8SH($Y?OC5[N_+7B)_/>N3&V4;DV-ZDCZ"B
MXAGO.^A:[AKLI5Z]SWCU@$FU+R4BH#I/C:^>/G`1D96(\V59_!T_Y-T5H1GM
M(QRC'C.++U'F"^VL0Z[-'7(-O$.D^!IWR'7W'7+$4'E(G62#5#;:I>/7VO'Y
MB3DVI+'9R0FWM?P>R(F1DYY0Y>FX=C',JIA[UOMY?',7O?W"@>N0&-`,\SX!
M[.P*'VT`.YL4:8?\8Q.ZG`C\F$53FM0.9W3!FR.%H$/BAQEG[316^7T7Y@ZF
MK/`.[=(37E@_'6C\&&$.)L"(3B!HE4>^KP74F`Y-B1.P,C=K-DS]Y\6WWYU<
M?G=^<GY^?B)*3W_X7?Y]X>@OHM"\0B9V!I/@Y29@R^/M[GDBIQ:#]N#0EG!Q
MI0S'??1I,=FM*K'#;AA-'++$'1D7QXI]A\13"Z#_3]171M3!,W;YJ>+Q8D%;
MG<1R2U@A!HJ>>HQ59N;2*!-'0KZ+3EBM@VB+L:KQRS_#:G0IMEIC9U+=M?$H
M"C,4-SZUI>AKJVANM22HEC?"K&6VB<+33`/E*MWUR)%B>"#UB1FG;*57"-[A
MDY>#'JH1/BS#<N3Z#G,Q\[F*S3`\:0J;8BJAD5W,(XWW@B%UFP*<K*^X%5$\
M%57?'<X<D,(=V4UG'+`7`ZMC-!!MNT>_.]-];_&M2+%!R?<J%=.20@Q4?^DQ
MVCLE(U9.VEO9V\7L:LR+1HY(S!9&"8KQVJ$K!QQLL_.)NRY=Y-<;QUE&R]9M
M;`_[/P_H`B#93C8/=%US&T1.*;&,5*#E/379EJ@>5\W`XY)(B"(NV]%VIKCV
MH+\A!"N23A4%`#2T'E=]0<VD3E`JUVDCJUL77+,:VK.C9BS<S*$A;%T*4/-J
MP%6;NB#:-7_[SMJGAL(=VX(>TR%KR2>AF*Z07'4_&)4`=8L]UGH*`*Z)N"HJ
MZ)Z@G7;W[XOA10'4%3)4FE>CJR@@9FL]1H&'22P,.&D$4$T*4$-KP$E#?E+1
M;Y`01L5LJ,P(G3@PJ,YN);'J'9,.H+ZRAJIY4_B*0(AWU$ECNFIQF',_O7U8
M.BK5A`!U@QI;[6ZF3!)EHEVWN4CS?:<XZ"(1@]CN$G3JED\O97W+Q-]UU/S#
M,,',H9*R0-;T%1%`S:Y"5G=,"+F,ZQVU-;6WHC)1-*VN%`;4_F:,DCV+J,;_
M5*F[5R![9T5.9[:]NZ'XTA>5FLK7>!$1G-]#@.,;^B%.?%?^NNQ='*"N/48M
M%)=0B_%.!+WM"D:[DM$#+QH5+ZT^05GQG;*$8DG9>BVNBU`SH"8*KG?5"-77
MAV=#*'J;ZG3UUO9<EV!^6D@<QDBSL+.4>"S.DIFA$X)7_F85&^XZW*\D0+UY
M8`5J+K2L./2V6.`[MO>2E\F-]:S4$S2TNQ+Q9=_/RDD$6@\.=8I=[#^IKH"S
MT0/4UXW@2EYCKH3>9NKOV-Y*5@+:%0&F$RG%6,3T#5Y@0K"7CCZ4T>+Z'Z7?
M>K^20'=THPI8=GU:9CZJL[>:%X<Z=:2K63YQMLW?Y%0)=.^JL#9]AU/]KI8X
M.&%YOWC`C(>]Z^U]C+UAF*]Y>V[B/RD=OO;:@+IR#]"U51%.$$_5FQ6"'K;H
M[;W8^GZ'=AZ#75D=]6\:*!S/HY[[SXW/\M>P]5RRG=`*)70L8OX['E$KZU][
M;4#]NP?H:O].=C'+*"T$9:6<(%[.2>[]Y$5!Z5Z#Z:R3A]R%-F:PK-.Z-W,5
MHXT`MN\`*]$&U'M[@&XXP.9%=3_`3G%VP&&\N(O");NZ7K'Y*^O@!NJ`>G@?
MU/5C=?G)$+I.9:6<)K08I-S_[GB(G>*`1?_.H[GSS*[@8MMEE(&W$;%/X+!O
M68"Z_N`J*(?MM$0V?#._5:%0'I3-BST562+ZW66),`QRMR+D<<]Q7:(-J.OW
M`-UP7,^+ZFY</^(1UZO.>\X6H?*"I;K.:S[+":-#K""JKS#JO$M`9)Z&,RH>
M!+_6S:PP9@]EV:?IQ,=53E!6).)E%F3B7*BSV#7;E+YP>DT"2I[-=Z+(YEO\
MZHY^HE]G7]'_8V8*_>;_`%!+`P04````"`"3AJU"[>4R18X8``"A;0$`%``<
M`'!T;BTR,#$S,#,S,5]P<F4N>&UL550)``.54I%1E5*1475X"P`!!"4.```$
M.0$``.U=W7/;.))_OZK['WC>AYM[</PUV9UD)[<ER[)'-;:DE>1D9RI5*9J$
M9%PH0@=2_LA?OP!)290(@`V*-""7YV'LR&BHNW_=^&@T&K_^XVD6.`^(1IB$
MGPY.WAT?."CTB(_#Z:>#V]%A:]3N=@^<*'9#WPU(B#X=A.3@'__[G__AL/]^
M_:_#0^<2H\#_Z%P0[[`;3LC?G9X[0Q^=*Q0BZL:$_MWY[`8+_@FYQ`&B3IO,
MY@&*$?M#^L4?G;-W/R/G\!#0[6<4^H3>#KNK;N_C>/[QZ.CQ\?%=2![<1T*_
M1^\\`NMN1!;40ZN^!A^_=BZN6D/\`]&O[0"C,(Z^#MS`C7'X]5_GP^NOI\<G
M9\=G9R=?YW'(?_)_OWN:,"DOW)CUP/]]=/S^Z.1L?/+^X\G)Q[-?@)S$;KR(
M5IP</QUG_Z7DOP8X_/Z1_^_.C9##8`NCCT\1_G20D__Q[!VATZ/3X^.3HW_=
M7(^\>S1S#W'(X?/0P9**]R*B._GPX<-1\M=ETT++ISL:++_C[&C)SJIG]E>L
M:)_C),(?HX2]:^(Q[7+K*_T:1]J"_^MPV>R0?W1X<GIX=O+N*?(/ELI/-$A)
M@(9HXO"?S(I6WSI/06:&,SOB?SMB^"QF#/]6Z'?"&,?/'"PZ2WAE_">=W5,T
M^73`+.%P:1;\"_\"(8V?Y\R7(LQ=X<`YJL;C.?N`J7-TCU`<W88+U\<Q\DNX
M4Q,UR-?`I4PI]RC&GAM48E+80RT<<^]#'+.H/^G/^<#%L(I*F%03U<Y7VXWN
M+P/RJ,-6@:86KOITZH;X!\071$UKLK$(,P$'%$5,5`@K"HIZL%K,9BY][D]&
M>!KB";-1-@1X'EFP,2"<#DB`/8Q*P=/JI!:^6U.*$GOY@N/[5A13]P>;NSVW
MA-,RLEIXNW0Q36;$&^1&"YJ:=0EC2IJ:O))XW^])X+/U2^?_%VR$+W5)&4'M
M_@BT,Q7)"WI#K5[1B!Q":QJ[=T$ITP#*VM&_0+&+@ZCG4CX;/2`-*Y"1OJ`U
M:'*_6Z>-CIV:DNAVTYQE9]]8Q;2W2!L::75M!-R!BM]Y;LUPS3[8($%/,=N4
MKI?0G/'=]A7L8]X%V_R=.(?.DB+_*]N..RFYDZ?/F%ZR'1!O@].`[[4(+5'9
M8-S[IN*R=<<-U(N7W03N'0J2SK\Q4ACE415.,Y4F6[\(>>^FY.'(1YAM`4].
M^2]<C-/#XY-LX_<7]M&WE(<AFF+^U6',-]MBQL4MMQG-6T*+>@ZAS+(85,L^
M7>IMX%_<JV8MF&7PS<RA=X^#E>E,*)EI:C+3&BF1(Z]<QL&+(]!F@E`WZ#)'
M>?H=/:L@*#0%8G!B'0@2H4V@L)1CS+I5.V[:`JCS4XMT+A+1I*H'B&+")/!Y
M9%"M\ZVF0.6?6:A\H=`F4&@Q;GS.T67@3L7:WVH"U/K/%FE=**0);;<7E$MX
MB2//#?Y`+E6:O;PU$(/W%F%0)KJY.?<+"H+?0_(8CM@JG83([T;1`E'5W"LE
M`0+S5XN``2G!'#J?2<`VJFS_FIR*12I4"DV!:/S-.C0D0AM<EZ;>.T1S0GG4
M(#V&4RY/)11`3'ZQ#A.U"LQ!DYA(FXVD4T*5&X:MAD`@/E@'A%!@<_H?+.X"
M[%T&Q)5L]07-P%LUZY0OD#:G>B;'!#$W\:]3#4B933E=+H*3UB\_II'9C(1)
MY&MTSY06]1=QDL'!G%LYLBGIH-!:N`T'Z,/D1C%=.J8[ITOVF63Z432'8F/C
M=ETJO7E(^&H>#$BN,10.&S?P$LD%8/QZ5!#NFGW05."\)&]E%3(_=0Z=50H$
M^[U-PH@$V&>?^$[6B9/VXORTZN=_*L7.\R8V<:.[!*Y%=#AUW7EJ9RB(H^4G
MVP:7??QMQ6U_<HE#QA]F_D`B7!YLAU'N[#W516M%$=.S6HCM-@9#[CI(Y,,P
M0BGK'+]V12!;XT.`*#0U&7Z7:'9;]1+Q[$"`YV"QP9C_X">0#V[`3TM;<=NE
M])DM09*#5$F@#$9J,EBO!H#HBF(3<*-[MB$>(SKKA@\HBC?RB+;&86%+DV%\
M*"PJ&>U`(<OHB(;(0\QL[@)T14FT%$TRDI70F`SU0Y&!R6T'1D-F.A1[;!TE
M=G,Q2N54)H\#H#A!9;<#J0%%<Q?[G:<Y"B/$N.W']XANR"H&"T1H\I0`BI>&
M!NR`#`!.-1@:.1X`#V\E"M>+N,4D=H.ZHFV[>!>9(QH_#P(WW8"S86#.Y]0>
MDKJ5BL)D*!ON3^4RV^%(.4?OD=!3.92DJ='P-A00I9AV()%RIQK+#,>;]4:Q
MUS)\76/W#@<XQBABCEQ,G56'#^#41N.C%6,\NKJQP]%R7(-"0*KV4-0:V35I
MJU^(G.5QHCGFPP!R(]2_"_`TO4^H7/B5T4`Q:V0'!5`\`4MB$U++K?G`?>;[
M<E`H8KLM%)E&]DI:R*BEM081NF"3;4$N*2BRYE!<&MD\Z>*BEMD.:#JS>4">
M$1JB@!_!02$"D$&A:B3E2@LJL`[L@`R*T2Z@-+)GU0(%A,)>KN,E<VG9IA=`
M!CUI:F13ML,:$*R1RM`_('I'(F0>_(N,ZR&3JLU^XK@,=S4%%/)&3A=W@!RB
M!^N&V])Q%HY'(YOG>K9AKV6<U8V0U!`3.6UDIU8Q)K(O49#!TK@2AA7Y%L*&
M4&0:V:EIN9A"3CN`R&7BJK)>"JV@$#2R*=-;:$@DM$/_+=]/?)IYMXO];I@M
MBR2;9%EC*!J-[+NTT"B1UPY0AKP@18C\CDM#'$XCMJ]?S!;)1I&M8;"');,)
MA`X*52.[,2VHX%JP`S5Y2:>R.5\C,<PX*F6%J_9W[5:VDJUVQ@7'MI$=<M4%
MN5(#M2)MQ:4!<1W)U0V"LVHW")R?-OI]NU'P`FMYIO$^37CVD^76`-'DBA=D
M>2^GW;\;"'I:L6,&W>0YO9G76L3WA.(?:_]6(5BD,7E7H1;H9&JP%[*DGH(&
M7,OV)B\MU`C5IOCVPE1Z![B4R.1UAAH!:_CR;RW!$;UI#41H\LI#1?0T%&(=
M@K#I3$E@\O+#[HC9/9$5&%7-8M+&)J\[U(60C?.7?@&+6DI7-!0]K@<GV+3U
MPMOKDA<05COJGU4[ZG4G#IDXZV[XWMI=&+^=WPV9N&C%I'K[+&UL-+[\@,*%
M[&QY_5>#N]X2'6^$B3>%L6/`RHPVG&:WRDHJ'BB:F]P5P5$HE=<.6(9,=XP'
M?BGS@ME-0))[21G/,G=0DIC<`Y4KG4#%L`FD]*&P@'':\F<X3*I6\[KL2IA*
MB4QN=W2``DIO!U0%P8##F]F]C`X<4@GW_;AK)5@ZR%^3J`R\?$.3"^@*LU)1
MQGV'KT="LBG=\OZZ<J$!(#-YQ1@.+5A^.P;*=3&5E-EN&".F5^FF0=;:Z'UC
MN,X)0!2[X$FY4BXQ"HV,7DBN!H903/VQ\$,Z%H9HFMQ>,3X:YC(75B\1M?S_
M6Z265YJY(:0Q6D*S"KHP)=CA<%<N#OETW`]';H#X&XRYFA&K@A&2I3Z0UNBE
M\BH`ZBG%#B"E<FJN/PS?)J\"5ZGH^[[&7*^:+YFNVH2_HK=@PJXCLN=H0BA*
MVXW=)Q1=L%^B&'NJ8&C%#HW>CX8O3&M0VNNP&R9:Y@_G*$036=*RM+'1>]>Z
M>$N%W?^U50_%92&"K29&;_QJ;"%%@NV[[RVSY9?Y$/R-:\EH+&EJ]$8O'#VE
MH':LC;X@/+UG/MQZ8$/_%/46LSM$^Y.$W=SI;<(YC\OC8!'+4@ZJ]F7T<B@<
MS=U49=>Y-R_W>1F01\&Q]WOXL3?OQ4FZL>38.Y>WL)(0G#HNH#`[I7&&V/[J
M`3.(SY]O(^1WPU6XN.7%^"&]!Z&.IE;HQXY4<BF"F_-C12W9,?PVMW!I9`=:
M7=OP)8W1FZ;+2%0T)D/DD=##`=I@>$QJ\<IFOLF2['2(XS:I:CN,Z0(Q]7LX
M43[[/4`)"J'?FO$7ZWZX^;?3MTN;0"B-%NIO$CVBJ0B;0.?ES5(N<RSV)Q<X
M2LO1,>8'%,WP8A:5OL]0M2^C[P2\C&'LIN;]CW=8=#31S#,&+V-&E0\S]M1L
MED$(Y+?)C$<"%9.0K*W1UQ)>QBS4:K)CHC%XFMS,"PPO`ZWV^?.>>CK3&N5E
M`R]0^C.GIZR<3.F5`#`]T&P:*JRCM>O05XL=WE[DN_C0$A1($:7A?#I=3%2`
MRA7S&KTZ>Q=H6392^#X0U#!@?1G-[JO95G2T]QJM9ZM(NNX(LB(SFF38T/BQ
MI9/]+[$K%'6K%KN&!10HC>8BUF\$$LWLNAZ8QR$'Z.SX+(.'?;\`FML0N33D
M=8!5UR`A=$8S#&N&1:85.Q9I\-.174_J#"<B[H2JOI;V/=U%(G$:F-S])%?9
MC]&$Q'K.<@%ZLL/_&>,>0GZ24RF()^9?&10#K-6!T=3#':`BU<2U"FCW.0M4
MM3S&(46Z.&O0&WTNIAZ8M;6U_UNM@LREAWUJ"J/9JLU8P:L\EX.K:M<I7B/9
MPUJ;T-?6*UT*9C66=EX**OLQ^B1./4M!@)[L6"$,T3P;[_J3:Q).QXC.)*\Y
MB0'6ZL!H_O0.4)%JXKZ6R6(Y)6;OZXW)V'WZ@N-[7L^<*>Z24)WS^NJ]0<VG
MF4N-=9C/KII\!;:4VTOQXHB\VGN?IKLJU=,`$#JCCSS58Q]@[=@Q?<"%WG5Y
M8/BAJ%K0U=?6OB\CN;ALX\Q_</-]8(;,3ZP0Q<3?#LZ*+42O!\-O)VDM':OH
MQ@ZO%W/>8L9-Z3.S8]7C8S!2PT_XU("C1!N5'7J>V`5CC<:VNG5]!O#M%&X"
M-NP"P4+58@2=T()UW&@QGP>)BMQ@J:)N."%TY@*>P8$20XV@Z;KZ$"/0U(@=
M0_FRB!5_P$]V=)]O`06DF;+YFAHNUNK*BVG^GG.?3MUP^W;0ZGKS7YU#A]\3
M"4BTH(C]HS^\:O6Z?[;&W7[/X-7E/-?K*]?I?:=!3CFYBNSKR]@EE9OKZ=ID
M(=!=)%BC/6:&=,[8_-Z`GH3?8O`B=:WVE*]7VA`4YL<-7K@AXH?0ZQZ+P\??
MMH>/\]:H.W+ZE\Y@V!EU>N.W<<3B<22#.,OQE#[,(6CV"CU9J@SSKCA:S&8N
M?>Y/1G@:X@GV>*;`BL\!TX"7#^>LO/.7;>\<W=[<M(9_</\<=:]ZW<MNN]4;
M.ZUVNW_;&W=[5\Z@?]UM=SLC@RY;E*RD>("BO<F]BPJKDJD72FO0#<M1RN]:
MM'1AWN%:4XJ2`8,?F[2X6#]0B#RWZ&(?MEVL=37L=&[8S.=\Z8Y_<UJC\;#U
M9Z?7:;<JN90P05K&7HF?E%*9O,"Y/.8D8<),U*<#2J;4G<$7K+I]F/0>((+Y
MNYJ5-&3>EU872V^0RUG<S'%:.M+)\;8C7;:Z0^=SZ_JVX]QT6J/;8>)5)B>F
ME21K/DNF)C6%07<3,5;B724D!IT)@DO.D4"RF_<;Q6/N*Z<Y*2SPQOWV[[_U
MKR\ZP]%_.YU_WG;'?QCT&/'[]5LU+;?:F%RR%53>(S$"SS\:Y`:]18Q)?K&F
MJP7SOI+?$TJW0R>GJEBG\].2L%K%1N%"3<07/*A@U7:FY\9,::(G(K>2+03M
M+(D6`#8J<BGM.$FYQLPA?>:2\$6QDL)D^41-:""BVP$26Z%[*(Q3`QKBZ'N;
M(L8X_TUR7*TB,%G%4!,B@.#FYPI8,$T^BYQ5#ZHU,L?HR5-V9%ZM+[/.M@X!
M)YP]EXR(:@J3Q7YW0G+3#TMU8L=0>1OQG-,HQC,WEJ5O;K<Q.6?5!I%8<#M`
MD>0,@GP+1FJT,F]M7J:C)CN07=\R!*&I:&ZRW&YM"):JPP[45@&KW)%F-V12
M+69KBRL)VJE)3=;(K0U-+379@:ST[C?(/>'4)HO7UH:OKK+L@+@[FS.[3!(\
M*=LVS$GD!NFMOFO\@/RTJAIL-*[4D\D"M?4-U#LHT0XS6!;5RVHU@<,W$#J3
MA6IK@QBN(#L`S?CDM7F9X.#-)X#,:`'9NN`$J\<6-"/$>.#K^0O&>4"2B26K
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MZY0AN'42HZ<=.Q8ZA7P)-JOS#]PI.@%FBFQ0V)(JH@,=0`7FAT#8\JU\<"S<
MMM;)'6ERZ*PF8!W))%8.MZL+@V/Y0R#;;<J<KV#+AC89&LZY+6(^9F$#.LRK
M49?]*IGT1.TL0$EH6R*MY]C.5Z^U+C.D]805RPY9^SU`0L5^+LO(;-PZIMB+
MD2_F5?SI#9K=(2J&;+<>S8-:;J*;,>T=A%TOA`U:P`T)T?.-2[^C^'(1^DIL
M96U-9M358<$Y1-7JL&/9?SL:TR0D\#SB`8`L1B"'3=7>Y)*_9NC*U6('?*MI
M([T<Q0]&F-$IY\$2$O.C)GQ1(I8@9V8F#PXV>;L@,Q=+ZD-+FEJ$A,JZ\@<"
M8D&LF)L&R[J#[<"-HI9JC),T-9F]I+2FC;PTA91V#%F;+)[#@3C7!**1'*-J
M0)S;"$358J8UE+%MM'AE82>^M8O2JEEK0[K`\LUUG"8\)`_@KM]D+\D>*",V
M>OT!`IFF&JS!CB[K=I+9C(3)`3FS-[9(O5O$R>D:X=53F.FQ5L%S4ON>?9JV
MDV*Z6Z=&+TH`L:Y#;7;80(NQZ>-@P0.;ZUU$Y\D+%C[R^8,'?!I9+"O$;6=3
MM&8\6"JVA)JZ-GK5`F(/M:K0_-&-K-)2^6%-H;:EO+17LX<S4!&JE?^J^0!&
M*,$U]E`8\;R')1,)`W]N%%7;KEN@)+&P=I?&P0I('[N.J$(DLKSL(@-M1HD]
M-QA3[`;29[B`Q"8#BC7`HZFD1H"ZP0&*8K;AR5YSZ@1XBI.,(DF6LI+`Y(JS
M!D``RC#[W($0PO6B"8JAFL+D4K(&$"'JJ!U%&[)>,QT55QB%^KS2M->LBZ;S
M7K.OJ9#X6J"T(4"_5]D;.H"\Y6C8<AQR_9:C\9:C\9:C\9:C\9:C\9:C\9:C
M80M\J\74^?/JU]\PHOP"\_,UO[XLGQ"AM.;'T=+)$2J*'>D;PA5PD6]56H=F
M%^8AU#-4$;0P2:V8!U?L=</Y(HX2\4Y4HZJ2P.1)2B53%:$GUX1E`VF.T5-=
MR$YMR")I`K+3?8'L3!>R,^UUY[Y@=F8C9N)EF."E"IT]O)!\'[*%M#1A_HBY
M^&!"^>%RX=THT<L=#=_Y*V6[Y'Z?!KT-D<B]B@;K@_,6$WZ+"4O3HAY=ZH_9
MM\AWO5M-]D#?6QS;$>P5%\QJ,9\-I^GRY?QYW28["$TD68L3^KR<5L^=(=56
MMYEO,H^[T%9+2Y+M*K<5^^-DT$^+JZG6ZX)F1DN`-FCRV\]2B91CQPH^QYXR
M4"QJ9[3BYXNC9V7`>!TG3SB]#7$<#4>WL%,X(8G9BH$O@RI(:XVDQR57$;*G
M[#C'2I^3-H9BM,^>5Z(I.]SO[4[MVYW:MSNUL)IAR1T=/MRJACQ!,Y/'T-`K
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MH<?D+](X`(C4]KP'+0U8#5I:%Z(::@5:DVGON^`F4<(>`)=^?DDH3\&I`-X6
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MM-FQ==P0CH3!((!2RLKKI`=$[TB$P&7%LK_P_]TQ9M@G_P902P,$%`````@`
MDX:M0G!1[<C_!P``,3T``!``'`!P=&XM,C`Q,S`S,S$N>'-D550)``.54I%1
ME5*1475X"P`!!"4.```$.0$``.U;6W/;MA)^;F?Z'U"]G)S)2!2MV(U5NQU:
MMW".)*JZ.(G',QV(A"1,*$`%0%O.KR_`BVZ\F%*26CV*'BP*^':QWRZP``CX
MZO?EW`4/B'%,R75!+Y4+`!&;.IA,KPNC0=$8U$RS`'[_[:<?@?Q<_5PL@B9&
MKE,%=6H733*AOX(NG*,J:"&"&!24_0INH>NI$MK$+F*@1N<+%PDD*X*6JJ!2
M>H-`L9A#[2TB#F6COKE2.Q-B4=6TQ\?'$J$/\)&R3[QDTWSJ!M1C-EKIZE7O
M&_66T<>?$;NON1@1P>][T(4"D_L/-_WV_5E9KY0K%?U^(8CZ5K]+RXED68="
M:E"_M?*YIE>&^GE5UZN5MSDM$5!X?&5)>5D./_G$.YC;*^'7T%SP7Y9]_&&*
MR%OOW<>*WK'@Z]KKL>4\WIU?H#OWYJ%U^W;<GU^PIPZ]?#.^L)[*Y3\F]*SQ
MT>@$35YQ>X;F$,@^0?AU8<//CY4295/MK%S6M0^=]L#'%0)@=>EB\BD)KE]>
M7FI^;02-(9=CYD:J*YJJ'D..5IIE+<[`8\(%)/86WA$K@4WPN194;D%Q(O0B
M@.((ZO'B%,+%"CN!?.QCPPHIHY\5RWJQHF^(,.HBGBCCUR0($4J(-T^FZPBF
MB:<%TB2H*%&(87LE][S0MH"T014G6^?7)%C7&W97^$4P0.2@FVO1^)")PT5S
M.7Z:E,WK:`(]5T;B+P^Z>(*14P`"LBD2JO/R!;11MK)H`$!"J!PG,F>$):IL
ML<!R(,B"'ZY4CZDJAPZEV4`]R$R1J%K5:7(0><I&@S@-(K!X4B.*S?T&"@`[
MUX5,A&I2&N`WZJ`))MBW3(Y9'11!)+KY"(D#`CU@0]&5MJMB0[''D6.1W_SG
M!4-<JO&%VK(@%`PA*4(V=&W/W4]F;4JB2%@0.?H0U]_(`CE4!S.$!!\1#SI8
MJ&ZAG)Y2E^[N,^ECE3]1Z.\:)9RZV)$E#@BU@4`=>+52^-_O?H]<T8-,\ILA
M@:7564'8!J9'I')81,"KK09.,D(KMW%K8BW4&DHVQH.@I-2EQ^%-5AS6V@"=
M@+4^%1'HG>X8V?1R#?)9TZ6/"0%85Z7[_SR__Y4ZX.L[=?];;`H)_KPQ#6^5
MI'O[0LVU<B'L4NXQN:$`5K]E=,T[8VA:W5/TY`WD6/;4W@:C*+O'*]+]^LNN
M7V^,@3D`5A/T^HU!HSL\60</O/D<LB=K,L!3(E>V-I1K1=NFGESDD6E/#G4;
MHRAWY,.FA^'M;A@&HT['Z']4@1B8K:[9-&M&=PB,6LT:=8=FMP5Z5MNLF8W!
M*<;&F#+DI]?W6,P,+AC\C`BR81"-U-IT_U_N^M]H]1N-CNS_X+TY?`>,P;!O
MW#6ZC9IQBOYN0LS\%Q`=!)6#_)DM<'9R5:JG]?*NIYN&V0>W1GO4`)V&,1CU
M?;>?9+<>"&I_FE'708PW_O+D7C):FL3*TQVLQU+)T*K][YW5KC?Z@_^`QA\C
M<_CQ%+V[N=+83M^)->D>/LM:B\A]3JCA)!=X^6;"0V;/'(&I'#Z+GGC8$K/X
M$(Y=E)7F0T!Z0-[D3/;@5:#J)'V_F7WJ2$#L\BYD:L/^@.+Y*89(]_YY=IX*
M-8&5JI/T?K[DDQR7`V73(Q;;Y>Z3P+[',VMKD!S!W.CTF,5VT.E;A^\QRIAM
M0M=D3#<1(CT6L6UTZGP3ZCI)]\>W$RGI[7E<>BAB.^JD;<C_]X!0?]0A=Q]-
M@'\X7E5'KM<%CM4MB4)8-F-H<EU8"%*,SD3_E,Q*R[D;(93FC+-Q/Z:[S@C;
MC51`9L>TQ,[NI1*Z0$S(.4N+;(\4""R4^.9;1:#:D>-5^PJ,73C>E[$40>XW
MI-I6^K\F1]GU]N6XTUN_$=/:NI6OR5<.FWWY;H^T;T2WOFIDDVUXY4!;WSD(
M?^_>2[B2O"D3@,3N-V1=6PDNW+2I[:O*$%&_BI%<4145];-B12\MN;.V=!\C
MUF[8SXA([@`C?&T<V:4I?9!!Q5NW3%*L2)11#\6U<-[V,R_N9+6?**@A5_"H
MY`NMB5^Z.=P<7]<!]N2X;Y2GIVQ*=@-!U54N55?1+[[0F,,,><Z*\.*2O[KI
M#;M_UES(N?%>K3V(Z*#Y&+&";Z-,BHE5V'75BXKK@F">RBOJVEI5YAM,G:&?
M%1V/A6=Q098,KGI5'3J'F)@"S15,TO+&7*8C3T%;C'J+ZT*@"TO(<P;?I!L<
MJWII@QM+9'MJ76=-Y/Y8+B2WC4ZO?G'#Y>Q&GQ#:-3A6_-*&=BF)C*ICAFQ!
M=YV<B7AI\RTQ0RS871B/D#D[MJ=7O[3A6?<'C;%ZE6"+B$4^+`R?(DK[4PP0
M4@LFTR]G:!*;R>TWJJ/@VR0C@B`CR.FC!T0\]6XXX)<+N0>;H&X<7":3%6B,
MQ3;'.25RY\B>OIQEVBN@W1@^CSNV^"4=:^VRRL8<&Z/]3HIVN1XJ?6Q>R#B+
MV:6<"WIL_+*..[+Z;SKVV!@>=G!P6'_^]W@E[\OXO)GYW\.\+=>^A$M5*RH^
MC;OP4E-`\SG0D<ZOX0H@;GW-Q41=!1\R#-W54B(__'"^<I'B?#O"'2RSJY#J
M>O!)531</,5C[/K7>0*2V9!GB06OA\0_&\<:]=.*+$KG]0SF.(EEG37EFD]C
MV&-++\\?Y,2FECTDCHWMC2MM1ZS'Z`/F_K*`VPPO@@8#>MF0EU[>W5J^);RE
MWN2H_YP*^UZ\_$A3?O.VCY0W;&FEWY-&!`N^YI%2^_)LKK3@?:-\_!M02P$"
M'@,4````"`"3AJU"V4`SH^Q6```T&P,`$``8```````!````I($`````<'1N
M+3(P,3,P,S,Q+GAM;%54!0`#E5*1475X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`).&K4)VC*AEW0H``+![```4`!@```````$```"D@397``!P=&XM,C`Q
M,S`S,S%?8V%L+GAM;%54!0`#E5*1475X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`).&K4+_UA.KF`L``,F.```4`!@```````$```"D@6%B``!P=&XM,C`Q
M,S`S,S%?9&5F+GAM;%54!0`#E5*1475X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`).&K4)BF-<2>B@``$T*`@`4`!@```````$```"D@4=N``!P=&XM,C`Q
M,S`S,S%?;&%B+GAM;%54!0`#E5*1475X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`).&K4+MY3)%CA@``*%M`0`4`!@```````$```"D@0^7``!P=&XM,C`Q
M,S`S,S%?<')E+GAM;%54!0`#E5*1475X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`).&K4)P4>W(_P<``#$]```0`!@```````$```"D@>NO``!P=&XM,C`Q
M,S`S,S$N>'-D550%``.54I%1=7@+``$$)0X```0Y`0``4$L%!@`````&``8`
*%`(``#2X````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unuadited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 23,537,053<span></span></td>
        <td class="nump">$ 3,827,198<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
        <td class="nump">5,998,740<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">27,631<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">350,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">488,185<span></span></td>
        <td class="nump">532,010<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">30,023,978<span></span></td>
        <td class="nump">4,736,839<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">307,020<span></span></td>
        <td class="nump">318,653<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">58,337<span></span></td>
        <td class="nump">324,992<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">30,389,335<span></span></td>
        <td class="nump">5,380,484<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations</a></td>
        <td class="nump">23,591<span></span></td>
        <td class="nump">22,277<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">733,443<span></span></td>
        <td class="nump">294,894<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">1,986,240<span></span></td>
        <td class="nump">2,706,496<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">433,333<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">2,743,274<span></span></td>
        <td class="nump">3,457,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations</a></td>
        <td class="nump">2,048<span></span></td>
        <td class="nump">19,909<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump">44,764<span></span></td>
        <td class="nump">72,677<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">2,790,086<span></span></td>
        <td class="nump">3,549,586<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock of $.01 par value - authorized 10,000,000 shares; Series A Convertible; issued and outstanding 4,697 shares as of March 31, 2013 and 4,997 as of June 30, 2012</a></td>
        <td class="nump">47<span></span></td>
        <td class="nump">50<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $.01 par value - authorized 200,000,000 shares; issued and outstanding 38,947,912 shares as of March 31, 2013 and 34,900,591 as of June 30, 2012</a></td>
        <td class="nump">389,479<span></span></td>
        <td class="nump">349,006<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">282,597,134<span></span></td>
        <td class="nump">240,725,127<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(255,387,411)<span></span></td>
        <td class="num">(239,243,285)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">27,599,249<span></span></td>
        <td class="nump">1,830,898<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 30,389,335<span></span></td>
        <td class="nump">$ 5,380,484<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a, b<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableGrossCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 7, 10, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 7, 10, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Audit and Accounting Guide (AAG)<br><br><br><br> -Number AAG-BRD<br><br><br><br> -Paragraph 80<br><br><br><br> -Subparagraph Exhibit 4-8, 3<br><br><br><br> -IssueDate 2006-05-01<br><br><br><br> -Chapter 4<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ORGANIZATION<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;ORGANIZATION:</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Nature of Business</font> &#8211; Palatin Technologies, Inc. (Palatin or the Company) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin&#8217;s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, pigmentation disorders and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>The Company&#8217;s primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). The Company also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. The Company has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome, with drug candidates in preclinical evaluation.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>Key elements of the Company&#8217;s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that the Company is developing; and partially funding its product candidate development programs with the cash flow generated from the Company&#8217;s license agreements with AstraZeneca and any other companies.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Business Risk and Liquidity </font>&#8211; The Company has incurred negative cash flows from operations since its inception, and has expended, and expects to continue to expend in the future, substantial funds to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company has an accumulated deficit as of March 31, 2013 and incurred a net loss for the three and nine months ended March 31, 2013. The Company anticipates incurring additional losses in the future as a result of spending on its development programs. To achieve profitability, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and there can be no assurance that the Company will be able to achieve profitability on a sustained basis, if at all.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>As of March 31, 2013, the Company&#8217;s cash, cash equivalents and short-term investments were $29.5million. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including its clinical trial program with bremelanotide for FSD, preclinical and clinical development of its peptide melanocortin receptor-1 program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">Management believes that the Company&#8217;s existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) and initiating those studies, through at least calendar year 2013. Phase 3 clinical trials of bremelanotide for FSD will require significant additional resources and capital.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Concentrations &#8211;</font> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company&#8217;s cash and cash equivalents are primarily invested in one money market fund sponsored by a large financial institution and, secondarily, in U.S government securities. For the nine months ended March 31, 2013 and the three and nine months ended March 31, 2012, 100% of revenues were from AstraZeneca.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7880789&amp;loc=SL6228881-111685<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">(2)&#160;&#160;&#160;&#160;&#160;&#160; BASIS OF PRESENTATION:</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q.&#160;Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2013, and its results of operations and its cash flows for the three and nine months ended March 31, 2013 and 2012. The results of operations for the three and nine months ended March 31, 2013 may not necessarily be indicative of the results of operations expected for the full year, except that the Company expects to incur a significant loss for the fiscal year ending June 30, 2013.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended June 30, 2012, filed with the Securities and Exchange Commission (SEC), which includes consolidated financial statements as of June 30, 2012 and 2011 and for each of the fiscal years in the three-year period ended June 30, 2012.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccounting</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unuadited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, Series A Convertible, shares issued</a></td>
        <td class="nump">4,697<span></span></td>
        <td class="nump">4,997<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, Series A Convertible, shares outstanding</a></td>
        <td class="nump">4,697<span></span></td>
        <td class="nump">4,997<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">38,947,912<span></span></td>
        <td class="nump">34,900,591<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">38,947,912<span></span></td>
        <td class="nump">34,900,591<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>AGREEMENT WITH ASTRAZENECA (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2007</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract', window );"><strong>Agreement With Astrazeneca Details Narrative</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_LicensingAgreementAstraZeneca', window );">Research collaboration and license agreement with AstraZeneca</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_RevenueLicensingAgreementClinicalTrials', window );">Revenue recognized under clinical trail sponsored research agreements</a></td>
        <td class="nump">23,996<span></span></td>
        <td class="nump">10,361<span></span></td>
        <td class="nump">62,705<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_MilestonePaymentEligibility', window );">Milestone Payment Eligibility</a></td>
        <td class="nump">145,250,000<span></span></td>
        <td class="nump">145,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_ContingentPaymentEligibility', window );">Contingent Payment Eligibility</a></td>
        <td class="nump">$ 85,250,000<span></span></td>
        <td class="nump">$ 85,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_AgreementWithAstrazenecaDetailsNarrativeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_ContingentPaymentEligibility">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As a result of the amended research collaboration and licensing agreement with AstraZeneca, the Company is eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_ContingentPaymentEligibility</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_LicensingAgreementAstraZeneca">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount paid to the company from AstraZeneca as a result of a research collaboration and licensing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_LicensingAgreementAstraZeneca</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_MilestonePaymentEligibility">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As a result of the amended research collaboration and licensing agreement with AstraZeneca, the Company is eligible for milestone payments totaling up to $145,250,000, with up to $85,250,000 contingent on development and regulatory milestones and the balance contingent on achievement of sales targets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_MilestonePaymentEligibility</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_RevenueLicensingAgreementClinicalTrials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue recognized under clinical trial sponsored research agreements in conjunction with a research collaboration and licensing agreement with AstraZeneca.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_RevenueLicensingAgreementClinicalTrials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 10, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PALATIN TECHNOLOGIES INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000911216<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--06-30<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">38,947,912<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="nump">$ 26,554,986<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted prices in active markets (Level 1)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="nump">26,553,246<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Other quoted/observable inputs (Level 2)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant unobservable inputs (Level 3)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Funds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="nump">19,056,321<span></span></td>
        <td class="nump">3,344,146<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Funds | Quoted prices in active markets (Level 1)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="nump">19,056,321<span></span></td>
        <td class="nump">3,344,146<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Funds | Other quoted/observable inputs (Level 2)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Funds | Significant unobservable inputs (Level 3)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">US Government Securities</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="nump">7,498,665<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">US Government Securities | Quoted prices in active markets (Level 1)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="nump">7,496,925<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">US Government Securities | Other quoted/observable inputs (Level 2)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">US Government Securities | Significant unobservable inputs (Level 3)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value disclosure</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8<br><br> -Footnote 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES:</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 23,996<span></span></td>
        <td class="nump">$ 10,361<span></span></td>
        <td class="nump">$ 62,705<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">2,944,587<span></span></td>
        <td class="nump">4,705,662<span></span></td>
        <td class="nump">7,733,670<span></span></td>
        <td class="nump">9,683,112<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,079,197<span></span></td>
        <td class="nump">1,344,861<span></span></td>
        <td class="nump">3,141,751<span></span></td>
        <td class="nump">3,473,990<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">4,023,784<span></span></td>
        <td class="nump">6,050,523<span></span></td>
        <td class="nump">10,875,421<span></span></td>
        <td class="nump">13,157,102<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(4,023,784)<span></span></td>
        <td class="num">(6,026,527)<span></span></td>
        <td class="num">(10,865,060)<span></span></td>
        <td class="num">(13,094,397)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Investment income</a></td>
        <td class="nump">9,629<span></span></td>
        <td class="nump">5,955<span></span></td>
        <td class="nump">37,017<span></span></td>
        <td class="nump">28,229<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(1,103)<span></span></td>
        <td class="num">(1,830)<span></span></td>
        <td class="num">(4,746)<span></span></td>
        <td class="num">(6,650)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Increase in fair value of warrants</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(7,069,165)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposition of supplies and equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,700<span></span></td>
        <td class="nump">4,620<span></span></td>
        <td class="nump">4,700<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
        <td class="nump">8,526<span></span></td>
        <td class="nump">5,825<span></span></td>
        <td class="num">(7,032,274)<span></span></td>
        <td class="nump">26,279<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Loss before income taxes</a></td>
        <td class="num">(4,015,258)<span></span></td>
        <td class="num">(6,020,702)<span></span></td>
        <td class="num">(17,897,334)<span></span></td>
        <td class="num">(13,068,118)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,753,208<span></span></td>
        <td class="nump">1,068,233<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
        <td class="num">$ (4,015,258)<span></span></td>
        <td class="num">$ (6,020,702)<span></span></td>
        <td class="num">$ (16,144,126)<span></span></td>
        <td class="num">$ (11,999,885)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.17)<span></span></td>
        <td class="num">$ (0.17)<span></span></td>
        <td class="num">$ (0.34)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</a></td>
        <td class="nump">106,424,443<span></span></td>
        <td class="nump">34,900,591<span></span></td>
        <td class="nump">94,754,789<span></span></td>
        <td class="nump">34,900,591<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 36, 37, 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16381557&amp;loc=d3e4984-109258<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 1(i)<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Chapter V<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment to the amount at which a liability incurred or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ORGANIZATION (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_OrganizationPoliciesAbstract', window );"><strong>Organization Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
        <td class="text"><div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Nature of Business</font> &#8211; Palatin Technologies, Inc. (Palatin or the Company) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin&#8217;s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, pigmentation disorders and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>The Company&#8217;s primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). The Company also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. The Company has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome, with drug candidates in preclinical evaluation.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>Key elements of the Company&#8217;s business strategy include using its technology and expertise to develop and commercialize therapeutic products; entering into alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale and distribution of product candidates that the Company is developing; and partially funding its product candidate development programs with the cash flow generated from the Company&#8217;s license agreements with AstraZeneca and any other companies.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Business Risk and Liquidity</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block"></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Business Risk and Liquidity </font>&#8211; The Company has incurred negative cash flows from operations since its inception, and has expended, and expects to continue to expend in the future, substantial funds to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company has an accumulated deficit as of March 31, 2013 and incurred a net loss for the three and nine months ended March 31, 2013. The Company anticipates incurring additional losses in the future as a result of spending on its development programs. To achieve profitability, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals and successfully manufacture and market such technologies and proposed products. The time required to reach profitability is highly uncertain, and there can be no assurance that the Company will be able to achieve profitability on a sustained basis, if at all.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>As of March 31, 2013, the Company&#8217;s cash, cash equivalents and short-term investments were $29.5million. The Company intends to utilize existing capital resources for general corporate purposes and working capital, including its clinical trial program with bremelanotide for FSD, preclinical and clinical development of its peptide melanocortin receptor-1 program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">Management believes that the Company&#8217;s existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) and initiating those studies, through at least calendar year 2013. Phase 3 clinical trials of bremelanotide for FSD will require significant additional resources and capital.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Concentrations &#8211;</font> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company&#8217;s cash and cash equivalents are primarily invested in one money market fund sponsored by a large financial institution and, secondarily, in U.S government securities. For the nine months ended March 31, 2013 and the three and nine months ended March 31, 2012, 100% of revenues were from AstraZeneca.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_OrganizationPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_OrganizationPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number SOP94-6-1<br><br> -Paragraph 7, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 113<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14537-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6487554&amp;loc=d3e32600-158583<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 14<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13531-108611<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiquidityDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block"></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">(6)&#160;&#160;&#160;&#160;&#160; STOCKHOLDERS&#8217; EQUITY:</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Common Stock Transactions</font> &#8211;<font style="font-style: italic; display: inline">&#160;</font>On July 3, 2012, the Company closed on a private placement offering in which the Company sold, for aggregate proceeds of $35.0 million, 3,873,000 shares of its common stock, Series A 2012 warrants to purchase up to 31,988,151 shares of common stock, and Series B 2012 warrants to purchase up to 35,488,380 shares of common stock. These warrants are exercisable at an exercise price of $0.01 per share, and expire ten years from the date of issuance. The holders may exercise the warrants on a cashless basis. The warrants are subject to a blocker provision prohibiting exercise of the warrants if the holder and its affiliates would beneficially own in excess of 9.99% of the total number of shares of common stock of the Company following such exercise (as may be adjusted to the extent set forth in the warrant). The warrants also provide that in the event of a Company Controlled Fundamental Transaction (as defined in the warrants), the Company may, at the election of the warrant holder, be required to redeem all or a portion of the warrants at an amount tied to the greater of the then market price of the Company&#8217;s common stock or the amount per share paid to any other person.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify">&#160;</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">Because there were not sufficient authorized shares to cover all the outstanding Series B 2012 warrants in the private placement offering as of closing, under ASC 815, &#8220;Derivatives and Hedging,&#8221; the portion of the warrants above the then authorized level of common stock was required to be classified as a liability and carried at fair value on the Company&#8217;s balance sheet. The fair value was calculated by multiplying the number of shares underlying the Series B 2012 warrants above the then authorized level of the Company&#8217;s common stock by the closing price of its common stock less the exercise price of $0.01 per share.<font style="display: inline; font-family: Times New Roman"> The warrants were liability classified through September 27, 2012,</font>at which time the then fair value of the warrant liability was reclassified into stockholders&#8217; equity upon stockholder approval of the increase in authorized common stock. The increase in fair value, as a result of the Company&#8217;s common stock increasing from $0.50 per share at date of issuance to $0.71 per share upon shareholder approval, of $7,069,165 has been recorded as a non-operating expense for the nine months ended March 31, 2013.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify">&#160;</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;The purchase agreement for the private placement provides that the purchasers, funds under the management of QVT Financial LP, have certain rights until July 3, 2018, including rights of first refusal and participation in any subsequent equity or debt financing, provided that the funds own at least 20% of the outstanding common stock of the Company calculated as if warrants held by the funds were exercised. The purchase agreement also contains certain restrictive covenants so long as the funds continue to hold specified amounts of warrants or beneficially own specified amounts of the outstanding shares of common stock.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: justify">&#160;</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>The net proceeds to the Company were $34.4 million, after deducting offering expenses payable by the Company and excluding the proceeds to the Company, if any, from the exercise of the warrants issued in the offering.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="font: 10pt Times New Roman"><i>Stock
Options</i> &#8211; In July 2012, the Company granted 285,000 options to its executive officers, 182,500 options to its employees
and 112,500 options to its non-employee directors under the Company&#8217;s 2011 Stock Incentive Plan. The Company is amortizing
the fair value of these options of $182,000, $108,000 and $72,000, respectively, over the 48 months ending July 2016. The Company
recognized $35,550 and $106,649, respectively, of stock-based compensation expense related to these options during the three and
nine months ended March 31, 2013.</font></div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="font: 10pt Times New Roman">&#160;</font><br /></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt Times New Roman"></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt Times New Roman"></font></div>

<div style="text-indent: 0pt; display: block">&#160;</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Restricted Stock Units</font> &#8211; In July 2012, the Company granted 222,500 restricted stock units to its executive officers under the Company&#8217;s 2011 Stock Incentive Plan. The Company is amortizing the fair value of these restricted stock units of $160,000 over the 24 months ending July 2014. The Company recognized $30,037 and $84,622, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2013.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>In June 2011, the Company granted 500,000 restricted stock units to its executive management under the Company&#8217;s 2011 Stock Incentive Plan. Half of these restricted stock units vested on June 22, 2012 and the remainder vests 24 months from the date of grant. The grant date fair value of these restricted stock units of $430,000 is being amortized over the 24 month vesting period of the award. The Company recognized $26,875 and $80,625, respectively, of stock-based compensation expense related to these restricted stock units during the three and nine months ended March 31, 2013 and $80,625 and $241,875, respectively, for the three and nine months ended March 31, 2012.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>Stock-based compensation cost for the three and nine months ended March 31, 2013 for stock options and equity-based instruments issued other than the stock options and restricted stock units described above was $57,008and $203,433, respectively, and $183,355 and $474,425, respectively, for the three and nine months ended March 31, 2012.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESODI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 03, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Executive Officers</div>
        </th>
        <th class="th">
          <div>Jul. 03, 2012

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Jul. 03, 2012

</div>
          <div>Series A 2012 Warrants</div>
        </th>
        <th class="th">
          <div>Jul. 03, 2012

</div>
          <div>Series B 2012 Warrants</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Stock Option

</div>
          <div>Employees</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Stock Options</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Stock Options</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Stock Options

</div>
          <div>Non-Employee Directors</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Restricted Stock Units</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Restricted Stock Units</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>Restricted Stock Units

</div>
          <div>Executive Officers</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Restricted Stock Units

</div>
          <div>Executive Officers</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Restricted Stock Units

</div>
          <div>Executive Officers</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Restricted Stock Units

</div>
          <div>Executive Officers</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Restricted Stock Units

</div>
          <div>Executive Officers</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Other Equity Awards Not Separately Disclosed</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Other Equity Awards Not Separately Disclosed</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Other Equity Awards Not Separately Disclosed</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Other Equity Awards Not Separately Disclosed</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued</a></td>
        <td class="nump">$ 35,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, shares</a></td>
        <td class="nump">3,873,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash', window );">Sale of common stock units, net of costs, shares</a></td>
        <td class="nump">34,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,873,000<span></span></td>
        <td class="nump">31,988,151<span></span></td>
        <td class="nump">35,488,380<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash', window );">Sale of common stock units, net of costs</a></td>
        <td class="nump">34,407,446<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Warrant exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.01<span></span></td>
        <td class="nump">0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_BlockerProvisionDescription', window );">Blocker provision, description</a></td>
        <td class="text">The warrants are subject to a blocker provision prohibiting exercise of the warrants if the holder and its affiliates would beneficially own in excess of 9.99% of the total number of shares of common stock of the company following such exercise.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Increase in fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">7,069,165<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
        <td class="nump">$ 0.50<span></span></td>
        <td class="nump">$ 0.71<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.71<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">285,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">182,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">112,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_FVOptionsGranted', window );">Fair value of options granted, to be amortized over 48 months ending July 2016</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">182,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">108,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">72,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Stock Units granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">222,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_FVRestrictedStockUnits', window );">Fair value of restricted stock units granted, amortized over 24 month vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">160,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">430,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 475,329<span></span></td>
        <td class="nump">$ 716,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 35,550<span></span></td>
        <td class="nump">$ 106,649<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 30,037<span></span></td>
        <td class="nump">$ 84,622<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 26,875<span></span></td>
        <td class="nump">$ 80,625<span></span></td>
        <td class="nump">$ 80,625<span></span></td>
        <td class="nump">$ 241,875<span></span></td>
        <td class="nump">$ 57,008<span></span></td>
        <td class="nump">$ 1,883,355<span></span></td>
        <td class="nump">$ 203,433<span></span></td>
        <td class="nump">$ 474,425<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_BlockerProvisionDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The description for a blocker provision associated with the issuance of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_BlockerProvisionDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_FVOptionsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total fair value of options granted in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_FVOptionsGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_FVRestrictedStockUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total fair value of restricted stock units granted in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_FVRestrictedStockUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment to the amount at which a liability incurred or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued as consideration for cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as consideration for cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ORGANIZATION (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_OrganizationDetailsNarrativeAbstract', window );"><strong>Organization Details Narrative</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
        <td class="nump">$ 29,535,793<span></span></td>
        <td class="nump">$ 29,535,793<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue percentage derived from AstraZeneca</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">100.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_OrganizationDetailsNarrativeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_OrganizationDetailsNarrativeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashCashEquivalentsAndShortTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13531-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Principles of Consolidation</font> &#8211; The consolidated financial statements include the accounts of Palatin and its wholly-owned inactive subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Use of Estimates</font> &#8211; The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Cash and Cash Equivalents</font> &#8211; Cash and cash equivalents include cash on hand, cash in banks and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consist of $19,056,321in a money market fund and $1,499,925 in U.S. government securities at March 31, 2013 and $3,344,146in a money market fund at June 30, 2012.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Investments</font> &#8211; The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held-to-maturity when the Company has the intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available-for-sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet, based on the contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&#8217; equity.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>The fair value of substantially all securities is determined by quoted market prices. The estimated fair value of securities for which there are no quoted market prices is based on similar types of securities that are traded in the market.</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Fair Value of Financial Instruments</font> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts receivable, accounts payable, and capital lease obligations. Management believes that the carrying value of these assets and liabilities are representative of their respective fair values based on the short-term nature of these instruments.</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Property and Equipment</font> &#8211; Property and equipment consists of office and laboratory equipment, office furniture and leasehold improvements and includes assets acquired under capital leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under capital leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Impairment of Long-Lived Assets</font> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureTextBlock', window );">Deferred Rent</a></td>
        <td class="text"><div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Deferred Rent </font>&#8211;<font style="font-style: italic; display: inline">&#160;</font>The Company&#8217;s operating leases provide for rent increases over the terms of the leases. Deferred rent consists of the difference between periodic rent payments and the amount recognized as rent expense on a straight-line basis, as well as tenant allowances for leasehold improvements. Rent expenses are being recognized ratably over the terms of the leases.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Revenue Recognition </font>&#8211; Revenue from corporate collaborations and licensing agreements consists of up-front fees, research and development funding, and milestone payments. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. The Company estimates the performance period as the period in which it performs certain development activities under the applicable agreement. Reimbursements for research and development activities are recorded in the period that the Company performs the related activities under the terms of the applicable agreements. Revenue resulting from the achievement of milestone events stipulated in the applicable agreements is recognized when the milestone is achieved, provided that such milestone is substantive in nature. Revenue from grants is recognized as the Company provides the services stipulated in the underlying grants based on the time and materials incurred.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Research and Development Costs</font> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font><font style="font-style: italic; display: inline">Stock-Based Compensation &#8211;</font> The Company charges to expense the fair value of stock options and other equity awards granted. The Company determines the value of stock options utilizing the Black-Scholes option pricing model. Compensation costs for share-based awards with pro rata vesting are allocated to periods on a straight-line basis.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Income Taxes</font> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded a valuation allowance against its deferred tax assets based on the history of losses incurred.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>During the nine months ended March 31, 2013 and 2012, the Company sold New Jersey state net operating loss (NJ NOL)carryforwards, which resulted in the recognition of $1,753,208 and $1,068,233, respectively, in tax benefits.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="font-style: italic; display: inline">Net Loss per Common Share </font>&#8211; Basic and diluted earnings per common share (EPS) are calculated in accordance with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 260, &#8220;Earnings per Share,&#8221; which includes guidance pertaining to the warrants, issued in connection with the July 3, 2012 private placement offering, that are exercisable for nominal consideration and, therefore, are to be considered in the computation of basic and diluted net loss per common share. The Series A 2012 warrants to purchase up to 31,988,151 shares of common stock are exercisable starting at July 3, 2012 and, therefore, are included in the weighted average number of common shares outstanding used in computing basic and diluted net loss per common share starting on July 3, 2012.</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">The Series B 2012 warrants to purchase up to 35,488,380 shares of common stock were considered contingently issuable shares and were not included in computing basic net loss per common share until the Company received stockholder approval for the increase in authorized underlying common stock on September 27, 2012 (see note 6). For diluted EPS, contingently issuable shares are to be included in the calculation as of the beginning of the period in which the conditions were satisfied, unless the effect would be anti-dilutive. The Series B 2012 warrants have been excluded from the calculation of diluted net loss per common share during the period from July 3, 2012 until September 27, 2012 as the impact would be anti-dilutive.</font></div>

<div style="text-indent: 0pt; display: block">&#160;</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font id="TAB1" style="margin-left: 36pt"></font>As of March 31, 2013 and 2012, common shares issuable upon conversion of Series A Convertible Preferred Stock, the exercise of outstanding options and warrants (excluding the warrants issued in connection with the July 3, 2013 private placement offering), and the vesting of restricted stock units amounted to an aggregate of 27,672,437 and 27,462,700shares, respectively. These share amounts have been excluded from the calculation of net loss per share as the impact would be anti-dilutive.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_SummaryOfSignificantAccountingPoliciesPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 2110<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 20<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 5, 6, 16-19<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 140<br><br> -Paragraph 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959686&amp;loc=d3e355033-122828<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 96-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 97-2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 5<br><br> -Paragraph 83, 84<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 8, 10, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7-15, 26, 30-37<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 48<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 4<br><br> -Paragraph 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 6-34, 43, 47, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 10, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 7-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13433-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 7-18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27290-111563<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section C<br><br> -Paragraph 5<br><br> -Chapter 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 6<br><br> -Paragraph 5, 6, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 06-11<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 11, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_FairValueMeasurementsTablesAbstract', window );"><strong>Fair Value Measurements Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets at fair value</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">The following table provides the assets carried at fair value:</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left">
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="text-align: left; vertical-align: bottom; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Total carrying value as of March 31, 2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Quoted prices in </font><font style="display: inline; font: 10pt times new roman">active markets <br />
</font><font style="display: inline; font: 10pt times new roman">(Level 1)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Other quoted/observable inputs</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">(Level 2)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Significant unobservable inputs</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">(Level 3)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="text-align: left; vertical-align: bottom">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">March 31, 2013:</font></div>
</td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 36%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Money Market Fund</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">19,056,321</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">19,056,321</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 2px">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">U.S. government securities</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">7,498,665</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">7,496,925</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 36%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Total</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">26,554,986</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">26,553,246</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 36%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 36%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">June 30, 2012:</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Money Market Fund</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">3,344,146</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">3,344,146</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td></tr></table></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_FairValueMeasurementsTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_FairValueMeasurementsTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure related to assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a recurring and/or nonrecurring basis in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 6<br><br> -Footnote 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=SL7498348-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19279-110258<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19190-110258<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 33<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Preferred Convertible Class A</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Preferred Convertible Class A</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Preferred Convertible Class B</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Money Market Funds</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Money Market Funds</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>US Government Securities</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 19,056,321<span></span></td>
        <td class="nump">$ 3,344,146<span></span></td>
        <td class="nump">$ 1,499,925<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">NOL carryforwards sold, resulting in tax benefits</a></td>
        <td class="nump">$ 1,753,208<span></span></td>
        <td class="nump">$ 1,068,233<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Shares issuable upon conversion of warrants, considered to be contingently issuable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,988,151<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35,488,380<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,672,437<span></span></td>
        <td class="nump">27,462,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the difference, between total income tax expense or benefit as reported in the Income Statement for the year/accounting period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations, that is attributable to all other items not otherwise listed in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 48<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2538-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 30, 31, 32, 33, 34, 35, 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingently Issuable Shares<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 55<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2626-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (16,144,126)<span></span></td>
        <td class="num">$ (11,999,885)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">82,360<span></span></td>
        <td class="nump">737,120<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accrued interest and amortization on premium/discount</a></td>
        <td class="num">(451)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of supplies and equipment</a></td>
        <td class="num">(4,620)<span></span></td>
        <td class="num">(4,700)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">475,329<span></span></td>
        <td class="nump">716,300<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Increase in fair value of warrants</a></td>
        <td class="nump">7,069,165<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">27,631<span></span></td>
        <td class="nump">114,549<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, restricted cash and other assets</a></td>
        <td class="nump">660,480<span></span></td>
        <td class="num">(215,892)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">438,549<span></span></td>
        <td class="nump">60,994<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses, compensation and deferred rent</a></td>
        <td class="num">(1,181,502)<span></span></td>
        <td class="nump">578,144<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_PTN_IncreaseDecreaseInUnearnedRevenues', window );">Unearned revenues</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(46,105)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(8,577,185)<span></span></td>
        <td class="num">(10,059,475)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of supplies and equipment</a></td>
        <td class="nump">4,620<span></span></td>
        <td class="nump">4,700<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(70,727)<span></span></td>
        <td class="num">(15,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
        <td class="num">(5,998,289)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
        <td class="num">(6,064,396)<span></span></td>
        <td class="num">(10,300)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on capital lease obligations</a></td>
        <td class="num">(16,547)<span></span></td>
        <td class="num">(29,615)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of withholding taxes related to restricted stock units</a></td>
        <td class="num">(34,785)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the sale of common stock units</a></td>
        <td class="nump">34,402,768<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump">34,351,436<span></span></td>
        <td class="num">(29,615)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="nump">19,709,855<span></span></td>
        <td class="num">(10,099,390)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
        <td class="nump">3,827,198<span></span></td>
        <td class="nump">18,869,639<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
        <td class="nump">23,537,053<span></span></td>
        <td class="nump">8,770,249<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">$ 4,746<span></span></td>
        <td class="nump">$ 6,650<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PTN_IncreaseDecreaseInUnearnedRevenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net change during the reporting period in the amount of unearned revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>PTN_IncreaseDecreaseInUnearnedRevenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>PTN_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment to the amount at which a liability incurred or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow paid by the company to cover an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: bold 10pt Times New Roman">(5)&#160;&#160;&#160;&#160;&#160;&#160; FAIR VALUE MEASUREMENTS:</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="font: 10pt Times New Roman">The
fair value of cash equivalents and short-term investments are classified using a hierarchy prioritized based on inputs. Level
1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices
for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly
or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable
inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset or
liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the
fair value measurement.</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="font: 10pt Times New Roman">&#160;</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="font: 10pt Times New Roman">&#160;</font><br /></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: bold 10pt Times New Roman"></font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="font: 10pt Times New Roman"></font></div>

<div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt"></div>



<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt Times New Roman"><font style="margin-left: 36pt"></font>The following table provides the assets carried at fair value:</font></div>

<div style="text-indent: 0pt; display: block"><br />
</div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left">
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt times new roman; font-size: 10pt; font-family: times new roman">
<tr>
<td style="text-align: left; vertical-align: bottom; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Total carrying value as of March 31, 2013</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Quoted prices in </font><font style="display: inline; font: 10pt times new roman">active markets <br />
</font><font style="display: inline; font: 10pt times new roman">(Level 1)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Other quoted/observable inputs</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">(Level 2)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: black 2px solid">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">Significant unobservable inputs</font></div>

<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center"><font style="display: inline; font: 10pt times new roman">(Level 3)</font></div>
</td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr>
<td style="text-align: left; vertical-align: bottom">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">March 31, 2013:</font></div>
</td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td colspan="2" style="text-align: left; vertical-align: bottom"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 36%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Money Market Fund</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">19,056,321</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">19,056,321</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 2px">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">U.S. government securities</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">7,498,665</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">7,496,925</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 2px solid"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 2px solid; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 2px solid; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 2px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 36%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Total</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">26,554,986</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">26,553,246</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="vertical-align: bottom; width: 36%"><font style="display: inline; font: 10pt times new roman">&#160; </font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: white">
<td style="text-align: left; vertical-align: bottom; width: 36%">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">June 30, 2012:</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 11%; text-align: right"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
</tr><tr style="background-color: #cceeff">
<td style="text-align: left; vertical-align: bottom; width: 36%; padding-bottom: 4px">
<div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: left"><font style="display: inline; font: 10pt times new roman">Money Market Fund</font></div>
</td>
<td style="text-align: left; vertical-align: bottom; width: 3%; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">3,344,146</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="text-align: left; vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">3,344,146</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 3%; border-bottom: black 4px double"><font style="display: inline; font: 10pt times new roman">&#160;</font></td>
<td style="vertical-align: bottom; width: 1%; border-bottom: black 4px double; text-align: left"><font style="display: inline; font: 10pt times new roman">$</font></td>
<td style="vertical-align: bottom; width: 11%; border-bottom: black 4px double; text-align: right"><font style="display: inline; font: 10pt times new roman">&#8212;</font></td>
<td nowrap="nowrap" style="vertical-align: bottom; width: 1%; text-align: left; padding-bottom: 4px"><font style="display: inline; font: 10pt times new roman">&#160;</font></td></tr></table></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13504-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13433-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>52</ContextCount>
  <ElementCount>123</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - Consolidated Balance Sheets (Unuadited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/BalanceSheetsUnuadited</Role>
      <ShortName>Consolidated Balance Sheets (Unuadited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - Consolidated Balance Sheets (Unuadited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/BalanceSheetsUnuaditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unuadited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/Organization</Role>
      <ShortName>ORGANIZATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - AGREEMENT WITH ASTRAZENECA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/AgreementWithAstrazeneca</Role>
      <ShortName>AGREEMENT WITH ASTRAZENECA</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - ORGANIZATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/OrganizationPolicies</Role>
      <ShortName>ORGANIZATION (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - ORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/OrganizationDetailsNarrative</Role>
      <ShortName>ORGANIZATION (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - AGREEMENT WITH ASTRAZENECA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/AgreementWithAstrazenecaDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH ASTRAZENECA (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://palatin.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0002 - Statement - Consolidated Balance Sheets (Unuadited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2011'</Log>
    <Log type="Info">Process Flow-Through: 0003 - Statement - Consolidated Balance Sheets (Unuadited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0004 - Statement - Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>ptn-20130331.xml</File>
    <File>ptn-20130331.xsd</File>
    <File>ptn-20130331_cal.xml</File>
    <File>ptn-20130331_def.xml</File>
    <File>ptn-20130331_lab.xml</File>
    <File>ptn-20130331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
